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Preface
When the topic of mechanisms of tolerance/dependence was considered
by the National Institute on Drug Abuse for a major review, it
seemed at first to lack sufficient substance. Although there is
voluminous material on pharmacological dose response and on signs
and symptoms associated with the actions of opiates and other drugs,
only limited progress has been made on defining the basic mechanisms
involved.
For several reasons, progress has been slow in this area. As Eric
Simon stated at the symposium, progress has been encumbered by
several factors, some of which will eventually assist in defining
basic biochemical systems and subsequently the area of tolerance and
dependence. These include the discovery that there are several
types of opiate receptors, the discovery of at least three types of
endogenous pro-opioid peptides, the difficulties in measuring
dynamic biological turnover of these peptides and/or related
systems; the lack of an understanding of post-receptor events
(especially in vivo); and finally, the difficulty in establishing
any regulation of opiate receptors.
Yet progress has been made, and it is essential that we continue to
define the mechanisms of tolerance and/or dependence. This knowledge
is important in determining the underlying biological factors that
lead some individuals to abuse drugs. When we have more precise
knowledge of these processes we will be able to cope more
effectively with the ever increasing drug problem.
It took the quiet enthusiasm of Professor H.O.J. Collier during a
visit to NIDA in late 1982 to instigate this review. His confidence
in his colleagues and especially in his own work was contagious.
Once the seed had been planted with Institute Director Dr. William
Pollin and the rest of the NIDA staff, we undertook the task of
organizing this review of important recent findings defining the
mechanisms of tolerance and dependence.
We were buoyed by the interest and enthusiasm of those we spoke with
regarding a discussion of this topic--one that has been of major
concern to NIDA for a long time. Ever since the discovery of
endogenous opioids in 1975, the Institute has encouraged
investigators not only to identify the site of action of those
substances, but more importantly, to utilize these substances and
their systems to study the mechanisms through which tolerance and/or
dependence are mediated.
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Unfortunately, shortly before the meeting, Professor Collier died.
Thus, not only did the group miss his knowledgeable contributions,
we missed and will continue to miss his probing and articulate
discussions. In lieu of the original thoughts Professor Collier
would have contributed at the meeting, it is worth reflecting on his
most recent thoughts on the topic, which were published recently
following another symposium.1 We have drawn from this
illuminating manuscript pertinent and provocative excerpts which may
serve as guidelines for those interested in narcotic tolerance and
dependence.
Let us first consider what he thought to be important criteria for
defining tolerance and dependence:
To analyse cellular mechanisms of tolerance and
dependence, it is necessary to reproduce models of these
states in isolated or partly isolated preparations. It
is therefore important to have strict criteria of
tolerance and dependence with which to recognize them in
such models. Tolerance is generally agreed to be a
lessened response to a drug after its continued
application, and which may be observed in several ways:
1. Decreased response to the same dose of drug.
2. Increased dose of drug to yield the same response.
3. Lessened response to drug during continued exposure.
Dependence is, however, more difficult to define and
three criteria have largely been used:
1. "Spontaneous behavioural disturbance produced by
removal of drug and suppressed by its replacement.
2. Increased potency of the drug's specific antagonist.
3. Behavioural disturbance on precipitated withdrawal of
drug with its specific antagonist.
4. Heightened response to external stimulation after
withdrawal of inhibitory drug.....(p.109)
Another criterion, sometimes also used to measure the
intensity of dependence, is a heightened potency of the
drug's specific antagonist....A third criterion is also
sometimes used--that of increased excitability of the
preparation to external stimulation after withdrawal of
an inhibitory drug such as opiate....(p.109-110)
Whatever criteria of dependence we use, valid ones, in my
opinion, rely on withdrawing a drug from a preparation
exposed to it....We cannot measure tolerance, however,
without applying the drug. We therefore cannot measure
both tolerance and dependence in the same preparation at
the same time. This principle of uncertainty makes it
difficult to determine the relationship between opioid
tolerance and dependence, as may be illustrated by
experiments on the isolated ileum of the
guinea-pig....(p.11O)
Naturally, the uncertainty principle does not stop us
measuring tolerance and dependence in parallel
x
preparations at the same time, or in the same preparation at
different times. To validate such measurements, large numbers
of replicates are needed for which isolated preparations are
suitable....(p.111)
Based upon the above considerations, Professor Collier chose the
guinea-pig ileum as a model for exploring these areas of research.
Before he utilized the guinea pig ileum for these investigations, he
considered several important questions:
First, how closely does opioid dependence in the
preparation resemble that in experimental animals or man
in vivo? Second, can dependence on drugs other than
opioids be induced in the guinea pig ileum and, if so,
how are the different dependencies related? Third, what
neurone or combination of neurones of the myenteric
plexus participates in these dependencies? Fourth, what
are the cellular and molecular mechanisms of dependence
in the neurones involved? (p.116-117)
Furthermore, he considered the breadth of the problem:
That dependence occurs within the opiate-sensitive
neurone does not mean that factors outside this cell may
not also contribute to the effect. Among these factors,
which may be termed circumcellular, I include:
supersensitivity of a neurone or muscle cell downstream
of the opiate-sensitive neurone; and changes in the
production by adjoining cells of endogenous opioid
transmitter or of an enzyme destroying it. (p.115)
Thus, embarking on his inquest, he recently provided important
observations and conclusions to assist in the development of his
thoughts and hypothesis. These include:
...The same neurone can be made dependent on three
distinct types of agonist. When the neurone is dependent
on one of these agonists a withdrawal contracture cannot
be precipitated with specific antagonists of either of
the other two types of drug....Any one of the three
different types of agonist, however, readily suppresses
the withdrawal contracture of ileum made dependent on
either of the other two agonists. We have therefore
termed convergent those dependencies that begin through
activation of different recognition sites in the
cholinergic motor neurone and end in the common process
of liberating acetycholine at the terminal on withdrawal.
Since we have not yet observed any difference in
character between the three convergent dependencies in
this neurone, other than in the inducing drugs and their
specific antagonists, we provisionally assume that they
have a common mechanism, which must lie downstream of the
different recognition sites. (p.118)
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He further postulated:
That dependence occurs in the cholinergic neurone at a
point below the recognition site still leaves a number of
possible mechanisms for opioid dependence. The
likelihood that several of these operate is diminished by
the finding that withdrawal elicits a sharp increase in
impulse production recorded at the cell body...Hence the
most likely possibilities are that dependence occurs in
the post-recognition site part of the receptor apparatus
or in an associated second messenger system that
translates the message of site activation into the
language of cellular response. (p.120)
In regard to why progress in this area developed slowly, Collier
stated:
Until recently, there has been relatively little
opportunity to test these hypotheses in normal neurones,
but the discovery of convergent dependencies on
normorphine, clonidine and adenosine in the final
cholinergic motor neurone...now offers an opportunity to
do so. The general concept that dependence in normal
neurones arises in response to continued inhibition of
adenylate cyclase is supported by the fact that all of
the three agonists that induce dependence in the
myenteric plexus...have been shown to inhibit adenylate
cyclase in other biological preparations, as a result of
binding with their distinct and specific recognition
sites. Unfortunately, it has so far proved impossible to
test directly whether normorphine, clonidine and
adenosine each inhibits adenylate cyclase in the
cholinergic motor neurone of the myenteric plexus.
(pp.121-122)
Yet he remained optimistic that we were poised at the edge of a
major scientific breakthrough. He ended his paper with the
following statements those of us in the field should well remember.
1. The relationship between opiate tolerance and
dependence is not well understood...
2. The withdrawal syndrome of opiate dependence may
represent a physiological mechanism for rapid arousal
from inhibition induced by endogenous opioid.
3. The main site of opiate dependence is the opiate-
sensitive neurone...
4. The isolated ileum of the guinea-pig so far provides
the only model in which opiate dependence
and associated tolerance can be consistently induced and
measured in normal neurones in vitro....
xii
5. The characteristics of opiate dependence displayed by
the ileal model closely resemble those of dependence in
whole animals...
6. Distinct but convergent dependences on normorphine,
clonidine and adenosine can be separately induced in the
guinea-pig ileum in vitro.
7. ...The final cholinergic motoneurone of the myenteric
plexus participates in all three of these dependences.
8. With the cholinergic motor neurone these dependences
probably arise at a point below the separate recognition
sites and above the site of acetylcholine release at the
terminal.
9. A second transmitter, substance P, also participates
in dependences in the myenteric plexus. (p.123)
10. There is direct experimental evidence that opiate
dependence and associated tolerance in cultures of
neuroblastoma x glioma hybrid cells arises through an
hypertrophy of cellular adenylate cyclase.
FOOTNOTE
1. The quotations herein are taken from: Collier, H.O.J.
Cellular aspects of opioid tolerance and dependence. In:
Hughes, J.; Collier, H.O.J.; Rance, M.J.; and Tyers, M.B., eds.
Opioids, Past, Present and Future. London and Philadelphia:
Taylor & Francis 1984. pp. 109-125. Copyright 1984, Taylor &
Francis Ltd.
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In Memoriam: H. O. J. Collier
On 29 August 1983, Harry Collier passed away, the victim of a
failed heart that for the past several years was sustained by a
pacemaker. To those who knew him as a friend as well as a
colleague, his death is a severe personal loss. This news was
particularly poignant in our household because on the very day he
died we received a letter from Harry confirming that he would visit
us right after the technical review on mechanisms of tolerance and
dependence on November 11-12, 1983. Unfortunately, the visit was
not to be. Instead, with a heavy heart and tearful eye, I have
prepared a eulogy for the man to whom the meeting and this
monograph are dedicated.
For this purpose, I have borrowed heavily from the obituary which
appeared in the Times of London on 2 September 1983. It was
written by Harry's son, Joseph Collier, and his former son-in-law,
Andrew Herxheimer. both of whom are pharmacologists.
Henry Oswald Jackson Collier was born on March 14, 1912, and
educated at the Royal Grammar School, Worcester, from where he went
to Trinity Hall, Cambridge. Here he graduated B.A. with First
Class Honors in the Natural Sciences Tripos (an honors examination)
in 1933 and went on to do research in the Department of Zoology,
being awarded his Ph.D. in 1938.
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From 1937 to 1941 he was an assistant lecturer and demonstrator in
Comparative Physiology at the University of Manchester, and in 1941
he joined Imperial Chemical (Pharmaceuticals) Ltd. as a parasitolo-
gist. From here he was loaned to do research in chemotherapy at
Liverpool School of Tropical Medicine.
In 1945 he went to Allen and Hanbury's Ltd. at Mare to set up a new
pharmacology department for the firm. This he built up and ran
until 1958 when he left to join Parke-Davis at Hounslow as Director
of Pharmacological Research. Here he remained until 1969.
During this period, the natural materials known as prostaglandins
were discovered and recognized to be a novel kind of locally
produced and locally effective hormone, "the coinage of the body's
defenses," as Harry later described them.
In 1968, indeed, he even suggested that anti-inflammatory drugs
such as aspirin might function by interfering with the production
of naturally occurring hormones such as prostaglandins. Shortly
thereafter Harry became Director of the Stokes Court Laboratory of
Miles Laboratories, Ltd., and it was at this critical juncture of
his career that he did not have access to a laboratory wherein he
could test his hypothesis experimentally.
The demonstration that this is indeed what happens came 3 years
later, in Dr. J. R. Vane's Nobel Prize-winning study at the Royal
College of Surgeons.
In the latter part of his life his interests turned more
specifically to questions of the mechanism of tolerance and
dependence, and he published a number of papers on these and
kindred topics, many of which evoked considerable interest. This
work brought him international recognition as a leading authority
in the field.
In 1969 he and Hans Kosterlitz organized a satellite meeting on
opiates at the International Union on Pharmacology Congress in
Basel. This session, which attracted about 25 participants, was
the forerunner of the International Narcotic Research Conference
which has now a membership of over 500 scientists.
After his retirement from Miles in 1982, Harry Collier returned to
academic work as an Honorary Professor of London University at
Chelsea College, where he set up and directed a research unit to
study the mechanisms of drug dependence. There he showed that
adenosine, a substance which occurs naturally in the brain, can
interfere with the development of opiate dependence and its later
manifestations. This may well prove to be an important step
towards finding some means of preventing opiate dependence.
A highly literate man, Harry's interests outside his professional
concerns ranged widely over the cultural field, and he was
particularly fond of poetry and the theater.
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His favorite poet was William Shakespeare, and it was altogether
fitting that the funeral service for Harry Collier closed with a
reading of the song from Cymbeline, the first six lines of which
are:
Fear no more the heat o'th' sun
Nor the furious winter's rages;
Thou thy worldly task has done,
Home art gone, and ta'en thy wages.
Golden lads and girls all must,
As chimney-sweepers, come to dust.
Sydney Archer, Ph.D.
School of Science
Rensselaer Polytechnic Institute
Troy, New York 12181
Mechanisms of Tolerance and
Dependence: An Overview
Leo G. Abood
Despite extensive knowledge of the mechanisms involved in the acute
action of drugs of abuse, relatively little is known of their chronic
effects and the mechanisms responsible for drug dependence and
tolerance associated with the compulsive use of drugs. The phenomena
of tolerance and dependence occur with a variety of psychotropic drugs
and are not unique to the opiates and other drugs of abuse. Throughout
the symposium, it was repeatedly emphasized that the problem of
physical dependence is highly complex, involving a series of adaptive
changes beginning with the diverse and widely scattered opioid receptors
and extending to complex arrays of autonomic and sensorimotor neural
networks; adaptive changes which are influenced by genetic, species, and
environmental factors.
The main emphasis of the symposium was opiate dependence and
to l e rance ,  e xamin ing  the  b i o chemica l ,  pharmaco l og i c ,  and
electrophysiologic mechanisms in the central nervous and neuroendocrine
systems as well as various peripheral systems known to possess opioid
peptides and receptor subtypes. The most characteristic phenomenon
associated with opiate dependence is the abstinence syndrome following
drug withdrawal or administration of an opiate antagonist such as
naloxone. The phenomenon, which is manifested biochemically as well as
physiologically, involves virtually every system containing opioid
receptors, and it provides an index for assessing physical dependence in a
variety of animal species, organ systems, and cell cultures.
Martin stressed the fact that drug tolerance and dependence involves a
variety of adaptive mechanisms-both autonomic and sensorimotor-and
the necessity for model systems to be relevant to the problem of
tolerance and dependence in man as well as animals. Adler presented an
overview of neuropharmacologic procedures to assess drug tolerance and
dependence, including measurements of EEG, body temperature, brain
lesions, and behavioral paradigms. He pointed out that pharmacokinetic
factors, such as the dose schedule, route of administration, and lipid
solubility, influence the drug’s effectiveness in producing tolerance and
dependence. Dewey called attention to a recent report by Ternes
demonstrating tolerance and dependence with hydromorphone in rhesus
but not cynamologus monkeys and emphasized the differences in
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tolerance and dependence liability among animal species as well as of
various classes of opiates. Pharmacokinetic factors must be considered
both in accounting for the differential effectiveness of classes of opiate
agonists and antagonists in producing tolerance and dependence within a
given species and when accounting for dependence liability of a given
drug among different species. He stated that -THC (intravenously) is
as potent as morphine in producing analgesia in rodents and that only
tolerance and no withdrawal effects (loss of body weight) are seen with
the drug.
Herz considered tolerance and dependence to opiates to be a function of
the multiplicity of receptors. By taking advantage of the fact that
tolerance development to prolonged opioid exposure in a given receptor
subtype is selective for that subtype, one can demonstrate the presence
of µ, -receptors in the mouse vas deferens and µ and
receptors in guinea pig ileum. It appears that -receptor ligands induce
sedation, are not self-administered, and do not suppress withdrawal. His
observation that the rewarding and analgesic properties of diprenorphine
(a multiple receptor-ligand) are mediated separately by a (possibly) and
µ receptor, respectively, poses a challenge to the prevalent notion that
both e f fects  are mediated by the µ receptors.  Herz descr ibed
experiments with the opiate-dependent ileum which indicated that
tolerance and dependence were not interdependent. With the use of the
mouse vas deferens made tolerant to opiates, it was not possible to
demonstrate cross-tolerance among any of the various receptor subtypes.
Conceivably, tolerance involves a modification of the receptor, while
dependence is related to adaptive changes at either the effector or
regulatory (adenylate cyclase) link. During the discussion period, it was
noted that physical dependence reflects a drug-seeking behavior aimed
at attenuating the aversive withdrawal effects of opiates.
Shuster addressed the problem of the genetic factors influencing
responsiveness to opiates and other drugs of abuse, employing inbred and
congenic lines of mouse. The naloxone-induced jumping after chronically
administered morphine was observed in C57 but not A/J mice; and,
although little correlation was observed between 3H-naloxone binding to
brain membranes and analgetic responsiveness to opiates, those strains
having the lowest receptor density were the least responsive. The
observed re lat ionship between receptor  densi ty  and analget ic
responsiveness appeared to involve the µ but not or receptors. Such
pharmacogenetic studies reveal the significance of genetic factors in
determining individual vulnerability to physical dependence on drugs of
abuse.
One of the most useful and interesting preparations for studying opiate
dependence in vitro is the isolated myenteric plexus of the guinea pig
after chronic opiate administration. Dependency in the ileum is
manifested by a naloxone-precipitated contracture which can be
overcome by morphine. Tucker described the recent studies of the late
Collier demonstrating the existence of three separate but convergent
systems impinging on the final cholinergic motorneurons responsible for
ileal contraction. The ileum exhibits a dependency on normorphine,
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c l o n i d i n e -norepinephrine agonist), and adenosine (an activator of
adenylate cyclase); furthermore, cyclohexyladenosine, an adenosine
receptor antagonist, is a potent inhibitor of the withdrawal response of
the ileum.
A number of speakers focused on the possible role of adenylate cyclase,
which is presumed to be one of the regulatory links between the receptor
and the effector components of the opioid system. Evidence for the
involvement of adenylate cyclase in the opioid system stems mainly from
the work of Klee and collaborators demonstrating that opioids inhibit
adenylate cyclase in a neuroblastoma-glioma cell line (NG 108-15).
There also exist receptors which stimulate adenylate cyclase, such as Cl-
adenosine and prostaglandin El, the response of the latter being inhibited
by opiates. Klee expanded on his recent report that the suppressive
action of opiates on adenylate cyclase resulted from stimulation of
GTPase, which regulates the cyclase by controlling the levels of the
essential cofactor GTP. Some discussion was devoted to pertussin toxin,
which, by promoting ribosylation of the Ni subunit, abolishes the
hormone inactivation of adenylate cyclase in a variety of inhibitory
systems. The toxin also decreases opiate receptor binding as well as
inhibition of the cyclase in the NG cell line. From studies showing that
the toxin had no effect on the acute action of normorphine on ileum,
while inhibiting the withdrawal response of the ileum, in vivo and in
vitro, Tucker proposed that the toxin was activating an inhibitory
regulator of adenylate cyclase and that physical dependence may involve
such a regulator.
A possible mechanism for drug tolerance and dependence would involve
an alteration in either the density or affinity of its receptor. The well-
known phenomenon of supersensitivity to dopamine (DA) agonists
following chronic exposure to the neuroleptic DA antagonists is
Attributable to an increase in the number of DA receptors. Attempts by
many investigators to modify the density or affinity of opioid receptors
by chronic administration of opiate agonists or antagonists have led to
variable results. Zukin reported that chronic treatment of rats with
naltrexone resulted in a two-fold increase in the brain density of opiate
receptors (3H-etorphine binding), returning to normal levels after 6 days
without drug. Autoradiographic studies after chronic naltrexone
revealed that the density of µ and 6, but not and receptor, in
specific brain areas increased. Clouet viewed tolerance as any change
resulting from the occupancy of the receptor by an opiate and reviewed
changes in the neostriatum associated with acute and chronic exposure
to opiates. These included an increase in DA-stimulated adenylate
cyclase (acute and chronic), increase in DA turnover (especially with
agonists), a biphasic response in the Ca/calmodulin-dependent protein
kinase (acute morphine), and a suppression of the increased kinase
activity after chronic morphine. Protein phosphorylation, by regulating
neuro-transmitter turnover, adenylate cyclase, and ionic channels, may
be another mechanism associated with tolerance-dependence.
Loh described the use in his laboratory of the NG 108-15 cell line to
examine the phenomena of opiate desensitization and withdrawal.
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Chronic exposure to etorphine produces a down-regulation of opiate
receptors and a naloxone-reversible inhibition of PGE1-stimulated
adenylate cyclase. He postulates that the down-regulation is due to
internalization of the receptor; while the rebound effect, which is
suppressed by Cl-adenosine and NaF, may involve a restoration of the
uncoupled inhibitory regulatory-coupling units of the cyclase complex. A
similar mechanism for opiate desensitization was proposed by Wuster,
who provided additional evidence for the dissociation of tolerance and
naloxone-induced withdrawal in the mouse vas deferens and guinea pig
ileum as well as the NG cell line. The opiate desensitization resulting
from pertussis toxin involves a suppression of the inhibitory coupling unit
(Ni) of the cyclase complex; and insofar as opioid receptors are also
decreased by the toxin, he proposed that Ni is needed to maintain the
receptors.
Based on studies with a variety of opioid peptides including -endorphin
and dynorphin agonist), Lee proposed that a balance of endogenous
opioid peptides was involved in analgesia, -endorphin serving as the
major effector and the others as modulatory. Dynorphin alone was not
analgetic, and whereas it potentiated opiate-induced analgesia in naive
mice, it prevented withdrawal in mice, monkeys, and man and suppressed
opiate binding in vivo.
Cicero discussed the mechanisms involved in opioid tolerance and
dependence in the rat hypothalamic-pituitary-luteinizing hormone (LH)
axis. The release of LHRH from the hypothalamus is modulated by
opioid receptors of unknown subtype; after acute or chronic morphine
treatment followed by naloxone, there is a dramatic increase (order of
magnitude) in serum LH levels. When morphine is given 31 days
following castration, there occurs an increase (instead of a suppression)
of LH along with a tolerance to opiate analgesia. The study is
illustrative of the multifarious nature of the opioid system and its
vulnerability to physical dependence.
Mains briefly reviewed the current knowledge of the precursors,
biosynthesis, and processing of neuropeptides, particularly those that are
pro-ACTH/endorphin-derived. With the use of mouse pituitary tumor
cells, he studied the process of -amidation, which results in the
formation of TRH, vasopressin, substance P, and many other
neuropeptides from the corresponding peptides with a terminus COOH.
With the use of the hibernating ground squirrel, Beckman was able to
demonstrate an absence of naloxone-induced withdrawal (vocalization
and shakes) following chronic exposure to morphine. Since DA turnover
decreased, while DA levels increased 10-fold in the hibernating animal,
he inferred that DA supersensitivity, which may be a withdrawal
mechanism, could not develop. Autoradiographic studies revealed a
decrease of opiate receptors in regional brain areas. Henriksen
presented a review of the neurophysiological literature concerned with
opioid tolerance and dependence, highlighting the use of slices of rat
hippocampus and locus coeruleus. When dynorphin is iontophoretically
applied to the CA3 pyramidal neurons of the hippocampal slice,
excitation occurs without acute desensitization; however, the application
of a synthetic agonist, U50-488H, produces inhibition. Herz reported
an increase in field potentials of hippocampal slices with exposure to
met-enkephalin, hut not with morphine.
Crain described the use of organotypic cultures of mouse spinal cord and
senso ry  gang l i a  i n  s tudy ing  acu t e  and  chron i c  e f f e c t s  by
electrophysiologic analyses. Sensory-evoked synaptic responses from
dorsal, but not ventral, root ganglia are depressed in a naloxone-
dependent manner by morphine; and after exposure to morphine for 2
days, the depressant effect of opiates vanishes, but is restored by
naloxone. Proceeding on the assumption that drug tolerance should be
reflected in altered activity of regional brain areas, Elde measured
cytochrome oxidase histochemically in chronically morphinized mice.
The most apparent change was a decrease in the mammillary bodies.
With the use of the 14C-deoxyglucose method, others have reported a
decreased metabolism in frontal motor cortex and striatum and increases
in other brain areas. Because of the depressant effects of opiates in
respiration, it is difficult to determine whether the observed metabolic
changes are direct or indirect. With the demonstration of the existence
of opiate receptors in lymphocytes and other blood cells, interest has
centered on the possible functional role of the receptors in white cells.
Plotnikoff reviewed his and other findings showing that met-enkephalin
was an immunostimulant, which in mice increased the size of the
thymus, decreased the size of the spleen, increased lymphocytic
blastogenesis induced by mitogens, and enhanced the natural killer cell
activity on cancer cells.
The final session of the symposium was devoted to drugs of abuse other
than the opiates. Groves reported that since the stereotypic behavioral
effects of amphetamine are enhanced by long-term administration while
others are attenuated, multiple mechanisms must be involved in the
drug’s action. Apart from such mechanisms as increased release of
catecholamines and supersensitivity of postsynaptic and subsensitivity of
pre-synaptic DA receptors, there are widespread adaptive changes in
many brain areas affecting the integrative activity of brain in coping
with its disrupted environment. Karler found that increased sensitivity
to  the cannabinoids develops concomitant ly  with to lerance,  a
phenomenon that was first noted with cocaine. Furthermore, the
cannabinoids enhance the sensitization to convulsant drugs and
electroconvulsive shock, an effect which may endure for months.
Although some of the behavioral effects of cocaine may involve
activation of the catecholaminergic systems, many of the effects cannot
be accounted for by such mechanisms. In the search for alternate
mechanisms, Gale reported that chronic administration of cocaine or
cocaine + droperidol (a DA antagonist) resulted in a significant increase
in striatal glutamate decarboxylase, a concomitant increase in GABA,
and a decrease in 3H-GABA binding. The findings are indicative of
increased GABA turnover following chronic exposure to cocaine;
however, the neurotransmitter system directly involved in cocaine’s
action is still uncertain.
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Okamoto reported that the dispositional (pharmacokinetic) tolerance to
barbiturates had a rapid onset and was of long duration, while the
functional (CNS depression) tolerance developed slowly and progressed
with treatment. By examining a variety of barbiturates, various dose
schedules, and pharmacokinetics, she demonstrated that tolerance and
dependence were dependent on the blood level of the barbiturate needed
to maintain CNS depression.
Abood described the behavioral and biochemical studies in rats given
nicotine chronically. No changes were observed in the density or affinity
of (-)-3H-nicotine binding sites to brain membranes or in the metabolism
of nicotine by isolated hepatocytes. Although tolerance develops to the
central effects of nicotine, the effect is transitory.
In addition to providing a number of conceptual and methodological
approaches towards understanding drug tolerance and dependence, the
symposium has attempted to better characterize the terms for specific
drugs of abuse. The mechanisms for drug tolerance, which are
comparable for most drugs and better understood than those for
dependence, generally involve adaptive biochemical mechanisms
affecting the rate of drug metabolism and elimination, the sensitivity of
receptors, and responsiveness of secondary messenger systems. On the
other hand, the phenomenon of dependence, which is more characteristic
of drugs of abuse, is highly complex and involves a variety of
biochemical and neurophysiological mechanisms. A number of
experimental models, ranging from neuronal tissue cultures to the whole
animals, are available for exploring the mechanisms of withdrawal of
opiates and, to a lesser extent, barbiturates and amphetamines. Such
models, which provide the basis for examining the underlying
mechanisms for dependence and withdrawal, have yet to be developed
for the cannabinoids, cocaine, nicotine, and other abused drugs. The
further development and refinement of such experimental models will
continue to be significant factors in elucidating such mechanisms.
There arises the question concerning the nature of the physiological
substrate that is mimicked and, presumably, replaced by the dependent
drug and the possible dependence of the organism on the endogenous
substrate. With respect to the opiates, we have some knowledge of the
endogenous substrates ( endorphin, dynorphin, and enkephalins) and
their receptors (µ, and respectively); and one might concur with
Collier that the organism is “physically dependent” on the endogenous
opioids. A similar argument holds for amphetamine which interacts with
catecholaminergic systems. The nature of the endogenous substrates for
barbiturates and other drugs of abuse is not known; however, many of the
drugs do appear to involve specific receptors. One of the important
problems for future research is to characterize the endogenous substrate
for the receptors and demonstrate its ability to mimic drug-induced
dependence and withdrawal.
By encompassing a wide spectrum of abused drugs and a number of
disciplinary approaches, the symposium, in its attempt to deal with
mechanisms of drug dependence, has highlighted some important issues
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concerning the nature of the problem. If a drug’s action is receptor-
mediated, and the receptor exists in multiple forms, can a unitary
molecular mechanism be involved? Are there common mechanisms
among different drugs of abuse? Is the development of dependence
associated with more than one subtype (e.g., the µ-form) of the opiate
receptor? If it is assumed that dependence is a complex process
involving a number of neural circuits, is it necessary for an adaptive
molecular mechanism to occur at the level of the receptor or the second
intermediary messenger?
Much of our information concerning the involvement of receptor-linked
mechanisms in drug tolerance and dependence derives from studies on
neuroblastoma-glioma cultures, where the second messenger appears to
be a prostoglandin-stimulated adenylate cyclase linked to a receptor.
How applicable is this model to the central nervous system which
contains µ and receptors as well? With the possible exception of the
nigrostriatum, attempts to demonstrate the involvement of adenylate
cyclase in opiate action in brain have been unsuccessful. Relatively
little progress has been made in demonstrating a primary action of
opiates on ionic conductances and neurotransmitter function and
turnover. Answers to these and other questions relating to the complex
problem of drug dependence must continue to come from a multi-
disciplinary approach, so well exemplified by this symposium.
Finally, there remains the problem of the criteria for determining
whether a drug of abuse is addictive. Some might argue that any drug or
substance which is abused, i.e., used compulsively, is addictive; in which
case the term would be applicable to innumerable drugs, substances, and
compulsive behavioral patterns. Since the degree or intensity of abuse
varies greatly among drugs and substances, this definition requires a
categorization in terms of their degree of addictive liability. The term
“habitual,” which is more generally used to describe compulsive
tendencies, would be synonymous with “addictive.” It may, however, be
useful to reserve the term “addictive” for abused agents and tendencies
exhibiting a “high degree” of compulsiveness. The problem would then be
to define the psychophysical parameters associated with compulsive
behavior and to decide arbitrarily when an agent is to be labeled
“addictive.”
At the present state of our knowledge, the most characteristic psycho-
physical parameters associated with compulsive use of drugs are those
resulting from either their abrupt withdrawal or administration of an
appropriate antagonist. In the case of the opiates, barbiturates, amphe-
tamines, and alcohol, the withdrawal signs are well-defined and severe;
whereas, with the cannabinoids and nicotine, they are not easily de-
finable by physiological measures and tend to be far less severe. If the
term “addictive” is reserved for those drugs promoting severe, definable
withdrawal signs—often life-threatening in humans-the class of addic-
tive drugs would be small; but, if the term is to be more generally appli-
cable to abused drugs, it will be necessary to develop, in both animal and
human models, the psychophysical, pharmacologic, and biochemical
criteria for assessing their relative degree of compulsive liability.
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Phenomenology and Theoretical
Basis of Tolerance and
Dependence
William R. Martin
I am pleased to dedicate this chapter on tolerance and dependence to
an acquaintance of many years, Harry O. J. Collier. Our paths first
crossed in the early 1960s when we both were in the process of de-
veloping our ideas concerning tolerance and dependence. Over the
years, Dr. Collier became concerned with the phenomenology of tol-
erance and dependence and its basis.
Those of us who work on drug abuse problems tend to view the drugs
as toxins, tolerance as a protective mechanism, and physical de-
pendence as an aversive consequence of recruitment of these pro-
tective mechanisms. Yet another view is that dependence-producing
drugs are pleasure-giving and that physical dependence is the price
that is paid for their use; the view that if one dances one should
be expected to pay the piper. For several reasons included herein,
this chapter will deal with the underlying concepts of tolerance
and dependence. Both are fundamental biologic properties of most
animals and probably to some degree of all biological tissues.
They are intimately concerned with motivation, instincts, adaptive
behavior, survival, homeostasis, needs, drives, arousal and finally
with desires--concepts which have subtle but broad-reaching
distinctions and implications. Tolerance and dependence will be
approached here from a theoretical point of view as it relates to
these apparently diverse concepts.
Concepts of tolerance and dependence still plague us both concep-
tually and phenomenologically. Preoccupation with the phenom-
enology of tolerance and dependence and their molecular basis has
created problems that are new and important in their own right but
causes one to disregard important dimensions which relate these phe-
nomena to psychopathology and to public health. In the end all of
these phenomena have to be viewed from the standpoint of evolution
and survival and are unique in that therapeutic chemostimuli (drugs
interacting with receptors) are being developed systematically.
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It is important to remember that dependencies are needs. This
concept is frequently forgotten as we identify and use experimental
models which are presumed to be models of dependence.It will
serve a purpose to distinguish between two aspects of the concept
of needs. A general definition of need is a life requirement for
an environmental circumstance which is conducive to survival or
well-being. A more specific definition refers to the mechanisms
whereby congenial and hostile environments are recognized. It is
in this restricted meaning that needs will be used in the following
discussion.
figure 1 illustrates the simplest and presumedly most primitive
control mechanisms in organisms which have acquired the ability to
sense and to make integrated adaptive movements. In this model the
sensory system is the need system. We will assume for example that
the animal senses a nutrient need (environment) through a chemo-
receptive mechanism and moves toward it. Thus the organism is
dependent on a nutrient chemical (need) and has a motor mechanism
for acquiring it (drive). An important control mechanism which
must have evolved early was negative feedback regulation (tolerance
to chemostimulation). This was necessary for motor control so that
the organism could (1) slow, stop, and make directional corrections
as it approached a food-rich environment and (2) stop feeding when
satiation occurred. Thus it is reasonable to conceive that
tolerance to chemostimulation evolved early in evolution as an
adaptive mechanism.
A second major principle evolved when organisms became more
complex, had to integrate the activity of different functional
systems, eventually to regulate internal environments, and finally
to develop new abstract needs such as aggression, power, and
developmental dependencies related to complex ecological and social
influences. These new needs as well as old ones became manifest by
the activity of neuronal nets which were stimulated by disequilib-
riums and hostile environments. This neuronal activity produced
discomforting feelings such as pain, fear, anxiety, suffering,
depression, and hypophoria. Thus the activity of these neuronal
nets is the sine qua non of internal needs and associated affective
states. Figure 2 is a scheme indicating this internalization of
need mechanisms which maintain homeostasis and enhance survival.
With this internalization, new systems of controls evolved which
involve reciprocal inhibition, a type of negative feedback
regulation. Here, too, negative feedback is necessary for central
need reduction and provides the mechanism whereby an organism can
integrate movements and recognize satiety. It is important to
recognize that all drugs of abuse diminish a variety of needs
(table 1), a relationship first emphasized by Hlmmelsbach (1943)
and Wikler (1952). An extensive body of research indicating that
these drugs also alter brain neurohumoral processes has a number of
implications, among which is the proposition that chemostimulation
continues to play an important role in need states.
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FIGURE 1
BASIC IMPORTANCE OF TOLERANCE TO EXTERNAL
CHEMORECEPTIVE-NEED-DRIVE PROCESSES
FIGURE 2
PROPOSED PROCESSES RELATING NEEDS (DEPENDENCIES), AFFECT
AND NEGATIVE FEEDBACK MECHANISMS (TOLERANCE)
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Drugs of Abuse Which Reduce Needs and Drives and Alter Homeostats,
and the Putative Neurotransmitters and Neuromodulators Involved
DA, NE
TABLE 1
Endorphines
Opiates Enkephalins
and Dynorphins
Food
C O 2
Pain
Sex
Temperature Regulation
Vasomotor Function
Hypophoria
Amphetamines
Food
Sleep
Pain
Hypophoria
Alcohol GABA
Pain
Hypophoria
Tobacco ACh
Sex
Pain
Food
Hypophoria
Marijuana
Pain
Hypophoria
Benzodiazepines GABA
Sleep
Anxiety
Sedative-Hypnotics GABA
Sleep
Pain
Hypophoria
LSD-Like Hallucinogens Tryptamine
Serotonin
Pain
Hypophoria
Tolerance and physical dependence in man have been explored most
extensively for the opiates. Himmelsbach (1943) conceptualized the
processes of tolerance and physical dependence to opiates as an
alteration of autonomic homeostasis and the recruitment of
contra-adaptive mechanisms. This hypothesis has been very
attractive; however, it has been rigorously tested only for the
regulatory system in man. There are many complexities in
conceptualizing tolerance and dependence and in devising measures
of these phenomena (cf. Martin and Sloan 1977). In nonhuman
studies there is evidence that this mechanism may be of importance
in the regulation of certain endocrine functions and in the
temperataure regulation of the dog Table 2 and figure 3
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TABLE 2
The effects of morphine in nondependent, morphine-dependent (240
mg/day) and morphine-abstinent subjects on the responsivity (slope)
and sensitivity (intercept) of the respiratory system to CO2
(from Martin et al. 1968).
Slope ± S.E. Intercept ± S.E.
Preaddiction
Control 1.5 ± 0.1 51.7 ± 2.2
Morphine (30 mg/70 kg) 1.1 ± 0.1(0.05) 62.8 ± 2.6(0.05)
Late Dependence
Predrug 1.9 ± 0.2 62.1 ± 2.2
Morphine (60 mg/70 kg) 1.7 ± 0.2 63.4 ± 1.6
Early Abstinence (20 Hours)
3.2 ± 0.3(0.05) 52.7 ± 1.6
Protracted Abstinence
1.3 ± 0.2(0.25) 57.0 ± 1.9(0.005)
p values in parentheses when compared to control values
summarize the effects of morphine and morphine abstinence on the
responsivity and sensitivity of the respiratory center to CO,
(Martin et al. 1968). In the nondependent subject morphine shifted
the partial pressure of CO2-minute-volume stimulus-response
curve to the right and depressed its slope. In stabilized
dependent subjects the stimulus-response line remained shifted to
the right; however, its slope was steeper than that of the
stimulus-response line prior to the subject's becoming physically
dependent. Very large doses of morphine (60 and 120 mg/70 kg) had
no effect on the stimulus-response line, a not unexpected finding
since 240 mg/day of morphine probably produced maximum physical
dependence by occupying all of the morphine receptors (Martin et
al. 1972). When the subjects were abstinent 20 hours (mild to
moderate abstinence syndrome had developed), the slope of the
stimulus-response line was twice as steep as that of the control
stimulus-response line. Thus, even in this relatively simple
system, tolerance and dependence have complex dimensions. Morphine
continued to depress the respiratory center's sensitivity to CO,
throughout the period of chronic intoxication; however, chronic
intoxication enhanced the responsivity (increased the
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FIGURE 3
Mean calculated regression lines (solid) for partial pressure
(pCO2)-minute volume (Va) response curves obtained during the
control period, after 15 mg/70 kg of morphine, and during early
withdrawal in subjects dependent on 240 mg/day of morphine. The
means for each parameter were determined from values obtained in 7
subjects. There was great variability in the first and last points
of the response curves. The top of the regression lines represents
the maximum Va obtained. A control ( l ), a 15 mg/70 kg dose of
morphine (x) and a withdrawal paCO2-Va response of one
subject (dashed lines) are presented to further illustrate these
changes. (From Martin et al. 1968.)
slope) of the respiratory center to CO2. Despite the persisting
depression, additional morphine was without effect. The res-
piratory studies provided further evidence about the relationship
between need and affective state. When alveolar ventilation
exceeded 10 minute, subjects experienced some discomfort which
increased as the minute-volume increased. In these studies the
intensity of the discomfort was indicated by hand signals. No
discomfort was reported by the subjects after they received single
doses of morphine (15 or 30 mg/70 kg) even when minute-volume
exceeded 10 minute. This may mear that subjective discomfort
associated with a need can be diminished without producing an equal
diminution of the drive mechanism.
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Tolerance to and dependence on drugs of abuse are even more compli-
cated phenomena when other parameters and drugs are considered.
This point is of sufficient importance to be emphasized, as much of
our effort, at the more basic levels, may be describing phenomena
that are not obviously related to the phenomena of tolerance and
dependence as seen in man with chronic drug administration. Figure
4 illustrates the effects of chronic intoxication to morphine (240
mg/day) on a variety of physiologic parameters. It is believed
that 240 mg/day of morphine saturates nearly all of the u receptors
and produces a maximal degree of physical dependence. Chronic
administration of morphine increases blood pressure, pulse rate,
and body temperature and decreases pupillary diameter and res-
piratory rate. Single doses of morphine in nondependent subjects
do not markedly alter blood pressure, pulse rate, or body
temperature. It is emphasized that these changes persist
throughout the period of chronic intoxication.
FIGURE 4
The effects of chronic administration of morphine on clinical
variables. Each point represents the weekly mean a.m. observation
for 7 subjects. The horizontal line represents the mean of control
determinations for 7 subjects. (From Martin and Jasinski 1969.)
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Figure 5 illustrates changes that occurred in subjects who received
methadone in a dose of 100 mg/day chronically. A decrease in
pupillary diameter and respiratory rate and an increase in body
temperature was seen, changes similar to those produced by chronic
morphine. The chronic methadone syndrome differed from the chronic
morphine syndrome in that blood pressure and pulse rate were
decreased. Thus the chronic effects of closely related opioids
differ.
FIGURE 5
Changes in physiological indices and intensity of abstinence and
feeling state during cycle of methadone dependence. Horizontal
line in each graph represents mean of control observations made
three times daily (6 AM, 12 noon, and 6 PM) for 42 days in 5
patients. Each point represents mean weekly value. Triangles
indicate mean of observations obtained during last three weeks of
addiction cycle. (From Martin et al. 1973.)
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Figure 6 shows the various signs of the morphine abstinence syn-
drome. Blood pressure, pulse rate, body temperatures, and respir-
atory rate are significantly increased. Although pupils return to
control value following withdrawal, they do not markedly dilate. A
similar abstinence syndrome was seen in methadone-dependent subjects
(figure 5). Thus the abstinence syndrome is not the mirror image
of the signs of acute or chronic intoxication with morphine and has
unique dimensions of its own. Figure 5 and table 2 illustrate
another important feature of the morphine abstinence syndrome. The
acute abstinence syndrome persists for about a month and then a new
syndrome develops which is characterized by a mild hypotension,
bradycardia. hypothermia, miosis, and hyposensitivity of the
respiratory center to CO2. This syndrome persists for several
months and was still evident when the studies were terminated. It
is important to emphasize that there are both an acute and a
protracted abstinence syndrome which are different and indicate
FIGURE 6
Changes seen during early and protracted abstinence. Each point
represents the mean weekly a.m. values for 6 subjects. The first
point of each curve represents the mean value for the last 7 weeks
of addiction. The horizontal line represents the mean control
value for the 6 subjects. One subject was withdrawn from the study
near the end of the chronic intoxication phase because of episodes
of acute cholecystitis. (From Martin and Jasinski 1969.)
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that chronic administration of opioids alters neuronal excitability
in diverse ways and probably through several mechanisms.
Morphine-like drugs produce feelings of well-being (euphoria or
anti-hypophoria) in abstinent addicts. It is not generally
recognized or attended to that chronic opiate-intoxicated patients
become hypochondriac, develop feelings of tiredness, inefficiency,
unpopularity, and become withdrawn (table 3). These symptoms are
more marked during early withdrawal and remained exacerbated during
protracted abstinence (Martin et al. 1973). This constellation of
symptoms has been called hypophoria and their disappearance,
euphoria (Martin et al. 1977). All of these negative feelings are
decreased in a dose-related way by opiates, amphetamines (Martin et
al. 1971), and barbiturates (Martin et al. 1974; Jasinski 1977).
Although systematic studies have not been done, anecdotal accounts
indicate that they are also probably reduced by nicotine, alcohol,
marijuana, and the LSD-like hallucinogens. Thus the effect of
chronic opioid administration is not merely the loss of its ability
to produce feelings of well- being but the reduction of hypophoria
and withdrawal from social interactions. These feelings are
exacerbated during both early and protracted abstinence.
It is known that opiates in single doses decrease all types of
sleep (Kay et al. 1969). Figure 7 illustrates changes in different
types of sleep seen during a cycle of methadone dependence. As can
be seen, sleep is increased during both the stabilization phase of
dependence and protracted abstinence (Martin et al. 1973). Thus
the effect of chronic opioid treatment on sleep is not simply the
reduction of the insomniac action in the presence of opioids. It
also produces hypersomnia in protracted abstinence.
Whereas a single dose of opioids can reduce a number of needs,
chronic administration may both decrease (e.g.. CO2 elimination)
and increase (e.g., hypophoria, sleep) needs. Although many need
states are enhanced during early abstinence, some may be decreased
(e.g., sleep). Perhaps, more importantly, during protracted
abstinence some needs are increased (hypophoria and sleep) and
others decreased (responsivity to CO2) (see table 4).
CONCLUSION
Most, if not all, drugs of abuse are intimately involved in needs
and need reduction. These needs are dependencies which have
inherent tolerance mechanisms necessary for the control of need
reduction. With internalization of need states and the evolution
of cognitive processes, affect has become a fundamental need
mechanism. Chronically administered drugs of abuse interact with
and change need states. The characterization of these changes in
terms of conventional definitions of tolerance and dependence
greatly oversimplifies the impacts of chronic drug administra-
tion. Indeed this oversimplification of the concepts of tolerance
and dependence and the development of methods for assessing them
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TABLE 3
Changes in certain ARCI and MMPI scale scores during a cycle of addiction to methadone
Controlled Addiction Early Protracted
(4 and 10 Weeks) Abstinence Abstinence
ARCI Scale Score Negative Feelings
PCAG
Weak
Tired
Social
Withdrawal
48 55 73** 47
42 51 72** 47
44 61** 73** 47**
56 56 58** 61
MBG 55
Efficiency 58
ARCI Scale Score Positive Feelings
53 38**
48** 24**
MMPI Scale Scores
48
51**
Hs 54 71* 75* 53
Hy 53 66* 71* 58
SC 62 70** 74* 74*
PCAG=(Pentobarbital, Chlorpromazine, Alcohol Group Scale) - Apathetic Sedation
MBG=(Morphine, Benzedrine Group Scale) - Euphoria - Antihypophoria
Hs=(Hysteria); Hy=(Hypochondriasis); Sc=(Schizophrenia); * P<0.05; ** P<0.0l
FIGURE 7
Number of minutes during various phases of the addiction cycle of
total sleep, B-bursts, REM sleep, and -sleep. Each point
represents the mean obtained for 5 patients. Three control
observations were obtained (Cl, C2, C3) as well as observations
during the ascending (A) and stabilization (S) phases and during
withdrawal (numbers in weeks). Asterisks indicate values are
significantly different from control values: *P<0.1; **P<0.05.
(From Martin et al. 1973.)
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TABLE 4
Respiration
Mood
Sleep
Summary of the Effects of a Cycle of Opioid Dependence on Three Needs
Acute Stabilization
Effects (Tolerance)
Early
Abstinence
Protracted
Abstinence
Decreased
sensitivity
and
responsivity
to CO2
Decreased sensitivity Increased Increased
and increased responsivity and decreased
responsivity to CO2 and probably sensitivity
sensitivity
Decreased
hypophoria
(euphoria)
Increased
hypophoria
Increased
hypophoria
Increased
hypophoria
Decreased all
sleep stages
Increased total
sleep and
bursts
Increased and
total sleep
may result in the study of phenomena which may not be related to
the clinically relevant changes produced by chronic administrations
of opioids and perhaps of other drugs.
Chronically administered opiates clearly produce long-persisting
changes in need states and affect, enhancing some and depressing
others, and may induce new needs which can only be met with drugs
which may have the potential for abuse. The changes which are
induced are enormously complex, probably involving multiple
mechanisms such as homeostasis at molecular, cellular and tissue
levels, supersensitivities, up- and down-regulations of receptors
and their endogenous agonists and recruitment of redundant
mechanisms. The enormous amount of research which has been done
with chronic opiate administration has shown that these drugs
produce long-lasting changes. Our own work continues to show that
individuals with drug problems have exaggerated needs and
associated affective disorders (hypophoria).
Drug-induced tolerance and dependence still have major clinical
importance. Many patients with excessive needs and hypophoria
attempt to cope with these discomforting subjective states by using
drugs which possess antihypophorlc properties. Most of these drugs
interact with need states and alter them. Some of these
alterations may cause long-persisting changes and worsen existing
psychopathologic processes. Since one of the alternative
strategies for treating drug abusers is chemotherapy, an
understanding of the basic mechanisms of phenomena designated as
tolerance and dependence is important, as these phenomena may alter
brain functions related to needs and affect. Thus the search for
new chemotherapeutics for the treatment of drug dependence presents
a formidable challenge, for we will be interceding in functional
systems which are intimately concerned with basic motivation.
Interventions, because of the complexities of need systems, may
have unexpected outcomes.
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Contributions of Neurophar-
macology to Understanding
Mechanisms of Tolerance and
Dependence
Martin W. Adler and Ellen B. Geller
INTRODUCTION
Neuropharmacological research has played a major role in the
formulation of our concepts regarding tolerance and dependence
to abused drugs. As our knowledge about these phenomena has
increased, certain ideas have been reevaluated and modified. To
compile a comprehensive review of all the studies in this field
which have contributed to our present state of knowledge about
tolerance and dependence for all drugs of abuse is a formidable
task and one which will not be attempted here. By way of merely
indicating the diversity of research in this area, some of the
techniques and endpoints used in studying the neuropharmacology
of drugs of abuse appear in table 1. The necessity of having so
many approaches available to us has become more apparent as we
have gradually moved away from the notion of a single, global
mechanism of tolerance and dependence. Only a short time ago,
for example, the view that there must be one discrete locus in
the brain responsible for opiate dependence was generally
accepted. However, as a result of research involving brain
lesions (e.g., Linseman 1976; Adler et al. 1978; Calvino et al.
1979) and modification of neurotransmitter systems (review,
Takemori 1974), this idea has been largely abandoned. With the
recognition of the multiplicity of both chemical and anatanical
systems that are involved in tolerance and dependence to drugs
of even a single class, the value of examining a variety of
drug-induced responses is readily understood. Furthermore, in
light of the broad spectrum of drug classes to which tolerance
and/or dependence may develop, the need for such an array of
techniques and endpoints becomes even more obvious.
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TABLE 1. Neuropharmacological studies of drugs of abuse
Techniques Endpoints
EEG
Microiontophoresis
Operant Techniques
Brain Lesions
Intraventricular Cannulation
Selective Agonist & Antagonist
Drugs
Drugs to Modify Neurotransmitter
systems
Electrically & Chemically Induced
Seizures
In-vivo pA Determinations
Binding Studies
Isolated Tissue Studies
Drug Infusion Methods
Body Temperature
Body Weight
Antinociceptive
Thresholds
Pupil Size
Seizure Thresholds
Neuronal Firing Patterns
Neurotransmitter Levels
& Turnover
Locomotor Activity
Behavior
Drug Discrimination
Cross-Tolerance
Cross-Dependence
TOLERANCE
Despite the lack of a clear understanding of the mechanisms
responsible for the phenomenon we call tolerance, we can define
the term in an operational sense. Tolerance can be defined
either as the reduced effect of the same dose of a drug on sub-
sequent administrations, or as a need to increase the dosage in
order to maintain the same level of effect. This simple defini-
tion allows for a variety of pharmacokinetic, pharmacodynamic,
and other mechanisms to be implicated in the tolerant state.
Although our definition of tolerance has not changed, many of
our concepts relating to it have. For example, a belief held by
most workers in this field until recently was that "tolerance to
the depressant but not to the excitant effects of narcotics
develops at the spinal cord level, just as elsewhere in the
cerebrospinal axis" (Goodman and Gilman 1955). It is now known
that tolerance can be demonstarted to the classical excitant
effects, namely, pupillary response and gastrointestinal tract
activity. Both the miotic effect of heroin in humans (Tress et
al. 1978) and the mydriatic effect of morphine in mice (Adler et
al. 1980) and rats (Adler et al. 1981) are subject to tolerance
development. Similarly, tolerance has been found to the effects
of morphine on intestinal motility in dogs (Weisbrodt et al.
1980) and rats (Cowan et al. 1977). Although the degree of
tolerance may not be equivalent for all of the actions of an
opioid, at least a partial tolerance is demonstrable for most
effects. One exception may be found in the effect of morphine
on lowering reward threshold. Not only does no tolerance devel-
op on repeated administration, but an increased effect has been
reported (Kornetsky and Bain 1982).
Another commonly accepted idea in the recent past was that
tolerance develops to all of the effects of amphetamine. While
it is true that one sees marked tolerance to some of the actions
of this drug (e.g., anorexic, cardiovascular), reverse
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tolerance, or increased responsiveness with repeated administra-
tion, occurs with some stereotypies (Rebec and Segal 1980).
Interestingly, no tolerance to its effect against narcolepsy
seems to occur Weiner 1980). Marijuana, on the other hand, is
an example of a drug to which no tolerance was thought to devel-
op. In fact, it was felt by many that increased sensitivity
occurred with repeated administration. Experiments such as
those by Domino (1971), however, have shown conclusively that
tolerance does develop to at least some of marijuana's effects.
While it was once believed that tolerance development requires
repeated administrations of a drug, in recent years the
occurrence of single-dose tolerance to morphine has been
reported (e.g., Cochin and Kornetsky 1964; Kornetsky and Bain
1968; Huidobro et al. 1976). In some cases, tolerance can be
demonstrated within hours of a single priming dose; in other
instances intervals of days are necessary.
The examples cited above serve to illustrate how a more detailed
look at tolerance has resulted in a recognition of new elements
involved in that phenomenon. Examination of these factors has
yielded important insights into the mechanisms behind tolerance.
Although the terms tolerance and dependence are inextricably
woven into the fabric of our thinking about several classes of
drugs, there is recent in vivo evidence with opiates, for
instance, that the two phenomena, though linked, are not insep-
arable (Cochin and Mushlin 1976; Dafny 1982). Other types of
studies have also indicated the separability of the two phenom-
ena. One must be careful, however, to consider other explana-
tions, such as differences in dose or duration of drug
administration, that may be required for the demonstration of
each. Furthermore, if a drug acts on a particular receptor type
to produce a relatively irreversible or slowly reversible
canplex, tolerance may become apparent without concomitant
signs of physical dependence. Only careful evaluation can
determine if the tolerance exists without physical dependence.
There are also examples of drugs showing relatively low degrees
of tolerance but marked physical dependence (barbiturates), and
vice versa
DEPENDENCE
Traditionally, dependence has been defined in terms of the phys-
iological and psychological symptoms that appear when the drug
is withdrawn or antagonized. As our knowledge about dependence
has grown, acceptance of such a simple definition has waned.
Although the term may be used in an operational sense to denote
the entire series of events associated with chronic abuse of a
drug, dependence really comprises two components: the abuse
liability of a drug (potential for abuse) and its dependence
potential (potential for behavioral and/or physical signs of
abstinence). The "abstinence syndrome"can be reversed by read-
ministering the drug or another one with which it is cross-
dependent. Each class of drugs, however, has its own dependence
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characteristics, and thus it may be better to describe depend-
ence in term of a particular class. In fact, newer develop-
ments in pharmacology have even produced drugs of the same class
which show different dependence characteristics. Examples of
this situation can be found with the mixed agonist/antagonist
opioids. Although it was originally contended that these
opioids would not produce dependence, unfortunately, this has
turned out not to be the case for most drugs of this type. For
example, our view of pentazocine as a non-dependence-inducing
opioid has undergone radical change, and dependence to pent-
azocine is now well known (Jaffe and Martin 1980).
Buprenorphine seems to have little, if any, dependence asso-
ciated with it, as judged by the virtual absence of a withdrawal
syndrome. However, the weak withdrawal syndrome is probably the
result of the stability of the drug-receptor complex and its
slow dissociation, since some abstinence signs can be
demonstrated under certain conditions (Dum et al. 1981).
Amphetamine was at one time considered a nonaddicting substance.
Yet, both physical and psychological signs appear after cessa-
tion of drug administration following chronic use (Jaffe 1980).
Even more controversial is the dependence developed to nicotine.
Recent studies have documented both physical and psychological
withdrawal symptoms on cessation of cigarette smoking (Shiffman
1979). Although additional cases and more details could be
cited, the above examples serve to illustrate how our conception
of dependence has evolved. With each advance in our thinking,
we discover more about the mechanisms involved.
PHARMACOLOGICAL PRINCIPLES
One of the problem encountered in the evaluation of research in
this area is that too often the basic principles of pharmacology
are forgotten or ignored. What happens to a drug after admin-
istration is a critical determinant of its actions and this,
in turn, can influence interpretation of data on tolerance and
dependence. Obviously, the levels of drug in plasma and brain
can be markedly affected by first-pass effects through the liver
and by drug metabolism. Moreover, route of administration can
dramatically alter both free and bound drug levels, as in the
case of morphine (table 2). Peak plasma levels of free morphine
following a dose of 4 mg/kg were approximately three times
higher after subcutaneous (SC) than after intraperitoneal (ip)
injections, and brain levels were about four times higher. With
the 64 mg/kg dose, however, plasma and brain levels of free
morphine rose to a higher level and fell more rapidly after ip
than after sc administration.
The effect of route of administration on the amounts of pharm-
acologically active morphine is shown in table 3. These stud-
ies are discussed in more detail by Cerletti et al. (1980). An
additional factor to consider when dealing with centrally acting
drugs is the blood-brain barrier (BBB). What many investigators
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TABLE 2. Concentration of free morphine in rat plasma and
brain after injection of 4 mg/kg or 64 mg/kg morphine
sulfate sc or ip
Min Post- Plasma
Injection ng/ml ± S.E.M.
SC ip
4 mg/kg
Brain
ng/ml ± S.E.M.
SC ip
5 569±24 189±18* 29±3 12±1*
10 642±36 196±22* 50±5 20±2*
15 712±43 242±30* 64±5 21±2*
30 460±26 123±22* 87±3 17±4*
60 260±25 84±ll 53±11 19±2*
120 64±9 38±8** 35±1 13±3*
180 33±9 34±14 15±2 6±l*
64 mg/kg
15
15
4941±570 7202±819** 394±66 654±117
4823±395 1053±2777 562±43 1249±129*
60 10897±1416 12722±4228 1762±170 1980±374
120 6610±1276 5788±3065 1634±232 990±315
180 2 8 3 1 1849 ± 860 8 1 5 469±42
*p < 0.01 vs. sc; **p < 0.05 vs. sc
fail to take into account, though, is that even when the BBB is
circumvented by intracerebroventricular (icv) administration,
the drug must still leave the ventricular compartment and reach
specific areas of the brain in order to be effective.
Differences in drug distribution to various brain parts probably
contribute to the disparity in qualitative as well as quan-
titative responses often seen with systemic vs. central admin-
istration. For example, differences can be seen on seizure
threshold. Table 4 shows that although morphine and etorphine
are anticonvulsant after both SC and icv administration, pent-
azocine and meperidine are proconvulsant by the SC route but
anticonvulsant by the icv route. Normeperidine is proconvulsant
irrespective of the route of administration. Even sensitivity
to naloxone blockade may be altered by the route used (e.g.,
meperidine). Further details may be found in a paper by
Tortella et al. (1984, in press).
Another example may be seen with body temperature (figure 1).
Although morphine exhibits the well-known dual response after sc
administration, only a dose-related hyperthermia is produced in
rats when morphine is administered icv at an ambient temperature
of 20°C (Adler et al. 1983; Geller et al. 1983). The examples
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TABLE 3. Morphine in rat plasma following injection of 4 or 64
mg/kg morphine sulfate sc or ip. Glucuronide
percentage is calculated as (total- free
morphine) (total morphine)
Min Post- Total Morphine % Morphine
Injection ng/ml ± S.E.M. as Glucuronide
SC ip SC ip
4mg/kg
5 695± 31 283± 37* 18.1 33.2
10 726± 52 400± 51* 11.6 51.0
15 796± 74 748± 253 10.6 67.6
64mg/kg
15 6700± 894 19580±1190* 26.3 63.2
60 1559O±3649 24520±5186 30.1 48.1
*p < 0.01 vs. sc.
Substance and Alcohol Actions/Misuse, 1:65-70, 1980.
© 1980, Pergamon Press, Ltd. Reprinted by permission.
TABLE 4. Effect of route of administration on seizure threshold
changes induced by opioids in rats
Drug Route of Change in Flurothyl Antagonized
Administration Seizure Threshold by Naloxone
Morphine sc
icv
Etorphine sc
icv
Pentazocine sc
icv
Meperidine sc
icv
Normeperidine sc
icv
Yes
Yes
Yes
Yes
No
No
No
Yes
No
No
(Table courtesy of Dr. F.C. Tortella, Walter Reed Army Institute of
Research)
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cited above serve to demonstrate that comparisons of efficacy
and potency between drugs given by different routes are invalid
and can lead to erroneous interpretation of data and false
conclusions.
FIGURE 1 Effect of morphine on body temperature: icv vs sc
administration. Subjects were male Sprague-Dawley
rats.
Another basic pharmacological principle relates to receptor
occupancy. Whether or not a receptor is continuously occupied
by a drug may well determine the development of tolerance and
dependence and the degree to which they occur. A study by
Cochin and Mushlin (1976) showed that tolerance to morphine can
be blocked by the concurrent administration of naloxone.
Further work fran this laboratory has shown that tolerance can
be blocked even if naloxone is administered an hour or more
after morphine. This is illustrated in figure 2. As can be
seen, if a single dose of naloxone (6 mg/kg, SC) is administered
to mice at various periods of time after 15 q/kg morphine
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sulfate, tolerance to morphine is partially blocked when sen-
sitivity to morphine is tested 3 days later. The shorter the
time interval between the first dose of morphine and the admin-
isration of naloxone, the more effective the blockade. It
appears from this and other work by Cochin and his colleagues
that tolerance and cross-tolerance can be attenuated if the
drug-receptor complex is broken even after the agonist effect of
FIGURE 2 Results of hot-plate assay performed in mice 3 days
after initial drug treatment. The ordinate shows the
mean area derived from multiplying the number of min-
utes naloxone is given after morphine by the number of
seconds on the hot plate. (Figure courtesy of Dr. J.
Cochin, Boston University School of Medicine.)
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morphine has occurred. Work in our laboratory demonstrated that
the severity of the morphine abstinence syndrome depends on
whether the drug is administered continuously by pellet or
intermittently via injection (Cerletti et al. 1976). If the
morphine is given so that equivalent levels of drug are measured
in plasma over 72 hours, the pelleted animals display a more
pronounced withdrawal syndrome even though abstinence signs are
qualitatively identical.
SUMMARY
In summary, many of our once generally accepted ideas about
tolerance and dependence have been revised as the result of
neuropharmacological research. Included among these concepts
are the following: (1) Although tolerance and dependence are
usually linked, they appear to be separable phenomena in some
instances. Further exploration into each should be profitable.
(2) Although chronic administration of a drug is usually
required to produce tolerance and dependence, even a single dose
can result in these effects under certain conditions. That fact
may provide us with clues as to the neuroadaptive changes
occurring during the development of tolerance and dependence.
(3) A fruitful line of research emanates from the findings that
tolerance may be pharmacokinetic or neuronal and that time of
receptor occupancy appears to be a vital factor in neuronal
tolerance. (4) It is now known that tolerance does not develop
equally to all actions of a drug and reverse tolerance
(increased responsiveness) can occur. Further studies along
these lines are needed to correct many false assumptions about
this issue and to shed new light on the receptors and
transmitter systems involved. (5) We now accept the notion that
a drug usually exerts effects on more than one receptor type or
subtype. Consequently, the actions of drugs on the various
receptors and the responses to receptor blockade promise to
yield significant new knowledge about the mechanisms involved in
tolerance and dependence to a wide variety of drugs. (6) We
have become increasingly aware of species differences and genet-
ic determinants of responses to drugs of abuse, after both
acute and chronic dosing. Other papers in this volume will
focus on this topic.
Our current state of knowledge about tolerance and dependence
suggests a number of questions whose answers will undoubtedly
lead to a much better understanding of these phenomena. First,
we have learned much about the endogenous opioid peptides and
opiate receptors in the last few years. But what is the role of
these chemicals in tolerance and dependence? Moreover, are they
continuously released and, if so, why doesn't naloxone precipi-
tate an abstinence syndrome when administered to otherwise
untreated subjects? As they appear to be released when opioid
drugs are administered, what role does this release play in the
development of tolerance and dependence to opioids? Second,
since we live in a society where polydrug abuse is the rule and
not the exception among drug abusers, what are the interactions
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among the drugs of abuse? Right now we know very little about
these interactions per se, let alone the mechanisms that may be
involved. Third, is there a commonality of mechanisms for
tolerance and dependence among the drugs of abuse? Although
such hypotheses have been advanced, little scientific support
for these ideas has been forthcoming. Fourth, what are the
correlations between binding data and pharmacological effects?
This is a crucial question, for both acute and chronic admin-
istration of drugs, that must be addressed to a greater degree
than it presently is. Lastly, what are the interactions between
transmitter systems that have been implicated in tolerance and
dependence, both in cases where pharmacological receptors have
been identified (e.g., opioids) and in cases where they have not
(e.g., cocaine, marijuana)?
A little over 10 years ago, Harry Collier, to whose memory
this symposium is dedicated, wrote a paper entitled "A
Pharmacological Analysis of Drug-Dependence" (1972). In it he
stated that the neuropsychological properties of a drug help to
determine its abuse liability. He felt that since drugs produce
dependence, other drugs should be able to reverse or ameliorate
it. He proposed that "we should now try to develop drugs espe-
cially to help combat dependence. To do this effectively and to
make progress in the pharmacotherapy of drug abuse, we need to
know more about the basic mechanisms whereby dependencies arise
and about the interactions of other drugs with these
mechanisms." We have made good progress in elucidating the
mechanisms involved. Nevertheless, much more basic research
must be carried out before we can design specific drugs to
affect specific receptors in specific loci and before we can
develop drugs to correct any underlying deficiencies that may
play a role in drug dependence.
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Various Factors Which Affect the
Rate of Development of Tolerance
and Physical Dependence to
Abused Drugs
William L. Dewey
A recent study by Ternes and his colleagues (1983) showed that
tolerance and physical dependence developed to the chronic
treatment of hydromorphine in rhesus monkeys but not in
cynomolgus monkeys. This report prompted us to reevaluate the
factors which are involved in the differences which have been
reported for the rates of development of tolerance and physical
dependence in various species. It is clear that even in the same
animal tolerance develops to different effects of opiates and
other drugs at different rates. This observation rules out the
possibility of an alteration in drug absorption, metabolism,
excretion, etc., as a basis for the tolerance. There are certain
effects to which tolerance does not develop. For instance, most
reports indicate that although tolerance develops to many of the
effects of the opiates, miosis appears to be resistant to
tolerance development. Apparently, the drug receptors on the
cells of different tissues become less sensitive to the drug at
different rates, whereas pupil changes are always sensitive to
opiates. These observations support the hypothesis generated
from other types of data that many different types of opiate
receptors exist. The number might exceed by far the seven or
eight types reported to date. There is no question that
metabolic tolerance does occur with some drugs. When this is the
only factor involved in the development of tolerance, tolerance
would be expected to develop to all the effects of the drug at
the same rate. It is important to differentiate and quantitate
the contribution of metabolic and pharmacodynamic factors in the
development of tolerance. The discussion that follows will be
devoted to pharmacodynamic tolerance.
Aceto et al. (1977) have shown that the subcutaneous
injection of 3 mg/kg of morphine sulfate every 6 hrs for 30
days to rhesus monkeys did not render them dependent as
measured by the ability of naloxone or nalorphine to induce
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vomiting. Vomiting as a withdrawal sign is an indication of
severe dependence of the morphine type in rhesus monkeys. Some
other less severe signs of dependence were observed following the
30 days of treatment. The ED50 for naloxone required to induce
vomiting was higher following 60 days of morphine treatment than
following 90 days of treatment. These data support the
hypothesis that the level of dependence, like that of tolerance,
increases as the time of treatment is extended. These results
were confirmed further by the observation that nalorphine was
able to induce vomiting in rhesus monkeys only following 90 days
of treatment. These results along with those of Ternes et al.
(1983) make another important point concerning the development of
tolerance and dependence to drugs. That is, the end point
measured should be very carefully stipulated and monitored.
Ternes et al. (1983) reported that in the rhesus monkey
dependence and to some extent tolerance and withdrawal developed
following chronic treatment with hydromorphine. This was not
observed following more frequent and longer treatment with
morphine in rhesus monkeys (Aceto et al. 1977).
For a number of years, we have been investigating the effects of
chronic opiate treatment of rats using the ip infusion technique
of Teiger (1974). Animals are infused constantly, 24 hrs a day,
with the test drug. The animals are freely moving, with access
to food and water ad libitum. One of the advantages of this
procedure is that after the end of the morphine infusion,
spontaneous withdrawal symptoms are observed. These symptoms are
characterized by a pronounced loss in body weight of 20% or more
within 24 hrs after the infusion of the opiate. Other signs of
the opiate withdrawal previously described, including
hyperexcitability, irritability, chewing, scratching, wet dog
shakes and diarrhea, are quantitated at various times throughout
the first 96 hrs of withdrawal. We have utilized this technique
to study the importance of a number of variables on the
development of tolerance and physical dependence in the rat. We
first studied the alteration of the duration of morphine infusion
to determine the time required to induce physical dependence in
rats. We compared the infusion schedules, as shown, in the table
below:
TABLE 1
Study Dose of Morphine Infused (mg/kg/day)
1 200 for one day (on day 1)
2 100 on day 1
200 on day 2
3 50 on day 1
100 on day 2
200 on day 3
4 50 on day 1
100 on day 2
200 on day 3, 4, 5 and 6
40
PERCENT LOSS IN BODY WEIGHT
FOLLOWING ONE DAY MORPHINE
INFUSION
FIGURE 1. Loss in Body Weight Following Schedule 1
PERCENT LOSS IN BODY WEIGHT
FOLLOWING TWO DAY MORPHINE
INFUSION
FIGURE 2. Loss in Body Weight Following Schedule 2
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PERCENT LOSS IN BODY WEIGHT
FOLLOWING THREE DAY MORPHINE
INFUSION
FIGURE 3. Loss in Body Weight Following the 3-Day Schedule
There was no loss in body weight after 1 day of infusion (figure
l), whereas weight loss did occur as early as 6 hrs after 2 days
of infusion (figure 2); an even greater loss in body weight was
seen when the animals were infused on the 3-day schedule (figure
3). The 6-day infusion schedule presented in table 1 is used to
produce the greatest level of physical dependence to morphine
(figure 4).
As can be seen to the left of the dotted vertical line, the rats
in each group either maintained their body weight or gained
slightly during the last 2 days of the infusion period. The data
from the right of the vertical line indicates that rats infused
with morphine for 6 days and then given saline lost more than 20%
of their body weight during the first 24 hrs after infusion.
This was a greater weight loss than was presented in figure 3 for
rats which had been infused with morphine on the 3-day schedule.
This decrease in body weight persisted throughout the 96-hr
observation period. Signs, such as a loss in body weight, were
most pronounced 24 hrs after opiate infusion.
In similar studies measuring a longer period of withdrawal,
following the end of chronic morphine infusion, rats do gain
weight, but not to the degree of controls up to 20 days after
withdrawal. The results of the 6-day experiment indicated
infusion of saline or naloxone did not induce reduction in body
weight following the end of the infusion period. Also, the
exposure to naloxone with morphine completely blocks the loss in
body weight and other signs of opiate withdrawal in these rats.
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FIGURE 4. Loss in body weight following schedule 4. Placebo or
naloxone (75 mg) pellets were implanted immediately prior to the
start of the infusion. The end of the 6-day infusion period is
represented by the dotted vertical line indicated on the abscissa
as 0 hrs. All percent changes in body weight are calculated
based on the body weight of each rat at the end of the infusion.
In general, the rate of appearance of the other signs of
withdrawal correlate with the decrease in body weight.
It is our hypothesis that the constant infusion of naloxone
competitively inhibited access of the morphine to the opiate
receptors, thus blocking the initial step required for the
development of physical dependence, Naloxone has a shorter
duration of action than morphine and must be given in a fashion
similar to this in order to maintain proper levels at the opiate
receptors. This portion of the experiment also shows that
tolerance did not develop to the antagonistic effect of the
narcotic antagonist. These observations and hypotheses have
interesting implications. We are proposing that morphine causes
physical dependence and tolerance (see below) during constant
infusion by constantly or at least repeatedly interacting with
opiate receptors. When naloxone is infused simultaneously with
morphine, it too has an effect at the opiate receptors. That is,
it blocks the ability of morphine to induce physical dependence.
Tolerance does not develop to naloxone but does develop to the
constant exposure of another drug, morphine. Does this mean that
tolerance at the receptor level is specific for different drugs?
These data, like considerable data generated from binding assays
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and other in vitro experiments, are explained by the purported
lack of efficacy of naloxone at the opiate receptor.
Patrick et al. (1978) reported that during the induction of
tolerance and physical dependence on morphine using the 6-day
infusion procedure described in table 1, antinociceptive activity
correlated quite well with brain levels of morphine. The
antinociceptive activity, as well as the level of morphine in
brain following the 6-day infusion (that is, the 4th day of the
200 mg/kg/day dose) was significantly less than after the first
day of infusion of the 200 mg/kg/day dose of morphine. These
authors also reported that the brain level of morphine fell
precipitously after the end of its ip infusion. Yet tolerance to
subsequent injections of morphine remained for many hours beyond
the time they could measure levels of morphine in whole brain.
It was apparent from these results that the duration of the
phenomenon of tolerance far exceeded the presence of morphine in
the brain. Two possibilities exist to explain these results.
Either the analytical technique used in these experiments was not
sensitive enough to measure the low levels of morphine in the
brain at the end of the infusion, or morphine is not required in
the brain to manifest tolerance.
In other experiments using mice, the brain level of morphine
correlated closely with the antinociceptive activity as measured
by the tail-flick test after the implantation of a 75 mg morphine
pellet (Patrick et al. 1975; Way et al. 1969). Again, the
antinociceptive activity somewhat paralleled the brain level of
morphine as described in the rat experiments above; the peak
analgesic activity preceded peak brain levels in mice. When the
pellet was removed 72 hrs after implantation, the level of
morphine fell dramatically in mice as it did at the end of the
ip infusion of morphine in rats. Again, tolerance to an
injection of morphine lasted well beyond the time we could
measure levels of morphine in mouse brain. Taken together, the
data generated suggest that there is a temporal component to
tolerance development in animals and that once tolerance has
formed the duration of the phenomenon outlasts detectable levels
of morphine in brain.
In a further attempt to investigate the characteristics of the
temporal phenomena involved with tolerance development, we
injected a dose of 160 mg/kg of morphine or saline in many groups
of mice and determined the ED50 values for subsequent injections
of morphine in the mouse tail-flick test at 16, 24, 48 hrs and at
4 and 8 days after the initial injection. Morphine injected in
the saline-treated mice served as controls for the animals that
were pretreated with 160 mg/kg morphine. The ED50 values for
these groups were not significantly different at any time,
showing that tolerance did not develop in these experiments.
It can be inferred from these data that the pharmacokinetics of
opiates are such that one injection of a very high dose does not
induce tolerance. However, when we injected mice with 10 mg/kg
of morphine every 12 hrs for 10 days and then determined an ED50
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TABLE 2
Activity in the Mouse Tail-Flick Test
Injection schedule of
10 mg/kg morphine S.C.
1 injection
Percent analgesia
Group 1 - 83%
Group 2 - 83%
every 12 hrs for 10 days Group 1 - 10%
Group 2 - 10%
every 12 hrs for 10 days
(each given 10 mg/kg morphine, S.C.
10 min after 1 mg/kg naloxone, s.c.)
Group 1 - 59%
Group 2 - 56%
value for morphine in the tail-flick test, we found pronounced
tolerance to the antinociceptive action of morphine in mice.
These data are presented in table 2. The results obtained in
these mouse experiments were similar to those in the rat infusion
experiments, in that pretreatment with naloxone blocked the
development of tolerance to the chronic effects of morphine.
Thus, a total dose of 200 mg/kg morphine injected at regular
intervals over a 10-day period induced tolerance, whereas an
acute dose of 160 mg/kg did not. These data suggest the
necessity for a temporal relationship for the development of
tolerance to the antinociceptive effect of morphine in mice. It
is important to point out that these data do not indicate the
best temporal rate of injection of morphine to produce tolerance
to the antinociceptive activity of morphine in other species nor
do they tell us anything about the frequency of injection of
morphine to demonstrate the development of tolerance to any
effect of morphine in mice other than antinociception. Clearly,
tolerance develops to the same effect in various species at
different rates and also develops at different rates to different
effects in the same species.
In the next series of experiments, we compared the development of
tolerance and dependence to two other narcotic analgesics, methadone
and 1 acetylmethadol (LAAM). The antinociceptive potencies of
these drugs in mice and rats are presented in table 3.
TABLE 3
The Potency of Methadone and LAAM in Tail-Flick Test
Species
Mouse 10.8 (6.3-18.5)
ED50 in mg/kg
Methadone LAAM
10.8 (5.0-23.6)
Rat 14 2
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As can be seen in this table, methadone is equally potent to LAAM
in mice but 1/7 as potent as LAAM in rats. Rats were injected
chronically with oral doses of LAAM and methadone according to
the dosage schedule presented in table 4.
TABLE 4
Oral Dosage Schedule for Methadone and LAAM in Rats
Methadone (every 0-12 hrs or 2 times/day)
Days
1 - 3
4 - 7
8 - 12
LAAM (every 0-24 hrs or once daily)
Days
1 -3
4 - 7
8 - 12
Dose (mg/kg)
14
28
56
Dose (mg/kg)
2
4
8
Considerable tolerance developed to the antinociceptive activity
of LAAM, whereas tolerance did not develop to the same effect of
methadone following the injection schedule presented in table 4.
Methadone was given twice a day, whereas LAAM was injected only
once a day. Tolerance developed to LAAM much more rapidly than
to methadone. We next investigated the characteristics of the
temporal phenomena involved in the ability of these two agents to
produce physical dependence, using the oral administration
schedule in table 5.
TABLE 5
Oral Dosage Schedule for Mouse Jumping Test (mg/kg)
Day Methadone* LAAM
1 20 2
2 40 4
3 80 4
4 160 8
*Methadone was administered at these doses twice a day and
LAAM was administered once a day.
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The dose of naloxone required to produce jumping in 50% of the
mice was used as an index of physical dependence. The lower the
dose of naloxone required to induce jumping, the greater the
level of physical dependence. The results of these experiments
are presented in table 6.
TABLE 6
Naloxone ED50 (s.c.) in the Mouse Jumping Test
Methadone LAAM
74.5 mg/kg
(58.9-94.2)
0.47 mg/kg
(0-16-1.36)
(Potency Ratio = 158)
Methadone-treated mice appeared normal, LAAM-treated mice lost
weight and some died.
Physical dependence was more pronounced with LAAM than with
methadone in these experiments. There appears to be a
correlation between the temporal aspects of the development of
tolerance and the development of physical dependence for these
two substances. An explanation for this similarity becomes quite
apparent when one looks at the data obtained on the duration of
antinociceptive action of methadone and LAAM in mice and rats.
Rats treated orally with 6 mg/kg LAAM showed significant
analgesic activity up to 14 hrs after medication. The duration
of antinociceptive action of 16 mg/kg methadone given orally was
less than 2 hrs. These experiments were repeated in mice.
Methadone at a oral dose of 25 mg/kg produced significant
analgesia, but its duration of action was less than 2 hrs. The
duration of action of LAAM exceeded 12 hrs. These data suggest a
similar mechanism is involved in both species, and it seems
reasonable to suggest that this is so. In order to induce
tolerance, methadone must be in contact with brain receptors for
a longer period of time than is possible with this treatment
schedule. Equianalgesic injections of LAAM given half as
frequently as the injections of methadone are sufficient to
develop tolerance and physical dependence.
Since tolerance and dependence can develop to a particular effect
at different rates with two drugs in the same class, it is not
surprising that they can develop at different rates for a number
of drugs of abuse from different classes. We have previously
reported (Dewey et al. 1972, McMillan et al. 1971, 1972) several
characteristics of tolerance to THC. Tolerance is pronounced,
develops rapidly, and lasts for many days after the drug is
withdrawn. It is also important to note that withdrawal symptoms
do not develop following the cessation of chronic treatment with
cannabinoids in many species. Tolerance develops to the
cannabinoids even if the injections are given at infrequent
intervals. Tolerance develops to most of the effects of
cannabinoids that have been studied, and cross-tolerance among a
number of cannabinoids has been reported.
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The major portion of this article has been devoted to the
characteristics of tolerance and physical dependence that occur
with opiates. Also mentioned are some of the most important
aspects of tolerance and dependence to the cannabinoids. The most
important point is that tolerance and dependence develop to
different effects of drugs at different rates. Tolerance and
dependence are not interchangeable. The terms tolerance and/or
dependence should only be used to describe the state of an animal
when both characteristics have been quantitated in that animal.
An animal may be tolerant to a specific effect of an opiate and
not be physically dependent. Conversely, an animal may be
physically dependent and not be tolerant to a specific effect of
the drug. This is even more obvious for non-opiate drugs.
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Genetic Determinants of Re-
sponses to Drugs of Abuse: An
Evaluation of Research Strategies
Louis Shuster
The use of certain genetically defined animal models can be very
helpful in studies of drugs of abuse. The choice of model will be
influenced by the aims of the study. This overview is intended to
indicate the kind of information that can be obtained and some of
the strategies that can be employed.
GOALS OF GENETIC ANALYSIS
1. To explain individual variations in response. About 25% of
post-operative patients do not experience appreciable pain relief
when injected with a standard dose of morphine sulfate. Another
35% obtain substantial relief from a placebo injection of saline
(Lasagna and Beecher 1954). Sorting out the relative contribu-
tions of environment and heredity to such variability is very dif-
ficult to accomplish with human subjects. However, it is now
widely appreciated that genetic determinants can affect the re-
sponses of animals to psychopharmacologic agents in many ways,
ranging from altered metabolic inactivation to variations in popu-
lation of neurons and neuronal receptors. Differences between
inbred strains when all are raised and tested in the same environ-
ment are assumed to indicate the contribution of a genetic compon-
ent. For example, Brase et al. (1977) measured five different
responses to morphine in six inbred strains of mice and found
variations of as much as 12-fold in some of them, such as the
ED50 of naloxone for precipitated abstinence. The heritability or
relative genetic contribution to a drug response can be calculated
by testing the offspring of a few crosses and comparing them to
the parents (Falconer 1960).
There are still some workers who continue to document drug re-
sponses obtained with "rats" or "white mice" or "laboratory mice."
A larger number persist in using random-bred (outbred) populations
which may exhibit wide ranges of response. Such animals, e.g.
Swiss-Webster, may give results which vary with the supplier (Way
et al. 1969), and compound the difficulty of reproducing values
obtained in other laboratories. In general, however, it is widely
appreciated that responses to ethanol, morphine or cocaine can
vary with the genetic background of the test animal. Establishing
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this fact should no longer by itself be a major goal of pharmaco-
genetic investigations.
2. To separate different components of the response to a given
drug. By using different inbred strains of mice it can be shown
that motor stimulation by morphine can be dissociated from the
analgesic response (Castellano and Oliverio 1975). One can also
separate some manifestations of physical dependence, such as nal-
oxone-induced withdrawal jumping, from the development of toler-
ance (Brase et al. 1977).
Comparison of different rat strains has revealed similarities be-
tween some actions of morphine and ethanol on the central nervous
system which are not shared by barbiturates (Mayer et al. 1983).
Genetic evidence has also 'been advanced from correlations between
the number of D2 dopamine receptors in the brain and several drug
responses (Helmeste et al. 1981).
3. To develop models that differ quantitatively in a given drug
example, strain F344 rats and Buffalo rats differ in responses to
response. These models may be two or more inbred strains. For
dopaminergic drugs (Helmeste 1983); low doses of ethanol stimulate
the motor activity of BALB/c and DBA mice, but not C57B1/6 mice
(Kiianmaa and Tabakoff 1983); morphine stimulates the motor acti-
vity of C57B1/6 mice but not DBA mice (Oliverio and Castellano
1974).
An alternative approach is to breed selectively high-responding
and low-responding lines from a heterozygous foundation stock--for
example, mice that sleep for a longer or a shorter time after a
given dose of ethanol (McClearn and Anderson 1979).
4. To establish neurochemical mechanisms of drug action. A common
aim is to develop meaninqful correlations between a drug response
and variables such as the amount or turnover of a neurohormone or
the number of receptors. For example, F344 rats, which exhibit
greater spontaneous locomotor activity and more inhibition of
locomotion by apomorphine than Buffalo rats, also have greater
numbers of D2-dopamine receptors in the striatum and olfactory
tubercle (Helmeste 1983). There are also striking differences
between these strains in the epinephrine content, rate of epine-
phrine synthesis, and number of alpha adrenergic receptors in
certain brain regions (Perry et al. 1983).
5. To identify the genetic determinants of particular responses.
Does a single gene control narcotic analgesia, or are there multi-
ple genes? Are they dominant, recessive, autosomal? Which
chromosomes and which particular loci are involved? Do the same
genes modulate the responses to several different classes of
drugs? Can useful linkage be established between certain drug
responses and pleotropic markers such as coat color? For in-
stance, there is a report that the albino locus in mice is as-
sociated with decreased responsiveness to morphine (Katz 1980).
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STRATEGIES
Several useful strategies are now available to investigators who
are interested in the goals described here.
1. Selective breeding. A defined drug response, such as anal-
gesia, sleep time, motor activity, etc. is chosen, and a program
is developed to produce strains characterized by the two extremes
of this response. The foundation stock should exhibit consider-
able genetic variability. McClearn started by intercrossing eight
purebred strains of mice. Selective breeding of high-responding
and low-responding individuals has continued for over 25 genera-
tions. This selection has produced a long sleep (LS) line of
mice, which sleep several hours, and a short sleep (SS) line of
mice, which sleep several minutes, in response to a test dose of
ethanol (McClearn and Anderson 1979).
Ideally, up to several hundred animals should be started in such a
selection program in order to avoid premature inbreeding, and the
entire process, including maintenance of a control line, should be
replicated. A recent example of properly executed selective
breeding is that carried out by Crabbe et al. (1983a) for the
severity of withdrawal from ethanol.
The difference between LS and SS lines of mice seems to reflect a
difference in the sensitivity of the central nervous system rather
than a difference in ethanol metabolism (Heston et al. 1974).
Cerebellar Purkinje cells from LS mice are 10-20 times more
sensitive to depression by ethanol than those from SS mice
(Sorennsen et al. 1980). The latter's cells also develop toler-
ance to ethanol much more readily. The fluidizing effect of etha-
nol on synaptic membranes from LS mice is more pronounced than on
those from SS mice (Goldstein et al. 1982).
The main advantage of selective breeding is that it provides ani-
mals which were chosen specifically because of an inherited dif-
ference in a particular drug response. All other strategies yield
animals which were found to differ in a drug response only after
they had been selected or bred for other qualities such as coat
color or susceptibility to tumor growth. However, this method
also has some serious disadvantages. Selective breeding is cum-
bersome, expensive and slow. Repeating or comparing experiments
is almost impossible until homozygosity has been achieved--a mat-
ter of 40 generations or about 15 years.
Selective breeding for only a few generations in order to reveal
that a given drug response has a genetic component is usually not
worth the effort. For example, showing that mice could be selec-
tively bred on the basis of their running response to levorphanol
(Judson and Goldstein 1978) did not reveal any more than had
already been established by comparing inbred lines (Oliverio and
Castellano 1974). Correlations which develop during the first few
generations of selection can be misleading. When Wimer and Wimer
(1982) bred mice for high and low brain weight, the initial
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parallelism between brain weight and ability to achieve certain
learning tasks disappeared by generation 14.
2. The Use of Inbred Strains. A large number of inbred (purebred)
strains of mice are now available commercially. They are essenti-
ally homozygous, being derived from over 40 generations of
brother-sister matings (Heiniger and Dorey 1980). The choice of
which strains to compare can be based on a genetic similarity
matrix (Taylor 1972). As can be seen from figure 1, C57 Black
mice and related strains differ in a large number of loci from
BALB/c, A/J and DBA/2 mice. Furthermore, there are already
numerous examples in the literature of drug-related differences
between C57 and the other three strains.
Selections can also be made on the basis of neurochemical differ-
ences. For example, C57B1/6 mice have more choline acetyltrans-
ferase and tyrosine hydroxylase, but less glutamate decarboxylase,
in certain brain regions than A/J mice (Waller et al. 1983). They
also have fewer dopamine receptors in the corpus striatum and
olfactory tubercle (Boehme and Ciaranello 1981). Crabbe et al.
(1981) found that C57B1/6 mice have twice as much beta endorphin
in their pituitaries as BALB/c or DBA/2 mice. The striatum of
CBA/J mice is 20% smaller than that of BALB/cJ mice. There is a
corresponding difference in the activities of striatal tyrosine
hydroxylase and choline acetyltransferase (Baker et al. 1980).
BALB/cJ mice have half as many benzodiazepine receptors in the
brain as C57B1/6J mice (Robertson 1979). A compilation of neuro-
chemical values for different mouse strains has been published by
Ingram and Corfman (1980).
Extensive comparisons of the pharmacologic and biochemical re-
sponses of C57B1/6, BALB/C, and DBA/2 mice to morphine has been
carried out by Castellano, Oliverio and their colleagues. Mor-
phine produces analgesia in both strains, but increases the loco-
motor activity of only the C57B1/6 mice (Castellano and Oliverio
1975). Diallel analysis of crosses and backcrosses suggests that
the C57 trait is dominant (figure 2). Morphine increases the re-
lease of dopamine from the striatum and limbic forebrain in C57
mice but not in DBA mice (Racagni et al. 1979).
Reggiani et al. (1980) found that C57 mice have more receptors in
the striatum for enkephalins than DBA mice. On the other hand,
contraction of the vas deferens of DBA mice is more readily inhi-
bited by normorphine than that of C57Bl mice (Szerb and Vohra
1979). Another interesting difference between these two strains
is that it takes much less naloxone to produce withdrawal jumping
in DBA mice than in C57 mice (Brase et al. 1977).
An additional response to morphine that displays interesting
strain differences is sensitization, or reverse tolerance to motor
stimulation. C57Bl/6J mice are sensitized more than A/J mice, and
the F1 hybrid gives an intermediate response (Shuster et al.
1975a) (figure 3).
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FIGURE 1. Positions of 27 inbred mouse strains in a 2-dimensional genetic
similarity matrix. Reproduced, by permission, from Taylor 1972. Copyright 1972,
by the American Genetic Association.
FIGURE 2. Genetic triangles depicting the observed and expected
population means for the running activity, in response to mor-
phine, of BALB/cJ, C57B1/6J, and DBA/2J mice and their crosses.
The corner points of the triangle represent the mean values for
the parental lines. The expected mean for the F1 generation (M)
is halfway between the parental values. The expected means for
backcrosses of F1 to each parent (B1 and B2) are halfway between
the parental and F1 values. Observed values are indicated by
filled circles, with arrows pointing to the expected values. B
and C and D refer to BALB/cJ, C57B1/6J and DBA/2J respectively.
Reproduced, by permission, from Castellano and Oliverio (1975).
Copyright 1975, Springer Verlag New York, Inc.
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FIGURE 3. Changes in the running response of C57B1/6J, A/J, and
the B6AFl/J hybrid male mice to repeated weekly i.p. injections of
morphine sulfate, 25 mg/kg. Each point represents 10 mice ± SEM.
Reproduced, by permission, from Shuster, Webster, and Yu (1975).
Copyright 1975, American Society for Pharmacology and Experimental
Therapeutics.
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Crabbe et al. (1983b) have examined several responses to ethanol
in 19 different inbred strains of mice. They found that the
severity of withdrawal was inversely correlated to the initial
sensitivity and the degree of tolerance to ethanol hypothermia.
C57B1/6 mice are less sensitive to the activating and hypnotic
effects of ethanol than BALB/c or DBA/2 mice. (Kiianmaa and
Tabakoff 1983). Low doses of ethanol release less dopamine from
the striatum of C57B1/6 mice than from the striatum of the other
two strains (ibid).
It is unlikely that the kinds of differences and correlations de-
scribed here can lead to the identification of the genetic deter-
minants of the responses to morphine or ethanol. The inbred
strains that are compared in these studies may differ in hundreds
or thousands of genes. However, they can suggest which neuro-
chemical mechanisms are worth pursuing. They also provide readily
available animal models which can yield consistent, reproducible
results in different laboratories.
3. Recombinant-Inbred and Congenic Lines. Even elementary genetic
analysis of differences in drug responses between inbred lines
requires time-consuming crossing and backcrossing. The purpose of
these crosses is to shift around the genetic determinants in order
to establish which ones might be associated with the drug re-
sponse. Bailey (1971) has developed a method for randomizing and
fixing the genes from two inbred lines in a replicable, homozygous
form. A battery of recombinant-inbred (RI) lines is derived by
repeated sib matings for 40 generations or more from the F2 gene-
ration of the original cross. Because the distribution of histo-
compatibility loci among the lines has been defined by skin-graft-
ing, it is possible to ascribe linkage of drug responses to these
loci on the basis of a pattern of similarity to one or other of
the progenitor strains. Every time a different drug is tested,
the drug response itself becomes a new linkage marker for a given
chromosome region.
As the number of markers increases, so does the probability of
linking new characteristics. The seven RI lines derived from
C57B1/6 and BALB/c have been typed for about 80 loci, so that the
probability of detecting linkage with these lines is 0.37. For
the 24 RI lines derived from C57B1/6 and DBA/2. the identification
of 80 markers would bring this probability to about 0.7 (Taylor
1978).
The availability of a test battery of congenic lines enhances the
usefulness of the RI lines (Bailey, 1975). Repeated backcrossing
from the F1 generation to one progenitor strain (A) produces ani-
mals in which only a small portion of the genome is derived from
the other progenitor (B). This portion can be identified by his-
tocompatibility testing. If the histocompatibility follows the
same distribution pattern across the R1 lines (e.g. AABABBA) as a
drug response, then one can identify the genetic locus which
governs that response.
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RI analysis is most useful when a large difference in response
mexists between the two progenitor strains, and this difference is
controlled by a single gene. If more than one gene is involved,
then the phenotype of some RI lines may be unlike that of either
progenitor. This situation seems to describe running and analge-
sia in response to morphine (Shuster et al. 1975b; Oliverio et al.
1975). Furthermore, the strain distribution pattern for analgesia
was different with the hot-plate assay than with the tail-flick
assay (Shuster 1975).
Other responses that have been examined in RI mice include the
development of narcotic tolerance (Oliverio and Castellano 1974),
acute naloxone-induced withdrawal jumping (figure 4) and the motor
response to d-amphetamine (Oliverio et al. 1973). There are in-
teresting differences in the elimination of d-amphetamine (figure
5). We have observed marked differences in cocaine-induced liver
damage (table 1). The strain distribution pattern varies with sex
as well as with the inducer which serves to stimulate the conver-
sion of cocaine to a hepatotoxic metabolite. At least part of the
FIGURE 4. Naloxone-precipitated jumping in morphine-treated
recombinant-inbred mice. Twelve mice of each RI line were
injected daily for 5 days with 12.5 mg/kg morphine sulfate i.p.
On the first day and on the fifth day they were injected 2 hours
later with naloxone-HCl. 10 mg/kg i.p. The number of jumps was
counted during the first 9 minutes after naloxone injection. Each
bar represents the mean value for 12 mice. Stippled bars - first
day; solid bars - fifth day. B,C,BF1 and CF1 represent pro-
genitors C57B1/6By, BALB/cBy and the 2 reciprocal hybrids,
respectively.
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FIGURE 5. Rate of disappearance of tritium-labeled d-amphetamine
from the blood of RI mice. Mice were injected i.p. with 5 mg/kg
of generally labeled tritiated d-amphetamine sulfate (10 micro-
curies per mouse). At 15-minute intervals during the following 2
hours each mouse was warmed under an infrared lamp for 1 minute,
and 25 microliters of blood was collected from the tail into a
heparinized micropipette. The blood was transferred to 1 ml of 1
M K2HPO4 in a scintillation vial. Fifteen ml of toluene-based
scintillation fluid was added and the labeled amphetamine was ex-
tracted into the scintillation fluid for counting. The rate of
disappearance of d-amphetamine from the blood between 15 and 120
minutes after injection followed first order kinetics. Each point
represents the mean value for from 4 to 6 mice. The groups
separated by vertical lines showed a statistically significant
difference in half-time.
TABLE 1
HEPATOTOXICITY OF COCAINE IN R.I. MICE
STRAIN SGOT, K.U./ML X l03
Pine-Induced Phenobarbital-Induced
Male Male Female
BALB/cBy 0.2 ± 0.02 0.1 ± 0.03 4.6 ± 1.6
C57B1/6By 16.8 ± 9.8* 10.9 ± 1.4* 24.0 ± 1.7*
CXB D 8.2 ± 06
3.5 ± 1.7
2 2 ± 0.4 8.1 ± 11
E
G 28.7 ± 13.0*
12.0 ± 3.9* 9.l ± 1.6
3.6 ± 1.0 16.1 ± 0.8*
H 31.1 ± 6.6* 7.2 ± 1.4* 19.0 ± 1.1*
I 23.3 ± 10.6* 8.8 ± 3.9* 12.4 ± 1.9*
J 2.6 ± 1.6 7.2 ± 1.3 2.7 ± 0.7
K 3.0 ± 1.6 3.3 ± 1.0 12.6 ± 2.4*
Microsomal enzymes were induced by exposing the mice to pine bed-
ding for at least 7 days, or by giving phenobarbital in drinking
water (0.8 g/l). The mice were injected with 50 mg/kg cocaine HCl
i.p. and bled from the tail after 18 hrs. Each value is the mean
± S.E. for a group of 5 mice (on pine) or from 5-19 mice (pheno-
barbital induced).
*Significantly different from BALB/c progenitor, p < .05
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difference between the progenitor strains can be attributed to
differences in some of the metabolic steps involved (Thompson et
al. 1984).
RI analysis has turned up some interesting differences in narcotic
receptors. One of the Bailey lines, CXBK, has a decreased number
of naloxone binding sites in the brain associated with a decreased
analgesic response to morphine (Baran et al. 1975), to acupuncture
(Pomeranz 1978). D-amino acids (Cheng and Pomeranz 1979) and to
stress (Miczek et al. 1982). The binding of several ligands at a
single concentration to brain membranes from the same Rl lines was
examined by Reith et al. (1981). The lowest binding of naloxone,
dihydromorphine and ethyl ketocyclazocine was obtained with CXBK
membranes, and the highest with progenitor BALB/cBy. There were
no significant genetic differences in the binding of D-ala2-D-
leu5-enkephalin, which was assumed to be specific for delta
receptors.
Where a drug response shows a clear-cut difference between two
progenitor strains, it should be possible to define a chromosomal
locus by surveying all of the existing congenic lines. If these
lines each contain only a small chromosomal segment from progeni-
tor A, most of them will respond like strain B. The exception,
which responds like strain A, can be defined as having a genetic
determinant for the drug response located in a known fragment of a
single chromosome. However, sufficient numbers of congenic mice
for testing are not readily available. Furthermore, there is
still a 50% chance that the chromosome segment which has been iso-
lated in any given congenic line may contain more than one histo-
compatibility locus (Johnson 1981).
4. Defined Mutants. The use of defined point mutations avoids any
uncertainties which may be encountered with congenic lines. A
large number of such mutants are available on a C57B1/6J back-
ground (Heiniger and Dorey 1980; Green 1981). A survey of some of
these mutants has revealed at least three which differ in one or
more responses to morphine from the progenitor strain. The mutant
Pallid shows more running activity and hypothermia (Katz and Doyle
1980). We have found that mutants Sepia and Gunmetal display more
analgesia and running activity (figures 6 and 7). There was much
less naloxone-precipitated withdrawal jumping of Gunmetal (Gm)
mice than either C5781/6J or Sepia (figure 8). A comparison of
heterozygotes and homozygotes revealed dominance in some cases.
Other mutants which we tested resembled C57B1/6J. These included
Brown, Pearl, Viable Dominant Spotting, Black and Tan 33J, Ragged
and Ruby Eye (Heiniger and Dorey 1980).
It is intriguing that the mutations which affect the responses to
morphine do not seem to be directly related. The respective chro-
mosomes bearing the mutations Pallid, Gunmetal and Sepia, are 2,
14 and 1 (Heiniger and Dorey 1980). These mutations are assumed
to be pleiotropic, because they have been identified by a change
in coat color, or some other characteristic unrelated to drug re-
sponses. The Pallid mutant is known to have a defect in manganese
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FIGURE 6. Analgesic response to morphine sulfate of C57BL/6J mice
and homozygous and heterozygous single gene mutant mice. Sepia/+
and Gm/+ refer to heterozygotes. Bars indicate mean ± SEM change
in tailflick latency 30 min after injection of morphine. The cut-
off was 8.0 sec. The number (n) of mice in each group is indi-
cated in parentheses below the bars. A star indicates significant
difference from C5781/6J, p<.05.
metabolism (Erway et al. 1970). Mutants which exhibit defective
development of the central nervous system may display multiple
abnormalities (Nussbaum et al. 1969). This situation makes it
difficult to interpret the decreased responsiveness of Jimpy mice
to morphine as proof that cerebroside sulfate is an important con-
stituent of narcotic receptors (Law et al. 1978).
5. Sublines of Inbred Strains. The maintenance of separate
colonies in different laboratories has given rise to sublines that
differ in a small number of genes from the original breeding
stock. These differences can be attributed either to new muta-
tions or to residual heterozygosity. According to Bailey (1978)
sublines that have been maintained for 50 generations (20 years)
after branching should have only 14 gene differences due to new
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FIGURE 7. Running response to morphine sulfate of C57B1/6J mice
and homozygous and heterozygous single gene mutants. Bars indi-
cate mean number of photocell interruptions accumulated during a
2-hour test session following the injection of morphine. Each
mouse was tested individually. Mice were allowed to habituate to
the test cage for 1 hour prior to the injection of morphine. The
number of mice in each group is indicated in parentheses. A star
indicates significant difference from C57B1/6J, p<.05.
mutations. Because the original lines have been inbred for 40
generations or more, the extent of residual heterozygosity is also
very low--for example, 14 gene differences after 30 generations.
We have encountered clear-cut differences in drug response between
the Bailey (By) subline of C57B1/6 mice and the original Jackson
(J) line. The By mice were separated from the J line after the
latter had undergone 75 generations of inbreeding. The lines have
been separate for 62 generations and differ in less than 50 gene
pairs (Bailey 1978). In an animal possessing 30,000 structural
genes (Green 1981), it is extremely unlikely that as much as 1% of
these would be associated with one particular trait such as the
analgesic response to morphine. Hence, any difference between
the two sublines with respect to this trait can reasonably be at-
tributed to a single gene difference.
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FIGURE 8. Naloxone-precipitated acute withdrawal jumping in
C57B1/6J mice and homozygous and heterozygous single gene C57B1/6J
mutant mice. Sepia/+ and Gm/+ refer to heterozygotes. Bars re-
flect mean ± SEM number of jumps per mouse observed during a
10-min period after the injection of naloxone. Naloxone was in-
jected 2 hrs after an injection of morphine sulfate, 12.5 mg/kg
i.p. A star indicates significant difference from C57B1/6J,
p<.05; two stars, p<.01. The number of mice in each group is
indicated in parentheses.
The By subline shows a greater analgesic response to morphine than
J mice (Shuster 1982). Analysis of dose-response curves by the
method of Litchfield and Wilcoxon (1949) gave ED50 values of 2.5
mg/kg morphine sulfate for By and 8.0 mg/kg for J mice. The By
mice also showed more analgesia by the hot plate assay. Experi-
ments with tritiated morphine showed no difference between the two
lines in the rate of elimination of morphine from the blood.
Whole brain homogenates from the two sublines were used to measure
the specific binding of several ligands. Scatchard analysis re-
vealed that brain membranes from each subline had the same number
of low affinity receptors for dihydromorphine, but a marked dif-
ference in the number of high affinity receptors (22.5 ± 3 vs.
12.0 ± 2 fmoles/mg protein for By vs J, p=.0l). There was no dif-
ference in KD (about 0.6 nM). When other tritiated ligands were
used, both sublines had similar Bmax's and KD's for D-ala
2-met-
enkephalinamide, ethyl ketocyclazocine and naloxone (Cremins and
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Shuster 1982). The Bmax for dihydromorphine binding to brain
homogenates from F1 mice was not significantly different from that
of the By parent, and the analgesic response was also inherited as
dominant trait (Shuster and Cremins, in preparation).
These findings suggest that there is a single gene difference be-
tween By and J mice which controls both the analgesic response to
morphine and the number of high affinity mu receptors in the
brain. The situation in other parts of the body may be different.
Our preliminary experiments indicate that the By subline may actu-
ally have fewer mu receptors in the spinal cord than J mice.
We also examined the running response of By and J mice to mor-
phine, and found that J mice showed a greater response (Shuster
1982). The narcotic receptors which mediate the running response
appear to be different from the mu receptors which are believed to
mediate analgesia. An indication of the nature of these receptors
comes from the work of Reggiani et al. (1980). They compared the
binding of several ligands in different brain regions from C57/Bl
(high running response to morphine) and DBA/2 mice (no running re-
sponse). They found a greater number of binding sites for triti-
ated D-ala2-met-enkephalin and leu-enkephalin in the striatum of
C57 mice, with no difference in affinity. The binding of dihydro-
morphine and naloxone was the same in both strains. These obser-
vations suggest that delta receptors may be involved in the run-
ning response.
The subline differences in narcotic receptors also appear to af-
fect the responses of mice to endogenous opiates. One kind of
stress-induced, naloxone-reversible analgesia which we have ex-
amined is that seen when one mouse is attacked and defeated by
another mouse (Miczek et al. 1982). Here, too, By mice show more
analgesia than J mice (figure 9).
By mice also have more fatty liver damage after high doses of mor-
phine than J mice (Needham et al. 1981). There are indications
that a good part of this response can be attributed to morphine-
induced release of epinephrine from the adrenals. Here, also,
genetic comparisons suggest that mu receptors may be involved.
The Jackson subline of C57B1/6 mice shows a greater stimulant
response to amphetamine than the Bailey subline. In this case,
too, the By gene is dominant (Moisset 1977).
Additional subline differences await closer investigation. For
instance, the vasa deferentia from the Biobreeding subline of
C57B1/6 mice are about 3 times as sensitive to inhibition by nor-
morphine or by met-enkephalin as those from the Jackson line
(Szerb and Vohra 1979). Balb/cJ mice have higher levels of en-
zymes for synthesizing epinephrine than the NIH subline
(Ciaranello et al. 1974). Moisset (1978) found that BALB/cBy mice
sleep over twice as long after an injection of ethanol, four g per
kg, as mice of the Jackson subline.
64
FIGURE 9. Defeat-induced analgesia in mice of 6 different
strains. Bars indicate mean ± SEM change in tailflick latency
following 70 bites. An asterisk indicates significant difference
from C57B1/6J, p<.05.
CONCLUSIONS
Genetic differences in responses to drugs of abuse can be found if
one looks for them. The particular model system which is most use-
ful will depend to a great extent on the goals of pharmacogenetic
analysis. There is still a great need for systematic surveys of
the drug responses of available inbred strains, sublines and
mutants. These surveys should also extend to the assay of drug
receptors, drug metabolism, and the mapping of brain proteins by
two-dimensional gel electrophoresis. The heroic labors of selec-
tive breeding also pose a tremendous challenge. Eventually one
should be able to identify specific genes that determine drug re-
sponses and relate these to the mechanism of action.
REFERENCES
Bailey, D.W. Recombinant inbred strains. Transplantation,
11:325-327 1971.
Bailey, D.W. Genetics of histocompatibility in mice. I. New loci
and congenic lines. Immunogenetics, 2:249-256 1975.
65
Bailey, D.W. Sources of subline divergence and their relative
importance for sublines of six major inbred strains of mice.
In: Morse, H.C., III, ed. Origins of Inbred Mice, New York,
Academic Press, 1978. pp. 197-215.
Baker, H., Joh, T.H., and Reis, D.J. Genetic control of number of
midbrain dopaminergic neurons in inbred strains of mice: Rela-
tionship to size and neuronal density of the striatum. Proc Nat
Acad Sci USA, 77:4369-4373, 1980.
Baran, A. Shuster, L., Eleftheriou, B.E., and Bailey, D.W.
Opiate receptors in mice. Genetic differences. Life Sci,
17:633-640. 1975.
Boehme, R.R., and Ciaranello, R.D. Dopamine receptor binding in
inbred mice: Strain differences in mesolimbic and nigrostriatal
dopamine binding sites. Proc Nat Acad Sci USA, 78:3255-3259,
1981.
Brase, D., Loh, H.H., and Way, E.L. Comparison of the effects of
morphine on locomotor activity, analgesia and primary and pro-
tracted physical dependence in six mouse strains. J Pharmacol
Exp Ther, 201:768-374, 1977.
Castellano, C., and Oliverio, A. A genetic analysis of morphine-
induced running and analgesia in the mouse. Psychopharmacol,
41:197-200. 1975.
Cheng, R.S.S., and Pomeranz, B. Correlation of genetic differences
in endorphin systems with analgesic effects of D-amino acids in
mice. Brain Res, 177:583-587, 1979.
Ciaranello, R.D., Hoffman, H.J., Shire, J.G.M., and Axelrod, J.
Genetic regulation of catecholamine biosynthetic enzymes. II
Inheritance of tyrosine hydroxylase, dopamine hydroxylase and
phenylethanolamine methyl transferase. J Biol Chem,
249:4520-4536, 1974.
Crabbe, J.C., Jr., Allen, R.G., Gaudette, N.D., Young, E.,
Kosobud, A., and Stack, J. Strain differences in pituitary-
endorphin and ACTH content in inbred mice. Brain Res,
219:219-223, 1981.
Crabbe, J.C., Kosobud, A., and Young, E.R. Genetic selection for
ethanol withdrawal severity: Differences in replicate mouse
lines. Life Sci, 33:955-962, 1983a.
Crabbe, J.C., Jr., Young, E.R., and Kosobud, A. Genetic correla-
tions with ethanol withdrawal severity. Pharmacol Biochem
Behavior, 18:541-547, 1983b.
Cremins, J., and Shuster, L. A genetically controlled difference
in morphine analgesia and narcotic receptors in mice. Fed
Proc, 41:1314, 1982.
Erway, L., Hurley, L.S., and Fraser, A.S. Congenital ataxia and
otolith deficits due to manganese deficiency in mice. J
Nutrit, 100:643-654, 1970.
Falconer, D.S. Introduction to Quantitative Genetics. New York:
Ronlad Press, 1960
Goldstein, D.B., Chin: J.H., and Lyon, R.C. Ethanol disordering
of spin-labeled mouse brain membranes: correlation with
genetically determined ethanol sensitivity of mice. Proc Nat
Acad Sci USA, 79:4231-4233, 1982.
Green, M.C. Genetic Variants and Strains of the Laboratory Mouse.
Stuttgart, Gustav Fischer Verlag, 1981.
66
Heiniger, H.J., and Dorey, J.J., eds. Handbook on Genetically
Standardized JAX Mice, 3rd edition. Bar Harbor, Me: The
Jackson Laboratory, 1980.
Helmeste, D.M., Seeman, P., and Coscina, D.V. Relation between
brain catecholamine receptors and dopaminergic stereotypy in
rat strains, Eur J Pharmacol, 69:465-470, 1981.
Helmeste, D.M. Spontaneous and apomorphine-induced locomotor
changes parallel dopamine receptor differences in two rat
strains. Pharmacol Biochem Behavior, 19:153-155, 1983.
Heston, W.D.W., Erwin, V.G., Anderson, S.M., and Robbins, H. A
comparison of the effects of ethanol on mice selectively bred
for differences in ethanol sleep time. Life Sci, 14:365-370,
1974.
Ingram, D.K., and Corfman, T.P. An overview of neurobiological
comparisons in mouse strains. Neurosci Biobehav Rev,
4:421-435, 1980.
Johnson, L.L. At how many histocompatibility loci do congenic
mouse strains differ? Probability estimates and some implica-
tions. J Hered, 72: 27-31, 1981.
Judson, B.A., and Goldstein, A. Genetic control of opiate-induced
locomotor activity in mice. J Pharmacol Exp Ther, 206:56-60,
1978.
Katz, R.J. The albino locus produces abnormal responses to opi-
ates in the mouse. Eur J Pharmacol, 68:229-232, 1980.
Katz, R.J., and Doyle, R.L. Enhanced responses to opiates pro-
duced by a single gene substitution in the mouse. Eur J
Pharmacol, 67:301-303, 1980.
Kiianmaa, K., and Tabakoff, B. Neurochemical correlates of toler-
ance and strain differences in the neurochemical effects of
ethanol. Pharmacol Biochem Behavior, 18, Suppl. 1: 383-388,
1983.
Lasagna, L., and Beecher, H.K. The optimal dose of morphine. J
Am Med Assoc, 156:230-234, 1954.
Law, P.Y., Harris, R.A., Loh, H.H., and Way, E.L. Evidence for
the involvement of cerebroside sulfate in opiate receptor
binding: Studies with Azure A and Jimpy mutant mice. J
Pharmacol Exp Ther, 207:458-468, 1978.
Litchfield, J., and Wilcoxon, F. A simplified method of evaluat-
ing dose-effect experiments. J Pharmacol Exp Ther, 96:99-113,
1949.
Mayer, J.M., Khanna, J.M., Kim, C., and Kalant, H. Differential
pharmacological responses to ethanol, pentobarbital and mor-
phine in rats selectively bred for ethanol sensitivity.
Psychopharmacol, 81:6-9, 1983.
McClearn, G.E., and Anderson, S.M. Genetics and ethanol
tolerance. Drug Alcohol Depend, 4:61-76, 1979.
Miczek, K.A., Thompson, M.L., and Shuster, L. Opioid-like analge-
sia in defeated mice. Science, 215:1520-1522, 1982.
Moisset, B. Genetic analysis of the behavioral response to d-
amphetamine in mice. Psychopharmacology 53:263-267 (1977).
Moisset, B. Subline differences in behavioral responses to pharma-
cological agents. In: More, H.C. III ed. Origins of Inbred
Mice, New York, Academic Press, 1978. pp. 483-484.
67
Needham, W.P., Shuster, L., Kanel, G.C., and Thompson, M.L. Liver
damage from narcotics in mice. Toxicol Appl Pharmacol,
58:157-170, 1981.
Nussbaum, J.L., Nescovic, N., and Mandel, P. A study of lipid
components in the brain of the "Jimpy" mouse, a mutant with
myelin deficiency. J Neurochem, 16:927-934, 1969.
Oliverio, A., and Castellano, C. Genotype-dependent sensitivity
and tolerance to morphine and heroin: dissociation between
opiate-induced running and analgesia in the mouse.
Psychopharm, 39:13-22, 1974.
Oliverio, A., Eleftheriou, B.E., and Bailey, D.W. Exploratory
activity: Genetic analysis of its modification by scopolamine
and amphetamine. Physiol Behav, 10:893-899. 1973.
Oliverio, A., Castellano, C., and Eleftheriou, B.E. Morphine
sensitivity and tolerance. A genetic investigation in the
mouse. Psychopharmacologia, 42:219-224, 1975.
Perry, B.D., Stolk, J.M., Vantini, G., Guchhart, R.B., and
U'Prichard, D.C. Strain differences in rat brain epinephrine
synthesis: Regulation of alpha-adrenergic receptor number by
epinephrine. Science, 221:1297-1299, 1983.
Pomeranz, B. Do endorphins mediate acupuncture analgesia? Adv in
Biochem Psychopharm, 18:351-360, 1978.
Racagni, G., Bruno, F., Juliano, E., and Paoletti, R.
Differential sensitivity to morphine-induced analgesia and
motor activity in two inbred strains of mice: Behavioral and
biochemical correlations. J Pharmacol Exp Ther, 209:111-116,
1979.
Reggiani, A., Battaini, F., Kobayashi, H., Spano, P., and
Trabucchi, M. Genotype-dependent sensitivity to morphine: Role
of different opiate receptor populations. Brain Res,
189:289-294, 1980.
Reith, M.E.A., Sershen, H., Vadasz, C., and Lajtha, A. Strain
differences in opiate receptors in mouse brain. Eur J
Pharmacol, 74:377-380, 1981.
Robertson, H.A. Benzodiazepine receptors in "emotiona1" and
"non-emotional" mice: Comparison of four strains. Eur J
Pharmacol, 56:163-166, 1979.
Shuster, L. Genetic analysis of morphine effects: Activity,
analgesia, tolerance and sensitization. In: Eleftheriou,
B.E., ed. Psychopharmacogenetics, New York: Plenum Press, 1975.
pp. 73-98.
Shuster, L., Webster, G.W., and Yu, G. Increased running response
to morphine in morphine-pretreated mice. J Pharmacol Exp Ther,
192:64-72. 1975a.
Shuster, L., Webster, G.W., Yu, G., and Eleftheriou, B.E. A g-
enetic analysis of the response to morphine in mice: analgesia
and running. Psychopharmacol, 42:249-254, 1975b.
Shuster. L. A pharmacogenetic approach to the brain. In:
Lieblich, I., ed. Genetics of the Brain. Amsterdam, Elsevier
Biomedical Press, 1982. PP. 157-176.
Sorenssen, S., Palmer, M., Dunwiddie, T., and Hoffer, B.
Electrophysiological correlates of ethanol-induced sedation in
differentially sensitive lines of mice. Science,
210:1143-1145, 1980.
68
Szerb, J.C., and Vohra, M.M. Potencies of normorphine and
kephalin in the vas deferens of different strains of mi
Life Sci, 24:1983-1988, 1979.
Taylor, B.A. Genetic relationships between inbred strains
J. Heredity, 63:83-86, 1972.
Taylor, B.A. Recombinant-inbred strains: Use in gene mappi
Morse, H.C. III, ed. Origins of Inbred Mice. New York
Academic Press, 1978. pp 423-438.
met-en-
ce.
of mice.
ng. In:
Ihompson, M.L., Shuster, L., and Casey, E. Sex and strain differ-
ences in response to cocaine. Biochem Pharmacol, in press.
Waller, S.B., Ingram, D.K., Reynolds, M.A., and London, E.D. Age
and strain comparisons of neurotransmitter synthetic enzyme
activities in the mouse. J Neurochem, 41:1421-1428, 1983.
Way, E.L., Loh, H.H., and Shen, F.H. Simultaneous quantitative as-
sessment of morphine tolerance and physical dependence. J
Pharmacol Exp Ther, 167:1-8, 1969.
Wimer, R.E., and Wimer, C.C. A geneticists map of the mouse
brain. In: I. Lieblich, ed. Genetics of the Brain. Amsterdam,
Elsevier Biomedical, 1982, pp. 395-420.
ACKNOWLEDGMENTS
The research described here was supported by grants DA-01626 and
DA-01885 from the National Institute on Drug Abuse. Guy
Webster, Peter H. Short, Allison Wood, and Michell Hoffman
assisted with breeding and pharmacological assays. Drs. Earl
L. Green, Don W. Bailey, and Michael L. Thompson provided
helpful discussions.
AUTHOR
Louis Shuster, Ph.D.
Department of Biochemistry and Pharmacology
Tufts University School of Medicine
Boston, MA 02111
69
Opioid Tolerance and Dependence
in Light of the Multiplicity
of Opioid Receptors
Rüdiger Schulz and Albert Herz
Opioid tolerance and dependence are the consequence of chronic
activation of opioid receptors. To explain these phenomena,
several theories have been advanced to account for the respective
adaptational mechanisms (Collier 1980, Shuster 1961, Goldstein and
Goldstein 1968). A common postulate of these is the appearance of
tolerance and dependence in a unitary manner. They, thus, take in-
to consideration the well-known observations in man and animals
that tolerance and dependence appear in parallel. Within this
framework, the existence of cross-tolerance has been exploited as
an essential criterion for the characterization of opioid agonists.
That is, tolerance to one opioid is accompanied by cross-tolerance
to another opioid.
In recent years, these concepts have been seriously challenged. It
has become clear that the absence or the presence of cross-toler-
ance is by no means a prerequisite to judge whether or not a drug is
a narcotic. These findings are closely associated with the concept
of the multiplicity of opioid receptors, as originally proposed by
Martin et al. (1976). Indications for the existence of different
types of opioid receptors have come from experiments with intact
animals (Martin et al. 1976) but also from studies with isolated
tissues (Lord et al. 1977). Investigations with the isolated
mouse vas deferens and guinea-pig ileum, which have been employed to
study the development of tolerance and cross-tolerance Wüster et
al. 1981a), proved very successful.
The mouse vas deferens represents an isolated tissue preferential-
ly employed to study tolerance and cross-tolerance (Schulz et al.
1980). This preparation seems to be unique as it contains at least
each of the classical opioid receptors, such as the µ-,
type. It was the aim of several investigations to test whether
chronic stimulation of, for example, the µ-receptors is associated
with an adaptation of other receptor types. In other words, is
tolerance to a specific receptor type associated with cross-
tolerance to a different type of opioid receptor? Mice were treated
with an opioid, e.g., a µ-agonist, for several days, using osmotic
minipumps for the application of the drug. The vasa deferentia of
these animals here set up in vitro for electrical stimulation
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in the presence of the opioid applied in vivo. This procedure
allows for maintenance of tolerance in vitro. According to this
schedule, vasa deferentia were rendered tolerant in vivo to µ-,
receptor agonists. The preparations were challenged in
vitro for the degree of tolerance and cross-tolerance.
FIGURE 1: Tolerance and cross-tolerance studies of opioids on the
isolated mouse vas deferens. Vasa deferentia were rendered tolerant
in vivo to sufentanil (SUF), ethylketazocine (EK) and D-Ala2, D-Leu5-
enkephalin (DADL), respectively. The degree of tolerance, measured
by calculation of the quotient (Q) of the IC50 values of tolerant
arid naive preparations is plotted on the ordinate. Q=1 indicates
lack of tolerance. The druq chronically applied is indicated in
each panel. Abscissa: opioids tested for tolerance and cross-
tolerance. Each column represents the quotient of mean IC50 values.
For details see Wüster et al. (1981a).
Figure 1 depicts the deqree of tolerance and cross-tolerance of
vasa deferentia rendered tolerant to the µ-agonist sufentanil (SUF),
the agonist ethylketazocine (EK), and the agonist D-Ala2-D
Leu5-enkephalin (DADL), respectively. Apparently, preparations
highly tolerant to SUF display an almost uncharged sensitivity to
the or the agonist. Analogous results were obtained with pre-
parations rendered tolerant to EK or DADL.
These data clearly reveal the existence of a state of tolerance
and non-tolerance in the same vas deferens preparation. In prin-
ciple identical results were obtained with the isolated guinea-
pig ileum (Wüster et al. 1981a) and in experiments with intact ani-
mals (Schulz et al. 1981). Thus, these results do not favor the
notion that cross-tolerance between opioids is an essential crite-
rion to classify a druq as an opioid.
This demonstration of "selective tolerance" does not-in itself-
conflict with theories claiming a "unitary mechanism" for toler-
ance and dependence. The question arises, however, whether those
highly "tolerant receptors" also display a high degree of depen-
dence, and whether those receptors lacking tolerance also lack de-
pendence. If such assumptions are correct, each bindinq site for a
specific opioid should be firmly linked to a subsequent system and
such an entity should function independently from other opioid
71
FIGURE 2: Naloxone-induced contracture (twitch tension) of longi-
tudinal muscle-myenteric plexus preparations taken from a morphine
tolerant/dependent guinea pig. The preparations were kept in
Krebs-Ringer solution containing normorphine (200 nM), except
during the time indicated by the hatched field. Washes were con-
ducted in the presence and absence of the opiate every 5-10 min.
Naloxone was added to the bath l min after electrical stimulation
was turned off. The ordinate represents tension (contracture)
expressed as percent of the preceding electrically induced twitches.
For details see Schulz and Herz (1976).
receptor entities. A different situation would occur if one adapts
the "mobile-receptor hypothesis" (Cuatrecasas 1974) to the function-
ing of opioid receptors. In this case, the binding site is
suggested not to be linked to a single transducer system. That is,
the different opioid bindinq sites would have access to a common
subsequent system floating in the membrane. One may assume, thus,
that even those receptors which were not chronically exposed to an
opioid in a tolerant preparation should display dependence. This
argumentation remains vague, as the definition for "the receptor" is
still under discussion. It is generally accepted that the receptor
consists of a recognition site for its ligand and a subsequent
transducer system. While the interaction of the recognition site
with its ligand is well described, the function of the "subsequent
transducer system" is not. Since opioid tolerance and dependence
may find their expression at different sites of the receptor
entity, an understanding of the molecular mechanism is highly de-
sired. Basically, an association of tolerance and dependence de-
velopment with the "opioid receptor" does not exclude adaptational
mechanisms down-or upstream-from the neuron primarily affected by
the opioid.
These considerations prompted investigations into opioid dependence
and cross-dependence, extendinq, thereby, studies of tolerance and
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cross-tolerance. Since highly tolerant vasa deferentia of mice fail
to display any sign of dependence (Gillan et al. 1979), the studies
were conducted with the isolated longitudinal muscle-myenteric
plexus preparation of the guinea pig ileum. This preparation has
been widely used to study both opioid tolerance and dependence.
The demonstration of dependence in tolerant preparations requires
the displacement of the agonist (Schulz and Herz 1976). Thus, admi-
nistration of the narcotic antagonist naloxone may uncover depend-
ence; that is, it elicits a withdrawal contracture. A serious prob-
lem relates to the fact that naloxone covers the different types of
opioid receptors with only minor differences in affinity. This im-
plies that naloxone alone cannot be employed as a drug to study
dependence associated with a specific type of receptor. Since a
withdrawal sign can be precipitated by naloxone only by displacing
an agonist, dependence and cross-dependence were therefore studied
by use of highly selective µ- or agonists. A withdrawal contrac-
ture caused by naloxone under these conditions would reveal depen-
dence of the specific opioid receptor occupied by the agonist.
In the light of the above considerations, the experiments were de-
signed as follows: The ilea of guinea pigs, which had been chroni-
cally treated with low concentrations of morphine or EK, were set
up in vitro for electrical stimulation. The preparations were with-
drawn by washing in order to unmask all opioid receptors. A success-
ful removal of the agonist from its receptor is manifested in the
failure of naloxone to precipitate a withdrawal contracture. There-
after, the strips ware re-exposed for 30 min to a specific opioid
receptor agonist of a very low concentration. Subsequently,
naloxone was added to the bath to test for dependence (figure 2).
Figure 3, upper panel, displays the results obtained with prepara-
tions rendered in vivo dependent on the µ-agonist morphine (10 and
100 µg/h, 6 days). After the preparations were withdrawn, they were
re-exposed to either the K-agonist normorphine (NORM) or to the
agonists dynorphin Al-13 (DYN1-13) or neoendorphin1-8(ANE1-8).
Tests for dependence revealed a similar intensity of withdrawal
contracture in all preparations, regardless of whether a µ- or
agonist was employed for reexposure. Essentially identical results
were obtained with preparations taken from guinea pigs chronically
treated with EK (lower panel, 5 and 50 µg/h, 6 days). Taken to-
gether, dependence cannot be allocated to a specific opioid re-
ceptor type. The preparations chronically exposed to a µ-agonist
display dependence, but a sign of dependence can equally well be
demonstrated after the µ-agonist has been exchanged with a
agonist. This phenomenon may be called cross-dependence.
However, any overlap of the agonist employed for reexposure in
vitro to a different receptor type may affect the interpretation
of these above-mentioned results. Thus, the aim of further experi-
ments was to rule out the possibility that the naloxone-induced.
withdrawal contracture could relate to more than a single receptor
population. To accomplish this aim, the irreversible µ-receptor
antagonist ß-funaltrexamine (ß-FNA) (Ward et al. 1982) was employed
in these studies. The experimental design followed that described
above with the exception that the withdrawn preparations were ex-
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FIGURE 3: Opioid dependence and cross-dependence in the isolated
guinea pig ileum. The preparations were rendered dependent by in-
fusing guinea pigs with morphine or ethylketazocine (EK). After
withdrawal of the preparations, they were reincubated with opioids
with a high receptor selectivity such as normorphine (NORM) for,
µ-receptors, and EK, dynorphin Al-13 (DYN1-13) and neo-endor-
phin1-8 (ANE1-8) for receptors. The reincubation concentrations
of the drugs are indicated on the abscissa and the elicited strength
of the withdrawal interaction is given on the ordinate. For details
see Schulz et al. (1982).
posed to ß-FNA (Seidl and Schulz 1983). This treatment provides
preparations containing receptors only. The intensity of the
withdrawal contractions of preparations exposed in vivo to fentanyl
(FEN) and treated in vitro with ß-FNA are given in figure 4. The
left panel (A) illustrates the data of preparations exposed in
vitro to different concentrations of FEN. In preparations not ex-
posed to ß-FNA, the contracture evoked by naloxone amounts in all
tissues to about 50 percent of the electrically evoked contractions.
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In the presence of ß-FWA, the response was greatly reduced, al-
though the intensity of the contractions increased as the concen-
tration of FEN increased. The fact that ß-FNA-exposed preparations
responded to naloxone in the presence of FEN most likely relates
to an incomplete inactivation of µ-receptors upon ß-FNA treatment.
Under analogous experimental conditions, but exposing the prepara-
tions in vitro to the agonist EK instead to FEN, the withdrawal
contractions were of similar intensity in both the ß-FNA-exposed
and non-exposed preparations (panel B). Thus, the studies employing
the irreversible antagonist ß-FNA, which interacts selectively with
µ-receptors, confirm previous results. They indicate the develop-
ment of dependence at µ- and K-receptors (cross-dependence), al-
though only a single type of receptor has been chronically activated
in vivo.
A different issue relates to the assumption that tolerance and
dependence are phenomena of a common mechanism. It would follow
that these phenomena should both be displayed together under appro-
priate conditions. Applying these considerations to the isolated
muse vas deferens, opioid tolerance has never, in fact, been
FIGURE 4: Withdrawal contractions precipitated by naloxone in
isolated guinea pig ileum preparations rendered dependent to fen-
tanyl (FEN) in vivo. Open columns are data from preparations not
exposed to ß-FNA in vitro; hatched columns indicate data from
preparations exposed in vitro to ß-FNA. The ordinate reflects the
tension of the withdrawal contracture. The abscissa reflects the
concentrations of FEN and ethylketazocine (EKC) employed to expose
the preparations in vitro. For details see Seidl and Schulz (1983).
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demonstrated to be associated with any sign of dependence. Although
electrophysiolcgical data have been reported indicating that the
neuronal firing rate increases in the tolerant mouse vas deferens
upon naloxone exposure (North and Vitek 1980), the question under
discussion remains whether or not this observation, in fact, repre-
sents a sign of dependence or an overshoot reaction subsequent to
the disinhibition of the opioid effect. In contrast to the mouse
vas deferens, both tolerance and dependence are commonly observed
in the isolated guinea-pig ileum. However, a detailed analysis of
the development of both parameters casts doubts on the principle
of a simultaneous and parallel appearance.
FIGURE 5: Correlation between tolerance and dependence in the
isolated guinea pig ileum. Guinea pigs were treated with different
dosages of morphine. The isolated preparations taken from these
guinea pigs were maintained in vitro at different concentrations
of normorphine. Each dot represents data from a single strip which
was used once to assay tolerance and dependence. The dotted line
indicates the tolerance/dependence curve obtained by best-fit
computer analysis. The solid lines indicate the regression lines
for the degree of tolerance (Q) ranging from to 10 and from 50-
200. bl and b2 reflect the respective regression coefficients.
Abscissa: degree of tolerance (Q) calculated from IC50 values of
tolerant and naive preparations. Ordinate: intensity of withdrawal
contracture expressed as percent of the preceding electrical stim-
ulation. For details see Schulz et al. (1982).
In order to investigate this matter, guinea pigs were infused
chronically with different amounts of morphine (10 to 100 µg/h,
6 days). The strips were set up in vitro at corresponding concen-
trations of morphine in plasma and were tested for tolerance to
morphine and for dependence by addition of naloxone to the organ
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bath. Figure 5 correlates the degree of tolerance with the intens-
ity of withdrawal contracture (dependence). Apparently, a very
steep slope of the curve at low degrees of tolerance is followed by
an extremely flat slope at high degrees of tolerance. In fact,
dependence was observed already in preparations which did not
display a measurable degree of tolerance. From these experiments,
it became obvious that the degree of tolerance and the degree of
dependence do not appear in a parallel fashion in the isolated
quinea pig ileum.
While the aforementioned experiments do not always demonstrate a
separation between tolerance and dependence, a clear-cut disso-
ciation of these phenomena can be obtained by experimental manipu-
lations. Cholera toxin, a neurotoxin which interferes with the
receptor mechanism, specifically with the guanyl regulatory unit
(Rodbell 1980), has been shown to reduce the expression of depen-
dence in the isolated guinea-pig ileum without changing the deqree
of tolerance to opioids (Lux and Schulz 1983). This result, thus,
represents a further hint for a dissociation of tolerance from
dependence.
CONCLUSIONS
Theoretical considerations have intimately linked opioid tolerance
with dependence and provided the conceptual basis for a postulated
"unitary mechanism" underlying these phenomena. Several recent
findings are not in correspondence with this notion. Similarly, it
has become clear that cross-tolerance between opioids is not a
criterion for the classification of a drug as an opioid.
The studies with the mouse vas deferens reviewed here exemplify
the above-mentioned issues in two respects. First, a highly opioid-
tolerant vas deferens fails to display any sign of dependence.
Second, a lack of cross-tolerance between different opioid recep-
tor agonists has been convincingly demonstrated. A plausible ex-
planation of these phenomena may be derived from studies of adapta-
tional mechanisms observed in neuroblastoma cells. These cultured
hybrid cells respond to chronic opioid exposure with a "down regu-
lation" of the binding sites for opioids (Chang et al. 1982, Law
et al. 1982). Thus, assuming a sufficiently high degree of "down
regulation," the tolerance phenomenon could be explained by this
mechanism. On the other hand, an uncoupling of the opioid binding
site from its subsequent system has already been suggested (Rubini
et al. 1982) as being responsible for tolerance. Such a mechanism
may, in fact, occur in neuroblastoma hybrid cells (Wüster et al.
1983, Wüster and Costa, this volume). Both mechanisms would imply
a disruption of the receptor function and could, thus, explain
tolerance. In contrast, however, the expression of dependence
demands a functioning opioid receptor. Since the highly tolerant
mouse vas deferens fails to display any sign of dependence,
the mechanisms underlying tolerance in the neuroblastoma cells and
the vas deferens may be similar. Thus, both tolerance and depen-
dence may dissociate in the vas deferens. This would suggest that
only tolerance develops in the nerve terminals of the mouse vas
deferens. Attempts, however, to demonstrate alterations of opioid
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binding sites in the tolerant mouse vas deferens have not, as yet,
proven successful (Rubini et al. 1982). In contrast to the cellular
development of tolerance (Collier 1980), adaptive processes may
occur in transmission between neurons, that is, subsequent to the
primary opioid-affected cell (Williams and North 1983).
An analysis of the findings with the isolated ileum would suggest
multiple adaptational mechanisms. Since dependence has been demon-
strated in all preparations chronically exposed to an opioid, a
functional opioid receptor must be assumed to exist under these
conditions. However, there appears to be a discrepancy between
the degree of tolerance and the intensity of dependence. A maximal
withdrawal sign is observed already at a low degree of tolerance.
As tolerance gradually increases, dependence does not develop to
the same degree. Apparently, two adaptive mechanisms maybe in-
volved. One involves tolerance and dependence, the second mainly
the development of tolerance. If the second mechanism is due to
a disturbance of the function of the opioid receptor, only a
certain fraction may be affected. The remaining receptors must be
intact since a withdrawal sign is still precipitated under these
conditions. One may argue that the extremely high degree of toler-
ance seen in this preparations may be due to mechanisms similar
to those assumed to account for the tolerant mouse vas deferens,
or those manifested in neuroblastoma cells (Chang et al. 1982,
Law et al. 1982, Wüster et al. 1983). Then the discrepancy men-
tioned above between tolerance and dependence could be explained.
Promising tools for the further investigation of these mechanisms
seem to be neurotoxins, such as pertussis toxin and cholera toxin.
Both toxins have already been employed for studies of opioid
tolerance/dependence in the guinea-pig ileum (Collier et al.
1983, Lux and Schulz 1983).
Of considerable interest is the observed cross-dependence between
different opioid receptors in the isolated guinea-pig ileum
(Schulz et al. 1982, Seidl and Schulz 1983). This finding may
imply that all receptor binding sites are somehow linked to a
common transducer system which adapts to chronic stimulation. A
theoretical basis for such a mechanism would be subsumed in the
"mobile receptor theory" (Cuatrecasas 1974).
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Sites and Mechanisms of De-
pendence in the Myenteric Plexus
of Guinea Pig Ileum
H. O. J. Collier and J. F. Tucker
INTRODUCTION
The understanding of drug dependence mechanisms has probably
reached its highest point so far with opioids. This is due to
several factors. including: (1) the availability of a specific
opiate antagonist, naloxone; (2) the feasibility of inducing and
measuring opiate dependence in two in vitro preparations (a) neuro-
blastoma-glioma hybrid cells in culture and (b) guinea pig ileum;
and (3) a better understanding of the complex processes regulating
adenylate cyclase activity.
The isolated guinea pig ileum has been used frequently in the study
of the long-term effects of opiates (Paton 1957; Ehrenpries et al.
1972; Goldstein and Schultz 1973; Hammond et al. 1976; Schultz and
Herz 1976; Villarreal et al. 1977; Lujan and Rodriquez 1978;
Gintzler 1979; Collier et al. 1981b). Tolerance and dependence in
this tissue and in the whole animal have many characteristics in
common (table 1).
Two recent developments have enabled the analysis of the problem of
opiate dependence to be carried forward using the guinea pig ileum
model. One is the demonstration that dependence on adenosine can
be induced in the isolated ileum (Collier and Tucker 1983). The
other is the demonstration that pertussis vaccine, through its
content of islet activating protein, can selectively interfere with
the inhibitory regulation of adenylate cyclase (Katada and Ui 1980,
1981; Hildebrandt et al. 1983).
SITE OF DEPENDENCE IN THE ILEUM
Subsequent to the demonstration that prolonged in vivo or in vitro
exposure of the guinea pig ileum to opiates results in dependence,
it has been shown that a similar phenomenon is associated with both
clonidine (Collier et al. 1981a) and adenosine (Collier and Tucker
1983). Exposure of guinea pig ileum to either clonidine (10-6M)
or adenosine (4 x 10-6M) for 18-24 hr induces in the tissue a
dependence, the withdrawal from which is expressed as a contracture
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TABLE 1. Characterization of Opiate Dependence in Both Guinea Pig
Isolated Ileum and Experimental Animals (based on work in Collier
et al. 1981 a,b)
1. Dependence does not appear immediately, but requires a period
of continued exposure to opiate.
2. Dependence is accompanied by tolerance to the acute effects of
opiate.
3. Withdrawal of opiate elicits a "spontaneous" behavioral
disturbance that can be suppressed by retreatment with opiate.
4. Withdrawal disturbance can be precipitated with a specific
antagonist, the potency of which is related to the degree of
dependence.
5. Induction of dependence requires the activation of a specific
and stereospecific opiate receptor.
6. Precipitation of withdrawal requires a specific and
stereospecific opiate antagonist.
7. Clonidine inhibits the opiate withdrawal disturbance.
Collier 1984. Copyright 1984, by Taylor Francis Ltd.
in response to adrenoceptor antagonists or adenosine receptor
antagonists respectively.
Although normorphine, clonidine, and adenosine each induce
dependence in the ileum, there are reasons for believing that the
dependencies are distinct. Firstly, the three agents induce
dependence by interaction with different receptors, activation of
which inhibits the release of acetylcholine from neurons of the
myenteric plexus (table 2).
Secondly, withdrawal from these drugs can only be precipitated with
a selective antagonist of the dependence-inducing agent (Collier et
al. 1981a; Collier and Tucker 1983). For example, neither
yohimbine nor naloxone will produce a response in tissues
previously incubated for 18-24 hr in adenosine, but challenge with
the adenosine antagonist 8-phenyltheophylline produces a marked
withdrawal contracture (figure 1).
All the evidence to date suggests that the site of dependence in
the ileum is within neurons of the myenteric plexus. This is
illustrated by the fact that normorphine, clonidine, and adenosine
withdrawal contractures can all be blocked with tetrodotoxin
(Collier et al. 1981a,b; Collier and Tucker 1983). Additionally,
North and Karras (1978) have demonstrated that after continued
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Table 2. Selective Agonists and Antagonists at Specific Receptors
Inhibiting Acetylcholine Release From the Final Cholinergic
Motoneuron of Guinea Pig Ileum
Receptor Agonist
example
Opioid, Mu Normorphine
Kappa Ethylketo-
cyclazocine
dynorphins
Adrenoceptor, Clonidine,
alpha2 noradrenaline
adrenaline
Purinoceptor, Adenosine,
Al (Ri)
2-chloro-
adenosine
Antagonist
example
Naloxone
---
Yohimbine
8-Phenyl-
theo-
phylline
Reference
Lord et al. 1977
Schultz et al. 1981
Chavkin & Goldstein
1981
Paterson et al. 1983
Kosterlitz et al. 1970
Tanaka & Starke 1979
Malta et al. 1981
Paton 1981
Collier 1984. Copyright 1984, by Taylor Francis Ltd.
exposure to morphine, a burst of impulse production can be elicited
with naloxone in neurons of the myenteric plexus. In this last
study, electrical activity was recorded from cell bodies via
suction electrodes, suggesting that dependence develops in the soma
of neurons of the myenteric plexus rather than in the axon or nerve
terminal.
MEDIATORS OF THE WITHDRAWAL CONTRACTURE
Early studies of the withdrawal response in the guinea pig ileum
supported the contention that the consequence of neuronal firing,
occasioned by naloxone-precipitated morphine withdrawal, was
acetylcholine release. Recently it has been shown that a second
transmitter, first observed by Gintzler (1980) and later by Tsou et
al. (1982), also participates in the normorphine withdrawal
contracture. Experiments with capsaicin, densensitization to
substance P (SP), and SP antagonists have shown that this second
transmitter is SP. Chahl (1983) has shown that the relative
contributions by acetylcholine and SP to the [Met]enkephalin
withdrawal contracture in the guinea pig ileum vary depending on
the duration of exposure to enkephalin. Short periods of exposure
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FIGURE 1. Lack of Responsiveness to Yohimbine (YO) and Naloxone
(Nx) of 8-Phenyltheophylline (8-PT)-Sensitive Guinea Pig Ileum.
Pieces of ileum were incubated in 4 x 10-6M adenosine for 18-24
hr at 19-21° and for 30-40 min at 37°C.
appear to be associated with a withdrawal contracture due to both
acetylcholine and SP, whereas the withdrawal contractures associ-
ated with longer periods of contact are predominantly due to SP
alone.
We have extended these observations and shown that the same neuron
or neurons that are involved in opiate withdrawal in the ileum are
also likely to be involved in adenosine and clonidine withdrawal
contractures. That is, in the ileum, withdrawal from these agents
can only be completely antagonized by abolishing responses to both
acetylcholine and SP. For example, figure 2 shows that after
adenosine withdrawal, a hyoscine-resistant component of the
withdrawal contracture remains which can be abolished by SP
desensitization. Similar results have been obtained by using a
combination of hyoscine and the SP antagonist D Pro2-D Trp7,9
SP.
CONVERGENT DEPENDENCE IN THE ILEUM
Since the dependencies on normorphine, clonidine, and adenosine
appear not to differ in character other than in the nature of the
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FIGURE 2. Prevention by Substance P (SP) [Desensitization] of the
Hyoscine (Hy)-Resistant 8-Phenyltheophylline (8-PT)-Precipitated
Adenosine Withdrawal Contracture. Upper strip shows effect of Hy
alone; lower strip shows effect of Hy and SP-desensitization.
Details as in figure 1.
FIGURE 3. Suppression by N6-Cyclohexyladenosine (CHA) of
Withdrawal Contracture Precipitated With Naloxone (Nx). Pieces of
ileum were incubated in 10-6M normorphine for 18-24 hr at 4°C
and for 30-40 min at 37°C. ES: electrical stimulation with 0.5
ms pulses at 0.1 Hz; ACh: acetylcholine (Tucker et al. 1983).
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inducing drug and its selective antagonist, these dependencies have
been termed convergent (Collier 1983). That is, dependence can be
induced through binding of a particular drug with a specific
recognition site on the neuron, but beyond this point the
mechanisms converge, so that withdrawal of all three is expressed
through liberation of the same transmitters, and any one of the
three agonists can suppress withdrawal of the other two (Collier et
al. 1981a,b; Collier and Tucker 1983). For example, activation of
purinoceptors with N6-cyclohexyladenosine (CHA), a stable deriva-
tive of adenosine, can abruptly terminate naloxone- precipitated
normorphine withdrawal contractures in the ileum (figure 3).
A possible useful consequence of convergent dependence is that not
only clonidine but also adenosine derivatives might be useful in
inhibiting opiate withdrawal symptoms in man. We have previously
shown that 2-chloroadenosine (2-CA), a stable derivative of
adenosine, potently suppresses morphine withdrawal signs in the
mouse (Tucker et al. 1983). Recently we have compared CHA, with
clonidine with respect to inhibition of jumping, diarrhea, and
weight loss in naloxone-precipitated morphine withdrawal in mice.
Mice were made dependent by implanting one 50 mg pellet of morphine
subcutaneously under ether anesthesia. Three days later, mice were
treated ip with CHA, clonidine, or saline; 25 min later, withdrawal
was precipitated with 1 mg/kg ip naloxone.
TABLE 3. Inhibition with N6-Cyclohexyladenosine (CHA) and
Clonidine (CLON) of Withdrawal Effects Precipitated With Naloxone
in Morphine-Dependent Mice
Drug Dose Jumps/l5 min Incidence of Weight Loss
(mg/kg) n ± SE Diarrhea (mg ± SE)
Control 58 177 ± 10 78 743 ± 55
CHA 0.1 17 91 ± 11* 24* 468 ± 62*
0.5 6 77 ± 25* 0* 143 ± 76*
3.125 6-7 35 ± 12* 0* 63 ± 32*
CLON 0.05 10 121 ± 20* 10* 441 ± 80*
0.2 11 125 ± 11* 0* 325 ± 9O*
* P < 0.01 for significance of difference from control value
From table 3 it is evident that clonidine is about equipotent with
CHA in suppressing naloxone-precipitated diarrhea and weight loss
but less potent in suppressing jumping. This may be explained by
van der Laan's finding (1983) that at higher doses than those shown
here clonidine can in fact potentiate naloxone-precipitated
morphine withdrawal jumping.
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The demonstration that, in the ileum at least, dependence can
develop to adenosine has important consequences. It has recently
been demonstrated in mice that interference with adenosine uptake
or antagonism of its effects can modify the action of acutely and
chronically administered alcohol [Dar et al. 1983). This raises
the possibility that adenosine might mediate some of the effects of
alcohol and might be involved in the dependence phenomenon
associated with its chronic use.
There is as yet no evidence that chronic administration of
adenosine or its derivatives induces dependence in the whole
animal, but after repeated administration of CHA to mice, tolerance
to some of its actions develops (unpublished observation).
Adenosine has also been implicated as a mediator of some of
morphine's actions (Sawynok and Jhamandas 1976; Stone 1981).
Additionally, in NG 108-15 cells, enhanced sensitivity of adenylate
cyclase to the excitatory action of adenosine has been reported to
occur after prolonged incubation with morphine (Griffin et al.
1983). Moreover, adenosine has been identified as the cytosolic
component responsible for the enhanced activity of adenylate
cyclase in morphine-dependent NG 108-15 cells. It is difficult to
equate the work with NG 108-15 cells with that in the ileum, as in
the latter it is believed that adenosine inhibits rather than
stimulates adenylate cyclase activity.
CYCLIC AMP HYPOTHESIS
The adenylate cyclase/cAMP system and its involvement in the
mechanisms of drug dependence has been the subject of extensive
work over the past 10 years. Collier and Roy (1974) showed that
opiates specifically inhibit prostaglandin El (PGE1) stimulated
CAMP production and proposed that opiate tolerance and dependence
represent a compensating hypertrophy of a part of the inhibited
PGE1/cAMP mechanism. At about the same time, Sharma et al.
(1975) demonstrated that cultivation of NG 108-15 cells in the
presence of morphine slowly increases PGE1-stimulated and basal
adenylate cyclase activity. Their observations led them to propose
that late positive regulation of adenylate cyclase counteracts the
inhibitory action of morphine and is responsible for narcotic
dependence and tolerance. Recently, further evidence supporting
this theory has come from work with pertussis toxin and NG 108-15
cells (Wuster et al. 1983).
Until recently it has been difficult to test the CAMP hypothesis of
dependence in normal neurons, but the demonstration of dependence
on normorphine, clonidine, and adenosine in the ileum now makes
that possible.
The general concept that dependence arises in normal neurons in
response to inhibition of adenylate cyclase is supported by the
fact that all three agonists that induce dependence in the ileum
have been shown to inhibit adenylate cyclase in other biological
preparations as a consequence of binding with their distinct
recognition sites (table 4).
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TABLE 4. Inhibition of Adenylate Cyclase by Activation of Various
Receptors
Receptor Agonist Site Reference
Opioid, mu
kappa
delta
Adreno-
ceptor,
alpha2
Purino-
ceptor,
Al (Ri)
Morphine
Ethylketo-
cyclazocine
Rat brain
(Leu)5- NG 108-15
enkephalin cells
Clonidine,
noradrenaline
Adenosine
2-chloro-
adenosine
Mammalian
brain
rat brain
Thrombo-
cytes
Adipocytes
NG 108-15
cells
Adipocytes
brain
membranes
Brain glial
cells in
culture
Collier & Roy 1974
Collier 1980
Barchfeld et al. 1982
Pay & Bhoola 1983
Barchfeld et al. 1982
Lampert et al. 1976
Brandt et al. 1976
Law et al. 1981
Garcia-Sainz
& Fain 1982
Burns et al. 1982
Limbird 1983
Sabol & Nirenberg
1979
Londos et al. 1980
Bruns et al. 1980
van Calker et al. 1979
Collier 1984. Copyright 1984, by Taylor Francis Ltd.
Because of the difficulty of separating nervous from muscular
tissue in the ileum, it has so far proved impossible to test
directly whether normorphine, clonidine, and adenosine inhibit
adenylate cyclase in the cholinergic neurons of the myenteric
plexus. Recently, however, some indirect evidence relevant to this
matter has been obtained.
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Katada and Ui (1980, 1981) and Hildebrandt et al. (1983)
demonstrated that pertussis vaccine through the islet-activating
protein-toxin can inactivate an inhibitory regulator of adenylate
cyclase. More recently, Costa et al. (1983) have shown that
pertussis toxin can reduce opiate inhibition of adenylate cyclase
in NG 108-15 cells, possibly due to an uncoupling of the opiate
receptor and the inhibitory regulator (Ni) of adenylate cyclase.
We have explored the CAMP hypothesis of dependence by determining
the effect of pertussis vaccine on the actions of normorphine on
the myenteric plexus of the ileum (Collier et al. 1983). Initially
we looked at the effect of pertussis vaccine on the acute effects
of normorphine.
The IC50 values for normorphine in vaccine-treated tissues and
nontreated tissues were not significantly different, being 36 and
37 nM respectively for in vitro treatment, and 21 and 23 nM respec-
tively for in vivo treatment. However, in normorphine-dependent
ileum, treatment with vaccine affects contraction (table 5).
TABLE 5. Inhibition by Pertussis Vaccine of Normorphine Dependence
in the Guinea Pig Isolated Ileum
Vaccine treatment n Mean response to Nx ± SEM
Treated Control
In vitro 14 ±  14 19.2 ±  2.7* 36.1 ±  5.7
In vivo 5 ± 5 21.1 ±  4.9** 49.7 ±  4.9
Responses expressed as per cent maximal response to acetylcholine.
Nx, 0.3 x 10-6M Naloxone.
*p < 0.02; **P < 0.01 for difference from control.
Collier et al. 1983. Copyright 1983, Elsevier Science Publishers BV.
In vitro treatment with vaccine reduced the withdrawal response by
about 47%. In ilea from guinea pigs treated with vaccine, the
withdrawal contracture was reduced by nearly 60% when compared to
control. In both sets of determinations, responses to electrical
stimulation and acetylcholine were unaffected by vaccine treat-
ment. We have also shown that pertussis vaccine has similar
inhibitory effects on adenosine dependence in the ileum.
We conclude from this that although pertussis vaccine does not
change the acute potency of normorphine it profoundly inhibits the
dependence mechanism, possibly by inactivating the inhibitory
regulator of adenylate cyclase which opiates and adenosine normally
activate.
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It has recently been reported that cholera toxin, a nonspecific
activator of adenylate cyclase, inhibits the expression of opioid
dependence in the myenteric plexus of the guinea pig (Lux and
Schulz 1983). This complements the work with pertussis vaccine.
The latter prevents the prolonged inhibition of adenylate cyclase
by morphine by inactivating the inhibitory regulator of adenylate
cyclase (Katada and Ui 1980, 1981; Hildebrandt et al. 1983), and
cholera toxin opposes the prolonged inhibition of adenylate cyclase
by direct activation of its excitatory regulator (Gill and Meren
1978). Thus both agents prevent the prolonged inhibition of
adenylate cyclase which is proposed to be central to the
development of dependence on opiates.
SUMMARY
The isolated guinea pig ileum provides a model in which drug
dependence can be induced in normal neurons.
The characteristics of opiate dependence in the ileum closely
resemble those of dependence in whole animals.
Convergent dependence on normorphine, clonidine, and adenosine can
be separately induced in the ileum in vitro.
Use of selective antagonists indicates that both acetylcholine and
substance P participate in the withdrawal response associated with
all three of these dependencies.
The demonstration that adenosine derivatives suppress opiate
withdrawal in the guinea pig ileum and in mice raises the
possibility that they might act similarly in man.
The point at which the dependencies on normorphine, clonidine, and
adenosine converge is probably below their separate recognition
sites and is possibly at the level of adenylate cyclase
regulation.
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Biochemical Reactions Between
Opiate Receptor Binding and
Inhibition of Neurotransmission
Doris H. Clouet and Norifumi Yonehara
An account of the mechanisms by which opiate tolerance develops at
the molecular level should begin with two caveats: there is no rea-
son to assume (1) that all opioids act through the same mechanisms
in all neural tissues (although a general response of a depression
of neuronal firing when an opioid is applied to a cell suggests a
commonality of mechanisms) or (2) that all subtypes of opioids pro-
duce the same states of biochemical tolerance (the lack of cross-
tolerance among the different subtypes suggests that there are
differences in the tolerant state).
One aspect of this review will be to note similarities and differ-
ences in the molecular events leading to tolerance among opioid
subtypes and also among various nervous tissues. The studies from
this laboratory have been carried out exclusively in the rat nigro-
striatal system, both because the relationship between behavior and
the dopaminergic system has been examined rigorously and because
opiate receptors and endogenous opioids have a relatively enriched
distribution in rat striatum. In the nigrostriatal dopaminergic(DA)
pathways, the cell bodies, located in the substantia nigra, have
long axons with extensive terminal arborization in the caudate nu-
cleus of the striatum. The very numerous nerve terminals make syn-
apses with GABA, acetylcholine and probably enkephalin-containing
neurons, leading to the presence of large numbers of pre- and post-
synaptic DA-responsive neurons. Important neurochemical effects in-
duced by acute or chronic opioid treatment that have been found in
neuronal cells in culture, in peripheral nerve, or in brain areas
other than striatum, will be included in this review.
EFFECTS OF ACUTE OPIOID TREATMENT
The binding of an opioid agonist to a presynaptic receptor on the DA
terminal leads to a sequence of biochemical events that are disrupt-
ed by the administration of an opioid. In table 1, some of the bio-
chemical steps between opiate receptor binding and impulse transport
between striatal neurons are listed, together with the effects pro-
duced at these steps by acute opioid administration. The inhibition
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TABLE 1
Reactions Between Opiate Receptor Binding and the In-
Neurotransmission in Rat Striatum: Responses to Acute
Opiate Administration
Biochemical Step Responses
Binding of Ligand to * Coupling of signal from binding to
Receptor amplifier impaired (Childers et al. 1983)
Formation of cAMP
GTP-binding * Decreased GTP binding due to enhanced
GTPase activity (Koski and Klee 1981;
Parenti et al. 1983)
Adenylate cyclase * Inhibition of adenylate cyclase (Collier
and Roy 1974; Shanna et al. 1977;
Barchfeld et al. 1982; Gentleman et al.
1983)
Stimulation by DA * DA binding inhibited (Gentleman et al.
1983)
* Levels of CAMP and cyclase activity in
striatum back to normal by 120 minutes
(Clouet et al. 1975).
Ion Fluxes
Influx of K+, Ca++
Efflux of Na+
Depolarization
Retention of intraterminal Ca++ and in-
creased Ca++ dep. K+ conductance
(North and Williams 1983)
Hyperpolarization and inhibition of
firing of most neurons
(Zieglgansberger and Fry 1978)
* Increased firing of nigrostriatal DA
neurons (Iwatsubo and Clouet 1977)
Protein Phosphorylation * Increased phosphorylation of some mem-
brane proteins (Williams & Clouet 1982)
* Increases in calmodulin-Ca++ dep. prot-
kinase activity (phosphorylation of
tyrosine hydroxylase, Ca++ATPase, etc.)
(Williams and Clouet 1982)
Calmodulin * Movement from cytosol to membranes in-
creased (Clouet and Williams 1982b)
* Inhibition "in vitro" by opioids of Ca++-
dep. kinase not due to interaction
between calmodulin and opioid
(Clouet et al. 1983)
Synthesis and Release of Generally inhibited by opioids
Neurotransmitters
* DA biosynthesis increased (Clouet and
Ratner 1970; Gauchy et al. 1973)
* Delta inhibition of DA release (Wood et
al. 1980; Yonehara and Clouet, in press)
* Effect shown in rat striatum
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of adenylate cyclase activity by an opiate was first reported by
Collier and Roy (1974), who found that prostaglandin-stimulated
adenylate cyclase activity was inhibited by morphine in brain homo-
genates. In neuroblastoma-glioma (NG) hybrid cells in culture, Klee
and his colleagues reported that DA-stimulated adenylate cyclase
activity was inhibited by ß-endorphin (Sharma et al. 1977). Later,
the inhibition of cyclase was shown to be related to a destruction
of the GTP required in the coupling of opiate receptor and adenylate
cyclase by an increased GTPase activity induced by opioids (Koski
and Klee 1981). The same changes in DA-dependent adenylate cyclase
and GTPase activities have been found in rat striatal membranes
(Gentleman et al. 1983; Parenti et al. 1983). Both cyclase activity
and CAMP levels in striatum are restored to control levels 30 to 120
minutes after opiate administration (Clouet et al. 1975).
Ion fluxes change during the passage of a nerve impulse from neuron
to neuron: the influx of calcium ions and potassium ions is in-
creased while the efflux of sodium ions is also increased. Opiate
treatment can produce a hyperpolarization that prevents subsequent
firing of the cell in most neuronal systems (Zieglgansberger and Fry
1978). The nigrostriatal DA system is one that is highly regulated
by both presynaptic and feedback controls, so that neuronal firing
is increased by opiates due to the inhibition of an inhibitory neuron
(Iwatsubo and Clouet 1977). Thus, there are opposing forces regula-
ting DA release during acute opioid treatment, an increased propaga-
tion of the nerve impulse to the nerve terminals that promotes neuro-
transmitter release, and presynaptic opiate effects that promote
decreased neurotransmitter release. In many species (cat, mouse) DA
release in striatum is stronger than any presynaptic inhibitory
effect and opioids induce DA release (Chesselet et al. 1981; Wood et
al. 1980). In rats, the presynaptic inhibitory effect predominates
and there is no release of DA when opiopeptides or narcotic drugs
are administered (Yonehara and Clouet, in press). In these studies,
the delta opiopeptides had greater effect on DA turnover than the
mu opiopeptides.
The two "second messengers" are involved in opiate actions. The
formation of CAMP is decreased when an opioid is introduced into a
neuron, or a NG cell in culture, in an "in vitro" tissue preparation
or into an animal. All of the consequences of a limited CAMP supply
come into play, including decreased Ca++ influx into nerve terminals,
decreased phosphorylation by CAMP-dependent protein kinases, etc.
The role of the other "second messenger" calcium, in impulse conduc-
tion is well known. Other sites of calcium activity involve a number
of enzymes that are phosphorylated by Ca++/calmodulin-dependent pro-
tein kinases or Ca++/phospholipid-dependent protein kinases (Green-
gard 1978; Takai et al. 1979). We have found that the increased phos-
phorylation of striatal SPM proteins following the acute administra-
tion of an opioid had a protein pattern after gel electrophoresis
that was very similar to that produced by Ca++/calmodulin stimulation
of phosphorylation, in terms of increased radioactivity in certain
protein bands after phosphorylation with ATP32 (Williams and Clouet
1982). We examined the levels and intracellular site of calmodulin
after opioid administration to see whether calmodulin availability
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was the cause of the opioid-induced effect. Calmodulin is a Ca++
binding protein primarily localized in nervous tissue. While local-
ized in the cytosol, it is relatively inactive. Its movement into
membranes seems to be related to increased cellular activity in many
forms: a capping of cell wall prior to endocytosis (Salisbury et al.
1981); an activation of the red cell calcium pump (Hinds et al. 1978);
and the binding of soluble proteins to membranes (Geisow and Burgoyne
1983). The acute administration of either etorphine or met-enkepha-
lin to rats resulted in a significantly higher level (60-80% above
control) of calmodulin in both striatal synaptic membranes and in
synaptosomal cytosol, with the ratio of cytosolic to membranal cal-
modulin remaining at about 3:7 (Clouet and Williams 1982b). It is
possible that the excess calmodulin was sequestered so effectively in
control animals that it was not removed by homogenization in deter-
gent, but was mobilized by increasing levels of Ca++ in the neurons.
The acute effects of opioids in increasing the endogenous phosphory-
lation of striatal membrane proteins could be ascribed completely to
the increased calmodulin available in the preparation to activate
Ca++-calmodulin-dependent protein kinases found in SPM preparations.
EFFECTS OF CHRONIC OPIOID TREATMENT
A common consequence of repeated stimulation of many neurohormone
receptors is a down-regulation that decreases the number of active
receptors. Such a phenomenon has been demonstrated for the opiate
receptor after chronic opioid exposure. Hippocampal slices incubated
with d-ala2d-leu5enkephalin for 4 hours had decreased numbers of
delta (d-ala2,d-leu5enkephalin) receptors, but no changes in the num-
ber of mu receptors (Dingledine et al. 1983). The NG hybrid cells
and fetal brain cells exposed to opiates or opiopeptides similarly
showed a down-regulation of opiate receptors (Lenoir et al. 1983;
Wuster et al. 1983). The levels of enkephalins in the striatum seem
to be fairly stable and resistant to change during opiate treatment
when examined at time periods from five to 180 minutes after opioid
treatment. It is possible that the response to opiate receptor occu-
pation related to enkephalin biosynthesis may be dependent temporally
on the initial binding of opiates to receptors rather than on the
period of pharmacological responses. Enkephalin levels are, however,
responsive to treatment with other types of neuroactive drugs. Stri-
atal enkephalin levels are increased by the administration of either
benzodiazepines or neuroleptics (Duka et al. 1980; Hong et al. 1978).
Long-term chronic treatment of rats with opiates did decrease both
leu- and met-enkephalin levels in the striatum (Przewlocki et al.
1979). The chronic administration of an opiate antagonist, naltrex-
one, to rats produced an up-regulation of both delta and kappa recep-
tors (Zukin et al. 1982) (table 2).
Adenylate cyclase activity was normal in brain areas of opiate-toler-
ant animals (Clouet et al. 1975). The enzyme, however, was super-
sensitive to both DA (Clouet and Iwatsubo 1975) and to GTP (Parenti
et al. 1983). The increase in GTPase activity found after acute
opioid administration was no longer seen in tolerant tissues including
striatal synaptic plasma membranes (Parenti et al. 1983). The large
increases in rat striatal DA turnover produced by an initial dose of
an opioid no longer occur as tolerance develops. The release of DA in
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TABLE 2
Biochemica
Inhibition
l Reactions Between Opiate Receptor (O.R.) Binding and the
of Neurotransmission in Rat Striatum: Responses to Chronic
Opiate Administration
Biochemical Step
Binding of Ligand to
Receptor
Responses
Down-regulation of O.R. in hippocampus
or NG cells (Parenti et al. 1982)
Up-regulation of O.R. after chronic
antagonist treatment
(Zukin et al. 1982)
Formation of CAMP * GTPase decrease (Parenti et al. 1983)
GTP binding
Adenylate Cyclase * Basal activity normal
Stimulation * Supersensitivity to DA
(Clouet and Iwatsubo 1975)
* Supersensitivity to GTP
(Parenti et al. 1983)
Ion Fluxes
Influx of K+ Ca++ * Ca++ fluxes normal
Efflux of Na+
Depolarization * Some tolerance to hyperpolarization
(Zeiglgansberger and Fry 1978)
Protein Phosphorylation * Decreased phosphorylation of some mem-
brane proteins
(O'Callaghan et al. 1979)
Calmodulin * Calmodulin in cytosol
(Clouet and Williams 1982b)
* Chronic trifluperazine blocked effect
of morphine on calmodulin levels
(Williams et al. in press)
Synthesis and Release Generally normal in tolerant tissue
of
Neurotransmitters * No increase in DA turnover
* DA-receptor supersensitivity
(Parenti et al. 1983)
* Effect shown in rat striatum
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areas other than rat striatum is no longer inhibited.
In the striatum of morphine-tolerant rats, the levels of endogenous
phosphorylation of SPM proteins are greatly reduced (O'Callaghan
et al. 1979). When separated by SDS-gel electrophoresis, the many
specific protein bands in which phosphorylation is reduced by chronic
opioid treatment are the same as those in which phosphorylation is
increased by acute opioid treatment or by Ca++-calmodulin stimulation.
To remedy the defect in phosphorylation, supplementation of the pro-
tein kinase assay with calmodulin was examined. In contrast to the
situation in acutely treated animals, when calmodulin supplementation
was able to restore phosphorylation, extra calmodulin was never able
to restore the rates of phosphorylation to those in the striata of
placebo-treated rats (Clouet and Williams 1982a). A transfer of cal-
modulin from membranal to cytosolic sites was also seen in rat striata
from morphine-tolerant rats (Clouet and Williams 1982a).
FIGURE 1. Effect of supplementation with calmodulin on the phosphory-
lation of striatal synaptic plasma membrane (SPM) proteins measured
in densitometer units for autoradiographs.
Calmodulin (CaM) was added as units described in Clouet and Williams,
1982b. Optimal Ca++ levels were maintained in all assays except the
zero control.
a= Acute etorphine vs. Saline-control; b = Acute methadone vs. Saline-
control; c= Chronic morphine vs.. Placebo pellets; d= Etorphine added
to assay vs. Same preparation without drug.
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FIGURE 2. Phosphorylation of two striatal SPM proteins.
Supplementation of striatal SPM proteins from morphine-tolerant
(stippled) or control (clear) rats with Ca++ and/or CaM in assays
of protein kinase activity. The proteins have aparent M.W. in 
SDS-gel of 54 kilodaltons (left panel) or 63 kilodaltons (right
panel).
The effect of calmodulin supplementation in the protein kinase assay
is shown in figure 1. As described above, control levels of total
phosphate incorporated into protein can be brought to the increased
levels found 10 minutes after the injection of etorphine by adding
calmodulin (1a). The decreased levels found 30 minutes after metha-
done administration were not brought to control levels by adding
calmodulin (lb), nor were the levels found in SPM proteins from mor-
phine-tolerant rats (1c). The effect of an opioid in reversing the
inhibition of Ca++-calmodulin stimulation is shown in 1d. It should
be noted that different effects of calmodulin supplementation can be
seen between individual protein bands (figure 2). After SDS gel
electrophoresis of SPM proteins from the striata of tolerant rats, a
protein band with an apparent M.W. of 54 kilodaltons was increasing-
ly phosphorylated with the addition of Ca++, calmodulin or both to
the assay, maintaining a constant ratio with a sample from placebo-
treated rats (left panel). A protein with a M.W. of 63 kilodaltons
was phosphorylated more in response to calmodulin than to Ca++, al-
though the protein from placebo-treated rats responded to both co-
factors (right panel). Yamauchi and Fujisawa (1980) attributed the
phosphorylation of the 63K protein to protein kinase III, that acts
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on only two proteins in brain. One is believed to be a protein kinase
subunit. The band at 54 K is probably a mixture of proteins such as
a tubulin subunit, an adenylate cyclase subunit, etc. Four soluble
Ca++-calmodulin-dependent protein kinases have been found in rat
cerebral cortex (Yamauchi and Fujisawa 1980) and membranal kinases
are also activated by the same cofactors. These enzymes may be un-
equally affected by opioid treatment.
A phenomenon that we noted several years ago is a reversal of the
stimulation of protein kinase activity by Ca++-calmodulin by adding
opioids to the assay tubes (Clouet et al. 1978). Using a rapid flow
multi-mixer to conduct short-time assays of protein kinase activity,
we found that the inhibitory effect of opioids was apparent in less
than 200 milliseconds (Clouet and Williams 1982a). The possibility
that opioids, like neuroleptics, interact directly with calmodulin,
removing it from the enzyme assay, was examined. The stimulation of
endogenous phosphorylation of striatal SPM proteins by Ca++-calmodu-
lin is inhibited by etorphine, methadone, beta-endorphin and d-ala2
met enkephalin with KiS of 5x10
-7M (Clouet et al. 1983) (figure 3).
The constant ratio for inhibition of calmodulin to opioid suggested a
direct interaction. As shown in figure lc, additional calmodulin can
reverse the opioid effect. However, when a calmodulin-free purified
preparation of phosphodiesterase was examined in the same paradigm,
FIGURE 3. The effect of opioids on CaM-dependent enzyme activity
The basal (lower  curves) and Ca++-CaM stimulated (upper curves)
activity of protein kinasesin striatal SPM preparations and of a
purified phosphodiesterase are shown. The dose-dependent effects of 
(a) beta- endorphin, (b) d-ala2met enkephalin, (c) methadone and (d)
etorphine are depicted as inhibition of stimulated enzyme activity.
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stimulated phosphodiesterase activity was inhibited by beta-endorphin
and etorphine with Kis of 2x10
-4M and not inhibited by methadone or d-
ala2met enkephalin. Thus, a direct interaction of calmodulin and opi-
oids may be ruled out as obligatory for this "in vitro" inhibition of
Ca++-calmodulin dependent enzyme, although it may play a role in some
effects of beta-endorphin. The importance of changes in the state of
phosphorylation of proteins, particularly enzymes, may be assessed by
tentatively identifying some of the proteins in a striatal SPM prepa-
ration that are phosphorylated by Ca++-calmodulin-dependent protein
kinases, and are affected by opioid treatment. Needless to say, a pro-
tein can not be identified by M.W. in SDS gel alone, but a consensus
is beginning to be formed concerning certain brain proteins (table 3).
Some protein kinases are relatively non specific as to substrate pref-
erence (e.g. , protein kinase II (table 3). Others like protein kinase
III have only two substrates that seem to be subunits of another pro-
tein kinase (Yamauchi and Fujisawa 1980). In depolarized neurons or in
synaptosomal preparations from depolarized cells, Ca++ uptake into the
cell stimulated both neurotransmitter release and phosphorylation of
two proteins in synaptic vesicles (DeLorenzo et al. 1979). These pro-
teins of 55 and 62K M.W. are believed to participate in the endocyto-
tic process. Synapsin I, a neuron-specific protein, also participates
TABLE 3
Molecular weights and possible identities of brain proteins of their
subunits that are phosphorylated by Ca++-calmodulin dependent protein
kinases
Approximate M.W. Protein References
**185 Clathrin A
96 Ca++ATPase SU B
** 87-82 Synapsin I B
74 Protein Kinase SU C
68 Neurofilament SU B
***63 Protein kinase A
62 Synaptic vesicle SU C
60 Tyrosine hydroxylase B
55 Synaptic vesicle protein C
54 Adenylate cyclase SU D
**52 Tublin SU D
50 Protein kinase SU A
**45 (Substrate) A
**37 A
*21 A
18 Myelin basic protein B
**17 A
16.5 GABA modulin B
***15 A
14 Myeline basic protein B
Proteins may be phosphorylated by Ca++-calmodulin-dependent protein
kinases I (*), II (**) or III (***) SU=Subunit. References are to:
A= Yamauchi and Fujisawa 1980; B= Nestler and Greengard 1983;
C= DeLorenzo et al. 1979; D= Burke and DeLorenzo 1981.
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in endocytosis since its phosphorylation decreases its affinity to pro-
teins on the outer wall of the vesicles (Forn and Greengard 1976). The
total amount of Synapsin I is regulated by various hormones, and also
by morphine (Nestler and Greengard 1983). Also, in depolarized neurons,
the biosynthesis of neurotransmitter is accelerated by the activation
of tyrosine hydroxylase through a Ca++-calmodulin-dependent process
(Mestikawy et al. 1983). The phosphorylation of GABAmodulin decreases
its affinity for the GABA receptor leaving the receptor free to bind
GABA (Wise et al. 1983).
Interconnections in the striatum between the DA system and other neuro-
transmitter systems make it possible for opioid effects to be extend-
ed to other systems. Both morphine and ß-endorphin injections into rat
striatum cause a decreased turnover of GABA in the caudate nucleus and
an increased turnover in the globus pallidus (Moroni et al. 1979).
Since an activation of caudate DA neurons by electrical stimulation or
by apomorphine does not change GABA turnover, it seems that enkephalin-
ergic neurons may impinge directly on GABA cells (Oertel et al. 1983).
Similarly, a direct correlation between opioid effects on cholinergic
neurons and on DA in the striatum has been ruled out by studies in
which acetylcholine turnover and binding were not affected by opioid
treatment (Schurr et al. 1983). In other areas of the central and
peripheral nervous system opioid effects on GABA and acetylcholine
have been shown.
CONCLUSIONS
In the striatum a variety of responses to chronic opioid exposure have
been discovered. Some phenomena are merely reversals of activations
or inhibitions that were produced as part of the response to the ini-
tial exposure to the opioid; e.g., the reversal of GTPase activation
in samples from tolerant rats, thereby increasing the GTP supply for
opiate receptor binding and adenylate cyclase activation. Other molec-
ular effects of chronic opioid exposure involve changes in the sensi-
tivity of receptors; e.g.; the down- and up- regulation of opiate
receptors in response to chronic treatment with opioid agonists or
antagonists, respectively; or the supersensitivity of DA receptors to
DA in tolerant rat striatum.
The reversal during tolerance to the initial responses to opioid treat-
ment in the phosphorylation of striatal SPM proteins does not seem to
be simple, since the acute effects are reversed by the addition of
calmodulin to the assay, suggesting a lack of active calmodulin, while
the lack of complete activity after supplementation of the assay with
calmodulin and Ca++ in assays of protein kinase activity in striatal
samples from tolerant animals suggests a decreased amount of active
enzymes. Calmodulin is active as a Ca++ cofactor when at least two
out of four Ca++ binding sites are occupied by Ca++. The same Ca++
binding is required for calmodulin to be localized on the inner surface
of neuronal membranes or the outer side of synaptic vesicles (Means
and Dedman 1980). Thus, the availability of Ca++ regulates calmodulin
effectiveness and determines its intracellular site to some extent. The
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movement of calmodulin to SPM after acute opioid treatment and to the
cytosol during chronic treatment is probably a consequence of opioid
effects on the levels and localization of Ca++.
We conclude, in common with other participants in this symposium, that
the biochemical mechanisms of opiate tolerance are diverse. The bio-
chemical effects produced by an initial exposure of nervous tissue to
opioids are largely specific to each tissue, although a common response
is inhibition of neurotransmission. Neurochemical changes following
chronic opioid exposure tend to result in a diminution of disturbance
of neuronal cell function with succeeding doses of drug by an avail-
able mechanism (change in number or sensitivity of receptors, in acti-
vation or inhibition of biosynthetic enzymes or in cellular localiza-
tion of cofactors, etc.). Thus, the usual ways in which biochemical
events are regulated are evoked during the development of tolerance to
enable the nervous system to limit the aberrations produced by opioid
exposure. It is possible that in largely unexplored systems psychic de-
pendence may result from a series of biochemical responses tending to
limit the wide mood swings due to sequential euphoria and withdrawal.
REFERENCES
Barchfeld, C.C. Maassen, F.A. and Medzihradsky, F. Receptor-related
interactions of opiates with PGE-induced adenylate cyclase in brain.
Life Sci 31:1661-1665, 1982
Burke, B.E. and DeLorenzo, R.J. Ca++ and calmodulin-stimulated en-
dogenous phosphorylation of neurotubulin. Proc Natl Acad Sci 78:
991-995, 1981.
Chesselet, M.F. Cheramy, A. Reisine, T.D. and Glowinski, J. Morphine
and delta opiate agonists locally stimulate in vivo dopamine release
in rat caudate nucleus. Nature 291:320-322, 1981.
Childers, S.R. Lambert, S.M and LaRiviere, G. Selective alterations
in guanine nucleotide regulation of opiate receptor binding and
coupling with adenylate cyclase. Life Sci 33:215-218, 1983.
Clouet, D.H. and Iwatsubo, K. Dopamine-sensitive adenylate cyclase
of the caudate nucleus of rats treated with morphine. Life Sci 17:
35-40, 1975.
Clouet, D.H. and Ratner, M. Catecholamine biosynthesis in the brains
of rats treated with morphine. Science 168:854-856, 1970.
Clouet, D.H. and Williams, N. The role of calmodulin in opioid-in-
duced changes in the phosphorylation of rat striatal synaptic mem-
brane proteins. Neurochem Res 7:1135-1148, 1982a.
Clouet, D.H. and Williams, N. fhe effect of opioids on striatal cal-
modulin levels. Life Sci 31: 2283-2286, 1982b.
Clouet, D.H. Gold, G.J. and Iwatsubo, K. Effects of narcotic anal-
gesic drugs on the cyclic AMP- adenylate cyclase system in rat brain.
Br J Pharmac 54: 541-548, 1975.
Clouet, D.H. Williams, N. and Yonehara, N. Is a calmodulin-opiopep-
tide interaction related to the mechanism of opioid action?
Life Sci 33:727-730, 1983.
105
Clouet, D.H., O'Callaghan, J.P. and Williams, N. The effect of opiates
on calcium-stimulated phosphorylation of synaptic plasma membrane
proteins in intact synaptosomes from rat striatum. In: VanRee, J and
Terenius L.eds. Characteristics and Functions of Opioids, Amsterdam,
North-Holland, 1978, pp. 351-352
Collier, H.O.J., and Roy, A.C. Morphine-like drugs inhibit the stimu-
lation by E prostaglandins of cyclic AMP formation by rat brain
homogenate. Nature 248:24-27, 1974.
DeLorenzo, R.J. Freedman, S.D. Yohe, W.B. and Maurer, S.C. Stimula-
tion of Ca++-dependent neurotransmitter release and presynaptic
nerve terminal protein phosphorylation by calmodulin and a calmodu-
lin-like protein isolated from synaptic vesicles. Proc Natl Acad
Sci 76:1838-1842, 1979.
Dingledine, R. Valentino, R.J. Bostock, E. King, M.E. and Chang,
K-J. Down regulation of delta but not mu opioid receptors in hippo-
campal slice associated with loss of physiological response. Life
Sci 33: 333-336, 1983.
Duka, T., Wuster, M., and Herz, A. Benzodiazepines modulate striatal
enkephalin levels via a GABAergic mechanism. Life Sci 26:771-776,
1980.
Forn, J. and Greengard, P. Regulation by lipolytic and antilipolytic
compounds of the phosphorylation of specific proteins in isolated
intact fat cells. Arch Biochem Biophys 176(2): 721-733, 1976.
Gauchy, C. Agid, Y. Glowinski, J. and Cheramy, A. Acute effects of
morphine on dopamine synthesis and release and tyrosine metabolism
in the rat striatum. Eur J Pharmacol 22:311-319, 1973.
Geisow, M.J. and Burgoyne R.D. Recruitment of cytosolic proteins
to a secretory granule membrane depends on Ca++-calmodulin.
Nature 301: 432-435, 1983.
Gentleman, S. Parenti, M. Neff, N.H. and Pert, C.B. Inhibition of
dopamine-activated adenylate cyclase and dopamine binding by opiate
receptors in rat striatum. Cell Mol Biol 3:17-26, 1983.
Greengard, P. Phosphorylated proteins as physiological effectors.
Science 199:146-152, 1978.
Hinds, T.R. Larsen, F.L. and Vincenzi. F.F. Plasma membrane Ca2++
transport: Stimulation of soluble proteins. Biochem Res Commun
81(2): 455-61. 1978.
Hong; J.S. Yang; H-Y-T. Fratta, W. and Costa, E. Rat striatal meth-
ionine-enkephalin content after chronic treatment with catalepto-
genic and non-cataleptogenic antischizophrenic drugs. J Pharm Exp
Therap 202: 141-147, 1978
Iwatsubo, D. and Clouet, D.H. Effects of morphine and haloperidol
on the electrical activity of rat nigrostriatal neurons. J Pharm
Exp Therap 202: 429-436, 1977.
Koski, G. and Klee, W.A. Opiates inhibit adenylate cyclase by stim-
ulating GTP hydrolysis. Proc Natl Acad Sci 78: 4185-4189, 1981
Lenoir, D. Barg, J. and Simantov, R. Down regulation of opiate
receptors in serum-free cultures of aggregating fetal brain cells.
Life Sci 33: 337-340, 1983.
Means, A.R. and Dedman, J.R. Calmodulin-an intracellular calcium
receptor. Nature 285: 73-77, 1980.
106
Mestikawy, S.El., Glowinski, J. and Hamon, M. Tyrosine hydroxylase
activation in depolarized dopaminergic terminals-involvement of
Ca++ dependent phosphorylation. Nature 302: 830-832, 1983.
Moroni, F. Peralta, E. Cheney, D.L. and Costa, E. On the regula-
tion of gamma aminobutyric acid neurons in caudatus, pallidus and
nigra, Effects of opioids and dopamine agonists. J Pharm Exp
Therap 208: 190-194. 1979.
Nestler, E.J. and Greengard, P. Protein phosphorylation in the brain.
Nature 305: 583-588, 1983.
North, R.A. and Williams J.T. Opiate activation of potassium con-
ductance inhibits calcium action potential in rat locus coeruleus.
Br J Pharm 80: 225-228, 1983
O'Callaghan, J.P., Williams, N. and Clouet, D.H. The effect of mor-
phine-on the endogenous phosphorylation of synaptic plasma membrane
proteins of the rat. J Pharm Exp Therap 208: 96-106, 1979
Oertel, W. Riethmuller, G. Mugnaini, E. Schmechel, D.E. Weindl, A.
Gramsch, E. and Herz, A. Opioid peptide like immunoreactivity
localized in GABAergic neurons of rat neostriatum and central amyg-
daloid nucleus. Life Sci 33: 73-76, 1983
Parenti, M. Gentleman, S. Olianas, M.C. and Neff, N.H. The dopamine
receptor adenylate cyclase complex: Evidence for a post recogni-
tion site involvement for the development of supersensitivity.
Neurochem Res 7:115-124, 1982.
Parenti, M. Gazzotti, G. Tirone, F. and Groppetti, A. Opiate toler-
ance and dependence is associated with a decreased activity of
GTPase in rat striatal membranes. Life Sci 33: 345-348, 1983
Przewlocki, R. Hollt, V. Duka, T. Kleber, G. Gramsch, C. Haarmann,
I. and Herz, A. Long time morphine treatment decreases endorphin
levels in rat brain and pituitary. Brain Res 174: 357-361, 1979
Salisbury, J.L. Condeelis, J.S. Maihle, N.J. and Satir, P. Calmodu-
lin localization during capping and receptor-mediated endocytosis.
Nature 294: 163-166, 1981
Sharma, S.K. Klee, W.A. and Nirenberg, M. Endorphin from pituitary
inhibits cyclic AMP formation in homogenates of neuroblastoma x
glioma hybrid cells. Nature 265: 362-363, 1977
Schurr, A. Rigor, B.M. Strong, R. and Gottesfeld, A. The choliner-
gic system in rat striatum during morphine tolerance and dependence
Life Sci 33: 2521-2525, 1983.
Takai, Y. Kishimoto, A. Iwasa, Y. Kawahara Y. Mori, T. and
Nishizuka, Y. Calcium-dependent activation of a multifunctional
protein kinase by membrane phospholipids. J Biol Chem 254:
3692-3695, 1979.
Williams, N. and Clouet, D.H. The effect of acute opioid administra-
tion on the phosphorylation of rat striatal membrane proteins.
J Pharmacol Exp Therap 220: 278-286, 1982.
Williams, N. Yonehara. N. and Clouet. D.H. Synergistic effect of
trifluoroperazine on analgesia and-turnover-of dopamine responses
induced by morphine in rats. Ann NY Acad Sci (in press).
Wise, B.C. Guidotti, A. and Costa, E. Phosphorylation induces a
decrease in the biological activity of the protein inhibitor
(GABA-modulin) of gamma-aminobutyric acid binding sites.
Proc Natl Acad Sci 80: 880-890, 1983.
107
Wood, P.L. Stotland, M. Richard, J.W. and Rackham, A. Actions of
mu, kappa, sigma, delta and agonist/antagonist opiates on striatal
dopamine function. J Pharmacol Exp Therap 215:697-703, 1980.
Wuster, M., Costa, T. and Gramsch, Ch. Uncoupling of receptors is
essential for opiate-induced desensitization (tolerance) in
neuroblastoma x glioma hybrid cells:NG 108-15. Life Sci 33:341-
344, 1983.
Yamauchi, T. and Fujisawa, H. Evidence for the distinct forms of
calmodulin-dependent protein kinases from rat brain. FEBS Lett
116: 141-144. 1980.
Yonehara, N. and Clouet, D.H. The effects of delta and mu opio-
peptides on the turnover and release of dopamine in rat striatum.
J Pharmacol Exp Therap (in press).
Zieglgansberger, W. and Fry, J.P. In: Developments in Opiate Research.
Herz, A. ed. New York: Marcel Dekker, 1978, pp 192-299.
Zukin, R.S. Sugarman, J.R. Fitz-Syage, M. Gardner, E.L, Zukin, S.R.
and Gintzler, A.R. Naloxone-induced opiate receptor supersensi-
tivity. Brain Res 245:285-297, 1982.
ACKNOWLEDGEMENT
The experimental work was supported in part by Research Grant DA00087
from the National Institute on Drug Abuse.
AUTHORS
Doris H. Clouet, Ph.D.
New York State Division of Substance Abuse
Services Research Laboratory
80 Hanson Place
Brooklyn, New York 11217 and
Professor of Psychiatry
Downstate Medical Center
Brooklyn, N.Y. 11203
Norifumi Yonehara, Ph.D.
New York State Division of Substance Abuse
Services Research Laboratory
80 Hanson Place
Brooklyn, New York 11217
now at
Osaka University School of Medicine
Osaka, Japan
108
The Role of Adenyl Cyclase in
Opiate Tolerance and Dependence
Werner A. Klee, Graeme Milligan, William F. Simonds,
and Bruno Tocque
The topic of this paper is one which was very important to H.O.J.
Collier because it concerns an area of research in which he and
his colleagues made pioneering contributions. It was with great
sadness that I delivered it at a symposium dedicated to his memory
rather  than in  h is  presence  as  or ig inal ly  p lanned.  With  Harry
Collier's death, some of us have lost a good friend, and all of us
have lost a clarifying and civilizing influence in our work. Harry
Collier's contributions to the understanding of the relationships
between the acute and chronic actions of opiates and the production
of cyclic AMP are relatively well known and will be referred to in
the body of this paper. His contributions to the understanding of
the mechanisms of drug receptor action in general go much deeper
and are, perhaps, even more profound and original. In 1972, at the
International Pharmacology Congress in San Francisco, he predicted
the existence of the endogenous opiates, long before most of the
rest  of  us  were  thinking in  such terms:  " . . .  the  receptor  for  a
foreign drug is really the receptor for a humoral substance, with
which the foreign molecule also interacts. . . . . we do not yet know
the natural function of the macromolecule with which morphine
speci f ica l ly  interacts . "  (Col l ier  1973) .  In  only  3  years  the  dis -
covery of the enkephalins proved the correctness of this speculation
(Hughes et al.  1975). If we were all to emulate the precision in
thought and in language that Harry Collier demanded so successfully
of himself, our studies of tolerance and dependence would undoubted-
ly progress much faster.
One well-established biochemical mechanism by which opiates exert
their  acute  ef fects  i s  by  inhibi t ion of  adenylate  cyclase  in  neu-
ronal cell membranes. This action of opiates was first described
by Collier and Roy (1974),  and has since been demonstrated in a
var iety  of  systems inc luding both cul tured ce l ls  (Sharma et  a l .
1975), and, more recently, brain membranes (Wilkening et al. 1976;
Law et al. 1981; Neff et al. 1981; Cooper et al. 1982). The immedi-
ate result of opiate-mediated inhibition of adenylate cyclase is a
decrease in cellular CAMP levels. As a direct consequence of this
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decrease ,  the  act iv i ty  of  CAMP-dependent  prote in  k inase  i s  di -
minished, so that many cellular proteins whose phosphorylation is
effected by this kinase will remain unphosphorylated. Thus, opiate
receptor  occupancy is  the  f i rs t  s tep in  a  cascade of  processes
leading to a panoply of effects on neuronal metabolism and excit-
a b i l i t y .  T h e  e x i s t e n c e  o f  s u c h  a  c a s c a d e  p r o v i d e s  a  p o w e r f u l
amplification mechanism in terms both of amounts and of rates.
A mechanism for tolerance and dependence is implicit in the above
formulation of acute opiate actions, as Collier and Roy realized in
t h e i r  v e r y  f i r s t  p u b l i c a t i o n  o n  t h e  s u b j e c t  i n  1 9 7 4 .  B e c a u s e
opiates inhibit adenylate cyclase and lower CAMP levels in their
acute actions, the homeostatic response of the cell to the chronic
p r e s e n c e  o f  o p i a t e s  m i g h t  w e l l  b e  t o  s e e  t o  i t  t h a t  a d e n y l a t e
cyclase  act iv i ty  levels  increase .  Evidence  that  such a  response
actually occurs in neuroblastoma x glioma hybrid, NG 108-15, cells
was supplied by the work of Sharma et al. (1975b) and of Traber et
al.  (1975). The NG 108-15 cell line is richly endowed with opiate
receptors  (Klee  and Nirenberg  1974) ,  and the  adenylate  cyc lase
activity of such cells is inhibited by up to about 50% when these
receptors are occupied by opiate agonists (Sharma et al.  1975a).
After culture of these cells for 12 or more hours in the presence
of opiate agonists such as morphine (Sharma et al. 1975b) or enke-
phal in  (Lampert  e t  a l .  1976) ,  adenylate  cyc lase  act iv i ty  i s  in-
creased. In these experiments enzyme activity was measured in the
presence of naloxone to insure reversal of inhibition by any opiates
remaining in the membranes of the washed cells. Interestingly, the
increase in activity found after culture in the presence of morphine
was such that, even though functional opiate receptors are present
in undiminished amount, CAMP levels in the cells were normal. Thus,
the cells had become tolerant to morphine, because they exhibited
normal metabolism, growth, and morphology in the presence of amounts
of morphine which greatly diminish the CAMP levels of control cells.
They are also dependent upon morphine in the sense that addition of
naloxone causes  a  dramat ic  r i se  in  C AMP levels ,  a  b iochemical
analogy of the withdrawal syndrome.
The increased levels of adenylate cyclase activity of chronically
exposed ce l ls  are ,  in  large  part ,  re f lec t ions  of  changes  in  the
state  of  the  enzyme rather  than in  i t s  amount .  Thus ,  when the
adenylate  cyclase  act iv i t ies  of  control  and opiate- treated ce l l
membranes are compared in the presence of sodium fluoride, or of
nonhydrolyzable GTP analogues, no differences are found (Sharma et
a l .  1977) .  Because  much,  i f  not  a l l ,  o f  the  regulatory apparatus
for controlling adenylate cyclase activity is completely activated
under these conditions, changed levels of the catalytic component
of the enzyme should have resulted in changes in activity here too.
Furthermore, it was found that simultaneous treatment of the cells
with morphine and the protein synthesis inhibitor, cycloheximide,
still  allows the expression of opiate-induced increases in adeny-
l a t e  c y c l a s e  a c t i v i t y .  T h e  d e t a i l e d  n a t u r e  o f  t h e  r e g u l a t o r y
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changes taking place is an intriguing mystery, awaiting solution.
Some experiments aimed at clarifying this mechanism will be reported
below.
Important advances in the understanding of the mechanisms of recep-
tor  control  of  adenylate  cyc lase  act iv i ty  have  been made in  the
past few years. It had been known since the work of Rodbell et al.
(1971), that the presence of GTP is essential for hormone stimula-
t ion of  adenylate  cyclase .  I t  i s  now c lear  that  the  GTP binding
prote in  N s  (a lso  ca l led G s  or  G/F) ,  which is  the  substrate  for
cholera toxin catalyzed ADP-ribosylation, is the mediator of such
stimulation (Ross and Gilman 1980). Agonists coupled to the appro-
priate receptors, such as ß- adrenergic and glucagon, for example,
facilitate the interaction of GTP and N s ,  and this complex (or a
c o m p o n e n t  o f  i t )  a c t i v a t e s  t h e  c a t a l y t i c  s u b u n i t  o f  a d e n y l a t e
cyclase. A second GTP binding protein N i  (sometimes called G i)
mediates receptor-coupled inhibition of the enzyme. This protein
is the substrate for pertussis toxin catalyzed ADP-ribosylation, a
process  which great ly  diminishes  the  abi l i ty  of  inhibi tory  hor-
mones, including opiates, to attenuate adenylate cyclase activity
(Katada and Ui 1979, 1982a, 1982b). These recent advances have laid
the foundation for a deeper understanding of opiate actions at the
molecular level.
Among the earliest observations made with NG 108-15 membranes was
the lack of opiate inhibition when measured in the presence of the
nonhydrolyzable GTP analogue, GppNHp (Sharma et al. 1975a). These
observations have recently been repeated with highly purified mem-
branes. In such a system it was also possible to show that opiate
inhibi t ion of  adenylate  cyc lase  i s  ac tual ly  the  reversal  of  GTP
s t i m u l a t i o n .  S u c h  o b s e r v a t i o n s  l e d  t o  t h e  i n f e r e n c e  t h a t  G T P
hydrolysis is a step necessary for opiate inhibition of adenylate
cyclase. Cassel and Selinger (1977) had already demonstrated that
a low Km-GTPase is associated with the adenylate cyclase of turkey
erythrocyte membranes. Using their methodology, Koski and Klee
(1981) showed that opiates stimulate a low Km-GTPase in NG 108-15
membranes. The GTPase stimulation is receptor mediated since it is
blocked by naloxone, is observed only in cells known to posess
opiate receptors, and the potencies of a series of opiate-stimula-
tors of GTPase match exactly the same drugs inhibition of adenylate
cyclase. Perhaps more tellingly, even the efficacies (intrinsic or
maximal activities) of the opiates in the two types of assay match
very well (Koski et al. 1982). Thus, the relative amounts of GTPase
stimulation and of adenylate cyclase inhibition observed at satura-
ting concentrations of opiates are very close to the same over the
range from apparently full agonists such as dalamid (D-Ala2, Met5 -
enkephal in  amide)  to  the  pure  antagonis t ,  naloxone (Table  1) .
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TABLE 1
Relative Efficacies of Opiates as Inhibitors of Adenylate Cyclase
and as Stimulators of GTPase in NG 108-15 Membranes*
OPIATE ADENYLATE CYCLASE GTPase
Dalamid
Etorphine
Morphine
Levorphanol
Diprenorphine
Nalorphine
Buprenorphine
Naltrexone
Naloxone
100
99
79
79
61
50
35
21
0
100
95
60
67
52
23
18
12
0
*Efficacy was determined by measuring the inhibition of adenylate
cyclase, or stimulation of GTPase produced by each opiate at concen-
trations high enough to be saturating. Data are expressed relative
to those of dalamid. Linear regression analysis of the data results
in a correlation coefficient of 0.94. Taken from Koski et al.  (1982).
Opiate inhibition of adenylate cyclase requires the presence of both
Na+ and GTP as first shown by Blume et al. (1971). Importantly there-
fore, opiate stimulation of GTPase activity was also found to exhibit
a  s imi lar ly  absolute  requirement  for  Na+ (Table  2) .  Surpr is ingly ,
perhaps, the effect of Na+ is to inhibit GTPase (in the presence of
Mg 2 + )  and opiates  s imply  reverse  th is  inhibi t ion .  These  data  are
strongly supportive of the proposal that opiate inhibition of adeny-
l a t e  c y c l a s e  i s  t h e  d i r e c t  r e s u l t  o f  i t s  s t i m u l a t i o n  o f  a  G T P a s e
component of the adenylate cyclase complex. Thus, in diagramatic
fashion:  adenylate  cyc lase  shutt les  between two s tates ,  an  act ive
one with bound GTP, and an inactive one with bound GDP. Stimulatory
receptors facilitate exchange of GTP for bound GDP, whereas inhibitory
exchange
Rs
CYCLASE-GTP CYCLASE-GDP
(active) R i (inactive)
hydrolysis
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receptors, including those for opiates, stimulate the GTPase activity
which converts GTP, bound to the adenylate cyclase-N protein complex,
to GDP.
TABLE 2
Effects of Na+  and Mg2 +on Basal and Dalamid Stimulated GTPase
in NG 108-15 Membranes*
Salt Added GTPase Activity
Basal 1 µM Dalamid
none 64.8 ± 2.5 67.9 ± 3.4
1OOmM NaCl 63.1 ± 2.5 66.0 ± 3.6
5mM MgCl2 51.0 ± 2.5 63.0 ± 0.7
lOOmM NaCl + 5mM MgCl2 30.0 ± 1.5 64.8 ± 4.4
*GTPase is expressed as pmols of GTP hydrolyzed/min/mg protein.
Data are means ± S.E. for triplicate determinations. Taken from
Koski et al.  (1982).
Because GTPase is an essential part of the adenylate cyclase mecha-
nism and opiates stimulate its activity, it  was natural to wonder
whether chronic exposure of cells to opiates modifies the activity
of the enzyme. Answering this question experimentally has been a
surprisingly difficult undertaking because of the unfortunate fact
that optimum conditions for the study of the GTPase require a re-
latively highly purified membrane. However, the stimulatory effects
of opiate pretreatment upon adenylate cyclase activity are largely
lost during the long times required to prepare such membranes.
Table 3 shows data obtained with membranes prepared from control
and opiate-treated NG 108-15 cells using a rapid preparative pro-
cedure to preserve some of the opiate-induced increase in adenylate
cyclase  act iv i ty .  As  shown in  the  table ,  t reatment  of  ce l ls  with
etorphine led to both increased adenylate cyclase activity and de-
c r e a s e d  G T P a s e  a c t i v i t y .  N e i t h e r  o f  t h e  s t r u c t u r a l l y  r e l a t e d
part ia l  agonis ts  tes ted af fected e i ther  enzyme act iv i ty .  These
data suggest that the chronic effects of opiates include a modifi-
cation of Ni which lowers its GTPase activity in a manner analagous
to  that  of  pertuss is  toxin  (Klee  e t  a l .  1984) .  Interest ingly ,  only
relatively pure agonists affect either adenylate cyclase or GTPase
a c t i v i t i e s .
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TABLE 3
Chronic Opiate Effects on Adenylate Cyclase and GTPase*
Adenylate Cyclase GTPase
Control l 0 0  ±  4 100 ± 3
Etorphine 1 3 2  ±  7 8 4  ±  9
Diprenorphine 111  ±  6 98 ± 8
Buprenorphine 111 ± 13 112 ± 17
*NG 108-15 cells were cultured for 48 hours in the presence of 1 µM
drug. Membrane suspensions were assayed in the presence of 100 µM
naloxone. Data are expressed as per cent of control ± S.E. of quad-
ruplicate determinations.
Until recently, little attention has been paid to the quantitation
of  opiate  agonist  e f f icacy or  to  the  quest ion of  the  re lat ionship
between efficacy in acute experiments and the ability of a substance
to produce tolerance and dependence. However, the precipitation of
abst inence  by part ia l  agonis ts  such as  nalorphine ,  for  example ,
clearly indicates a need for a more quantitative approach to the
question. As already seen in Table 1, measurements of adenylate
cyclase inhibition (or GTPase stimulation) by opiates at saturating
concentrat ions  of  drug provide  a  re l iable  quant i tat ive  index of
agonist  e f f icacy.  Because  of  the  greater  prec is ion of  adenylate
cyclase assays, we prefer to base efficacy determinations on them.
One immediately striking aspect of the data presented in Table 1 is
that morphine is clearly a partial agonist,  with less than 80% the
ef f icacy of  dalamid.  In  assess ing the  s igni f icance  of  th is  fact ,
it is important to remember that efficacy is defined so as to be
independent of potency (the concentrations at which drugs bind to
receptors or exert other actions) since it is based upon measure-
ments made at saturating levels of the drugs.
Because  morphine  is  a  part ia l ,  ra ther  than ful l ,  opiate  agonis t ,
much of  the  l i terature  in  which i t  was  used as  the  inducer  of
tolerance and dependence may need to be reexamined. As a case in
point, consider the effects of chronic opiate treatment upon recep-
tor numbers. It had been quite well established that chronic mor-
phine treatment has no measureable effect upon receptor numbers or
speci f ic i ty ,  both  in  animals  (Klee  and Streaty  1974 ;  Hol l t  e t  a l .
1975) and in NG 108-15 cells (Sharma et al. 1975a; Simantov et al.
1 9 8 2 ) .  R e c e n t l y  i t  h a s  b e c o m e  c l e a r  t h a t  a g e n t s  s u c h  a s  t h e
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enkephalins and etorphine effect dramatic decreases in the number
of opiate receptors present in neuroblastoma cells (Simantov et al.
1982) and that chronic naloxone administration can result in an
increased number  of  opiate  receptors  in  rat  brain  (Zukin,  th is
volume). Clearly, opiate receptor numbers can be regulated by the
prolonged presence of some agonists but not by others. We asked
whether there is a relationship between agonist efficacy and recep-
tor down-regulation in NG 108-15 cells by exposing them to each of
a series of opiates of defined efficacy for 48 hours and subsequent-
ly measuring receptor numbers. Following the opiate treatment, the
cells were washed and homogenized and the membranes were washed
further after exposure to GppNHp and Na+ at 37° in order to maximize
dissociation of the bound opiate. Receptor numbers were then mea-
sured by studying 3[H]-dalamid binding over a range of concentra-
tions between 1 and 40 nM. Scatchard analysis of the data gave the
r e s u l t s  l i s t e d  i n  T a b l e  4 .  T h e  r e s u l t s  s h o w  t h a t  o p i a t e s  w i t h
efficacies greater than 90% that of dalamid, and which are therefore
considered to be full agonists, lead to marked receptor down-regula-
tion. Enkephalin is apparantly somewhat weak in this respect, but
its concentration is greatly diminished during the experiment by
proteolys is  (Lampert  e t  a l .  1976) .  Opiates ,  inc luding morphine ,
with efficacies less than 80% that of dalamid do not produce signi-
ficant down-regulation. Because chronic morphine administration
leads to an increased adenylate cyclase activity and no receptor
down-regulation, the two may be completely independent manifesta-
tions of chronic drug treatment.
Opiate
None
Dalamid
Phenazocine
Etorphine
Enkephalin
Butorphanol
Naloxone
Diprenorphine
Morphine
Buprenorphine
TABLE 4
Opiate Regulation of Receptor Numbers
Receptor Numbers Remaining
% of control
100 (9)
9 (2)
18 (2)
21 (4)
55 (4)
76 (1)
83 (2)
Eff icacy
%
100
96
100
100
72
0
96 (4) 58
96 (4) 79
123 (4) 35
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I t  i s  of  some interest  that  chronic  morphine  adminis trat ion to
animals does not lead to a loss of receptors. The implication of
these findings is that the partial agonist character of morphine is
not limited to the delta receptors of NG 108-15 cells, but applies
t o  b o t h  t h e  m u  a n d  d e l t a  p o p u l a t i o n s  o f  r a t  b r a i n  a s  w e l l .
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Mechanisms of Multiple Cellular
Adaptation Processes in Clonal
Cell Lines During Chronic Opiate
Treatment
Ping-Yee Law, Michael T. Griffin, and Horace H. Loh
Among the various in vitro models for studies of opiate action,
the clonal cell line, neuroblastoma x glioma NG 108-15 hybrid
cells, represents the simplest model of brain origin in which the
molecular  basis  of  opiate  act ion is  being invest igated.  The
hybrid cells possess many neuronal properties, such as having
excitable membrane containing light and dense core vesicles;
also the hybrid cells can be synapsed onto striatal muscle cells
(Hamprecht 1977). Furthermore, the NG 108-15 cells possess a
homogeneous opiate delta receptor system (Chang et al. 1978) and
can synthesize opioid peptides (Glaser et al. 1983). The opiate
receptor is coupled to a well-defined second messenger system,
the adenylate cyclase. Opiate agonist inhibits the adenylate
cyclase activity (Sharma et al. 1975) and the agonist inhibition
requires the presence of Na+ and GTP (Blume et al. 1979). For
this delta receptor system, enkephalin and its analogs possess the
greatest potencies in regulating the adenylate cyclase activity
(Law et al. 1983). Most interestingly, the hybrid cells exhibit
adaptation processes in response to the chronic presence of opi-
ates. Continuous exposure of the NG 108-15 cells to the agonists
resulted in a gradual loss of opiate ability to inhibit adenylate
cyclase activity. Eventually, the intracellular CAMP level in
the presence of opiate returns to that in the control cells when
the opiates  are absent .  At  this  point ,  addit ion of  naloxone
results  in an increase in adenylate cyclase act ivity .  This
increase in the CAMP level in the hybrid cells could be the
biochemical correlate for the proposed increase in cyclic nucleo-
tide's metabolism during opiate withdrawal in the animal. Hence,
the hybrid cells represent a good model for studies of the chro-
nic opiate effect at the cellular level. In the current review,
we will examine the multiple cellular adaptation processes which
occur in the chronic presence of opiate agonists. The possible
mechanisms for these adaptation processes will be discussed.
MULTIPLE CELLULAR RESPONSES TO CHRONIC OPIATE TREATMENT
The ability of naloxone to increase the adenylate cyclase activity
in NG 108-15 cells after chronic opiate treatment led Sharma et al.
(1977) to conclude that the loss of opiate ability to inhibit aden-
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ylate cyclase activity was due to the concomitant increase of
the enzyme’s activity. The opiate receptor remained coupled to
the adenylate cyclase after chronic agonist treatment. This hy-
pothesis suggested that there was no desensitization of the
opiate receptor or uncoupling of receptor from adenylate cyclaee.
Loss of  opiate act ivity ,  or  tolerance to  the opiate drugs in
NG 108-15 cells, was simply due to the increase in production of
CAMP. In this model, the heterologous desensitization of other
receptors which inhibit the adenylate cyclase activity in NC 108-
15 cells is predicted, i.e., chronic exposure of the hybrid cells
to opiate agonist would eliminate or, at least, attenuate the
ability of muscarinic or alpha2-adrenergic agonist to inhibit the
adenylate cyclase activity. However, when such experiments were
carried out, it could be shown that opiate receptor desensitiza-
tion after chronic opiate treatment was homologous only (table
1). The ability of carbachol and norepinephrine to inhibit the
adenylate cyclase after 24 hrs of 10 nM etorphine treatment re-
mained intact, even though the ability of etorphine to inhibit
the adenylate cyclase activity was completely abolished. This
observation does not support the notion of concomitant increase
in adenylate cyclase activity as the cause of the observed loss of
opiate activity in NC 108-15 cells.
There is other evidence to support the hypothesis that the opiate
receptor is indeed desensitized during chronic drug treatment.
If the model proposed by Sharma et al. (1977) is correct, then
treatment of an opiate drug would produce the loss of all opiate
l igands ’  abi l i ty  to  regulate  adenylate  cyclase.  As shown in
figure 1, treatment of the hybrid cells with opiate ligands with
various intrinsic activities and potencies produces dissimilar
responses. Treatment of the NG 108-15 cells with enkephalin or
its analogs or an agonist such as etorphine results in a complete
loss of D-Ala2-Met5-enkephalin’s (DAME) ability to inhibit aden-
ylate cyclaee activity. However, treatment of the NG 108-15
cells with a partial agonist, such as cyclazocine or morphine,
though completely abolishing the partial agonist’s ability to
regulate the adenylate cyclase, did not completely abolish DAME’s
activity. In all these treatments, the magnitude of adenylate
cyclase activity increase was the same. Furthermore, concentra-
tion-dependent studies revealed that the concentration of drugs
required to elicit these two effects, the loss of opiate inhibi-
tion and the increase of adenylate cyclase activity, was not
identical. The concentration of etorphine to produce 50% loss of
opiate inhibition after 24 hrs of chronic treatment was deter-
mined to be 14.3±5.0 nM. This was considerably higher than the
concentration required to elicit the increase of adenylate cy-
clase activity. As shown in figure 2, at 1 nM etorphine, the
increase of adenylate cyclase after chronic treatment for 24 hrs
was already at its maximum.
The separation of the loss of opiate receptor activity and the
increase in the adenylate cyclase activity after chronic treat-
ment could be further demonstrated by the use of another cell
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TABLE 1. Chronic Etorphine Treatment on Receptors' Activities
in Neuroblastoma x Glioma NG 108-15 Hybrid Cells
Ligand-receptor binding
Receptor
Opiate,
5.9 nM 3H-diprenorphine
Muscarinic,
3H-QNB, 3.6 nM
2-Adrenergic,3H-Rauwolscine, 1.5 nM
Prostaglandin,
3H-PGE1, 1.2 nM
Regulation of 3H-cAMP level
-Adrenergic,
norepinephrine
IC50, uM
n H
Maximal inhibition, %
Muscarinic, carbachol
IC50 uM
nH
Maximal inhibition, %
Prostaglandin, PGE1
EC50, uM
nH
Maximal activity,
cpm/mg prot/20 min
Specific binding, fmole/mg protein
Control Chronic etorphine
596.0±18.7 200.0±12 (-66.3)
38.6±1.3 34.5±1.2 (-10.2)
59.9±6.5 62.6±4.6 (+7.9)
7.3±0.2
Control
6.8±0.4 (-6.5)
Chronic etorphine
2.08±0.36
1.50±0.17
50 .0± l . 9
1.92±0.50
1.40±0.16
41.0±2.3 a
0.99±0.31
1.55±0.16
49.3±2.3
2.12±0.04a
0.90±0.10a
35.9±2.3 a
0.103±0.018
1.15±0.23
0.108±0.022
1.16±0.16
2.96±0.04 x 105 2.85±0.02 x 105
Neuroblastoma x glioma NC 108-15 hybrid cells were treated with 10
nM of etorphine for 24 hrs. Receptor binding was carried out with
membrane preparations from the hybrid cells. Carbachol- or norep-
inephrine-inhibition of PGE1-stimulated production in chronically
treated cells was measured with 10 nM of etorphine present in
incubation mixture to prevent the spontaneous increase of cAMP due
to the absence of opiate agonist. The values presented are the
average ± S.E.M. of determinations from 3 cell samples. The
numbers in parentheses are the % changes in receptor binding after
chronic etorphine treatment.
a = p values <0.05 when compared with control.
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FIGURE 1. The relationship between the intrinsic activity of
opiate ligands and opiate receptor desensitization in NG 108-15
cells. PGE1 (5 uM)-stimulated cAMP production in suspensions of
hybrid cells were inhibited by various concentrations of D-Ala2,
Met5-enkephalin (DAME) in control  cel ls  ( -0-0- )  or  in cel ls
treated chronically with opiates Hybrid cells were
treated for 24 hrs with (a) 5 nM DAME, (b) 1.0 uM Sandoz FK33824,
(c) 100 nM cyclazocine or (d) 1.0 uM naloxone. Control activit-
ies in the absence of added opiates were 2.3±0.09 x 10 cpm/
mg protein/ 20 min (n = 9).
line, neuroblastoma N 18TG2. In these neuroblastoma cells, one
of the parents of NG 108-15 hybrids, opiate agonist also inhibits
adenylate cyclase activity (Law et al. 1982). Chronic treatment
of  this  cel l  l ine with etorphine also  produced loss  of  etor-
phine's ability to inhibit adenylate cyclase. However, addition
of naloxone after chronic treatment did not elicit an increase of
the intracellular CAMP level (figure 3). Hence, in this cell -
line, the loss of opiate activity after chronic treatment clearly
is not due to the concomitant increase of adenylate cyclase
activity.
During the chronic incubation of the neuroblastoma x glioma NG-
108-15 hybrid cells with opiates, a third cellular adaptation
process occurs.  Incubation of  the hybrid cel ls  with opiate
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FIGURE 2. Etorphine concentration-dependent desensitization of
the opiate receptor in NG 108-15 cells. Hybrid cells, cultured on
17 mm plates, were treated with various concentrations of etor-
phine for 24 hrs. PGE1 (5 uM)-stimulated 
3H-cAMP production was
determined in the presence of 100 uM naloxone (curve I) or in the
presence of 1 uM etorphine (curve II). Values represent the aver-
age ± standard error of the mean of 3 cell samples. Quadrupli-
cate 17 mm plates were used in each treatment. The control value
for PGE -stimulated 3H-cAMP production was 1.52±0.06 x 105 cpm/mg
protein/ 10 min.
agonist  resulted in a  decrease in detectable  opiate  binding
sites from the cell's surface, i.e., receptor down-regulation.
It can be demonstrated that receptor desensitization is not due
to receptor down-regulation, for both opiate agonists and par-
t ial  agonists  could desensit ize  the receptor .  However,  only
opiate agonist could elicit receptor down-regulation. As shown
in table 2, after treating the hybrid cells with approximately
5 X the Kd  value of various ligands, the decrease in the 
3H-
diprenorphine binding, a reflection of receptor density, was
observed with ligands with intrinsic activities greater than
0.9. Some metabolically labile peptides did not elicit down-
regulation in normal growth medium, which contains fetal calf
serum. Replacement of the serum with chemically defined med-
ium resulted in down-regulation by all opioid peptides following
chronic treatment. Opiate partial agonists, such as cyclazocine,
morphine, levorphanol and, and diprenorphine did not cause a reduc-
tion in 3H-diprenorphine binding. Cyclazocine, morphine and le-
vorphanol could attenuate diprenorphine's ability to regulate
adenylate cyclases. Furthermore, concentration-dependent studies
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FIGURE 3. Effect of the concentration of etorphine during prein-
cubation (2.5 hrs) on PGE -stimulated cyclic AMP production. (a)
NG 108-15 cells (2.3 x 105 cells) were treated with various con-
centrations of  etorphine for  2 .5 hrs.  Sixty min before the
assay, (3H)adenine was introduced to the media containing varying
concentrations of etorphine. The amounts of radioactivity being
taken up by the cells in the presence and absence of etorphine were
identical .  During the enzyme assay (10 min at  37°C) ,  after
removal of  (3H)adenine from the preincubation mixture, 10 uM PGEl
+ 1 uM etorphine (curve I) or 10 uM PGE1 + 100 uM naloxone (curve
II) were added. (b) Neuroblastoma N 18TG2 cells were pretreated
with etorphine as described in (a). The number of cells present
in each assay was 9.5 x 105. Curve I represents the amount of 3H-
cyclic AMP formed during the 10 min assay in the presence of 10
uM PGE1 + 1uM etorphine. Curve II represents the 
3H cyclic AMP
formed in the presence of 10 uM PGE1 + 100 uM naloxone.
also revealed the differences in the concentration of drug re-
quired to  el ic i t  these two responses.  The concentrations of
drugs to promote down-regulation are analogous to the drugs’ Ki
values while the concentrations to promote desensitization are
similar to the Kd values. Time-dependent studies also suggested
differences in receptor desensitization and receptor down-regula-
tion.
Receptor desensitization occurs prior to the appearance of re-
ceptor down-regulation. Reappearance of opiate regulation of
adenylate cyclase activity precedes the reappearance of opiate
binding. Cycloheximide and tunicamycin both can prevent the
reappearance of the binding sites after chronic treatment, but
neither inhibitor  prevents  the desensit ization of  the opiate
regulation of the adenylate cyclase. Therefore, it can be con-
cluded that the receptor desensitization and receptor down-regula-
tion are two separate cellular adaptation processes during chro-
nic opiate treatment. It can be concluded, also, that there are
multiple cellular processes in response to the presence of the
opiate agonist.
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TABLE 2. Chronic Treatment of NG 108-15 Hybrid Cells with Opiate
Alkaloids and Opiate Peptides: Relationship Between Intrinsic
Activity and Ability to Down-Regulate the Opiate Receptor
Opiate Alkaloids Intrinsic % Control
Incubation Concentration Activitya Binding
Etorphine, 10 nM 1.00 41.0±0.7
Ethylketocyclazocine. 500 nM 0.96 41.3±1.3
GPA1657, 500 nM 0.96 64.9±7.9
Cyclazocine, 50 nM
Diprenorphine, 20 nM
Levorphanol, 300 nM
Metazocine, 600 nM
Morphine, 100 uM
N-allylnormetazocine, 200 nM
Nalorphine, 300 nM
Oxymorphone, 400 nM
0.62 91.8±2.9
0.70 95.7±3.7 108±8.0*
0.65 96.8±6.7
0.69 105±3.4
0.69 98.2±6.3 92.6±4.7*
0.40 100±10 93.3±4.8
0.18 103±2.9*
0.68 98.1±2.9
GPA2163, 500 nM 0 98.7±7.7
Naloxone, 20 uM 0 100±5.7 95.8±4.1*
Opioid Peptides
Leu5-enkephalin, 20 nM
Met5-enkephalin, 20 nM
D-Ala2,Met5-enkephalin, 10 nM
D-Ala2,Met5-enkephalinamide.
15 nM
D-Ala2,D-Leu5-enkephalin, 5 nM
Sandoz FK33824
N-CH3-D-Ala
2,D-Met5-enkephalin,
500 nM
N-CH3-D-Ala
2,D-Leu5-enkephalin,
5 00 nM
Dynorphin 1-13, 300 nM
-Neo-endorphin, 100 nM
Bh-endorphin, 100 nM
0.94
0.95
0.98
0.98
0.92
1.01
0.94
0.94 52.7±4.7
0.96 83.9±1.9 65.1±2.7*
0.97 27.9±2.6*
0.99 65.2±3.2*
50.6±2.4*
47.6±5.8*
78.8±3.5 50.6±2.6"
53.3±8.9
51.5±8.9
41.4±3.7
50.4±4.9
NG108-15 hybrid cells were incubated with various opiates or opi-
oid peptides for 24 hrs at 37°C. Concentrations of ligands were
approximately 5 x the Kd values for each ligand. Before assay,
identical concentrations of opiate ligands were added to control
plates and incubated at 37°C for 5 min, then washed free of li-
gands and incubated with 3H-diprenorphine to measure binding.
Control binding was 497.0±12.4 fmole/mg protein (n=39). Values
are the average ± standard error SEM from three cell samples.
* Denotes incubations were carried out in Sato medium (Law et al.
1983). a Intrinsic activities of opiate ligands were from Law et
al. 1983.
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POSSIBLE MECHANISM OF RECEPTOR DESENSITIZATION
As discussed in the previous section, loss of the opiate ago-
n i s t ' s  ab i l i t y  t o  r egu la te  adeny la te  cy c lase  a c t i v i t y  a f t e r
chronic opiate treatment is due to the homologous desensitiza-
t ion of  the opiate receptor .  To faci l i tate  understanding the
mechanism involved, possibly involving the uncoupling of the
binding sites from the effector, it is necessary to investigate
agonist binding properties in the control membrane. In other
receptor systems, in which the agonist regulates adenylate cy-
clase activity (e.g., the beta-adrenergic receptor) the ability of
agonist to induce the receptor to change to a high affinity state
is a prerequisite for activity. The intrinsic activities of vari-
ous beta-adrenergic agonist correlates with the percent of the
receptor in the high affinity states after agonist binding (Lef-
kowi t z  e t  a l .  1980 ) .  Because  th i s  h igh  a f f in i ty  s ta te  i s  a
measurement of coupling, desensitization of the receptors would
result in the decrease in the percent of agonist-induced form-
ation of the high affinity states (Lefkowitz et al. 1980). This
results in an overall reduction of the agonist affinity for the
binding sites.
Apparently, opiate receptor desensitization follows such a path-
way. Computer analysis of competition binding data indicated
that opiate binding sites in the NG 108-15 cells could undergo
changes which represent multiple affinity states (table 3). In
the presence of Na+ and guanine nucleotides, the two components
which are required for coupling, DADL could change the receptor
from a single affinity state in the presence of Mg+2 to show at
least  two aff inity states.  The K d  o f  the high af f inity  s ites
compare favorably with that of the Ki value of DADL to inhibit
adenylate cyclase. If this altered affinity is related to recep-
tor coupling, then it should be agonist specific. Opiate anta-
gonist naloxone competes with 3H-diprenorphine binding in a
single affinity manner, regardless of the condition of the binding
assays. As in the case of B-adrenergic receptor desensitization,
chronic opiate treatment of the NC 108-15 cells reduces the
percent of agonist-induced high affinity states. After exposing
the hybrid cells to 100 nM DADL for 3 hrs at 24°C, when there was
minimal receptor down-regulation but significant receptor desen-
sitization, competition binding studies with DADL in the presence
of Na+ revealed a reduction of the percent of binding sites in
the high affinity states (figure 4). There was a decrease from 75%
of the total binding sites in the high affinity states (Kd = 2.5
nM) to 45% in the DADL treated membrane. This resulted in an
overall reduction of the DADL affinity constant from 12.5 nM to
269 nM. Thus, chronic treatment of hybrid cells with opiate
agonists results in the uncoupling of the binding sites from the
effector systems. What causes this uncoupling remains to be
elucidated.
RECEPTOR INTERNALIZATION AS THE CAUSE FOR RECEPTOR DOWN-REGULATION
Another cellular response to the chronic opiate treatment is the
disappearance of detectable binding sites from the cell surface.
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In other polypeptide hormone receptor systems (e.g., insulin,
light-density-lipoprotein and epidermal growth factor), down-regu-
lat ion of  the receptor  is  due to  the internal ization of  the
receptor (Brown et al. 1983). Receptor internalization usually
is accompanied by the internalization of the ligand. As a matter
of fact, Chang and his coworkers (Chang et al. 1982), using
neuroblastoma N4TG1, reported the accumulation of 3H-DADL within
the cells during chronic treatment with the radioactive peptides.
However, chronic treatment of the cell with 10 nM 3H-DADL did
TABLE 3. DADL Affinities for Opiate Receptor in NG 108-15 Cells
under Various Conditions.
DADL affinities were determined by computer analysis of competi-
tion binding experiments carried out with P2P3 membrane prepara-
tions of NG 108-15 hybrid cells. Membranes equivalent to 0.25 mg
3H-diprenorphine, 2 nM. Binding assays were carried out at 24°C
protein were used per assay. Opiate receptor was labelled with
for 90 min.
not result in the accumulation of radioactivity. Rather, there
was a time-dependent decrease in the 3H-DADL associated with
the cells, which paralleled that of the 3H-diprenorphine binding
decrease. These observations suggested that either down-regula-
t ion of  opiate  receptors  in NG 108-15 cel ls  did not  involve
receptor internalization or that internalization occurred without
accumulation of the opiate ligands. These two possibilities were
resolved by carrying out the chronic peptide exposure in the pre-
sence of chloroquine, a lysosomotropic agent. In the presence of
0.1 mM chloroquine, which inhibited the degradation process within
the lysosomes, accumulation of 3H-DADL within the lysosomes was
observed during chronic treatment. The magnitude of increase in
3H-DADL accumulated corresponded to the magnitude of receptor
down-regulated. The intracellular location of the isotope could
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FIGURE 4. DADL affinities' alteration after chronic opiate
treatment. NG 108-15 cells treated with 100 nM DADL for 3 hrs at
24°C were harvested and excess DADL was removed by repeated wash-
ing of membrane preparations. 3H-Diprenorphine binding was car-
ried out in the presence of various concentrations of DADL. Com-
puter analysis of binding data was then carried out.
represents binding data with control membranes and repre-
sents chronic opiate-treated membrane.
KH = Kd for high affinity state
KL = Kd for low affinity state
RH = receptor in high affinity state
RL = receptor in low affinity state
be demonstrated by insensitivity toward trypsin treatment, inabil-
ity of excess diprenorphine to displace the accumulated 3H-DADL,
and by the Percoll gradient fractionation of the subcellular par-
ticles. There was a time-dependent translocation of the radioac-
tivity from the plasma membrane-enriched fractions to the lyso-
some-enriched fractions in the Percoll gradients (figure 5). The
translocation could be prevented by lowering the incubation
temperature during chronic treatment. The accumulated 3H-DADL
can be demonstrated to be associated with macromolecules by the
detergent extraction of the 3H-DADL-macromolecular complexes and
resolution of free ligand from the bound form using Sephadex G-50
chromatography. The accumulated 3H-DADL was released into the
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medium upon removal of chloroquine and exhaustive washing of the
cells. Hence, it is concluded that during chronic opiate agonist
treatment, internalization of the ligand-receptor complexes occur
with the delivery of the complexes to the lysosomes, where degra-
dation of the receptors occurs. The free ligands are then re-
leased into the medium.
The mechanism for this overall decrease of receptor level in
the cell surface is unknown. Although our chloroquine studies
indicated that the receptor internalizes, our cycloheximide and
tunicamycin studies indicated that the degradation, synthesis
and processing of the receptor were not affected by the presence
of agonist. Chronic opiate treatment of the hybrid cells must
then interfere with the normal recycling process of the opiate
receptor in order to elicit the observed down-regulation. At
which step of the life cycle
act remain to be determined?
of the receptor does the agonist
FIGURE 5. Time-dependent translocation of 3H-DADL from the plas-
ma membrane to the lysosomes of NG 108-15 cells. Hybrid cells were
incubated with 10 nM 3H-DADLE in the presence of 0.1 mM chloroquine
for (a) 5 min, (c) 1 hr, (d) 2 hrs, (e) 4 hrs, and (f) 12
hrs. Percoll gradient fractionation of the homogenates (minus
nuclei) was carried out. Then, 0.65 ml fractions were collected
and radioactivity in each fraction was determined. In (e) and
( f ) , represents the Percol l  gradient prof i le  of  the
homogenates from the hybrid cells treated with 10 nM 3H-DADL
chronical ly  in the absence of  chloroquine.  In (b) ,  the cel ls
were treated with 0.1 mM chloroquine for 4 hrs and exposed to
3H-DADL for 5 min at 37°C.
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INVOLVEMENT OF CYTOSOLIC FACTORS IN THE INCREASE OF ADENYLATE
CYCLASE ACTIVITY
It has been suggested by Nirenberg and his coworkers that the
increase in adenylate cyclase act ivity after  chronic  opiate
treatment was not due to the de novo synthesis of adenylate
cyclase molecules, but rather due to the activation of the exist-
ing enzymatic molecule. Wilkening and Nirenberg (1980) suggested
that serum lipids or linoleic acid were required for the full
expression of this increased activity since the culturing of the
hybrid cells in delipidized serum reduced the magnitude of the
adenylate cyclase response, an effect which was reversed by the
addition of linoleic acid. We can demonstrate that selective
hydrolysis of the phospholipids with phospholipase C, but not
phospholipase A2, can attenuate the increase of the adenylate cy-
clase activity during chronic treatment. However, culturing hy-
brid cells in a serum-free chemically-defined medium did not
alter the magnitude of the increased response. Hence, it can be
concluded that the acyl side chains of the phospholipids did not
play a role in the increase of the adenylate cyclase activity
during chronic opiate treatment.
If an increase in membrane fluidity cannot account for the posi-
tive regulation of adenylate cyclase activity, then what cellu-
lar components could stimulate adenylate cyclase activity during
chronic treatment? One such candidate is calmodulin. It has
been reported that opiates can acutely decrease the amount of
calmodulin bound to the plasma membrane (Nehmed et al. 1982) of
the hybrid cells. Since the ability of calmodulin to stimulate
adenylate cyclase is well known (Brostrom et al. 1978), it is
possible that during chronic treatment, there is a retransloca-
tion of the calmodulin. There is evidence to suggest that the
naloxone-induced increase in adenylate cyclase activity following
chronic opiate treatment may be calcium dependent. When the
experiments with intact cells were carried out in calcium free
medium, in the presence of EGTA, it could be demonstrated that
the increase in adenylate cyclase is attenuated. Furthermore,
addition of La+3, the calcium antagonist, completely abolished the
increase in adenylate cyclase activity (figure 6). When membrane
fragments are prepared from hybrid cells chronically treated with
opiates in the presence of EGTA, a reduction in the magnitude of
the increased adenylate cyclase activity is observed. Upon com-
bining the cytosol preparations, there was a potentiation of the
increased activity (table 4). Intermixing of membranes isolated
from both control cells and opiate treated cells with cytosols
from these same two conditions revealed that maximal stimulation
of the adenylate cyclase was achieved when the chronic opiate-
treated cytosol was added with the membranes isolated from cells
treated with opiates. Resolution of the cytosol preparations
with a Bio-Gel P6DG desalting column revealed two components
which stimulated adenylate cyclase. One component, which is at
the void volume of the column, representing a M.W. greater than
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FIGURE 6. Effect of La+3 and Other Cations on Naloxone-Induced
Increase in Adenylate Cyclase Activity.
5,000, is calcium dependent (figure 7). The other component,
which has a molecular weight approximately equal to 300, is not
calcium dependent. We have determined that a second component
which stimulates adenylate cyclase activity is adenosine, since
its  act ivity  is  inhibited by 1)  an adenosine antagonist ,  2)
desensitization of the cells to adenosine and 3) adenosine deamin-
ase. During chronic opiate treatment, there was an apparent
increase in the adenosine level within the hybrid cells. Further-
more, the activity of adenosine and the first component, possibly
calmodulin, is synergistic in cells chronically treated with an
opiate. Hence, a model for the increase of the adenylate cyclase
could be formulated to involve these two components. One can
postulate that after chronic opiate treatment there is an increase
in the efficiency of coupling between stimulatory receptors such
as adenosine, and an increase in binding of calmodulin to the
adenylate cyclase molecules. Since phospholipase C could attenu-
ate the increase, and phospholipase C could hydrolyze the polar
head groups which bind calcium, and since there are also reports
of alteration in ganglioside metabolism during chronic opiate
treatment (another calcium binding component), the increase in
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the adenylate cyclase activity could be due to an alteration in
the membrane-bound calcium level in the plasma membrane. These
events must remain under the control of the opiate receptor,
since the increase in adenylate cyclase activity is only observed
upon the removal of opiate agonist. This hypothesis is currently
under investigation in our laboratory.
TABLE 4. Effect of Cytosolic Factors on Adenylate Cyclase
Activities Following Acute and Chronic Etorphine Treatment.
Adenylate Cyclase Activity (pmole/min/mg protein)
% Increase % Increase
Additions Over Control Chronic Over Control
to Membrane Control Membranes Etorphine Membranes
None 3.35±0.10 4.88±0.43 ±  4 5 . 8
Peak I
(control)
6.22±0.76 ± 85.9 8.89±0.76 ± 165.6
Peak II
(control)
9.01±1.05 ± 169.5 10.08±0.35 ± 201.0
Peak I + II 11.56±0.85
(control)
± 245.1 16.14±1.04 ± 381.9
Peak I 8.08±0.20 ± 141.2 10.85±0.65 ± 223.9
(etorphine)
Peak II 10.47±0.88 ± 212.8 12.74±0.05 ± 280.3
(etorphine)
Peak I ± II 180.2±1.96
(etorphine)
± 437.9 25.81±1.84 ± 670.7
Following vehicle or chronic etorphine treatment (100 nM, 16
hrs), cells were lysed and separated into membrane (control and
etorphine) and cytosol (control and etorphine) preparations.
Cytosol was further separated by column chromatography into two
fractions (Peak I and Peak II). Adenylate cyclase activity was
assayed in the presence of 100 nM etorphine + 400 uM naloxone and
contained equal equivalents of cytosol and membrane protein.
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FIGURE 7. Adenylate cyclase activity profiles of cytosol from
chronic etorphine-treated cells following gel chromatography on a
Bio-Gel P-6DG desalting column (exclusion limit 6,000 daltons).
Hybrid cells were treated with 1 uM etorphine for 4 hrs and sepa-
rated into cytosolic and membrane fractions. Following chromato-
graphy, equal portions of cytosol fractions were added back to
membrane fragments and adenylate cyclase was assayed in the
presence and absence of 0.5 mM Ca
++.
CONCLUDING REMARKS
From our current studies, it is clear to us that multiple cellu-
lar adaptation processes occur during chronic opiate treatment.
Thus far, we have identified three: receptor desensitization,
receptor down-regulation and the increase in adenylate cyclase
activity. This does not mean that these three processes are the
only ones. Because of the complexity of the cyclic nucleotide's
systems,  i t  is  possible  that  other cel lular reactions which
involve the cyclic nucleotides, e.g., protein phosphorylation,
are also altered during chronic opiate treatment. A possible
mechanism for receptor desensitization, i.e., the uncoupling of
the receptor from the effector system, could be caused by a
phosphorylation or dephosphorylation of the receptor molecules.
Other cellular adaptation processes remain to be identified.
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If one assumes that receptor desensitization and increase in
adenylate cyclase activity after chronic treatment are the bio-
chemical correlates of tolerance development and the dependence
behavior (hyperactivity of the system), then from our current
data, it could be suggested that these two events are separate
cellular adaptation processes. The mechanisms involved are dif-
ferent and it is possible to induce one process without inducing
the other. Hence, probably, tolerance and dependence behavior in
animals are also two separate processes.
Although the neuroblastoma x glioma NG 108-15 hybrid cells have
proven to be an excellent model in studies of the molecular
basis  of  chronic  opiate ef fects ,  one must real ize  i ts  l imita-
tion. Unfortunately, most of the observations reported with
NG 108-15 cells have not been repeated with brain preparations.
Conceivably, because the hybrid cells are transformed cells,
there might be some unusual expression of chromosomal material.
However, one must also realize that the complexity of the cell
types in brain might mask some of the effects. For example,
not until recently, because of the relatively small inhibition
(20%), opiate inhibition of brain striatal adenylate has not been
reported.  Thus,  the fai lure to  observe opiate ef fects  in the
brain similar to those in the hybrid cells does not necessarily
invalidate the model. On the other hand, interpretation of the
results  from the model  should be restrained,  also.  I f  such
guidelines are followed, the studies with neuroblastoma x glioma
NG 108-15 hybrid cells can provide us with some excellent insights
into the molecular basis of chronic opiate action.
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The Opioid-Induced Desensitization
(Tolerance) in Neuroblastoma X
Glioma NG 108-15 Hybrid Cells:
Results from Receptor Uncoupling
Michael Wüster and Tommaso Costa
The phenomena of tolerance and physical dependence arising from
chronic opiate exposure have attracted the interest of numerous
investigators for many years, and several concepts for the under-
lying biochemical processes have been advanced (Collier 1980;
Goldstein and Goldstein 1968; Martin 1968; Shuster 1961). The
different theories, though diverging with respect to the precise
nature of the adaptive mechanisms, are in agreement that the
developnent of both tolerance and dependence is due to the same
substrate.
Investigations from this laboratory on the development of opioid
tolerance and dependence in isolated tissue preparations rejected
the idea of a common mechanims between these two phenomena (see
Schulz and Herz,this volume). The isolated mouse vas deferens,
offering a system where extremely high degrees of opioid tolerance
can be developed, does not show any sign of dependence, as evi-
denced by the absence of withdrawal signs after discontinuing opi-
oid action, as well as the lack of increased sensitivity towards
excitatory compounds under these conditions (Gillan et al. 1979,
Schulz et al. 1980). Another classical tissue preparation used to
study opioid effects, the isolated guinea pig ileum preparation,
exhibits both tolerance and dependence on chronic opioid treat-
ment. It is obvious, however, that a quantitative correlation of
both phenomena is missing; indeed, in the mouse vas deferens most
of the tolerance development occurs without a concomitant genera-
tion of dependence (Schulz et al. 1982, Wiister et al. 1982).
Electrophysiological investigations in the central nervous system
have revealed that the locus coeruleus slices, obtained from mor-
phine-pretreated animals, display a significant degree of opioid
tolerance; again, no signs of dependence are detectable (Andrade
et al. 1983). Taken together, there are increasing indications
that opioid tolerance and dependence may be generated by distinct
adaptive processes; the underlying biochemical mechanisms for
these events, however, are still obscure.
These difficulties are due mainly to the extreme complexity of
neuronal networks in both the central and peripheral nervous sys-
tem, which severely limits any investigation into the cellular
processes bywhichopioidreceptors exert a control on neuronal
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activity. It is evident that such studies are test perfomed on in
vitro systems such as cultured cell clones; their availability has
facilitated numerous studies on the cellular regulation of the
intracellular second messenger system, adenylate cyclase. The
classical cell clone for investigations of opioid-receptor inter-
actions is the mouse neuroblastoma x rat glioma hybrid cell line
NG 108-15 which has been extensively employed to study the cellu-
lar mechanisms of opioid-receptor mediated inhibitory effects
(see also W. Klee and H.H. Loh, this volume). Apart from the opioid
receptors, there are other inhibitory receptors (adrenergic,
cholinergic) that control cAMP-synthesis in these cells (Traber
et al. 1975a, Hamprecht 1977). Also, excitatory receptor systems
(prostaglandin, adenosine) have been demonstrated in this cell
line (Hamprecht 1977). Thus, a single pool of adenylate cyclase
is under multireceptor control (Sabol and Nirenberg 1979).
The experiments described here focus on the problem of whether
opioid-induced tolerance and dependence result from a common bio-
chemical process within the opioid receptor system. There are a
number of questions of particular interest: 1. Is tolerance devel-
opment towards opioid agonists associated with desensitization
towards the other prototype inhibitory compounds acting via differ-
ent receptor types? The recent concept of receptor functioning
supports the existence of a common intermediate for excitatory
as well as inhibitory hormone receptors (N-unit, G/F protein),
(Rodbell 1980), but their significance for the adaptive processes
has not yet been investigated. 2. Is the development of subsensi-
tivity towards opioids necessarily correlated with supersensitivi-
ty of adenylate cyclase towards excitatory hormones? Earlier inves-
tigations employing this cell clone have suggested that an increase
in adenylate cyclase activity as a consequence of chronic opioid
receptor activation is the common biochemical mechanism underlying
both tolerance and dependence (Sharma et al. 1975; Traber et al.
1975b). 3. What is the significance of the recent investigations
that revealed a dam-regulation of opioid binding sites in neuro-
blastma x glioma hybrid cells as a consequence of prolonged treat-
ment with particular opioid agonists (Chang et al. 1982; Law et
al. 1982)? Receptor down-regulation could eventually explain a
phenomenon such as drug tolerance but not dependence.
Mouse neuroblastoma x rat glioma hybrid cells NG 108-15 were kindly
donated by Dr. B. Hamprecht, Würzburg, FRG, and cultured as de-
scribed (Hamprecht 1977). Chronic drug treatment was performed
over a 24-hr period by the addition of different concentrations of
D-Ala2,D-Leu5-enkephalin (DADL), morphine or other opioid agonists
to the cell medium. Thereafter, cells were harvested and divided
into aliquots to test for the acute effects of DADL and other in-
hibitory compounds upon the PGEl-stimulated cAMP-formation. Care
was taken to maintain during the acute testing period the drug
concentration which was employed for the chronic treatment, in
order not to disturb the newly established equilibrium. Details
of the methods and materials employed are given elsewhere (Wüster
et al. 1983).
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Figure 1. Effect of chronic DADL pretreatment upon the inhibition
of PGEl-stimulated CAMP accumulation by an acute DADL challenge.
Values are given as percent of the respective cAMP content ob-
tained in the absence of the acute DADL. Each point is the mean
of three experiments performed in duplicate. SEM was generally
less than 10%.
DADL inhibits the PGEl-stimlated cAMP accumulation in control
cells by 75%. Pretreatment of cells for 24 hr with increasing
doses of DADL resulted in a dose-dependent decrease in the inhibi-
tory effect of a subsequent acute opioid challenge (figure 1). It
was apparent that the pretreatment solely affected the maximal in-
hibition obtainable: the doses needed for a half-maximal effect
were not significantly different from controls. These findings
are at variance with results obtained in the intact animal and in
isolated tissue preparations such as the guinea pig ileum and the
mouse vas deferens, where drug tolerance is characterized by a
parallel shift of the dose-effect curve to the right. Drug toler-
ance has been explicitly defined as a state of the organism, where
"an increased dosage will again elicit the typical drug response"
(Goldstein 1974). The findings with the opioid-pretreated hybrid
cells obviously do not fit such a definition; it is appropriate,
therefore, to employ the term "desensitization" rather than "tol-
erance" for the observed effect. However, the correlation of the
desensitization observed in hybrid cells to the tolerance phe-
nomena in intact nervous tissues is indicated by the fact that
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careful analyses of tolerance phenomena have, in fact, revealed
that similar noncompetitive mechanisms also occur in the isolated
guinea pig ileum (Schulz, unpublished) and intact animals (Bläsig
et al. 1979).
Complete desensitization of NG 108-15 cells by DADL occurred with
a treatment of 100 nm DADL for 24 hr. Thus, doses which induce
a maximal inhibitory effect in naive cells also produce a maximal
desensitization after long-term exposure. This close correlation
between the dose necessary to produce maximal acute inhibition
and maximal desensitization was also confirmed using other types
of opioid agonists. Morphine and dynorphin A produced results
qualitatively identical with those of DADL; a concentration of
100 µM morphine and l µM dynorphin A induced a maximal inhibition
and a maximal desensitization. These experiments furthermore re-
vealed a complete cross-desensitization between the different
prototypes of opioid ligands, supporting the notion that NG 108-15
cells contain a homogeneous opioid receptor population (Chang
et al. 1978; McLawhon et al. 1981).
Opioid-desensitized cells were also tested for dependence, as re-
vealed by the ability of the opiate antagonist naloxone to precip-
itate a "withdrawal sign" in the form of elevated cAMP-levels.
However, these "withdrawal signs" were either highly variable or,
in highly desensitized preparations, not apparent. Indeed, a nalox-
one challenge affected only preparations which had not yet re-
gained their initial (naive) cAMP levels, as the doses of DADL
or morphine were too small to induce a complete desensitization
within 24 hr. Thus, the activity of naloxone was attributed to
the reversal of a still persisting agonistic effect in these
preparations. A minor (< 20%) net overshoot (rebound effect) of
cAMP formation over control data was observed in some of these
experiments.
The specificity of opioid desensitization was investigated using
non-opioid compounds by testing their inhibitory effect on cAMP-
formation. The adrenergic agonist noradrenaline and cholinergic
agonist carbachol retained their potencies, irrespective of the
degree of desensitization which was displayed towards opioids
(figure 2). Thus, the opioid-induced desensitization is "specific"
and does not occur with a change of the inhibitory effects media-
ted via adrenergic or muscarinic receptors. Accepting that the
different inhibitory receptors control adenylate cyclase activity
through a uniform transducer component (Ni), these findings there-
fore reveal that the adaptive process is localized neither at the
level of the catalytic unit nor at the Ni-component.
Down-regulation of opioid binding sites within the cell membrane
has been demonstrated to occur after long-term DADL administration
(Chang et al. 1982; Law et al. 1982) and could explain an opioid-
specific desensitization; however, the present data are at variance
with such a hypothesis. In contrast to effects seen with DADL,
chronic morphine treatment does not affect receptor density in
the cells (Chang et al. 1982), yet, the present investigation re-
veals an identical desensitization process. Furthermore, the DADL-
139
FIGURE 2. Effect of maximal inhibitory concentrations of DADL,
noradrenaline and carbachol on the PGEl-stimulated cAMP forma-
tion in controls, morphine and DADL-pretreated preparations. For
further information see legend to figure 1.
induced changes in opioid receptor density become apparent at
concentrations which are 10- to 100-fold higher than those re-
quired for desensitization.
In summary, these results draw attention to the functional in-
tegrity of the opioid binding protein as the point where the
opioid-induced adaptive processes occur. It is concluded, there-
fore, that the binding sites in these cells are still capable of
binding opioid ligands, but have lost their ability to function
properly in mediating agonistic effects to the subsequent N-units.
The concept that chronic opioid treatment of NG 108-15 hybrid
cells results in an uncoupling of the binding sites from Ni-units
has gained considerable support from our experiments employing a
recently available toxin from Bordetella pertussis (pertussis toxin,
islet activating protein, IAP). IAP has been shown to catalyze the
ADP-ribosylation of a specific, neuronal membrane protein with the
molecular weight of 41,000 daltons and this coincides with an
elimination of all inhibitory hormone effects upon adenylate
cyclase (Katada and Ui 1981; Hazeki and Ui 1981; Aktories et al.
1983; Hildebrandt et al. 1983). Thus, by analogy with excitatory
hormone effects being abolished by cholera toxin, pertussis toxin
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FIGURE 3. Effect of pertussis toxin pretreatment upon the inhibi-
tion of PGE1-stimulated CAMP accumulation by DADL. For further
explanation, refer to legend of figure 1.
impairs the signal transmission at inhibitory hormone receptors
by permanently affecting the function of Ni (Katada and Ui 1982;
Hildebrandt et al. 1983).
Using methods similar to chronic opioid treatment, NG 108-15
hybrid cells were grown in the presence of increasing concentra-
tions of pertussis toxin and tested for the ability of DADL to
inhibit PGE-stimulated cAMP formation (figure 3). As was observed
with chronic DADL treatment (figure 1), pertussis toxin dose-
dependently reduced the maximal inhibitory effect of DADL. With
1 ng x ml-l of toxin all opioid effects were completely abolished.
Concerning the inhibitory effects of adrenergic and muscarinic
agonists on cAMP accumulation, the results are identical with
those of DADL (data not sham). The mechanism underlying the per-
tussis toxin effects may be related to the particular modulations
which are exerted in the binding of opioid agonists, but not of
antagonists, in neuroblastoma x glioma hybrid cells (Costa et al.
1983).
When comparing the kinetics of pertussis-toxin induced desensitiza-
tion (figure 3) with those produced by chronic opioid treatment
(figure 11, the similarity is striking. In both cases the curves
are superimposable: the maximal opioid effects are changed without
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alterations of half-maximal effective concentrations. This indi-
cates that both treatments are non competitive with respect to
the ligand inhibitory effect. This may suggest that although the
phenomena are induced in both cases at different sites and they
differ in selectivity- both treatments have a similar consequence:
regulatory proteins (Ni) have an impaired ability to interact with
the receptor binding sites and therefore fail to receive hormone
signals.
CONCLUSIONS
The results presented here may advance our understanding of adapt-
ive processes occurring as a consequence of chronic opioid action.
On theoretical grounds, a unitary mechanism underlying both toler-
ance and dependence has been postulated for many years and there
are several studies in support of such a concept. Indeed a signifi-
cant role for adenylate cyclase in the expression of opiate toler-
ance and dependence appeared indicated (Sharma et al. 1975). In re-
cent years, however, an increasing number of reports have investi-
gated the relationship of the development of opioid tolerance and
dependence in vitro: in several cases data from these studies re-
vealed a pronounced dissociation of the two phenomena (Schulz et
al. 1980; Schulz et al. 1982; Wüster et al. 1982; Andrade et al.
1983). Accordingly, the present data on NG 108-15 hybrid cells
further support the notion of a development of opioid tolerance
(desensitization) separate from the development of dependence.
This hypothesis is strengthened considerably by the cross-tolerance
studies, which reveal an unaltered sensitivity of the adenylate
cyclase pool of opioid-pretreated cells towards non-opioid inhibi-
tory compounds. An analogous investigation, employing the identical
cell clone, has reported similar observations on carbachol-pre-
treated preparations (Green and Clark 1982). Thus, the earlier
concept which assumed a counterregulatory hypertrophy of adenylate
cyclase (Sharma et al. 1975) is in need of reevaluation. Evidence
now indicates that chronic opioid receptor activation results from
an inability of the binding proteins to properly interact with the
subsequent N-units, thus failing to transmit its signal to the
catalytic units of adenylate cyclase.
In contrast to these in vitro observations, chronic opioid admini-
stration into an intact animal or humans clearly induces the devel-
opment of both tolerance and dependence. Extrapolating the observa-
tions derived from model preparations such as the NG 108-15 hybrid
cells, it may be speculated that drug tolerance and dependence are
initiated by different biochemical mechanisms and are localized at
separate neuronal levels. Opioid tolerance in vivo may, indeed, be
produced by an uncoupling of the opioid binding sites, analogous
to the events in in vitro preparations. Drug dependence, on the
other hand, is displayed in intact nervous circuits, and may be,
for example, caused by a compensatory hypertrophy of any intra- or
extracellularly localized mechanism which is involved in signal
transmission within an opioid-affected nervous pathway. A prereq-
uisite for the initiation of such a hypertrophy, however, is a
continuing opioid inhibitory effect. Consquently, adaptation to-
142
wards opioids within the complexity of an intact nervous system may
be characterized by the simultaneous uncoupling of particular
opioid receptor populations, resulting in the phenomenon of drug
tolerance, whereas others remain coupled. Their persisting in-
hibitory effect generates a hypersensitivity within the inhibited
pathway, an event which gives rise to withdrawal symptoms upon
cessation of the opioid inhibitory effect.
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Opiate Receptor Upregulation and
Functional Supersensitivity
R. Suzanne Zukin, Ann Tempel, and Eliot L. Gardner
Opiate narcotic analgesics are well known to produce tolerance
and dependence in vivo and desensitization in vitro. The obser-
vation of these phenomena originally raised the question as to
whether opiate receptor populations undergo up- or down-
regulation in response to long-term administration of opiate
drugs. Drug- and lesion-induced receptor up-regulation were
well documented in other neurotransmitter systems. Snyder and
coworkers (Burt et al. 1977; Creese et al. 1977) investigated
[3H]halaperidol binding. They found that chronic treatment with
the influence of denervation and functional dopamine blockade on
the neuroleptic drugs haloperidol or fluphenazine elicits a 25%
increase in striatal dopamine receptors. In addition, they
showed that 6-hydroxydopamine-induced lesion of the nigrostria-
tal tract results in enhanced apomorphine-induced rotational
behavior which is reflected in increased numbers of [3H]halo-
peridol binding sites in rat striatum.
Although the evidence for behavioral and biochemical super-
sensitivity in the CNS was greatest in catecholaminergic path-
ways, the clinical problems presented by opiate tolerance and
dependence made the endogenous opioid system an obvious target
for research into molecular mechanisms of neural plasticity.
Lesion-induced receptor up-regulation has been found in the
enkephalinergic system. Our laboratory studied the influence of
6-hydroxydopamine lesions of the substantia nigra on opiate
receptors of specific brain regions (Gardner et al. 1980). In
the case of lateral nigral lesions, enkephalin receptor nunber
was found to be significantly increased in the striatum and
amygdala on the lesioned side relative to that of the same
regions in the intact hemisphere.
Opiate receptor supersensitivity has also been induced by
chronic blockade of receptors with specific opiate antagonists.
In preliminary studies, Tang and Collins (1978) found that long-
term treatment with naloxone resulted in enhanced morphine-
induced analgesia. Because naloxone was rapidly metabolized, it
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was necessary to prepare rats with indwelling venous cannulas.
Lahti and Collins (1978) determined that the enhanced analgesia
correlated with an increased number of [3H]naloxone binding
sites. Almost simultaneously, Schulz et al. (1979) reported
that guinea pigs exposed to naloxone for 1-2 weeks by implanta-
tion with naloxone pellets showed increased sensitivity to the
inhibitory properties of opiates in the isolated ileum prepara-
tion. Chronic naloxone treatment also resulted in increased
[3H]etorphine binding in the ileum and brainstem of guinea pigs.
These studies were preliminary reports and as such did not
control for 1) possible changes induced in endogenous opioid
peptide levels that might give rise to apparent changes in
receptor densities and 2) the effects of acute antagonist admin-
istration.
In 1982 our laboratory published the first detailed study of
opiate receptor up-regulation (Zukin et al. 1982). A coord-
inated up-regulation of Mu and Delta opiate receptors was obser-
ved following chronic, but not acute, exposure to naltrexone.
No change in the density or other properties was observed in the
case of the Kappa or Sigma receptors (Tempel et al. 1982).
Chronic, but not acute administration of antagonist was shown to
elicit the up-regulation phenomenon. Thorough washing and a
37°C preincubation of the brain were shown to be crucial for
obtaining accurate results. These procedures facilitate the
dissociation of endogenous ligand and of residual naltrexone.
FIGURE 1. Scatchard analysis of 3H-etorphine binding to whole
brain homogenates from chronic naltrexone and control-treated
rats. Reprinted with permission from [Life Sciences, 31, A.
Tempel, R.S. Zukin, and E.L. Gardner, Supersensitivity of brain
opiate receptor subtypes after chronic naltrexone treatment]
copyright (1982), Pergamon Press, Ltd.
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This chapter presents a review of 1) the molecular events
associated with opiate receptor up-regulation, 2) the nature of
opiate functional supersensitivity, 3) the neuroanatomical
patterns of receptor up-regulation as visualized by in vitro
autoradiography and 4) the neurochemical correlates of this
receptor phenomenon. These studies document both quantitatively
and visually an important example of neuronal plasticity. An
understanding of the molecular mechanisms underlying this up-
regulation phenomenon will hopefully shed light on the
mechanisms subserving opiate tolerance and dependence.
DEMONSTRATION OF OPIATE RECEPTOR UP-REGULATION BY IN VITRO
BINDING STUDIES
Naltrexone, a long-acting opiate antagonist, has been used in
clinical studies of heroin withdrawal. Our laboratory investi-
gated the molecular correlates of chronic naltrexone administra-
tion (Zukin et al. 1982; Tempel et al. 1982). In vitro binding
studies of [3H]etorphine binding to whole rat brain homogenates
were carried out. We observed a 95% increase in opiate receptor
number with no change in receptor affinity in brain tissue from
naltrexone-treated rats relative to that from control (untreat-
ed) animals (figure 1). Half-maximal increase in receptor
number occurred at 4 days. Receptor number increased until 8
days, after which it leveled off (figure 2a). Withdrawal from
chronic naltrexone treatment resulted in a decrease from elevat-
ed receptor levels to nearly control receptor levels in a period
of about 6 days, as revealed by [3H]etorphine binding (figure
2b).
In order to determine whether the state of coupling of the
receptors undergoes a change, the sensitivity of opiate binding
to inhibition by guanyl nucleotides was examined. The newly
synthesized or unmasked receptors were shown to be more sen-
sitive to guanyl nucleotide modulation. That finding suggested
that up-regulation is accompanied by an increased coupling of
the receptors to a guanyl nucleotide binding protein (Zukin
et al. 1982).
FUNCTIONAL SUPERSENSITIVITY
The observation of a pronounced up-regulation of opiate receptor
sites raised the question as to whether long-term treatment with
naltrexone also produced a behavioral supersensitivity to
morphine. Chronic naltrexone treatment was seen to result in
enhanced morphine-induced analgesia as determined by the flinch-
jump paradigm for measuring pain threshold (figure 3). Morphine
produced an increased pain threshold in a dose-dependent manner
as measured by this paradigm. After chronic naltrexone treat-
ment, a leftward shift in the dose-response curve for morphine
was observed. This finding suggested that a behavioral super-
sensitivity develops following long-term administration of nal-
trexone. Following removal of the naltrexone pellets, morphine
supersensitivity decreased monotonically to pre-naltrexone
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FIGURE 2. Time-course of the a) increase in brain opiate receptors following implantation of naltrexone
mini-pumps and b) decrease in brain opiate receptor number following withdrawal from chronic naltrexone
treatment.
FIGURE 3. Morphine-induced analgesia as a function of morphine dose in animals treated chronically with
naltrexone (8 days). Thresholds were determined a) 24 hours or b) 6 days after removal of the naltrxone.
Male Sprague-Dawley rats were used in the flinch-jump paradigm. Reprinted with permission fran [Journal of
Pharm. Exp. Ther., in press, A. Tempel, E.L. Gardner, and R.S. Zukin] copyright (1984), The American Society
for Pharmacology and Experimental Therapeutics.
treatment levels within 6 days. These behavioral data suggested
a functional significance for the naltrexone-induced opiate
receptor up-regulation, as the time course is well correlated
with that for the disappearance of opiate receptor up-regulation
following withdrawal from chronic naltrexone. These results
serve to confirm those of Tang and Collins (1978) and are con-
sistent with the functional supersensitivity observed in the
dopaminergic system (Burt et al. 1977; Creese et al. 1977).
VISUALIZATION OF OPIATE RECEPTOR UP-REGULATION BY LIGHT
MICROSCOPY AUTORADIOGRAPHY
Preliminary studies, in which the effects of chronic naltrexone
blockade on opiate receptors were examined in dissected brain
regions, revealed a heterogeneous distribution of receptor
density changes. In order to visualize neuroanatanical patterns
of brain opiate receptor up-regulation, light microscopy
autoradiography was carried out on thaw-mounted frozen brain
sections from chronic naltrexone-treated and control rats
(Tempel et al. 1984). Figure 4 shows autoradiograms of coronal
sections through the telencephalic region. In the striatum
discrete patches of densely-labeled Mu opiate receptors were
observed, surrounded by areas of diffusely organized receptors.
Dense labeling was also observed along the subcallosal streak.
This topographical organization of receptors is similar to that
previously reported for the striatum (Atweh and Kuhar 1977). In
the case of brain exposed to chronic naltrexone (figure 4b),
receptor density in the striatal patches was markedly increased
relative to that of control brain (figure 4a), whereas the
diffusely labeled receptors of surrounding areas remained
essentially unchanged. Additional structures shown in these
autoradiograms which exhibited pronounced receptor density
changes were the dopamine-rich nucleus accumbens and lateral
septal nuclei (figure 4). In the neocortex dense labeling by
[3H]dihydromorphine (DHM) along molecular layers was observed as
had been previously reported (figure 4a) (Goodman and Snyder
1982). Whereas layers I and III showed significant increases in
receptor density after chronic naltrexone treatment (figure 4b) ,
layers II, IV, V, and VI remained unchanged.
Nuclei of the thalamus exhibited high densities of [3H]dihydro-
morphine (DHM) binding (figure 5). Long-term naltrexone adminis-
tration (figure 5b) resulted in an increase in binding to the
posterior thalamic nucleus (PO), but produced no significant
change in binding to the lateral or medial ventroposterior
thalamic nuclei (VPL or VPM) relative to control brains (figure
5a). In the region of the hippocampus (figure 5) very dense
labeling of Mu receptors was seen to overlie the molecular
layers; diffuse labeling was observed in the surrounding areas.
Autoradiography (figure 5b) revealed antagonist-induced
increases in opiate receptor density closely opposed to the
pyramidal cells within the molecular layers of the hippocampus
(e.g. mossy fiber tract and CA3 area) but not in the dentate
gyrus; surrounding areas were not affected. This pattern is
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FIGURE 4. Autoradiographs of [3H] DHM binding in the telencephalic region of brains fran (a) a control
animal and (b) from a chronic naltrexone-treated animal. Note the specific regions of high grain density
relative to control brain in the lateral septum and nucleus accumbens. Opiate receptor patches of the
striatum showed significant increases in optical density while surrounding areas of the striatal patches did
not show changes in density. Abbreviations are: N. ACC = nucleus accumbens; LS = lateral septum; CP =
caudate putamen; NC = neocortex.
FIGURE 5. Autoradiographs of [3H] DHM binding tobrain sections from (a) control and (b) chronic
naltrexone-treated animals. Large increases in density were observed in the posterior thalamic nuclei of
naltrexone-treated brain (b) relative to control brain (a). Note the high grain density in the molecular
layers of the hippocampus of naltrexone-treated brain (b) relative to control brain (a). Abbreviations:
LP = lateral posterior thalamic nucleus; PO = posterior thalamic nucleus; VPL and VPM = lateral and medial
ventroposterior thalamic nucleus; NC = neocortex; HP = hippocampus.
similar to that observed for the striatum, in that only densely
organized Mu receptors were observed to undergo up-regulation.
Table 1 summarizes the quantification of opiate receptor density
changes following chronic naltrexone treatment throughout the
brain. Largest increases were observed in Layer I of the neo-
cortex, the nucleus accumbens, the amygdala, the ventral tegmen-
tal area, the ventromedial hypothalamus, and the substantia
nigra compacta. Moderate increases were observed in Layer III
of the neocortex, the striatum, the lateral septum, the
posterior thalamic nucleus and the superior colliculus. No
significant changes in density were found in areas surrounding
the striatal patches, the medial septum, the ventral thalamic
nuclei and the substantia nigra reticulata. Opiate receptor
binding to the rat brainstem at the level of the locus coeruleus
revealed dense labeling in the parabrachial nuclei and the locus
coeruleus as previously reported (Herkenham and Pert 1982;
1980). Chronic naltrexone treatment produced significant
increases in density in the parabrachial nuclei (+39%), but no
significant change in the locus coeruleus, which contains almost
exclusively norepinephrine cell bodies (table 1). These results
document in a visual manner neuroanatomical patterns of opiate
receptor up-regulation.
NEUROCHEMICAL CORRELATES OF OPIATE RECEPTOR UP-REGULATION
In order to examine correlate patterns of peptide regulation,
methionine-enkephalin content in brain regions of naltrexone-
treated and control animals was measured by radioimnunoassay.
The distribution of methionine-enkephalin throughout the brain
following long-term exposure to naltrexone is summarized in
table 2. Two dopamine-rich structures, the striatum and nucleus
accumbens, Showed significant increases in methionine-enkephalin
content after chronic naltrexone treatment (+94% and +40%, res-
pectively; t-test, p<.05). Moderate increases were detected in
the periaqueductal gray and hypothalamic areas. Neccortex did
not show a significant change in methionine-enkephalin levels
after chronic naltrexone treatment.
Changes in the levels of other opioid peptides have also been
reported. Ragavan et al. (1983) found dramatic decreases in ß-
endorphin levels in rat brain following long-term administration
(36 days) of naltrexone (4 mg/kg). Preliminary findings showed
greatest decreases in the hypothalamus and amygdala with no
significant change in the periaqueductal gray.
Thus, we have shown that specific brain regions vary markedly
with respect to peptide and receptor density changes. Two
possible mechanisms to account for this finding are 1) that the
drug does not have uniform effects throughout the brain or 2)
that the receptors or endogenous peptides themselves may be
associated with specific functional pathways. In support of the
latter possibility, several functionally defined pathways were
found to show particularly large increases in opiate receptor
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TABLE 1. Optical Density Measurements of Opiate Receptors in
Chronic Naltrexone vs. Control Treated Rat Brain
Brain sections were labeled in vitro with 5 nM [3H]DHM, and
exposed to tritium-sensitive film for 12 weeks. Optical density
readings were taken from at least three sections from each
structure per rat and averaged. Averages across rats are
expressed as average ± deviation.
Region Control Brain Naltrexone %
Treated Brain Change
(n=2) (n=2)
Neocortex
Layer I
Layer II
Subcallosal streak
Striatun
Patches
Other areas
Nucleus Accumbens
Septun
Lateral
Medial
Amygdala
Habenular Nuclei
Lateral
Medial
Thalamus
Post. Thal. Nuc.
Dorsal Thal. Nuc.
Ventral Thal. Nuc.
Hippocampus
Molecular layer
Other areas
Hypothalamus
Ventromedial
Central Gray
Superficial Gray Layer
of Superior Colliculus
Substantia Nigra
Compacta
Reticulata
Ventral Tegmental Area
Locus Coeruleus
Parabrachial Nucleus
.11 ± .04
.17 ± .03
.36 ± .06
.38 ± .ll
.22 ± .03
.29 ± .06
.16 ± .03
.28 ± .01
.23 ± .01
.18 ± .01
.28 ± .02
.33 ± .02
.46 ± .04
.14 ± .01
.34 ± .03
.19 ± .03
.12 ± .02
.20 ± .01
.27 ± .01
.10 ± .02
.21 ± .02
.12 ± .01
.24 ± .03
.39 ± .03
.22 ± .02
.27 ± .01
.31 ± .04
.55 ± .02 +45%
.26 ± .04 +18%
.55 ± .02 +90%
.29 ± .01
.26 ± .01
.51 ± .03
.16 ± .01
.53 ± .01
.57 ± .03
.61 ± .02
.13 ± .02
.51 ± .02
.23 ± .02
.45 ± .02
.42 ± .04
.50 ± .02
.30 ± .04
.21 ± .03
.45 ± .02
.21 ± 0.0
.54 ± .04
+loo%
+59%
--- (-14%)
+81%
--- ( -7%)
+122%
--- (-11%)
+89%
+73%
+33%
--- ( -7%)
+50%
+21%
+275%
+110%
+85%
+200%
+275%
--- (-13%)
+39%
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density after chronic naltrexone treatment. One example is the
limbic system, consisting of the nucleus accumbens, the lateral
septal nucleus, various nuclei of the hypothalamus, and the
amygdala. These areas are known to contain dopamine as a neuro-
transmitter. There is, to date, considerable evidence support-
ing the notion of dopaminergic-enkephalinergic anatanical and
functional interactions (Gardner et al. 1980; Zukin and Zukin
1981; Goodman et al. 1980; Biggio et al. 1978). Several
laboratories have reported that opiates and opioid peptides
inhibit dopamine release from rat striatal slices in vitro
(Pollard et al. 1977; Schwartz et al. 1978; Celsen and
Kaschinsky 1974) a finding which suggests a possible modulatory
effect on dopamine-mediated behaviors. A second important
system which exhibits pronounced up-regulation is the
periaqueductal gray matter, thought to play a role in
nociception and analgesia (Loh et al. 1976; Sabramanian et al.
1977). A third system includes several of the major structures
which receive input fran afferent sensory pathways. These areas
include the superficial layers of the superior colliculus, the
molecular layers of the hippocampus, layers I and III of
neocortex and the parabrachial nuclei. All of these structures
are particularly rich in opiate receptors relative to other
areas (Atweh and Kuhar 1977). These findings are congruent with
suggestions that opiates may function as neuromodulators in the
CNS. When the system is challenged, as by chronic opiate
antagonist treatment, specific enkephalinergic pathways (i.e.,
limbic, pain, sensory pathways) respond by synthesizing or
unmasking new receptors. It is also possible that enkephalin
levels increase first and that the receptor changes are of a
compensatory nature.
Other examples of drug- and lesion-induced opiate receptor up-
regulation have also been reported. Recently, Simantov and Amir
(1983) showed that lesions of the hypothalamic arcuate nucleus
of the mouse, produced by neonatal application of monosodium
glutamate (MSG) (Hong et al. 1981; Krieger et al. 1979; and
Romagnano et al. 1982), increased the binding of [3H]
dihydromorphine to membranes prepared from the midbrain. These
MSG-treated mice also exhibited an enhanced response to morphine
and naltrexone regarding thermal pain sensitivity. The some
lesion in neonatal rats produced an increase only in the number
of Delta receptors in the thalamus (as measured by [3H]DADLE),
with no changes in mu receptors (Young et al. 1982). The
apparent discrepancy in these two studies may be due to an
interspecies difference. Bardo and coworkers found that rat
pups (ages 1-21 days) treated chronically with naltrexone
exhibited an increased number of opiate binding sites, but did
not demonstrate a functional supersensitivity to morphine (Bardo
et al. 1982). These studies underline the importance of
monitoring neurochemical correlates of chronic drug or food
additive administration.
In contrast to the case of opiate receptor up-regulation, opiate
receptor down-regulation has been difficult to document.
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Several groups have reported that chronic administration of
narcotic agonists in vivo does not produce any change in either
receptor number or affinity (Holaday et al. 1982; Hitzemann et
al. 1974; Klee and Streaty 1974; Pert et al. 1973; Simon and
Hiller 1978; Perry et al. 1982; Bardo et al. 1982). More
recently, Holaday and coworkers reported 17-20% increase in
opiate receptor density following chronic morphine treatment.
Using a different approach, Davis and markers (1979) showed
that the development of tolerance to morphine is accompanied by
a reduction of opiate binding as measured by [3H]naloxone, [3H]
etorphine and [3H] morphine binding in the brain-stem slice
preparation. Homogenization was carried out after ligand
incubation in this preparation, a procedure which may be impor-
tant for maintaining membrane-receptor integrity. More
recently, down-regulation has been observed in neurotumor cell
lines following long-term exposure to enkephalin (Chang et al.
1982: Hazum et al. 1981: Blanchard et al. 1983) but not to
alkaioid agonists (Chang et al. 1982). Possible interpretations
of the latter findings are 1) opioid peptides and opioid
narcotic agonists bird differently to the same receptor or 2)
only a subpopulation of opioid receptors can be so modulated.
These findings are discussed in more detail in another chapter
in this monograph by Law et al.
The question arises as to the molecular mechanisms underlying
opiate receptor up-regulation and functional supersensitivity.
One possible hypothesis is that active opiate receptors in the
absence of drug treatment exist in a dynamic equilibriun with a
nearly equal concentration of inactive, "silent" receptors.
Long-term exposure of the system to opiate antagonist leads to
the activation or unmasking of the "silent" receptors, giving
rise to an apparent up-regulation. Long-term exposure of the
system to opiate agonists or opioid peptides might lead to
coupling of the receptors to cyclase, followed by internaliza-
tion. As active receptors disappear, these would be replaced by
the conversion of "silent" receptors to active ones. In the
case in which activation paralleled internalization, no apparent
change in receptor density would be observed. Only in the case
in which internalization exceeded reactivation (i.e. opioid
peptides) would apparent down-regulation occur. It is possible
to test aspects of this hypothesis by binding studies involving
an in vitro system. Explant cultures of spinal cord with
attached dorsal root ganglia provide a valuable in vitro system
for studies of such mechanisms. Those experiments are discussed
in another chapter in this monograph by Crain.
The overall significance of these studies lies in their ability
to shed light on the mechanisms subserving the phenomena of
opiate supersensitivity and tolerance and neuronal plasticity in
general. There are potential clinical ramifications for nal-
trexone-induced supersensitivity. For example, naltrexone is in
use as a treatment for opiate dependence (Resnick et al. 1974;
O'Brien et al. 1978). After cessation of naltrexone therapy in
humans, a resulting supersensitivity could be reflected in
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TABLE 2. Regional Distribution of Met-Enkephalin After
Long-Term Exposure to Naltrexone
Methionine-enkephalin content was measured by radioimmunoassay.
Values are reported as means of 4 determinations from 4 individual
sets (1 naltrexone brain, 1 control brain) of rats.
Naltrexone-Treated Control %
(ng/mg Protein) (ng/mg Protein) Change
(n=4) (n=4)
Neocortex 10.0 ± 0.6 11.8 ± 1.5 -15%
Hypothalamus 9.5 ± 0.1 7.3 ± 0.8 +30%
Periaqueductal Gray 9.6 ± 0.3 7.6 ± 0.7 +26%
Nucleus Accumbens 11.6 ± 0.5 8.3 ± 0.8 *+40%
Striatum 18.4 ± 2.1 9.5 ± 1.0 *+94%
*Asterisks indicate statistically significant differences (t-test,
p < .05).
increased susceptibility to a dosage of heroin which would have
been well tolerated initially, and thus lead to an unintentional
overdose. A potential use of naltrexone-induced supersensitiv-
ity might be to enhance the analgesic effects of opiates prior
to surgery. The studies of the effects of long-term agonist
treatment on opiate receptors are important to our understanding
of the molecular basis of opiate tolerance and of receptor down-
regulation in general. Together these studies should contribute
significantly to our understanding of how the brain works in
regard to the regulation of enkephalinergic transmission and
receptors for the opioid peptides. Ultimately, studies with the
purified opiate receptor subtypes should enable a precise deter-
mination of the molecular mechanisms underlying brain receptor
regulation.
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The Role of Dynorphin in Narcotic
Tolerance Mechanisms
Nancy M. Lee
A central unsolved problem in the study of opiate drugs is the
mechanism of the development of tolerance and physical depen-
dence. Although there are many ways to prevent these phenomena
from occurring or to alter the rate at which they develop, there
is no known way of reversing tolerant and dependent states once
they have been established, except through the slow and painful
process of withdrawal. A promising new alternative approach to
this problem, however, has recently been offered by the discovery
of a variety of endogenous opioid peptides in the brain. Many of
these peptides are not analgesic, yet they seem to play a modula-
tory role; that is, they may affect the analgesic potencies of
other substances. This conclusion is supported by studies of
both the enkephalins and dynorphin, which have been shown under
certain conditions to enhance or inhibit the analgesic effect of
morphine and of the endogenous peptide endorphin (Vaught and
Takemori 1979; Friedman et al. 1981). These observations sug-
gest that pain regulation may be a reflection not of a single
opiate, but of the interaction of several.
In the development of tolerance and dependence to opiates, dynor-
phin seems to be particularly important because it has been shown
to alter  their  analgesic  potency di f ferently in chronical ly-
treated and naive animals. While dynorphin inhibits morphine
analgesia in the latter, it potentiates it in tolerant animals.
Thus both analgesia and tolerance may result from disruption of a
balance or equilibrium normally existing among the three estab-
lished endogenous opioid systems, represented, for example, by
dynorphin, B-endorphin and enkephalin. In this article, we will
discuss the evidence for this idea in some detail, as well as its
implications.
PHARMACOLOGICAL PROPERTIES OF DYNORPHIN
Dynorphin is a 17 amino acid peptide first isolated from pitui-
tary glands by Goldstein and his colleagues (Goldstein et al.
1979). In in vitro bioassays such as the guinea pig ileum and
the mouse vas deferens, dynorphin and one of its fragments,
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dynorphin-(1-13), proved to have greater potency than most other
opiates. It also displaced tritiated opiate ligands, including
dihydromorphine (DHM), D-ala2-D-leu5-enkephalin (DADLE) and nalox-
one from brain tissue in in vitro binding assays.
In the ileum, dynorphin exhibits properties similar to the proto-
typic k-agonist, ethylketocyclazocine (EKC). This conclusion was
established on the basis of naloxone sensitivity and on cross-tol-
erance studies between dynorphin and EKC in the guinea pig ileum
myenteric plexus preparation (Huidobro-Toro et al. 1981). In
further support, other investigators (Oka et al. 1981; Rezvani et
al. 1983) demonstrated that in the rabbit vas deferens, which ap-
pears to be a specific bioassay system for k-like opiates, dynor-
phin, but not B-endorphin nor the enkephalins, mimics the actions
of EKC. Finally, Goldstein and his group reported that dynorphin
also behaves like a k-ligand in the protection of brain opiate
receptors from alkylation (Chavkin et al. 1982). That is, if
opiate receptors are preincubated with dynorphin and the alkyl-
ating agent B-chlornaltrexamine, the EKC binding sites are protec-
ted from alkylation but those of or ligands, are not protec-
ted. Thus, all these in vitro studies provide strong evidence
for the notion that dynorphin is a k-ligand.
Additional studies in our laboratory in the intact animal, how-
ever, revealed that dynorphin does not behave in the classic
manner of prototypic k agonists. For example, dynorphin displayed
no analgesic activity in mice (Friedman et al. 1981). While this
lack of effect was originally ascribed to rapid degradation of
dynorphin in the brain, we were able to show that dynorphin
exhibited other pharmacological effects, indicating it should have
remained intact long enough to produce analgesia. Of particular
interest, dynorphin was found to reduce the analgesic response to
both morphine and B-endorphin. but not to the synthetic enkepha-
lins, D-ala2-D-leu5-enkephalin and FK-33824 (Sandoz).
For striking contrast, a subsequent study in our laboratory
revealed that dynorphin had the opposite effect in tolerant ani-
mals; it potentiated the analgesic effect of both morphine and
B-endorphin (Tulunay et al. 1981). In the same study, dynorphin
also suppressed abrupt morphine withdrawal signs. Dynorphin has
also been demonstrated to be effective in preventing withdrawal
signs in both opiate-dependent monkeys and humans. In monkeys,
this peptide suppressed withdrawal signs in a dose-dependent
manner, being effective at doses as low as 0.06 mg/kg (Aceto et al.
1982). In humans, 0.06 mg/kg of dynorphin(1-13) suppressed
withdrawal signs and symptoms of heroin addicts. Only 3 out of 12
subjects reported mild side effects such as warmness or dizziness
(Wen and Ho 1982). Similar results have been obtained with
dynorphin in the morphine-tolerant guinea pig ileum; the effect
of morphine was restored and the naloxone-induced contraction of
the tolerant-dependent ilea was suppressed (Rezvani and Way
1983).
More recently, we have investigated the effects of chronic infu-
sion of dynorphin on tolerance and dependence development. Infu-
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sion of doses as high as 3.1 nmole dynorphin/hr for 72 hrs by
itself resulted in no development of dependence, as measured by
naloxone-induced escape jumping. Dynorphin also modulates the
action of morphine on body temperature and respiration rate.
Unlike morphine, which produces pronounced hypothermia 30-60
minutes after administration, dynorphin has a slight hyperthermic
effect. When combined with morphine, however, it potentiates the
latter's hypothermic action. Dynorphin-(1-13) alone has no effect
on the respiratory rate; however, it enhances the inhibitory
effect of morphine on this parameter in naive mice, while antagon-
izing it in morphine-tolerant animals (Woo et al. 1983), just the
opposite of its modulating effect with respect to analgesia.
Another peptide closely related to dynorphin, neo-endorphin, was
shown to have similar modulatory effects in naive mice, but not
in tolerant animals.
The effects of dynorphin, in summary, can be conveniently under-
stood in terms of a "set point" model. For example, in considering
analgesia, when dynorphin is administered with morphine, dynor-
phin tends to maintain the animals' sensitivity to the latter at
a more or less fixed level. In the naive animal, it raises the
ED50 for morphine from about 5 to 15-20 mg/kg, while in the toler-
ant animal, it lowers the ED50 from about 60 mg/kg to the range of
10-15 mg/kg. Thus, in the presence of dynorphin, both naive and
tolerant animals display approximately equal sensitivity to mor-
phine; in the absence of dynorphin, this sensitivity is less than
that exhibited by naive animals, but more than that observed in
tolerant animals. In essence, the effects of tolerance have been
partially nullified, with the animals' response to morphine large-
ly restored.
In the case of hypothermia and respiratory depression, a similar
model operates, but with opposite consequences. However, the
effect of dynorphin in tolerant animals is again to counteract the
acute responses to morphine; thus, dynorphin apparently acts to
maintain these physiological parameters at a level close to that
found in untreated animals. The overall effect of dynorphin in
the morphine-tolerant animal is, in every respect, a stabilizing
one on morphine action, attenuating the withdrawal signs, potenti-
ating analgesia and reducing its side effects.
DYNORPHIN BINDING SITES
An important approach to understanding dynorphin's role in the
brain would be to determine the nature of its receptors and their
relationship to  receptors  for  other opioid l igands.  This ,  of
course, would enable us to decide whether or not it is actually
a k-agonist in this system and, if not, decide what is its re-
lationship to other endogenous opioids. Tritiated dynorphin is
not yet commercially available, but we have studied the inter-
action of the unlabelled peptide with the binding of other tritia-
ted opioids in vitro. Somewhat surprisingly, we have found
evidence of dynorphin interaction with each of the three distinct
types of binding sites now believed to exist in brain and
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k (Garzon et al. 1982). These interactions are complex, with
concentration-displacement curves suggesting that dynorphin does
not interact with any of these sites in a simple competitive man-
ner, but seemingly non-competitively (Garzon et al. 1984). These
results thus contrast with those carried out in the guinea pig
ileum, where dynorphin seems to behave as a k agonist (Huidobro-
Toro et al. 1981), and suggest that dynorphin may not be a typical
k ligand like EKC.
The most important and unexpected result of these studies, how-
ever, is that a long-lasting inhibition of binding by dynorphin
was revealed. When mice were pretreated icv with 1 - 20µg of this
peptide, binding of 3H-DHM or 3H-DADLE to tissue fractions pre-
pared from the brains of these animals was significantly reduced.
The maximum reduction was observed 30 min to 3 hrs after injection,
with recovery not taking place until 6-12 hrs after injection.
The Bmax but not the affinity, was reduced for both ligands; the
high affinity site was most affected in each case. A similar inhi-
bition resulted from addition of dynorphin to tissue in vitro, al-
though in this case complete recovery occurred within 90 minutes.
These results are very provocative, since earlier studies have
shown that dynorphin is rapidly metabolized in brain. We actual-
ly confirmed this fact in these studies, showing by means of the
mouse vas deferens assay that over 95% of the peptide had disap-
peared from the incubation media within 20-45 minutes. It is
unlikely that dynorphin's inhibitory effect is achieved through
the small amount of dynorphin not metabolized, since this would
make the peptide several orders of magnitude more potent than any
other opioid known. It is also unlikely that a metabolite of dy-
norphin is responsible for the effect, since fragments of less
than 11 amino acids had no effect on opiate binding. We have
thus tentatively concluded that dynorphin remains bound to its
receptor for a long period of time to exert protracted effects.
We believe it may be the endogenous inhibitor of opiate binding
that several investigators have described (Simantov et al. 1976).
THE ROLE OF DYNORPHIN IN TOLERANCE
The data discussed above indicate not only that dynorphin can
modulate the activity of other opioids, but that the nature of
this modulation depends on the state of the animal. In naive
animals, dynorphin inhibits the analgesic action of morphine and
B-endorphin, yet it potentiates it in animals chronically mor-
phinized. Similar effects are observed with respect to other
opiate agonists, including meperidine, methadone, D-ala2-D-leu5-
enkephalin, FK33824, and ethylketocyclazocine (manuscript in pre-
paration). At the same time, dynorphin potentiates the "side
effects" of these agonists, such as respiratory depression, in
naive animals, but inhibits them in chronically morphinized
animals.
Since dynorphin, as well as B-endorphin, is endogenous, these
findings suggest a fresh way of viewing analgesia and its regula-
t ion.  The analgesic  state  is  not  s imply the outcome of  the
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interaction of a single type of ligand with its specific recep-
tors, but rather results from a complex interaction among several
ligands: B-endorphin, dynorphin and perhaps leu- and met-enke-
phalin as well. It is reasonable to speculate that in the normal
brain these substances exist in a state of dynamic balance; the
effects of morphine, both acute and chronic, are then seen as
upsetting this balance. This would explain why dynorphin, though
not itself analgesic, can suppress withdrawal signs and symptoms;
its administration restores an altered balance between endogenous
dynorphin and other peptides during tolerance. This operational
hypothesis can be subjected to experimental testing.
How exactly is this balance manifested? The most attractive, yet
unproven, possibility is that dynorphin and the other opiates
actually interact with a common receptor possessing multiple
binding sites. We have previously cited considerable evidence
indicating that morphine, B-endorphin and the enkephalins bind to
different sites on a common receptor complex (Lee and Smith
1980). One interpretation of the data presented in this paper is
that dynorphin also interacts with this receptor; alternatively,
it may interact with its own site, affecting B-endorphin binding
al losterical ly .
If this is true, of course, these peptides should coexist in cer-
tain areas of the brain; they definitely show marked differences
in their brain distribution (Weber et al. 1982). However, there
may be certain areas where the distribution and/or projections of
dynorphin and B-endorphin, at least, do coincide, e.g., the PAG
and hypothalamus; it is significant that pain transmission is
known to be mediated through both these areas. Alternatively,
these peptides may be in different, but interacting, regions of
the brain. Mapping studies should eventually settle this question.
In summary, dynorphin in the brain seems to regulate several
activities affected by opiates that may be a key factor in tol-
erance development. The latter results not from a perturbation
of one particular opiate in the brain, but from an imbalance among
several. A dramatic change in sensitivity to external opiates
may thus occur without any changes in receptors. Pharmacological,
electrophysiological and biochemical studies of the interactions
of these peptides should reveal more about these imbalances and
the way they underlie analgesia and tolerance.
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Post-Translational Processing of
Neuropeptide Precursors
Richard E. Mains and Betty A. Eipper
Neuropeptides, and in fact a very large number of small peptides,
are synthesized as portions of larger precursor proteins which are
themselves inactive; this review will frequently use the ACTH/en-
dorphin system as an example (figure 1; Mains et al. 1983).
FIGURE 1
Rapid DNA sequencing techniques have been instrumental in the
recent dramatic explosion of information about the structure of
such precursors, but there is still a great deal to be learned
about the enzymatic processing steps that must occur between the
synthesis of precursors and synthesis of their bioactive peptide
products. As it is now possible to proceed rapidly from the
amino acid sequence of a purified peptide to the nucleotide se-
quence and hence the entire amlno acid sequence of its precursor,
we are now in the position of knowing the sequences of a Iarge
number of precursors but not which product peptides are actually
made or even which product peptides are physiologically important.
Based on the limited number of examples that have been adequately
studied, It is clear that discrete cleavages in these precursors
result In the creation of a whole family of peptide products; alI
of the progeny peptides are secreted along with the particular
bioactive peptide that was originally thought to be the focus of
interest. Thus it is important to determine the structures of all
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of the product peptides (i.e. secretory products). One important
example of this rule was the old clinical observation that
peptldes related to ß-Iipotropin are secreted along with ACTH
under a variety of circumstances. This was a key observation In
the discovery that the molecule already known to be the precursor
to ACTH (pro-ACTH) also contained the structure of ß-Iipotropin
and thus the potent opiate peptide ß-endorphin (hence, the name
pro-ACTH/endorphin) (Eipper and Mains 1980).
Although a set of general principles for peptide hormone proces-
sing has been developed over the past years, they really only
define a set of likely products; the actual product peptides
produced must be determined for each tissue where those peptides
occur. For example, in the pro-ACTH/endorphin system a pair of
basic amlno acids (Arg-Lys) precedes the sequence in the
precursor (figure 2); instead of producing peptides with
Residue number 48 49 50 51 52 53
16K fragment -Pro-Arg-Lys-Tyr-Val-Met-
as predicted
by removal of Tyr-Val-Met-
pairs of basic residues
ActuaI product Lys-Tyr-VaI-Met-
FIGURE 2. Sequences of 16K Fragment and Progeny
at their amino terminus, bovine and rat intermediate pituitary
cells produce peptides with at their amino terminus
(Esch et al. 1981). The shows far greater binding
affinity for adrenal cortical cells (the presumed target in vivo)
than (Pedersen and Brownie 1983).
Neuropeptides and peptide hormones display quite an array of
Important co- and post-translational modifications. Since the
precursors are bigger than their product peptides, proteolytlc
processing is clearly a very important modification during biosyn-
thesis. For simplicity, these proteolytic modifications can be
grouped into three categories: removal of the signal peptide from
the precursor during or immediately after synthesis of the
precursor and its deposition into the lumen of the rough
endoplasmic reticulum; endoproteolytic steps which break the
precursor into the peptide regions which approximately comprise
the final product peptides; and exoproteolytic events which trim
the carboxyl and/or amino terminal ends of the peptides into the
forms found in the mature product. It is not yet clear how
distinct the endo- and exoproteolytic steps will be for any
peptlde family. It is not even clear whether a few proteases will
function in the biosynthesis of many different peptides or whether
a large number of proteases with narrow specificity will be
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involved. It is clear that expression of the proinsulin gene in
monkey kidney cells results in secretion of proinsulin into the
medium without production of insulin and C-peptide (Laub et al.
1983); thus the biosynthetic processing proteases of peptide
hormone biosynthesis are not normally expressed in all cells.
In order to discern the number of proteolytic steps that were
actuaIIy used in the cell to produce a product peptide from its
precursor, one must identify intermediates in the biosynthetic
pathway. However, many other co- and post-translational covalent
modifications are easily detectable in the smaller products, and
In several instances these alterations are very important in
determining the bioactivity of the peptide products. This list
includes glycosylation (both asparagine-linked and serine/thre-
onine-linked), N-acetylation, phosphorylation, sulfation, and
amidation. Neuropeptides are thought to function as
neurotransmitters or neuromodulators; synthesis of precursor and
the subsequent co- and post-translational modifications represent
the biosynthetic pathway for these molecules (Snyder 1984). In
order to understand the functioning and malfunctioning of these
peptidergic systems, we have to understand the physiological and
pharmacological factors that can regulate each step. Studying
these steps can be thought of as analogous to studying the role
and regulation of tyrosine hydroxylase, aromatic amino acid
decarboxylase, dopamlne ß-hydroxylase and phenylethanolamine N-
methyltransferase in catecholamine biosynthesis.
Another important point about bioactive peptides is that any given
peptide and its siblings can occur in more than one tissue in
major amounts. In addition, the final peptide products found in
the different tissues can differ structurally in very important
ways. For example figure 3), ACTH(1-39) is the peptide which
directs the adrenaI cortex to synthesize and reIease
glucocorticoids into the blood; ACTH(1-39) is a major product pep-
FIGURE 3. Biosynthetic Pathways
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tide of pro-ACTH/endorphin in the anterior pituitary. Alpha-
M S H ;melanotropin -N-acetyl-ACTH(1-13)NH2] stimulates skin
darkening in Iower vertebrates and may also have behavioral
act ions in higher vertebrates; MSH is a major product peptide
from pro-ACTH/endorphin in the intermediate pituitary, and
molecules similar to MSH also occur in the brain. Since it is
now clear that in several species there is only one pro-
ACTH/endorphin gene, the differences in the product peptides in
the different tissues must be due to differences in enzymatic
processing of the primary gene product.
FOCUS ON ENZYMES
This review will discuss two enzymatic activities which are
apparently important in the post-translational processing of pro-
ACTH/endorphin. Both enzymes are involved in late biosynthetic
events which determine the final structure and bioactivity of the
product peptides, after initial processing steps are done. Each
of the enzymatic activities is primarily localized in secretory
granules.
The first activity to be discussed will be the secretory granule-
associated N-acetyltransferase activity found in rat and beef
intermediate pituitary but not in rat anterior pituitary. Current
data argue that the same enzyme puts N-acetyl groups onto both
ACTH(1-13)NH2 [to produce or -meIanotropin] and ß-
endorphin(1-31) [to produce N-acetyl-ß-endorphin(1-31)] (figure
3, previous page).
The second enzymatic activity to be examined will be a peptidyl-
glycine amidation activity. Many neuropeptides terminate in a
carboxyl-terminal amide and data accumulated to date suggest
that amidated peptides are derived from precursor peptides that
have an additional glycyl residue at the carboxyl terminus. This
enzymatic activity cleaves within the original COOH-terminal
glycyl residue to liberate glyoxylate and leave a product peptide
bearing a COOH-terminal amide group. Some similarities of this
enzyme activity to other known enzymes, most notably dopamlne ß-
hydroxylase, will be discussed.
N-ACETYLTRANSFERSE
The enzymatic activity utilizing acetyl coenzyme A (AcCoA) to
mediate the N-acetylation of ACTH(1-13)NH2 and ß-endorphin(1-31)
has been examined by Woodford and Dixon (1979), Glembotski (1982b)
and O'Donohue and coworkers (O'Donohue and Dorsa 1982). The
thorough subcellular fractionation work of Glembotski (1981;
1982a,b) made clear two important points. First, only about 10-
30% of the acetylating activity in intermediate pituitary was
found in a secretory granule fraction with the rest of the
activity associated with other cellular organelles or cytoplasm.
The secretory granule-associated activity is the only acetylating
activity of physiological relevance to the N-acetylatlon of
MSH, since previous work (Glembotski 1982a) demonstrated that the
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-N-acetylation of ACTH(1-13)NH2 and ß-endorphin(1-31) in intact
cells occurs exclusively in secretory granules. In addition, it
was expected that other acetyltransferases would be detected in
the cell, mediating the acetylation of histones and the N-
acetylatlon of many nascent polypeptide chains (Simpson 1978;
Belikoff et al. 1980; Traugh and Sharp 1977; Pestana and Pitot
1975). These latter acetyltransferase activities would not be
expected to be tissue speclflc.
Second, a secretory granule-associated N-acetyltransferase
activity was only found in the intermediate pituitary and not in
the anterior pituitary (Glembotski 1982b). Thus the observed
tlssue specificity of N-acetylatlon could be explained by tissue
specific expression of an enzyme. Alternate explanations for the
observed tissue specificity of N-acetylation would be that
anterior pituitary granules possessed the appropriate
acetyltransferase enzyme, but did not express this enzymatic
activity in vivo. One way to achieve this result would have been
for the anterior pituitary cells to fall to provide the secretory
granule lumen with AcCoA; however, given adequate AcCoA in a test
tube, anterior pituitary secretory granule extracts still do not
have demonstrable N-acetyltransferase activity. Thus, the
current data argue that the tissue specificity of N-acetylation
is achieved by the inclusion (or not) of N-acetyltransferase
enzyme in secretory granules. Mixing experiments will be
necessary, however, to show that anterior pituitary secretory
granules do not contain inhibitors of N-acetylation.
The enzymatic activity studied by Glembotski (1982b) is probably
the physiologilcally relevant acetyltransferase activity for
several reasons. The peptide substrates acetylated by the enzyme
activity in a test tube--ACTH(1-13)NH2, ACTH(1-39), ß-endorphin(1-
31), ß-endorphin(1-27)--are also N-acetylated in intermediate
pituitary secretory granules, while several other possible
substrates--CLIP [ACTH(18-39); corticotropin-like intermediate
lobe peptide], histones, 16K fragment (the NH2-terminal
glycoprotein region of the pro-ACTH/endorphin precursor; figure
1)--are not utilized (table 1, next page). The 3H-labeled peptide
products created by incubation of ACTH(1-13)NH2 or ß-endorphin(1-
31) with secretory granule extracts are correctly N-acetylated,
rather than N-acetylated on the groups of lysine residues as
expected for a histone acetyltransferase (Simpson 1978). Finally,
the amount of enzyme activity detected is reasonable for the rate
and extent of N-acetylation of peptides that actually occurs in
intermediate pituitary secretory granules; it takes roughly
twelve hours to N-acetylate the peptides during biosynthesis in
the intact tissue, and the secretory granule enzyme activity would
also take about a half day to N-acetylate the relevant peptides
In the granules.
GIembotski (1983) has also shown that the N-acetylatlon seen in
intact intermediate pituitary cells is effectively irreversible.
in pulse-chase experiments using [35S]methionine and [3H]acetate
double labeling, there was no decrease in the acetate:methionine
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TABLE 1. N-Acetyl Transferase
ratio in MSH, diacetyl MSH or ß-endorphin-sized peptides during
incubations for up to 48 hours in nonradioactive medium. Both the
N-acetyI modifications of MSH and acetylated ß-endorphin and
the O-acetylation of diacetyl MSH were thus found to be quite
stable, at least while the peptides were still inside the
secretory granules. These double label experiments also suggest
that the same pool of 3H-acetyl CoA is used to N-acetylate
ACTH(1-13)NH2 and ß-endorphin and to O-acetylate
3H/35S ratios for MSH, N-O-dlacetyl- MSH and acetylated ß-en-
MSH, since the
dorphins were found to occur in a 1:2:1 relationship.
A full understanding of the enzymatic mechanism of the -N-
acetyltransferase from intermediate pituitary should be very
interesting. Current data of Glembotski (1982b; unpublished)
strongly suggest that the same enzyme N-acetylates both ACTH-
and ß-endorphin-related peptides. As expected, the N-acetylation
of ß-endorphin(1-31) is inhibited by product peptides such as
acetyl-ß-endorphin(1-31); interestingly, also inhibits the
acetylation of ß-endorphin(1-31). Likewise, N-acetylated
endorphins inhibit the acetylation of ACTH(1-13)NH2.
Substantially shortened peptides, such as ACTH(1-8) and ß-
endorphin(1-16) [also known as endorphin], are not detectably
N-acetylated under the same reaction conditions used for ACTH(1-
13)NH2 and ß-endorphin(1-31). Importantly, ACTH(1-8) and ß-
endorphin(1-16) each inhibit the N-acetylation of the longer
ACTH- and endorphin-related peptides. The very similar patterns
of inhibition of N-acetyltransferase activity by acetylated
product peptides and by shortened nonacetylated peptides are most
economically explained by the existence of one enzyme performing
the N-acetylatlon of both ACTH- and ß-endorphin-related
peptides. The requirements of the binding and catalytic sites of
this enzyme will be very interesting and probably quite complex.
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When rat intermediate and anterior pituitary cells are placed in
tissue culture, they are deprived of many of the influences they
receive in the animal. Anterior pituitary cells no longer receive
occasional bursts of corticotropin releasing factor in the
hypothalamic portal blood system, and the varying levels of
feedback from circulating glucocorticoids are also lost in tissue
culture. Intermediate pituitary cells lose the several kinds of
direct innervation they receive in vivo. It might be expected
that the loss of some of these inputs, which are believed to
control secretory rates in vivo, would result in the loss of some
of the tissue-specific differences seen in the intact animal.
However, the anterior pituitary corticotropes do not detectably
begin to N-acetylate ACTH or ß-endorphin in culture, nor do
intermediate pituitary cells cease to N-acetylate ß-endorphin or
ACTH. This result is in striking contrast to the rapid loss of
amidation seen when intermediate pituitary cells are placed in
culture (see below).
PEPTIDYL-GLYCINE AMIDATION ACTIVITY
Dozens of bioactive peptides have COOH-terminal amide groups
which are essential for the expression of full biological potency
(reviewed in Malns et al. 1983; Elpper et al. 1983a,b). Using the
small synthetic peptide substrate originally designed by Bradbury
et al. (1982), we have found peptidyl-glycine amidating activity
in secretory granules from anterior, intermediate, and neural
lobes of the rat and beef pituitary as well as from AtT-20 mouse
corticotropic tumor cells and rat hypothalamus (Eipper et al.
1983b,c; Glembotski et al. 1984; Malns et al. 1984; Emeson 1984)
(figure 4). In this assay the conversion of D-Tyr-Val-Gly into D-
Tyr-VaI-NH2 is monitored; substrate and product are easily
separated by ion exchange chromatography and the D-Tyr residue
provides a site for radioiodination as well as protecting against
proteolytic degradation.
[125I]-D-Tyr-Val-Gly + goodies
(passes through)
[125I]D-Tyr-Val-NH2 + glyoxylate
(binds; elutes)
Resin: SP-Sephadex
Bind/Wash: 10 mM NaPI, pH 5.0
Elute: 0.5 M NaCl, 10 mM NaPI, pH 5.0
FIGURE 4. Amidation Assay
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For all these cases, optimal enzyme activity requires the presence
of copper ions, reduced ascorbic acid, and molecular oxygen.
Enzyme activity is: 1) greatly decreased by removal of copper ions
wlth micromolar amounts of diethyldithiocarbamate, and rejuvenated
by replacement of copper (no other metal ion tested will
substitute for copper); 2) stimulated by addition of ascorbate
better than by addition of any other redox cofactors tested, and
largely abolished by pretreatment with ascorbate oxidase; and 3)
substantially diminished by replacement of much of the dissolved
oxygen in the reaction tube with nitrogen or argon. The enzymatic
activity is operationally soluble, in that simple repeated
freezing and thawing releases the enzyme from secretory granules
(summarized in table 2).
TABLE 2. Properities of Amidation Activity
1. Similar enzymatic activity in different tissues:
rat anterior, intermediate, neural pituitary
bovine anterior, intermediate, neural pituitary
rat hypothalamus
rat serum
mouse corticotropic tumor cells
human plasma and cerebrospinal fluid
2. Secretory granule associated
3. Requires molecular oxygen
4. Stimulated by copper
5. Enhanced by ascorbate
6. Inhibited by endogenous inhibitors
7. Soluble
8. Secreted along wlth peptides
9. Broad specificity for many peptides wlth a carboxyl terminal
glycine residue
In striking contrast to the N-acetyltransferase, peptidyl-
glycine amidation activity is found in a wide variety of tissues
and in particular is found in all three lobes of the rat and beef
pituitary. In most cases, the amidating activity cannot be
detected directly in crude tissue extracts made in hypotonic
buffers, due to the presence of high amounts of endogenous
inhibitory activity. The effect of the endogenous inhibitory
activity is greatly diminished when the amidation activity is
assayed using a secretory granule fraction, although some
inhibitory activity is still detectable even in secretory granule
preparations. Endogenous inhibitory activity is largely overcome
by addition of appropriate amounts of copper ions.
Its requirement for copper, ascorbate, and oxygen, plus the
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presence of endogenous inhibitors which can be neutralized with
addition of optimal levels of copper, make the peptidyl-glycine
amidating activity very similar to the well-known enzyme, dopamine
ß-hydroxylase (Rush and Geffen 1980).
The peptidyl-glycine amidating activity studied by our group and
by Bradbury and Smyth (1983) exhibits a very different pattern of
specificity for peptide substrates from that seen for the -N-
acetyltransferase (above). The amidating activity will produce
a peptide ending in -X-NH2 from a substrate with the structure -X-
Gly; although there are quantitative differences, neutral amino
acids such as Phe, Val, and Gly function effectively as the
residue (X) to be amidated. Based on ability to inhibit
amidation of D-Tyr-Val-Gly, peptides where X is Trp can also
interact with the enzyme. In addition, the peptide to be amidated
need not be very long (unlike the case for N-acetylation); the
synthetic tripeptide D-Tyr-Val-Gly gives Michaelis constants
indistinguishable from the Kl values for longer and presumed
natural substrates such as N-acetyl-ACTH(1-14) and MSH.
The original work of Bradbury et al. (1982) showed that porcine
pituitary granules contained an enzymatic activity which utilized
D-Tyr-Val-Gly as peptide substrate and produced D-Tyr-Val-NH2 and
glyoxylate (HCOCOOH) as products. The reaction scheme suggested
by Bradbury et al. (1982) is:
D-Tyr-Val-NH-CH2-COOH + oxidized cofactor + H20
D-Tyr-Val-NH2 + HCOCOOH + reduced cofactor
This scheme does not incorporate the subsequent findings of the
need for copper, reduced ascorbate and oxygen, although copper
could presumably function as the cofactor. One argument against
this scheme is the observation that oxidized cofactors (NADP, NAD,
FAD, FMN, ascorbate oxidase-treated ascorbic acid) do not
stimulate the reaction when relatively clean secretory granules
are used as the enzyme source; In addition, the requirement for
molecular oxygen would not be explained (Eipper et al. 1983b,c;
Glembotski et al. 1984; Mains et al. 1984; Emeson 1984).
A second possible reactlon scheme that takes into account the
dependence of the reactlon on molecular oxygen resembles that of
the amine oxidases:
D-Tyr-Val-NH-CH2-COOH + O2 + H20
D-Tyr-Val-NH2 + HCOCOOH + H202
Since several of the amine oxidases characterized as diamine
oxidases utilize copper to perform their reactions, the above
scheme deserves serious consideration (Gorkin 1983; Kapeller-Adler
1970). It does utilize molecular oxygen, but does not explain why
reduced cofactors such as ascorbate (and, less well, biopterin)
stimulate the reaction. Addition of a range of monoamine oxidase
inhibitors (pargyline, tranylcypromine, iproniazid phosphate, D-
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amphetamine) did not inhibit the amidation activity when the
inhibitors were used at concentrations of 1-2 mM. Addition of
semicarbazide, generally considered to be a relatively good
diamine oxidase inhibitor, had an inhibitory effect only at high
levels (slight inhibition at 2.5 mM; no inhibition at 0.5 mM).
Addition of millimolar levels of inhibitors such as cyanide and
azide does inhibit the enzyme but lower levels are ineffective.
The reaction scheme presently considered most plausible is that of
a monooxygenase:
D-Tyr-Val-NH-CH2-COOH + 2(ascorbate) + O2
D-Tyr-Val-NH2 + 2(semidehydroascorbate) + HCOCOOH + H20
A variant of the above scheme would involve only one ascorbate
molecule being fully oxidized to dehydroascorbate. This scheme
draws on our data and that of Bradbury et al. (1982) plus the
current data on the very similar reaction performed by dopamine ß-
hydroxylase (Skotland and Ljones 1980; Diliberto and Allen 1981),
in which semidehydroascorbate (ascorbate free radical) is now
believed to be the immediate reaction product (instead of
dehydroascorbate). SeveraI important aspects of this model must
be confirmed experimentally before it is accepted, however.
Peptide substrate-dependent ascorbate consumption will need to be
measured and compared to the simultaneous production of amidated
product peptides. Quantitation of glyoxylate production will be
crucial, as welI as the demonstration that the predicted amount of
oxygen is consumed without production of H2O2. Final confirmation
that this is a monooxygenase reaction would require use of 18O2
and detection of 18O in the glyoxylate by mass spectrometry
(Kaufman et al. 1962).
The fact that the peptidyl-glycine amidating activity is readily
released from secretory granules by simple freezing and thawing
suggested that the activity might be secreted along with peptide
hormones. When AtT-20 mouse corticotropic tumor cells are
stimulated to release ACTH- and ß-endorphin-related peptides,
amidating activity is also secreted. Both peptides and amidating
activity are released coordinately in response to severaI
secretagogues which can increase the secretory rate up to 20-fold
for brief periods: corticotropin releasing factor, isoproterenol,
BaCl2, and cycIic AMP (table 3, next page). The stimulated
release of peptides and of amidating activity is blocked by
addition of CoCl2 to the medium, consistent with previous
demonstrations that an inward flux of calcium ions is required for
the release of the soluble contents of the secretory granules by
exocytosis (Mains and Eipper 1981, Surprenant 1982, Adler et al.
1983). In each case cited above, the ratio of amidating
activity (measured at 0.5 µM D-Tyr-Val-Gly substrate) to hormone
in the stimulated secretion is the same as that ratio in the
secretory granules, again suggesting that release occurs by
exocytosis of all of the soluble contents of granules (table 3).
These co-release data also further strengthen the claim that the
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TABLE 3. Ratio of Amidation Activity to ACTH/ ß-endorphin Content
Enzyme/Hormone
AtT-20 Cells 0.15
Granules 0.15
Medium 0.15
Bovine Intermediate Pituitary Granules 0.02
Rat Anterior Pituitary Granules 14
Rat or human plasma 6000
Units: Enzyme pmol/ml/h
Hormone pmol/ml (nM)
amidating activity being studied is localized in secretory
granules rather than in a minor contaminating organelle with
similar sedimentation properties to secretory granules.
Since corticotropic tumor cells release amidating activity along
with the peptides derived from pro-ACTH/endorphin, it was
considered possible that amidating activity could be detected in
plasma and/or cerebrospinal fluid (CSF). Indeed, when human
plasma and CSF are assayed, amidating activity is easily
demonstrated; the plasma and CSF activities are dependent on
copper ions, ascorbate, and molecular oxygen (Wand et al. 1984).
The correct product (D-Tyr-Val-NH2) is produced, as demonstrated
by high performance liquid chromatography, and the plasma and CSF
activities have several other properties consistent with their
being similar to the pituitary activity.
However, there is far more amidating activity in human and rat
plasma than can reasonably be expected to have come from anterior
pituitary corticotropes (table 3). This has led to an examination
of amidation activity in other tissues in the rat, with the
interesting finding that the submaxillary glands contain
sufficient amidating activity to be major candidates to have
secreted a significant amount of the amidating activity found in
plasma. The hypothalamus and cerebral cortex certainly contain
enough amidating activity to provide the enzyme activity found
in CSF. The cerebellum has very low levels of amidating
activity (using crude extracts at a wide variety of copper
levels), consistent wlth the very low levels of bioactive peptides
usually reported for the cerebellum.
Cellular Studies of Peptide Amidation
Rat intermediate pituitary cells maintain or increase their
content of pro-ACTH/endorphin-derived peptides for at least 2
weeks in tissue culture (Eipper et al. 1983a). The cultured
intermediate pituitary celIs continue to carry out a large number
of co- and post-translational modifications in culture; some of
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the modifications are of the tissue-specific type [e.g., N-
acetylation and cleavage of ACTH(1-39) into amino and carboxyI
terminal pieces] and some are not (e.g., phosphorylation and
glycosylation of the COOH-terminal region of ACTH and many of the
proteolytic cleavages). However, rat intermediate pituitary cells
in tissue culture specifically lose the ability to amidate MSH;
the loss of peptide amidation occurs with a half-life of about
15-18 hours (Eipper et al. 1983a; Glembotski et al. 1983).
Instead of producing various acetylated forms of ACTH(1-13)NH2,
the cells produce the corresponding set of non-, mono-, and
diacetylated ACTH(1-14). The COOH-terminal sequence of ACTH(1-14)
is -Lys11-Pro12-Val13-Gly14, while MSH terminates -Lys11-
Pro12-Val13-NH2; normally, <2% of the MSH-related peptides in rat
or beef intermediate pituitary terminate in -Val-Gly rather than
in -VaI-NH2. Given the above discussion of the intricate
properties of the amidation enzyme, it was important to examine
whether any of these properties of the amidation enzyme could be
associated with the loss of the ability of the rat intermediate
pituitary cells to amidate peptides in tissue culture.
The tissue culture media in our previous work, as in nearly all
work with primary cells and cell Iines in the Iiterature,
contained no added ascorbic acid and very low levels of copper
ions ( .0055 µM). Although a large proportion of the copper in<
serum is bound to other molecules and is unavailable to tissues
(total serum copper is about 16 µM; Riordan 1983; Sarkar 1981;
Danks 1980), it seemed reasonable to explore the effect of
additional copper on amidation by the cells in culture. Serum
levels of ascorbate are about 50 µM and it is all in the reduced
form (Hornig 1975; Basu and Schorah 1982; Kabrt et al. 1981).
Ascorbate is synthesized primarily in the Iiver of mammals such as
rats that can synthesize their own ascorbate, and it seemed likely
that exogenous ascorbate would be needed by the pituitary cells.
The simple inclusion of 2 or 20 µM CuSO4 in the serum-free tissue
culture medium had no effect on the rapid loss of the ability to
amldate peptides (Eipper et al. 1983d). When ascorbic acid was
included in the culture medium along with copper, a significant
recovery of the ability to amldate newly synthesized peptides
was always seen (table 4, next page). Experiments varying the
time of addition of ascorbate indicated that ascorbic acid added
only for the incubation with radiolabeled amino acid, (during
which time the ability to amidate newly synthesized peptides was
being tested) was just as effective as ascorbic acid added for the
entire time in culture (even when added fresh every few hours). A
rough dose-response curve for the response of amidation to the
dose of ascorbate was also seen, with the buIk of the recovery
from the loss of amidation occurring between 0 and 200 µM
ascorbate, but with significant increases in amidation seen up
to 1.0 mM ascorbic acid. The full ability to amidate peptides
was never regained in these experiments, although the fraction of
the newly synthesized MSH-related molecules which were correctly
amidated increased up to four-fold in the presence of 2 µM CuSO4
and 1 mM ascorbate.
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TABLE 4. Reversal of Loss of Amidation in Tissue
Culture by Addition of Ascorbic Acid
Percent
Amidated
Experiment 1: control 12
0.2 mM ascorbate 37
0.5 mM ascorbate 41
1 .0 mM ascorbate 45
Experiment 2: control 15
0.05 mM ascorbate 30
2.0 mM ascorbate 42
Rat intermediate pituitary cells were incubated for a day in
complete serum-free medium plus 2.0 µM CuSO4 and the indicated
concentration of ascorbate. At the end of the pre-incubation,
cells were incubated in the same medium plus [3H]tryptophan for 3
hours; RP-HPLC analyses of the tryptic peptides of the labeled
MSH-sized molecules separated peptides derived from ACTH(1-
13)NH2- and ACTH(1-14)-related molecules.
Possible Consequences of Inappropriate Copper and Ascorbate Levels
in Vivo
Ascorbate is made in the liver of most mammals including rats, but
primates and guinea pigs must rely on the diet for their
ascorbate. The pituitary has a higher concentration of ascorbic
acid than any other tissue in the body (Hornig 1975; Kabrt et al.
1981), although ascorbate is also very high in the central nervous
system, most notably in the hypothalamus (MiIby et al. 1981;
Schreiber et al. 1979). Copper is an essential trace element in
the diet, and modern human diets are frequently low or only
marginally adequate in copper (Danks 1980; Sarkar 1981; Riordan
1983). Two human genetic disorders, Wilson's and Menkes'
diseases, involve altered copper metabolism; the mottled series of
mutant mice are considered to be a good model for Menkes' disease
(Riordan 1983; Danks 1980; Hunt 1980). Copper levels can be low
In patients undergoing disulfiram (Antabuse) therapy for chronic
alcoholism, or in people on high zinc or high ascorbate diets
(Danks 1980; Riordan 1983; Schreiber et al. 1979).
Experimental animals (rats, guinea pigs, mice, mottled mutant
mice) have been examined for the effects of altered ascorbate
and/or copper metabolism on dopamlne ß-hydroxylase levels and on
catecholamine production, and interesting but somewhat conflicting
observations have appeared in the literature. Since the
amidating activity has many striking similarities to dopamine ß-
hydroxylase, consideration of the catecholamine Iiterature is
particularly relevant to the study of amidation of peptides.
Since dopamine ß-hydroxylase is not the rate-limiting step in vivo
for norepinephrine biosynthesis, a fairly major drop in the
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expression of dopamine ß-hydroxyIase activity in intact tissue
would be needed in order to produce a decrease in norepinephrine
levels (Rush and Geffen 1980).
Copper deficiency due to dietary insufficiency or to a genetic
defect preventing an adequate supply of copper from reaching the
adrenaIs and the nervous system results in a marked decrease in
the norepinephrine content of the adrenals and the brain (Hunt
1980; Sourkes 1980; Danks 1980). A clear prediction from this
result is that copper deficiency (for dietary, genetic, or drug
therapeutic reasons) might also result in a marked decrease in the
levels of many crucial bioactive amidated peptides. The
response of dopamine ß-hydroxylase levels to copper deficiency,
when the dopamine ß-hydroxylase is tested in tissue extracts, is
less clear; some workers find enzyme levels to be decreased
(Holtzman 1976; Danks 1980; Sourkes 1980), while others report an
increase in enzyme activity (Hunt 1980; Prohaska and Smith 1982).
Some of the differences in results for the effect of copper
deficiency on dopamine ß-hydroxylase levels may reflect whether
assay conditions were optimized for copper levels (Hunt 1980). At
least for brief periods of time, purified dopamine ß-hydroxylase
is fully stable with all of its copper removed by chelation, and
activity is fully restored by the return of copper to the enzyme
(Skotland et al. 1980).
Ascorbate deficiency in guinea pigs results in a drop in brain
norepinephrine levels within 2 to 3 weeks in most (Hoehn and
Kanfer 1980; Saner et al. 1975; Deana et al. 1975) but not all
studies (Green et al. 1979). An elevated ascorbate diet in the
rat does not alter cerebral norepinephrine levels (Behrens and
Madere 1980). Since the rate of ascorbate reduction of enzyme-
bound copper on dopamine ß-hydroxylase is not the rate-limiting
step of dopamine ß-hydroxylation (Skotland et al. 1980), it is
actually quite striking that a drop in norepinephrine levels is
detected so rapidly in most studies. The clear implication from
these studies is that ascorbate deficiency in vivo will manifest
itself as a drop in the levels of key amidated peptides; already
there are good data from the tissue culture studies that ascorbic
acid supplies directly affect the cellular expression of peptide
amidation activity (table 4, previous page).
CONCLUSIONS
The study of the co- and post-translational biosynthetic
processing events leading to the production of bioactive peptides
is a fast-growing field wlth many potential ramifications in
studies of human health and disease. The interaction of various
drugs of abuse wlth bioactive peptides, both at their plasma
membrane receptors and during biosynthesis, is only beginning to
be examined.
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Opiate-Mediated Control of Lu-
teinizing Hormone in the Male:
Role in the Development of
Narcotic Tolerance and Physical
Dependence
Theodore J. Cicero
In this review, the possible involvement of opiate-induced
perturbations in endocrine status in the development of narcotic
tolerance and physical dependence will be discussed. Although the
opiates affect a wide range of neuroendocrine axes, the discussion
will be limited to their effects on the endocrine secretions of
the hypothalamic-pituitary-gonadal axis in the male rat, since
this system has been by far the most extensively examined. The
review has been divided into three sections: the impact of opiates
on the function of the hypothalamic-pituitary-gonadal axis; the
plasticity and physiological significance of endogenous opioid-
mediated control of LHRH; and, finally, the preliminary data
implicating opiate-induced alterations in hormonal status in the
development of tolerance to and physical dependence on the
narcotics.
DIRECT EFFECTS OF THE OPIATES ON THE HYPOTHALAMIC-PITUITARY-
GONADAL AXIS
It has been clearly established that serum testosterone levels are
markedly depressed following acute or chronic narcotic
administration in the male of every species (e.g., Cicero 1980;
Cicero et al. 1976, 1977, 1979; Cicero and Badger 1977; Mendelson
et al. 1979; Mirin et al. 1976). There are four mechanisms that
could account for this: first, narcotics could enhance the
metabolism of testosterone by the liver; second, they could block
the biosynthesis of the steroid at the level of the testes; third,
they could suppress the synthesis and/or release of LH from the
pituitary and, thereby, inhibit LH-dependent testicular steroido-
genesis; or, finally, they could inhibit the release of LHRH from
the hypothalamus.
Liver or other target organs. There are no reports in the
literature that either acute or chronic narcotic administration
enhances the catabolism of testosterone. Furthermore, it has been
shown (Cicero et al. 1976, 1977a) that narcotics do not affect the
fate of testosterone in its target organs.
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Testes. It has been conclusively demonstrated that narcotics do
not depress serum testosterone levels by a direct effect on the
testes. The relevant information can be summarized as follows:
first, narcotics are totally ineffective in lowering serum
testosterone levels when narcotic-induced reductions in LH are
prevented by administration of LH (Cicero et al. 1976; Cicero et
al. 1977 a,b); second, narcotics do not interfere with the basal
or stimulated production of testosterone in the testes (Cicero et
al. 1977a); and, finally, it has been shown (Cicero et al.
1977a,b; Cicero 1980) that the narcotics do not interfere with the
uptake or binding of LH in the testes.
Hypothalamic-pituitary-LH axis. A large number of studies have
demonstrated that narcotics exert their primary effect on the
hypothalamic-pituitary-gonadal axis by depressing the elaboration
of LH by the hypothalamic-pituitary-axis, which leads to a
secondary depression in LH-dependent testicular steroidogenesis
(Cicero et al. 1977a, 1977b; Bruni et al. 1979; Blank et al. 1979;
Kalra 1982; Mendelson et al. 1979; Mirin et al. 1976; Ieiri et al.
1980).
The locus of action of the narcotics within the hypothalamic-
pituitary-LH axis appears to be at the hypothalamus. The evidence
supporting this conclusion is as follows. First, morphine blocks
the postcastration-induced increase in serum LH in the male rat,
and this effect can be completely overcome by the administration
of LHRH (Cicero et al. 1977b). Second, it has been shown that
even very large doses of morphine do not reduce the elevations in
serum LH produced by LHRH in the rat (Cicero 1980; Cicero et al.
1977b). Third, it has been demonstrated that the narcotics do not
inhibit the basal or LHRH-stimulated synthesis and secretion of LH
from anterior pituitaries incubated in vitro (Cicero et al.
1977b). Finally, it has been shown that both exogenous and
endogenous opiates inhibit the release of LHRH from the
hypothalamus under in vitro conditions (Rotsztejn et al. 1978a,b).
PARTICIPATION OF ENDOGENOUS OPIOIDS IN THE FUNCTION OF THE
HYPOTHALAMIC-PITUITARY-LH AXIS
The findings described above indicate quite clearly that opiate
alkaloid drugs are potent inhibitors of activity within the
hypothalamic-pituitary-gonadal axis in the male and that they
exert their effects exclusively by inhibiting the release of LHRH
from the hypothalamus. As will be more fully discussed below, it
is clear that these drugs affect the release of LHRH via specific
opiate receptors in the hypothalamus which are as yet
unidentified. Since it is quite obvious that these receptors
would not exist simply to bind synthetic opioid compounds, it has
been hypothesized that endogenous opioids exist which normally
play a role in the physiological regulation of LHRH release.
This hypothesis has been impressively supported by the following
data: first, several endogenously occurring opioid peptides
significantly inhibit the secretion of serum LH (Blank et al.
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1979; Bruni et al. 1977; Meites et al. 1979); second, within
minutes after the subcutaneous injection of naloxone precipitous
increases in serum LH levels occur in the male and female of every
species (e.g., Blank et al. 1979; Mendelson et al. 1979; Mirin et
al. 1976; Cicero et al. 1979; 1980b; Ieiri et al. 1980; Sylvester
et al. 1980; Meites et al. 1979; Wilkes and Yen 1981); third,
under in vitro conditions it has been shown that opiate agonists
and antagonists increase and decrease, respectively, the efflux of
LHRH from the hypothalamus (Rotsztejn et al. 1978a.b; Wilkes and
Yen 1981); and, finally, the negative feedback control of the
hypothalamic-pituitary-LH axis exerted by testosterone (Cicero et
al. 1979) and estrogens (Ieiri et al. 1980; Sylvester et al. 1980;
Van Vugt et al. 1982) in the male and female, respectively, can be
blocked by the administration of naloxone.
The foregoing results have led to the hypothesis that opioid-
containing neuronal elements represent an intermediate link
between the effects of steroids on the hypothalamus and their
ultimate inhibition of the release of LHRH (Cicero 1980; Meites et
al.1979; Van Vugt et al. 1982). If this hypothesis is correct,
then it would follow that endogenous opioids, or narcotic drugs
with an affinity for the relevant opiate receptors, would mimic
the effects of gonadal steroids on the hypothalamic-pituitary-LH
axis. To assess this possibility, we have examined whether
morphine, as a prototypic opioid agonist, had androgen-like
effects in the castrated male rat (Cicero et al. 1980a). We found
that morphine was just as effective as testosterone in preventing
the initial castration-induced increase in serum LH levels and the
reduction in the hypothalamic content of LHRH in the male rat that
occurs 7 to 10 days following orchiectomy (Cicero et al. 198Oa).
Although it is now widely accepted that endogenous opioid systems
are in some way involved in regulating LHRH release from the
hypothalamus, many questions remain unanswered: (a) Which of the
many endogenously occurring opioids is the principal one
involved? (b) Which opiate receptor subtype mediates the effects
of endogenous and exogenous opiates on the hypothalamic-pituitary-
LH axis? (c) Are these systems integral and physiologically
relevant components of this axis?
PHYSIOLOGICAL SIGNIFICANCE AND PLASTICITY OF ENDOGENOUS OPIOID-
MEDIATED CONTROL OF LHRH.
As discussed above, a major problem encountered in assessing the
characteristics of opioid-mediated control of LHRH is the absence
of any information regarding the identity of the endogenous opioid
involved. This has precluded many crucial experiments, such as
increasing or decreasing the activity of the peptide to assess the
precise nature of the interaction between the relevant opioid
systems and LHRH release mechanisms-a traditional strategy used to
assess the role of neurotransmitters/neuro-modulators. As an
indirect means of examining this issue, we have developed an
different strategy in our laboratory over the last 2 years (Cicero
et al. 1983a,b,c). Specifically, we have used exogenous and
endogenous opioid agonists and antagonists, with presumed affinity
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FIGURE 1. The effects of morphine, ketocyclazocine and SKF-10,047
on serum LH levels in normal rats (N=12 to 18). T.J. Cicero, D.P.
Owens, P.F. Schmoeker, E.R. Meyer. Opiate-Induced Enhancement of
Naloxone's Effects on Serum Luteinizing Hormone Levels in the Male
Rat: Specificity for mu Agonists. The Journal of Pharmacology and
Experimental Therapeutics, 226:770-775, 1983. ©1983, Williams
and Wilkins. Reprinted by permission.
for specific opiate receptor subtypes in brain, to selectively
enhance or block opiate receptors and then assessed the response
to subsequently administered opiate agonists and antagonists. Our
rationale was that, since endogenous opioids must interact with a
receptor to exert their effects, an alteration in the
responsiveness of these receptors would have the same effect as
enhancing or depressing the actions of the peptide, accomplished
by more traditional means (e.g., destruction of the pathways).
Thus, our strategy been two-fold: first, to determine whether one
or more receptors appear to mediate the effects of endogenous and
exogenous opioids on the release of LHRH; and, second, to
determine whether these receptors are influenced by the prior
administration of opioid agonists and antagonists.
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FIGURE 2. Percent inhibition of serum LH levels produced by a
wide range of opiates. Each dose-response curve is the best-fit
line and represents at least 5 doses of each drug with an N of 18
to 40. The slopes of the lines were virtually identical except
for ketocyclazocine (p<.Ol) and cyclazocine (p<.O5) which were
significantly more steep than the others. Data for SKF have not
been included since it had no effect on serum LH levels. T.J.
Cicero, D.P. Owens, P.F. Schmoeker, E.R. Meyer. Opiate-Induced
Enhancement of Naloxone's Effects on Serum Luteinizing Hormone
Levels in the Male Rat: Specificity for mu Agonists. The Journal
of Pharmacology and Experimental Therapeutics, 226:770-775,
1983. ©1983, Williams and Wilkins. Reprinted by permission.
Effects of mu, kappa and sigma opiate agonists on serum LH
levels. The time-course for the effects of morphine.
ketocyclazocine and SKF on serum LH levels are shown in figure
1. As can be seen, following an injection of 5 mg/kg morphine
oketocyclazocine, serum LH levels declined sharply in a time-
dependent fashion, reaching peak levels of depression 1 to 3 hours
after the injection; thereafter, LH levels gradually returned to
control levels. Six to 8 hours after the injection, serum LH
levels "rebounded" significantly above control levels and then
returned to normal values 8 to 24 hours later. In contrast to the
effects of morphine and ketocyclazocine, 15 mg/kg SKF had no
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TABLE 1
ED50s and potencies of various opiate agonists
in depressing serum LH levels
Agonist ED50s (95% confidence limits
Morphine 0.41 (0.37-0.43)
P o t e n c y
(morphine=1
Etorphine 0.0012 (0.0009-0-0.0016) 341.6
Ketocyclazoeine 0.21 (0.19-0.24) 1.95
Cyclazocine 0.27 (0.23-0.30) 1.52
Levorphanol 0.29 (0.25-0.36) 1.41
Methadone 1.30 (1.19-1.38) 0.32
Codeine 6.0 (5.81-6.20) 0.07
T.J. Cicero, D.P. Owens, P.F. Schmoeker, E.R. Meyer, Opiate-
Induced Enhancement of Naloxone's Effects on Serum Luteinizing
Hormone Levels in the Male Rat: Specificity for mu Agonists. The
Journal of Pharmacology and Experimental Therapeutics, 226:770-
775 1983 © 1983, Williams and Wilkins. Reprinted by.
permission.
TABLE 2
Naloxone antagonism of opiate-induced
inhibitions of serum LH levels
Agonist Ke (nM)
Morphine 1.41(±0.23)
p A 27.86 (±0.07)
Levorphanol 1.44 (±0.05) 7.87 (±0.02)
Methadone 1.49 (±0.06) 7.82 (±0.01)
Ketocyclazocine 11.99 (±1.13) 6.92 (±0.05)
Cyclazocine 13.27 (±0.89) 6.87 (±0.50)
pA2 and Ke values 
(Tallarida et al 1981).
were determined as described elsewhere
T.J. Cicero, D.P. Owens, P.F. Schmoeker, Meyer, E.R., Opiate-
Induced Enhancement of Naloxone's Effects on Serum Luteinizing
Hormone Levels in the Male Rat: Specificity for mu Agonists. The
Journal of Pharmacology and Experimental Therapeutics, 226:770-
775 1983 © 1983, Williams and Wilkens. Reprinted by.
permission.
significant effect on serum LH at any post-injection time interval
examined .
On the basis of the preceding studies, a 2-hour time interval was
selected to construct LH dose-response curves for a wide range of
opiate agonists. Figure 2 depicts the best-fit lines, plotted on
log-probit paper; all opiates tested depressed serum LH levels in
a dose-dependent fashion, with the exception of SKF which had no
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FIGURE 3. Serum LH levels in animals injected with morphine (10
mg/kg) or saline and then injected with saline or naloxone (0.5
mg/kg) at the intervals shown. Values for saline + saline and
saline + naloxone groups have been pooled. T.J. Cicero, D.P.
Owens, P.F. Schmoeker, Meyer, E.R. Morphine-Induced Supersensi-
tivity to Naloxone's Effects on Luteinizing hormone Secretion in
the Male Rat. The Journal of Pharmacology and Experimental
Therapeutics, 225:35-41, 1983. ©1983, William and Wilkins.
Reprinted by permission.
appreciable effect at any dose examined. The ED50s and the
potencies of these compounds, relative to morphine, are shown in
table 1.
Naloxone blockade of opiate-induced depressions in serum LH
levels. The efficacy of naloxone in competitively inhibiting the
LH-depressing effects of several representative opiates is shown
in table 2. As can be seen, naloxone effectively reversed the
effects of both putative mu and kappa agonists, but was nearly 10
times more potent in antagonizing the effects of mu agonists than
it was for kappa compounds. In addition, it is also apparent that
two distinct binding sites appear to mediate the effects of these
agonists.
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FIGURE 4. The effects of naloxone (0.025 mg/kg) or saline on
serum LH levels in rats (N=20) implanted with morphine or placebo
pellets 48 hours earlier. *Significantly (p<.Ol) lower than
placebo-saline groups; **Significantly (p<.OOl) higher than all
other groups. T.J. Cicero, D.P. Owens, P.F. Schmoeker, Meyer,
E.R. Morphine-Induced Supersensitivity to Naloxone's Effects on
Luteinizing Hormone Secretion in the Male Rat. The Journal of
Pharmacology and Experimental Therapeutics, 225:35-41, 1983.
©1983, Williams and Wilkins. Reprinted by permission.
Influence of acute morphine administration on naloxone-induced
Increases in serum LH levels. The effects of a single morphine or
saline injection on the increase in serum LH levels produced by
naloxone at various intervals after the initial injection are
shown in figure 3. As can be seen, in animals receiving saline or
naloxone as the second injection, serum LH levels were substan-
tially depressed in morphine-pretreated rats when compared to
saline-pretreated animals from 2 to 4 hours after the initial
injections. Thereafter, LH levels returned to normal levels in
control values 6 to 24 hours after the injection. With respect to
the effects of naloxone on serum LH levels in morphine and saline
pretreated rats, 2-3 hours after the morphine injection, naloxone-
induced increases in serum LH were suppressed, when compared to
saline-injected controls. By 4 hours post-morphine injection,
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TABLE 3
Naloxone dose-response curves in controls and in
animals injected acutely with morphine or
implanted with morphine pellets.
Saline - Placebo
ED50(95% confidence limits)
0.23 (0.18-0.25)
Acute Morphine 0.124 (0.116-0.131)
Morphine Pellet 0.0053 (0.0048-0.0056)
normal LH responses to naloxone returned. However, 5-24 hours
after morphine, the increases in serum LH levels produced by
naloxone were markedly exaggerated in morphine pretreated animals
when compared to controls, with the peak degree of enhanced
sensitivity occurring at 6 hours.
Naloxone-induced increases in serum LH levels in morphine pellet
implanted animals. The effects of saline or naloxone on serum LH
levels in male rats implanted with a single morphine or placebo
pellet 48 hrs earlier are shown in figure 4. Serum LH levels were
significantly depressed in morphine-implanted animals when
compared to placebo controls. Moreover, at this dose of naloxone
(0.025 mg/kg) there was no statistically significant stimulation
of serum LH levels in placebo-implanted male rats. In marked
contrast to these results, naloxone was extremely effective in
elevating serum LH levels in morphine-implanted animals, producing
increases nearly 8 times greater than those found in controls.
Magnitude of the shift in the naloxone dose response curve after
acute and chronic morphine administration. The naloxone dose-
response curves generated in rats pretreated with saline/placebo,
a morphine injection or one morphine pellet implantation are shown
in figure 5. Both acute and chronic morphine administration
markedly shifted the naloxone dose-response curve significantly to
the left when compared to controls. However, this shift was much
more striking in chronically treated animals when compared to
controls or those animals receiving acute morphine pretreatment.
the ED50s in the respective groups are shown in table 3.
Opiate-induced enhancement of naloxone's effects on serum LH
levels. To assess whether the opiate-induced enhancement of
naloxene's effects was specific to morphine or represented a more
general property of the opiates, we assessed whether the wide
range of opiates utilized in the preceding studies (see figure 2)
produced an enhanced response to naloxone. The results of these
experiments are shown in figure 6. As can be seen, serum LH
levels in opiate-injected animals, receiving saline as the second
injection 6 hours later, were somewhat elevated with respect to
saline-pretreated animals (shaded area in this figure). When
naloxone was given as the second injection, a markedly enhanced
response was observed in those animals pretreated with mu
agonists, relative to saline-pretreated controls; the order of
potency was etorphine >levorphanol >morphine >methadone >codeine.
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FIGURE 5. Naloxone dose-response curves in animals (N=17 to 57)
injected with saline or morphine (10 mg/kg) 6 hours earlier or
implanted with morphine or placebo pellets 48 hr earlier. T.J.
Cicero, D.P. Owens, P.F. Schmoeker, Meyer, E.R. Morphine-induced
Supersensitivity to Naloxone's Effects on Luteinizing Hormone
Secretion in the Male Rat. The Journal of Pharmacology and
Experimental Therapeutics, 225:35-41, 1983. © 1983 Williams and
Wilkins. Reprinted by permission.
In contrast to these results neither ketocyclazocine, cyclazocine
nor SKF produced any facilitation of naloxone's effects.
Effects of FK 33-824 on naloxone-induced increases in serum LH
levels. To determine whether FK 33-824 as a metabolically stable
analog of the endogenously occurring methionine enkephalin (Roemer
et al. 1977), produced an enhanced sensitivity to naloxone's
effects on serum LH levels, rats were injected with saline or FK
33-824 at a dose (0.05 mg/kg) selected to produce modest decreases
in serum LH levels (Cicero et al. 1983c). At intervals, there-
after, the animals in each group received a second injection of
either saline or naloxone (0.25 mg/kg). The results of this study
are shown in figure 7. Serum LH levels were modestly reduced in
FK 33-824-saline injected animals, when compared to controls at
intervals up to 2 hours after the initial injection: thereafter
the two groups were indistinguishable. When naloxone was given as
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FIGURE 6. Serum LH levels in animals (N=20-28) injected with
saline or opiate followed 6 hours later by saline (see shaded area
within bar) or 0.25 mg/kg naloxone (open bars). The doses of each
opiate were selected to provide an initial 60-80% inhibition of
serum LH 2 hours after its adminitration, and were as follows:
etorphine .005 mg/kg, levorphanol 0.5 mg/kg, morphine 2.5 mg/kg,
methadone 2.5 mg/kg, codeine 7.5 mg/kg, cyclazocine 0.5 mg/kg,
ketocyclazocine 0.5 mg/kg, and SKF 5 mg/kg. *Significantly
(P<.01) greater than saline-naloxone injected animals;
†significantly (p<.05) greater than saline-saline injected
animals. T.J. Cicero, D.P. Owens, P.F. Schmoeker, E.R. Meyer.
Opiate-Induced Enhancement of Naloxone's Effects on Serum
luteinizing Hormone Levels in the Male Rat: Specificity for mu
Agonist. The Journal of Pharmacology and Experimental
Therapeutics, 226:770-775, 1983. ©1983, Williams and Wilkins.
the second injection to saline-pretreated rats, serum LH levels
were significantly elevated above values obtained in saline-saline
treated animals, but the increase was quite small at the very low
dose of the narcotic antagonist employed. In the case of FK 33-
824, the inhibitory effects of the peptide on serum LH levels were
initially (<2 hours) overcome by naloxone. However, at 4 to 6
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FIGURE 7. Serum LH levels in animals (N=10 to 15) injected with
saline or FK 33-824 (0.05 mg/kg) followed by saline or naloxone
(0.25 mg/kg) at the intervals shown. Values for the saline-saline
and saline-naloxone groups were pooled (shown as continuous solid
or dashed lines). *Significantly (p<.01) higher than respective
control; †Significantly (p<.O5) lower than control. T.J. Cicero,
D.P. Owens, K.S. Newman, P.F. Schmoeker, Meyer, E.R. Exogenous
and Endogenous Opioid-induced Enhancements of Naloxone's Effects
on Serum Luteinizing Hormone Levels in the Male Rat. European
Journal of Pharmacology, in press. © 1984, Elsevier Biomedical Press.
hours after the FK 33-824 injection, naloxone was substantially
more effective in increasing serum LH levels than it was in
saline-pretreated animals. By 8 hours after the injection of FK
33-824 essentially normal responses to naloxone had returned.
Naloxone-precipitated withdrawal behavior following acute and
chronic morphine pretreatment. Naloxone-precipitated withdrawal
sians in rats implanted with morphine or placebo pellets 48 hours
earlier are shown in figure 8. Naloxone (0.5 mg/kg) produced a
vigorous withdrawal response in morphine-implanted rats. No other
group of animals, notably morphine-implanted rats injected with
0.005 mg/kg naloxone, displayed any opiate withdrawal behavior.
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FIGURE 8. Naloxone-precipitated incidence of wet-dog shakes
(number/hour), body weight loss (gm/hour) and diarrhea (for rating
scale see Cicero and Meyer, 1973) in animals implanted with
morphine or placebo pellets 48 hours earlier. T.J. Cicero, D.P.
Owens, P.F. Schmoeker. E.R. Meyer. Opiate-Induced Enhancement of
Naloxone's Effects on Serum Luteinizing Hormone Levels in the Male
Rat: Specificity for mu Agonists. The Journal of Pharmacology and
Experimental Therapeutics, 226:770-775, 1983. © 1983 Williams
and Wilkins. Reprinted by permission.
Mechanisms involved in opiate-induced enhancement of naloxone's
effects on serum LH levels. In a series of studies we have
explored a number of mechanisms which could be involved in the
development of opiate-induced enhancement of naloxone's effects.
The experiments (Cicero et al. 1983a,b,c) can be summarized as
follows: first, morphine pretreatment did not influence the uptake
of naloxone into brain; second, changes in the sensitivity of the
pituitary to LHRH do not seem to be involved in this phenomenon,
since LHRH dose-response curves were identical in saline- and
morphine-pretreated animals; and, finally, we have been unable to
demonstrate any gross changes in the affinity or density of mu,
delta or kappa binding sites in whole brain or the hypothalamus of
morphine-pretreated rats when compared to controls.
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DISCUSSION
The results of these studies demonstrate that either acute or
chronic morphine pretreatment markedly sensitizes male rats to the
subsequent effects of naloxone on serum LH levels. This
phenomenon appears to represent a true example of "supersensi-
tivity", since the following criteria were met: a parallel shift
to the left in the dose-response curve, and an enhanced effect of
naloxone on serum LH levels at the same brain concentration of the
antagonist. Although both acute and chronic morphine
administration produced an enhanced sensitivity to naloxone,
relative to controls, there were substantial differences between
the two treatment regimens. For example, although acute and
chronic morphine administration produced an exaggerated LH
response to naloxone of approximately the same magnitude, the peak
effect was elicited by much lower doses of naloxone in morphine-
implanted rats than it was in morphine-injected animals. In
addition, at comparable doses, naloxone-induced increases in serum
LH levels were up to 20 times greater in chronically morphinized
animals than they were in those rats receiving a single injection
of morphine. Finally, although a single injection of 10 mg/kg
morphine significantly lowered the dose of naloxone producing the
half-maximal increase in serum LH levels, relative to controls,
the naloxone ED50 morphine-pelleted animals was several orders of
magnitude less than that found in controls or in acutely
morphinized animals.
Our studies also revealed that an enhancement of naloxone's
effects on serum LH levels is not a common feature of all drugs
which depress activity within the hypothalamic-pituitary axis
since neither non-opiate (ethanol and Nembutal) nor certain opiate
compounds (cyclazocine and ketocyclazocine) produced this effect,
despite a profound initial depression in serum LH levels (Cicero
et al. 1983a,b,c). Moreover, we found that this phenomenon is not
a general feature of all opiates, but rather is restricted to only
those agents with an established affinity for mu binding sites in
the brain. We were unable to demonstrate a facilitation of
naloxone's effects by the administration of ketocyclazocine,
cyclazocine or SKF, representative kappa and sigma agonists
(figure 6).
Our observations indicate that at least two receptors appear to be
involved in suppressing LH release. In this regard, it is somewhat
puzzling that an enhancement of naloxone's effects develops only
as a function of mu receptor occupancy, particularly since
ketocyclazocine and cylazocine were more potent in depressing LH
levels than the mu agonists assessed, with the exception of
etorphine. However, it should be noted that functionally important
changes in the activity of the hypothalamic-pituitary-LH axis,
such as those produced by castration and/or excess steroid
administration, have previously been shown to attenuate the
effects of mu agonists and antagonists on LH secretion (Cicero et
al. 1982; Owens and Cicero 1981) and to alter the density (Bmax)
of mu binding sites in whole rat brain (Hahn and Fishman 1979).
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If one makes the assumption that functionally important changes in
the activity of the hypothalamic-pituitary axis would be reflected
in changes in all components of the axis, including endogenous
opioid-containing neuronal systems, then the selective alterations
in mu receptor function observed in these and other studies could
indicate that they play a significant role in regulating the
release of LHRH.
Our data also indicate that a metabolically stable analog of
methionine enkephalin (FK 33-824) produced an enhanced response to
naloxone analogous to, and perhaps greater than, that generated by
opiate alkaloid agonists. These data indicate that an enhancement
of naloxone's effects on serum LH levels is not a unique event
associated with the administration of drugs, but can be generated
by endogenously occurring compounds. Moreover, since it has been
suggested in a number of recent reports (Cox and Baizman 1982;
Naber et al. 1981; Reid et al. 1982) that endogenous opioids, like
most neurotransmitters/neuro-modulators, are released in a
pulsatile manner, it seems probable that the changes in the
sensitivity of those opiate receptors involved in LHRH release
observed under our experimental conditions may occur under in vivo
conditions.
Based upon our results, it seems certain that the development of
an opiate-induced enhancement of naloxone's effects on serum LH
levels is due primarily to fundamental alterations in the
hypothalamus, rather than the pituitary. The nature of the
changes occurring in the hypothalamus are not clear, but we have
shown that the uptake, metabolism and regional distribution of
naloxone are not affected by prior opiate administration (Cicero
et al. 1983a) and, hence, it is unlikely that there is an increase
in the availability of the antagonist at its active binding
sites. Rather, the data are consistent with the interpretation
that the nature of the ligand-receptor interaction has been
altered in some way. However, we have been unable to demonstrate
any change in the Kd or Bmax of [
3H]-naltrexone binding to its
receptors in whole brain or hypothalamus, nor have we been able to
discern differences in the relative proportion of mu and delta
binding sites following morphine administration (Cicero et al.
1983a,b,c). It would be premature, however, to dismiss the
possibility that such changes may occur under in vivo conditions
since it is possible that morphine pretreatment produces subtle
changes in opiate receptors in the intact membrane in highly
discrete areas of brain which could be obscured by the in vitro
analysis of receptor properties using whole brain or gross
regional analysis.
The factors leading to the development of supersensitivity to
naloxone's effects on serum LH levels are not understood, but on
the basis of our studies, the following conclusions can be
drawn. First, only those opiates with an affinity for mu binding
sites in brain produce an enhancement of naloxone's effects on
serum LH levels; opiates which bind selectively to kappa or sigma
binding sites are devoid of such activity (Cicero et al. 1983c)
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Second, it appears that occupancy of mu receptors alone is
insufficient to promote the development of supersensitivity to
naloxone's effects, but that an initial depression in serum LH
levels, followed by a rebound to supranormal levels is an absolute
requirement (Cicero et al. 1983c). However, it should be noted
that a depression of LH per se cannot be the sole determining
factor, since many opiate and non-opiate compounds which depress
LH do not lead to the development of supersensitivity (Cicero et
al. 1983c).
The present results add to the growing evidence supporting the
hypothesis that endogenous opioid-containing neuronal systems play
an integral role in regulating LHRH release in the male and
female. Our results not only reinforce these conclusions but
indicate that these systems are markedly sensitive to transient
phases of depression and excitation.
As a potentially important offshoot of the work described in this
paper, it appears that naloxone-induced increases in serum LH
levels can serve as an extremely useful index of opiate
dependence. A sensitive and reliable index of the extent and
severity of opiate dependence should satisfy at least three
criteria: first, that naloxone produces increases in serum LH
levels in morphine pretreated rats which are greater than those
found in controls; second, that the naloxone dose-response curve,
and corresponding ED50 should shift in parallel to the left; and,
third, that the enhanced sensitivity to naloxone-induced increases
in serum LH levels should correlate with the development of other
behavioral and physiological indices of opiate withdrawal. From
the data presented above, it seems clear that the naloxone-
precipitated increase in serum LH levels in the morphine-exposed
male rat satisfies each of these criteria. Although acute
naloxone-precipitated withdrawal has been reported by a number of
investigators following morphine administration (Aceto et al.
1977; Cox et al. 1968; Kosersky et al. 1974; Meyer and Sparber
1977; Smits 1975; Wiley and Downs 19791, the increase in the
incidence of withdrawal signs has been generally unremarkable-
making quantifiable assessments difficult at best. In contrast,
we found in the present studies that a single morphine injection
produced an extremely exaggerated LH response to naloxone which
was readily quantifiable and highly reproducible. In addition, we
found that with chronic morphine exposure, naloxone-induced
increases in serum LH paralleled the development of other signs of
withdrawal and that the shift in the sensitivity to naloxone was
many times greater than that observed for these other signs.
CONSEQUENCES OF OPIATE-INDUCED ALTERATIONS IN HORMONES SECRETED BY
THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS
Because of the pervasive influence of hormones in the biochemistry
and function of every organ in the body, it seems reasonable to
postulate that acute or persistent drug-induced alterations in any
of these hormones could play a significant role in the effects of
these drugs, particularly in those adaptive changes occurring
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FIGURE 9. The effects of a single morphine or placebo pellet
implant on serum LH levels in male rats (N=10) that had been
castrated from 0 to 27 days earlier. * Significantly (p<.OOl)
lower when compared to placebo-implanted animals. T.J. Cicero,
E.R. Meyer, P.F. Schmoeker. Development of Tolerance to the
Effects of Morphine on Luteinizing Hormone Secretion as a Function
of Castration in the Male Rat. The Journal of Pharmacology and
Experimental Therapeutics, 223:784-789, 1982. © 1982 , Williams
and Wilkins. Reprinted by permission.
during the development of tolerance and physical dependence. We
have recently accumulated a good deal of evidence which supports
this hypothesis.
Functional tolerance. In earlier work (Cicero et al. 1980a). we
found that tolerance appeared to develop to the effects of
morphine on LH secretion as a function of castration. For
example, in male rats castrated for 3 days, morphine was a potent
suppressor of serum LH levels, but was virtually without effect in
animals that had been castrated for 2 weeks. In these studies,
however, morphine was administered by pellet implantation so that
it was not possible to ascertain the magnitude of the shift in
sensitivity to morphine. Because our earlier observations could
have considerable significance with respect to the plasticity of
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FIGURE 10. The percent inhibition of serum LH levels produced by
various doses of morphine (mg/kg) 30 min after its administration
to male rats (N=8 to 10) castrated 3 or 31 days earlier. T.J.
Cicero, E.R. Meyer, Schmoeker, P.F. Development of Tolerance to
the Effects of Morphine on Luteinizins Hormone Secretion as a
Function of Castration in the Male- Rat. The Journal of
Pharmacology and Experimental Therapeutics, 223:784-789, 1982.
1982, Williams and Wilkins. Reprinted by permission.
the endogenous opioid system controlling the hypothalamic-
pituitary axis and the possible involvement of hormones in the
development of tolerance to and physical dependence on the
opiates, the difference in the sensitivity of castrated male rats
to an opiate agonist (morphine), antagonist (naloxone) and
testosterone has been further characterized in several recent
studies.
Differences in the response of castrated male rats to morphine.
To examine the time course for the change in the response to
morphine in the castrated animal, groups of rats were implanted
with a single morphine or placebo pellet at intervals after
castration and were killed 24 hr later. The results are shown in
figure 9. When morphine pellets were implanted at the same time
or 1 day after castration, the post-castration-induced increases
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FIGURE 11. The percent inhibition of serum LH levels produced by
testosterone in rats (N=8) castrated 3 or 31 days earlier. T.J.
Cicero, E.R. Meyer, Schmoeker, P.F. Development of Tolerance to
the Effects of Morphine on Luteinizing Hormone Secretion as a
Function of Castration in the Male Rat. The Journal of
Pharmacology and Experimental Therapeutics, 223:784-789, 1982. ©
1982 Williams and Wilkins. Reprinted by permission.
in serum LH levels were nondetectable in morphine-treated rats.
morphine was administered 2 to 3 days after castration, it was
slightly less potent, but, even so, markedly (>80%) depressed
serum LH levels. Thereafter, morphine became progressively less
effective in reducing serum LH levels such that if it was
administered at 13 or 27 days after castration, it did not
significantly reduce serum LH levels.
Magnitude of the shift in sensitivity to morphine in castrates.
The foregoing studies revealed the time course of the change in
the sensitivity of LH secretion to morphine, but gave no
indication of the magnitude of the effect because only pellets
were employed. To determine the extent to which castrated rats
were resistant to the LH-reducing properties of morphine, acute
dose-response curves were determined in rats castrated 3 or 31
days earlier. The results are shown in figure 10. Morphine
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produced a 50% inhibition in serum LH levels at a dose of
approximately 1.5 mg/kg in animals castrated 3 days earlier, which
is comparable to that previously found in normal rats or those
castrated for similar periods (Cicero et al. 1979, 1980a,b). In
contrast to these results, long-term castration (31 days) produced
a parallel shift to the right in the morphine dose-response curve
and the ED50 was markedly reduced.
Magnitude of the shift in sensitivity to testosterone in
castrates. The dose-response curves for testosterone-induced
decreases in serum LH levels in animals castrated 3 or 31 davs
earlier are shown in figure 11. Testosterone more effectively
suppressed LH levels in animals castrated 3 days earlier than it
did in 31-day castrates.
Uptake of morphine into the brains of long-term castrated
animals. To rule out the possibility that the diminished response
to morphine observed in long-term castrates was due to an enhanced
metabolism of morphine and/or an altered uptake of the drug into
the brain, the amount of morphine found in the brains of 31-day
castrates was compared with that found in sham-operated animals 30
min after its injection. There was no significant difference in
the amount of morphine present in brain 30 min after its
administration in 31-day castrates relative to sham-operated
controls (data not shown).
Effects of castration on the antinociceptive activity of
morphine. In an effort to determine whether the apparent
tolerance to the effects of morphine on LH secretion was
generalizable to all effects of morphine on the central nervous
system, the antinociceptive activity of morphine was assessed in
31-day castrates and sham-operated controls. Castrated rats did
not differ significantly from sham-operated controls.
DISCUSSION
The results of these studies indicate that castration renders male
rats less responsive to the effects of morphine on LH secretion.
The decrease in sensitivity to morphine appears to satisfy the two
pharmacological criteria for tolerance: a parallel shift in the
dose-response curve to the right, and a reduced effect of the drug
at the same brain concentration. Our results further suggest that
the tolerance observed in the present studies is not generalizable
to other effects of morphine on the brain because the doses of
morphine required to produce inhibitions of serum LH levels in
long-term castrates by 60% or more (50-75 mg/kg) produced a
significant number of deaths (30-40%) which is comparable to that
observed in normal animals (Cicero and Meyer 1973). Moreover, we
also found that the antinociceptive activity of morphine was not
reduced in long-term castrated animals when compared with sham-
operated controls. Thus, our results indicate that the
development of tolerance to the effects of morphine in the
castrated male rat appears to be restricted to LH secretion. The
castration-induced development of tolerance to the effects of
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morphine on LH secretion was accompanied by a change in the
responsivity of the hypothalamic-pituitary axis to testosterone;
however, it should be noted that the shifts in the morphine and
testosterone dose-response curves were not equivalent in our
studies since the ED5O for morphine increased nearly 10-fold in
long-term castrates, relative to short-term castrates, whereas
only a 4- to 5-fold increase was found in the case of
testosterone. Furthermore, in terms of the absolute decrease in
serum LH levels, at specific doses of testosterone and morphine,
long-term castrates appeared to be slightly more resistant to
testosterone than they did to morphine. Nevertheless, it seems
clear that long-term castration produces decreases in the
sensitivity of the hypothalamic-pituitary axis to both morphine
and testosterone. These data, while correlational in nature,
support the previously suggested hypothesis that opioid-containing
neuronal elements tonically inhibit LHRH release and may represent
a bridge between the actions of steroids on the hypothalamus and
their ultimate inhibition of LHRH release.
The mechanisms underlying the development of tolerance to the
effects of morphine on LH secretion in castrated male rats are not
clear. Two prominent possibilities exist, however; first,
castration could produce testosterone-reversible changes in the
affinity (Kd) or density (Bmax) of the relevant opiate receptors
involved in  LHRH/LH release; and, second, castration could elevate
the levels of endogenous opioids in certain areas of brain. With
respect to the first of these possibilities, Hahn and Fishman
(1979) found marked increases in the Bmax of [
3H]-naltrexone
binding sites in whole brains of male rats castrated for 3 or more
weeks; testosterone readily overcame these effects. Although
these data support the hypothesis that castration-induced changes
in opioid receptors could be involved in the development of
tolerance to the effects of morphine on LH secretion that we have
observed in the present studies, we (Cicero et al. 1983d) and
several other groups (Bhanot and Wilkinson 1983; Diez and Roberts
1982: Wilkinson et al. 1981) have been unable to replicate their
observations. It is not clear what accounts for this difference
in results, but on balance it appears that castration does not
influence opiate receptor populations in brain.
The possibility that castration may produce testosterone-
reversible elevations in endogenous opioid levels in critical
regions of brain has not been systematically examined, but it has
been reported that a number of endocrine manipulations signifi-
cantly alter opioid levels in brain, pituitary and a number of
target organs (Mueller 1980; DuPont et al. 1982; Hong et al.
1982). If castration does in fact increase opioid levels in the
hypothalamus or other regions of brain, this mechanism could be
significantly involved in the effects we have observed.
Specifically, prolonged elevations in endogenous opioids could
lead to a desensitization of opioid receptors such that the
effects of subsequently administered exogenous or endogenous
opioids are attenuated, much as is seen in the opiate-dependent
animal. If this occurs, then one would expect, as we found, that
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the morphine dose-response curve with respect to increases in LH
would be shifted in parallel to the right. This explanation is a
parsimoniuous one and explains all of our data quite well, but it
should be reiterated that castration-induced changes in endogenous
opioid levels, synthesis and/or release in rat brain have yet to
be demonstrated.
The preceding results could have considerable significance with
respect to the plasticity of the endogenous opioid system
regulating the secretion of LH. In previous work, we have shown
that tolerance develops to the effects of naloxone on the
secretion of LH after acute or chronic administration (Owens and
Cicero 1981) and that morphine tolerance markedly sensitizes male
rats to the effects of naloxone. These observations, coupled with
the present results, suggest that there is a great deal of
plasticity in the opioid-regulated control of LHRH release. It
seems probable that these changes could have considerable
physiological significance and further studies directed at this
issue appear warranted.
In addition, our results suggest that the hormonal status of the
animal greatly influences the development of tolerance and
possibly physical dependence to the opiates. Since these
compounds exert potent effects on most neuroendocrine systems, it
seems probable that many of these changes may be intimately
involved in both the acute and chronic effects of this class of
compounds. Moreover, because most psychoactive compounds
influence neuroendocrine status, it may well be that the cross-
tolerance and interactions between these compounds may share a
common biochemical mechanism (i.e. perturbations in endocrine
status).
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Modulation of Opioid Physical
Dependence During the Hiberna-
tion Cycle
Alexander L. Beckman, Carmen Llados-Eckman,
Steven K. Salzman, and Toni L. Stanton
INTRODUCTION
One early cornerstone of the conventional wisdom
regarding opioid physical dependence is that it is an
inevitable consequence of the prolonged administration
of opioid agonists in the mammalian CNS. Although there
may be some species exceptions (see Dewey, this volume)
to this concept, each of the model systems that have
been most extensively studied commonly displays a
uniform profile of dependence liability to a given
opioid compound throughout its natural range of
function. However, experiments in the mammalian
hibernator suggest that, rather than being an invariant
feature of the response of the nervous system to the
presence of opioids, physical dependence is a CNS
state-dependent phenomenon whose presence is qualita-
tively and quantitatively determined by a requisite set
of variable characteristics of the CNS. Within one
domain of activity (the euthermic, or nonhibernating,
state in which the functional characteristics of the
CNS are like those of other more commonly studied
mammalian systems), prolonged morphine administration
produces robust signs of physical dependence.
Moreover, seasonal changes in the functional character-
istics of the euthermic CNS, as inferred by changes in
naturally occurring behavioral and physiological
variables, are associated with changes in the display
of morphine physical dependence. In contrast, a shift
in the operating mode of the CNS to the state that
produces and maintains hibernation, which is globally
characterized by a radical alteration of CNS activity
and, consequently, of the physiological and behavioral
Systems it controls, is associated with the failure of
prolonged morphine administration to produce physical
dependence.
This observation is interesting for reasons that go
beyond the sheer novelty of identifying a mammalian
system that displays a naturally occurring state-
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dependent resistance to the development of morphine
physical dependence. We may now pose questions regard-
ing the cellular responses that mediate the modulating
actions of opioids on physiological and behavioral
neural control systems, and how they compare to the
opioid-induced changes in neuronal function that
produce physical dependence and tolerance in those
systems.
This paper will establish a perspective for studying
opioid actions in the euthermic/hibernating model. We
will first review the characteristics of morphine phys-
ical dependence in hibernators (Citellus lateralis, the
golden-mantled ground squirrel) and then examine some
of the salient characteristics of the CNS during the
state of hibernation. Finally, we will consider the
potential of CNS mechanisms associated with the hiber-
nating state to modulate morphine physical dependence.
These will be discussed in relation to data obtained
from species that do not hibernate that are concerned
with morphine-induced changes in CNS neurotransmitter
dynamics and on neurotransmitter/neuromodulator-induced
reduction of morphine physical dependence and toler-
ance.
CHARACTERISTICS OF MORPHINE PHYSICAL DEPENDENCE DURING
THE NONHIBERNATING AND THE HIBERNATING STATES
We have described physical dependence on morphine in
the euthermic ground squirrel according to the commonly
used technique of administering morphine sulfate sub-
cutaneously via two 75-mg pellets inserted in the
interscapular region. In parallel with the development
of physical dependence during the 72-hour morphine
exposure period, we observed a biphasic effect on
behavioral activity (Beckman et al. 1981, 1982a, 1982b)
in which the initial phase was excitatory. The in-
creased locomotor activity usually resulted in the
destruction of the normally well-maintained cotton
nest, which the animals did not rebuild for the dura-
tion of the morphine exposure. Following the excitato-
ry phase, the animals became quiet, generally remaining
in a supine position. Those animals whose nests were
not flattened during the period of increased activity
generally remained outside their nest for the balance
of the behaviorally depressed phase of the development
of physical dependence on morphine. Seventy-two hours
after inserting the pellets, abstinence was precipitat-
ed by a subcutaneous injection of naloxone hydrochlor-
ide (1 mg/kg). In this manner, we established that the
euthermic ground squirrel develops strong physical
dependence on morphine, as evidenced by a pronounced
display of a substantial number of autonomio and behav-
ioral responses. These included most of the signs that
have been observed in many other species, plus some
signs that are novel to the ground squirrel and which
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resemble behaviors in the natural repertoire of this
animal. This constellation of signs, recorded in the
30-min period following naloxone injection, included
exploratory behavior, nesting behavior, grooming, vo-
calization, body and/or head shakes, mouth gaping
(giving the appearance of yawning), chewing, milky
dacryorrhea, digging, dyspnea, eyetwitch, flattened
posture, ptosis, and a forward-extended, fanned tail.
Seasonal Variations in Morphine Physical Dependence
Seasonal variations in the display of the abstinence
syndrome were apparent in the majority of the 14 absti-
nence signs. Figure 1 presents an example of this
variation for the 6 signs that were quantified. It is
apparent that among these 6 signs, those most intensely
displayed in a given animal were vocalizations and
shakes. Statistical analysis of the differences in the
mean number of occurrences of each sign showed that
significant differences were present in the seasonal
display of nesting, vocalizations, shakes, and mouth
gaping (Beckman et al. 1982a). Nesting responses were
significantly greater in the fall than in the summer.
Vocalizations were significantly reduced in the fall
compared with the winter and spring. Shakes were sig-
nificantly elevated in the fall compared to spring and
summer. In the fall, the occurrence of mouth gaping
was significantly greater than in any other season.
Exploratory behavior was more prominently displayed in
the summer and fall than in the winter and spring,
although these differences did not reach statistical
significance.
Another way of measuring physical dependence, that of
determining the percentage of the morphine-exposed
population exhibiting particular abstinence signs, also
demonstrated seasonal differences. This measure showed
that in 4 of the 6 quantified signs (exploring, nes-
ting, vocalizations, and mouth gaping), differences of
22-35% were apparent in the percentage of animals
displaying the signs across the four seasons. For exam-
ple, exploratory behavior was displayed by the fewest
animals during the winter, with an increasing percent-
age of the population displaying the sign through the
spring and the fall. Nesting and mouth gaping were
most commonly displayed in the fall, with a steadily
decreasing incidence through winter, spring and summer.
An increasing percentage of the population displayed
vocalizations in winter and spring compared to the
relatively small percentage observed in summer and
fall. Five of the 8 signs that were tabulated as being
present or absent in each animal following naloxone
administration (as opposed to being quantified on a per
occurrence basis) showed progressive seasonal differ-
ences. For example, chewing occurred in the highest
percentage of the population in the fall and declined
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progressively in winter, spring, and summer. The
incidence of milky dacryorrhea was lowest in the winter
and rose rapidly thereafter in the spring, reaching a
peak in the summer before declining in the fall.
The occurrence of dyspnea in the population rose
steadily from winter through fall. The display of
eyetwitch was lowest in the spring and increased
progressively in summer and fall before declining in
FIGURE 1. Seasonal changes in the number of occurrences
of quantified naloxone-precipitated abstinence signs in
morphine-dependent animals. Values are mean ± SEM.
(Reprinted with permission, from Beckman et al. 1982a,
Copyright 1982, Pergamon Press, Ltd.)
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winter. The sign of a forward, fanned tail was least
common in the summer and increased rapidly in the fall
to reach a peak occurrence in the spring. In contrast
to these progressive changes, abrupt changes occurred
in two signs, ptosis and flat posture. Ptosis alter-
nated between a high incidence in the summer and fall
and low values in winter and spring. A substantially
higher percentage of the population displayed flat
posture in the fall compared to the other three
seasons. No seasonal differences in the population
display of digging were apparent.
The seasonal differences in the display of various
abstinence signs must be a reflection of regional
differences in the development of morphine physical
dependence in the CNS. That is, although it is clear
that physical dependence is manifest throughout the
year, subtle changes in the action of morphine upon
particular behavioral or autonomic control systems
occur as a consequence of natural changes in the
nervous system. These changes, in effect, alter the
potency of morphine with respect to the production of
physical dependence.
Although there is currently no information available
comparing functional properties of the CNS throughout
the year in euthermic C. lateralis, reports of seasonal
changes in physiological and behavioral responses of
this species clearly point to underlying changes in CNS
mechanisms. These include differences in sleep cycles
(Walker et al. 1977), food consumption and body weight
(Pengelley and Fisher 1963; Mrosovsky 1975),
reproductive behavior (Heller and Poulson 1970) and, of
course, hibernation (Mrosovsky 1978). We have
suggested (Beckman et al. 1982a) that such changes
might conceivably involve the level of excitability or
activity of neural networks that controls these
variables. That is, slowly increasing levels of
excitability in particular networks would be expected
to eventually reach the threshold for the presentation
of seasonally observed responses. This concept is in
agreement with other observations (Muchlinski et al.
1983) in which the regional brain concentration of
neuropeptides (bombesin, neurotensin, somatostatin, and
cholecystokinin varied during the period of the year in
which C. lateralis undergoes a rapid increase in body
weight.
Thus, we might interpret our results to suggest that
the development of morphine physical dependence is
contingent upon morphine acting on neuronal populations
that exhibit a requisite level of intrinsic activity.
Differences in the level of endogenous activity within
these networks would therefore modulate the intensity
of physical dependence, as shown by differences in the
intensity of individual abstinence signs. This concept
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is supported by reports that discrete regions in the
CNS display unique patterns of neural responses to
morphine (Dafny et al. 1979) and that the influence of
morphine on striatal dopamine (DA) release varies
according to the frequency of nigrostriatal spike
activity (Moleman and Bruinvels 1979). Other evidence
of a relationship between neuronal activity and
response to morphine may be found in an autoradio-
graphic study of 2-deoxyglucose (2-DG) uptake in rats
(Wooten et al. 1982). Brain regions generally
d i s p l a y i n g  h i g h e r  b a s e l i n e  l e v e l s  o f  2 - D G
incorporation responded to chronic administration of
morphine with a significant reduction of 2-DG uptake
whereas those with lower baseline values showed
significant increases (Wooten et al. 1982).
The observation of seasonal differences in the
abstinence syndrome raises an important question
regarding the process underlying the development of
physical dependence: are the associated variables
p r i m a r i l y  t h o s e  o f  c h a n g e s  i n  t h e  b i n d i n g
characteristics of opioids, or is the variability
contained in the sequence of events that the agonist-
receptor complex initiates? Our hypothesis concerning
the relationship between morphine dependence and the
basal level of activity in target neural networks
contains an assumption that the basic dynamics of
morphine's cellular action do not change on a
seasonal basis in C. lateralis. However, data from an
invertebrate species, a marine mollusc, suggest that
seasonal variation in the binding of morphine may also
be a contributing factor (Stefano et al. 1980). The
seasonal differences in enkephalin binding that were
observed in the marine mollusc were associated with
differences in the ability of d-ala,met-enkephalinamide
(DALA) and met-enkephalin to alter dopamine parameters
in the pedal ganglia of this animal. The possibility
that a similar mechanism operates in the ground
squirrel will be considered in a subsequent section.
The profound difference in the hibernating ground
squirrel's responses to chronic administration of
morphine underscores the question as to where the
sequence of events leading to the development of
physical dependence may be broken. Our data (Figure 2)
show that physical dependence on morphine fails to
develop during deep hibernation (Beckman et al. 1981).
These animals received morphine either through
subcutaneous implantation of two 75-mg morphine sulfate
pellets or directly into the brain via an icv cannula
at the same dose parameters as those which produced a
robust naloxone-precipitated abstinence syndrome in
euthermic animals. Although the hibernating animals
only received morphine following entrance into deep
hibernation, they were tested for an abstinence
syndrome during the euthermic period immediately
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FIGURE 2. Quantified signs of abstinence precipitated
by naloxone during (A) the nonhibernating (euthermic)
state and (B) the hibernating state in ground squirrels
implanted with morphine pellets. Brackets denote SEM.
(From Beckman et al. 1981. copyright 1981 by AAAS).
following arousal. Whereas no abstinence syndrome was
apparent, some of the animals did respond to morphine
with a display of stereotyped behavior which began
while the animals were starting to arouse (i.e., prior
to naloxone administration) and continued into the
Post-arousal euthermic state. It is thus clear that,
although morphine does not produce physical dependence
in the hibernating state (at least at the dose
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parameters that we tested), it does evoke a strong
response in the CNS.
PROPERTIES OF THE CNS DURING THE STATE OF HIBERNATION
Whereas the euthermic ground squirrel presents itself
as a model of subtle modulation of opioid physical
dependence, the hibernating ground squirrel is a model
of the full extent of that modulation, in which the
phenomenon disappears with a change in the state of the
brain, Entrance into hibernation begins during sleep
and is characterized by a striking reduction of body
temperature and metabolic rate that reaches maximum
depression during deep hibernation. It is so charac-
teristic a feature that we commonly identify the de-
parture of the euthermic state by the fall in these two
variables. Thus, whereas internal temperature during
euthermia is regulated at approximately 38°C, during
deep hibernation in natural conditions, internal tem-
perature decreases to nearly 0°C (Wang 1978).
Current evidence clearly indicates that the entrance
into hibernation is controlled by the CNS and suggests
that this control is manifest by an increase in central
inhibitory level. For example, heart and respiratory
rates, which are depressed during hibernation, begin to
decline prior to any significant decrease in body
temperature during euthermia (Lyman 1958; Strumwasser
1959a). Likewise the amplitude of the EEG has been
observed to begin declining before any significant fall
in body temperature occurred (Wunnenberg et al. 1978).
As the entrance into hibernation progresses, the
amplitude of the EEG continues to decrease (Strumwasser
1959a; Shtark 1970; Walker et al. 1977), and changes in
the frequency distribution of the EEG occur with the
decline in body temperature (South et al. 1969; Shtark
1970). Observations taken from multiple EEG recording
sites within the same animal suggest that suppression
of EEG activity is first evidenced in the cerebral
cortex, followed by the midbrain reticular formation,
thalamus and, lastly, in areas of the limbic system
(notably in the hippocampus and hypothalamus)
(Shtark 1970).
Studies of the CNS regulator of body temperature
provide additional evidence for a controlled entry into
hibernation. During entrance into hibernation, the
threshold hypothalamic temperature for activating an
increase in metabolic rate was demonstrable at all
times, but at increasingly lower levels as time
progressed (Heller et al. 1977; Florant et al. 1978).
Electroencephalographic studies indicate that once
animals achieve the resting state of hibernation, the
level of electrical activity is similar to that of the
entry phase. That is, the cortex remains electrically
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depressed except for varying periods of increased EEG
activity (South et al. 1969; Shtark 1970; Walker et al.
1977) and, similarly, the midbrain reticular formation
displays long periods of silence that are punctuated by
short bursts of spiking activity (Strumwasser 1959b;
South et al. 1969; Shtark 1970). The limbic system
appears to diverge from this picture of general
electrical depression in that limbic structures
(notably the hippocampus, septum, and hypothalamus)
have been reported to display nearly continuous EEG
activity throughout the hibernation bout (Strumwasser
1959b; South et al. 1969; Shtark 1970). This charac-
teristic of limbic structures, contrasted with the
relative electrical silence of cortical and midbrain
areas, has prompted suggestions (South et al. 1972;
Beckman and Stanton 1976) that the proposed increase in
central inhibitory level accompanying the transition
from the euthermic state to the hibernating mode
(Luecke and South 1972; Hammel et al. 1973) is con-
trolled by neurons within the limbic system.
More recent analysis of regional CNS metabolic activity
using the 14C-2-DG autoradiographic method in ground
squirrels (Kilduff et al. 1982) confirms the earlier
descriptions of a general decline in activity through-
out the brain during hibernation. Of particular
interest is the fact that not all structures undergo a
similar reduction in activity. Those that undergo the
smallest reduction in relative 2-deoxyglucose uptake,
in comparison to euthermia, include the medial preoptic
area, ventral hippocampus, locus coeruleus, suprachias-
matic nucleus, and the lateral septal nucleus.
Presumably, these structures retain functional
significance during deep hibernation. Likewise, in
addition to the locus coeruleus and the suprachiasmatic
nucleus, we might expect structures such as the dorsal
tegmental nucleus, inferior co1liculus, superior
colliculus, and the habenular nucleus to perform
important control functions during deep hibernation
because this group of structures exhibits the greatest
relative 2-deoxyglucose uptake. It is worth noting
that these structures are components of the endogenous
opioid system, as shown by the presence of opoid
receptors (Hiller et al. 1973; Kuhar et al. 1973; Pert
et al. 1975; Simon and Hiller 1978; Pearson et al.
1980; Duka et al. 1981) or endogenous opioid compounds
(Watson et al. 1977; Matsukura et al. 1978; Gramsch
et al. 1979; Dupont et al. 1980).
Evidence for the maintenance of control functions
during hibernation has been provided by studies on the
CNS thermoregulatory system which show that it retains
functional activity and can defend the hibernating
animal against decreases in internal temperature below
a threshold level (Hammel et al. 1968; Heller and
Colliver 1974). Similarly, work in our laboratory has
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demonstrated the activation of a mechanism that is
capable of inhibiting disturbance-induced arousal from
hibernation (Beckman et al. 1976b).
Studies of the responsiveness of the hibernating brain
to the microinjection of putative neurotransmitters
such as norepinephrine (NE), 5-hydroxytryptamine (5-
HT), acetylcholine (ACh), and the neuropeptide thyro-
tropin-releasing hormone (TRH), have demonstrated that
these compounds continue to exert a potent effect on
the brain during this state (Beckman and Satinoff 1972;
Beckman et al. 1976a; Stanton et al. 1980). Micro-
injection of low concentrations of these compounds into
the hypothalamus, hippocampus, or midbrain reticular
formation can activate small thermogenic responses or
the trigger process for arousal from hibernation.
Additional studies in our laboratory, using ACh micro-
injections into the midbrain reticular formation or the
preoptic/anterior area of the hypothalamus, have
demonstrated that the hibernating brain undergoes a
decrease in excitability coincident with the entrance
into hibernation. CNS responsiveness then begins a
recovery towards euthermic levels of excitability as
time in the hibernation bout elapses (Beckman and
Stanton 1976; Stanton and Beckman 1977). Interesting-
ly, the profile of the increase in responsiveness to
ACh is different in the midbrain reticular formation as
compared with the preoptic/anterior area of the
hypothalamus. In the former structure, the increase in
responsiveness is gradual and progressive, whereas in
the latter structure it occurs more abruptly at the
half-way point of the bout. This increased
responsiveness is probably a reflection of the higher
level of EEG (Strumwasser 1959b; South et al. 1969;
Shtark 1970) and metabolic (Kilduff et al. 1982)
activity observed during hibernation in the hypo-
thalamus.
It is therefore clear, both from the maintenance of
neural activity and from the physiological responses
that actively maintain the state of hibernation against
disruption, that the hibernating brain is a functional-
ly intact system.
CHARACTERISTICS OF THE HIBERNATING CNS THAT MAY MEDIATE
THE MODULATION OF PHYSICAL DEPENDENCE ON MORPHINE
From the foregoing description of the functional
characteristics of the hibernating brain, it is
apparent that a number of major differences from the
euthermic brain could contribute to the blockade of
morphine physical dependence. We have outlined
(Beckman et al. 1981) four possibilities which merit
early consideration in light of recent findings in
nonhibernating species: a) restrictions in the
intracerebral distribution of morphine following icv
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administration in the hibernating brain, b) differences
in the turnover (synthesis, release, reuptake and/or
degradation) of neurotransmitters or neuromodulators
across the two states, c) differences in the character-
istics of opioid receptors (changes in regional recep-
tor density or ligand binding affinity), and d) low
temperature-induced differences in the development of
physical dependence that are associated with the
conditions of deep hibernation.
Intracerebral Distribution of Morphine During
Hibernation
It is conceivable that some of the characteristics of
the state of hibernation, such as the widespread
reduction in the level of function of physiological
systems or possible changes in tissue characteristics
(Beckman and Stanton 1982) could reduce the efflux of
icv-administered compounds into the brain and/or
restrict patterns of intracerebral distribution
compared to the euthermic state. In consideration of
this, we have begun to examine autoradiographically the
intracerebral distribution of tritiated morphine
following icv administration during hibernation. In
these experiments, tritiated morphine was infused
continuously into the lateral ventricle of hibernating
ground squirrels for periods of 4 to 30 hours.
Qualitative results obtained by visual inspection of
the autoradiographs revealed that the radiolabeled
compound did leave the ventricular space and diffuse
widely into the brain. The zones of increased optical
density were clearly evident in the cortex, lateral
ventricles, third ventricle, caudate nucleus, dorsal
hippocampus, amygdala, bed nucleus of the stria
terminalis, septum, medial preoptic area, thalamic
structures, the aqueduct of Sylvius, and the peri-
aqueductal gray. These regions were among those
identified in previous studies as being sites of
importance to the development of physical dependence
and the expression of naloxone-precipitated abstinence,
as shown by regional 2-DG uptake in dependent and
withdrawing animals (Wooten et al. 1982) and by the
ability to modify the display of physical dependence
following focal lesions or drug administration (Kerr
and Pozuelo 1971; Herz et al. 1972; Wei et al. 1972;
Wikler et al. 1972; Wei et al. 1973).
We are beginning to analyze these autoradiographic data
using computer-assisted densitometry in order to
improve the qualitative resolution and to quantify the
magnitude of regional optical density. We are, in
addition, in the preliminary stages of analyzing the
regional content of brain areas displaying increased
autoradiographic density to determine whether the
radioactive label is associated with morphine or its
metabolites. Thus, while yet qualitative, our data do
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not indicate any decrement in the intracerebral
distribution of morphine in the hibernating brain
following continuous icv infusion.
Changes in Neurotransmitter Turnover During Hibernation
The second feature of the hibernating CNS that may
contribute to the state-dependent block of physical
dependence concerns the changes that occur in neuro-
transmitter level or turnover during deep hibernation.
The notion that these changes, described below, may be
of significance to the development of physical
dependence is derived from the literature on the
effects of morphine administration on neurotransmitter
level or turnover, as well as the effect of changes in
the brain level or activity of putative neurotrans-
mitters on physical dependence and tolerance. The
catecholamines (NE and DA), 5-HT, and ACh have received
the most attention.
The earlier literature describing morphine's effects on
the brain levels of these compounds is contradictory in
that morphine has been reported to increase (Gunne
1959; Akera and Brody 1968) and decrease (Vogt 1954;
Gunne 1959; Maynert and Klingman 1962; Gunne 1963; Lee
and Fennessy 1970) NE levels, to increase DA levels
(Clouet and Ratner 1970) and to decrease (Lee and
Fennessy 1970) or have no effect (Maynert et al. 1962;
Sloan et al. 1962) on 5-HT levels in the brain.
Similarly, morphine may increase the level of ACh
(Large and Milton 1970; Domino and Wilson 1973) or,
depending upon the dose administered, produce biphasic
effects on ACh level (Vasco and Domino 1978). Other
reports have described effects of morphine administra-
tion on the turnover of these compounds. In view of
the data on morphine's effects on neurotransmitter
content, it is not surprising that morphine administration
has been reported to increase or decrease the turnover
of NE (Costa et al. 1974; Gomes et al. 1976; Arbilla
and Langer 1978; Bensemana and Gascon 1978), DA (Loh et
al. 1972; Costa et al. 1974; Bensemana and Gascon 1978;
Moleman and Bruinvels 1979), 5-HT (Bensemana and Gascon
1978; Snelgar and Vogt 1980; Vasko and Vogt 1982), and
ACh (Vasco and Domino 1978). The heterogeniety of these
effects is most probably due to methodological
differences (species, dose, sites of administration).
In any case, the major point established by these
studies is that chronic morphine administration affects
the dynamics of major neurotransmitter systems in the
brain. It seems reasonable to assume that such changes
would be reflected in a functionally significant change
in the matrix of inputs received by neural networks
within the CNS, thereby producing an altered output
that underlies the development of physical dependence.
This interpretation is supported by ample evidence for
morphine-induced supersensitivity in monoamine-
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sensitive systems, particularly with respect to DA
(Schulz and Herz 1977; Kromer and Steigemann 1982;
Ritzmann et al. 1982; Rae and DeMorhes 1983).
The foregoing evidence established that chronic
morphine administration produces changes in the turn-
over of several neurotransmitter systems in the CNS and
therefore supports the concept that physical dependence
is, at least in part, a manifestation of these changes.
If this is indeed the case, then experimental
manipulation of neurotransmitter level or turnover
should result in the modulation of physical dependence.
The results of such experiments, while not conclusive,
do provide some support for this notion. They show
that decreases in 5-HT levels resulted in decreases
(Way et al. 1968; Ho et al. 1972) or no change
(Schwartz and Eidelberg 1970; Cheney and Goldstein
1971) in the intensity of the morphine abstinence syn-
drome and in diminished (Way et al. 1968; Ho et al.
1972) or unaltered (Cheney and Goldstein 1971)
development of tolerance to morphine. Decreases in the
level of catecholamines have been reported to have no
effect on the development of tolerance (Bhargava et al.
1973) and to increase (Friedler et al. 1972) or
decrease (Schwartz and Eidel berg 1970) the intensity of
the morphine abstinence syndrome.
Given the matrix of intense responses that are elicited
during the antagonist-precipitated withdrawal from
morphine, it seems appropriate to characterize
morphine-induced changes in neurotransmitter dynamics
as a disruption of normal CNS function. Viewed from
this perspective, the hibernating CNS is a particularly
interesting model because the dynamics of several
neurochemical systems are markedly changed from that
observed in euthermia. Low levels of brain protein
renewal during hibernation, and dramatic increases
during arousal, have been measured in ground squirrels
(Belik and Kracho 1961). In hibernating golden
hamsters, brain cholinesterase activity is depressed,
perhaps reflecting the decrease in electrical activity
of the cortex (which is high in cholinesterase concen-
tration in the euthermic state) (Robinson and Bradley
1963). In contrast, glutamic acid decarboxylase activ-
ity, which is associated with the formation of GABA,
increased in the brain of hibernating golden hamsters
(Robinson and Bradley 1963). Measures of the turnover
of NE and 5-HT during euthermia and hibernation gener-
ally indicate that the activity of 5-HT systems is
accelerated prior to entrance and during deep hiber-
nation whereas that of NE-releasing systems is de-
pressed prior to entrance and remains low during deep
hibernation (Wang 1982).
As we have pointed out, evidence obtained from non-
hibernating species clearly suggests that the
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development of morphine physical dependence may stem
from the effects of alterations in neurotransmitter
dynamics. The hibernating CNS also displays changes in
neurotransmitter dynamics which may contribute to the
failure of morphine to produce physical dependence
during hibernation. For example, we note that although
the transition from euthermia to hibernation is accom-
panied by changes in distribution and quantity of ac-
tivity within the brain as well as changes in neuro-
chemical parameters, brain function does not appear to
be disrupted or functionally impaired. It is likely
that the preservation of this functional integrity is
dependent upon such changes which are themselves mani-
festations of the hibernator’s adaptive specializations
that buffer the CNS against the effects of otherwise
disruptive conditions.
With this in mind, we studied the turnover of DA in the
caudate nucleus of drug-naive ground squirrels during
euthermia and hibernation, as a prelude to examining
the effect of chronic morphine administration on DA
turnover in these two states. As we noted earlier,
morphine-induced changes in DA turnover, and super-
sensitivity of DA systems following chronic opioid
administration, suggest that sustained perturbation of
normal dopaminergic activity is an important component
of opioid physical dependence. In our experiments, we
stereotaxically implanted four ground squirrels with a
unilateral push-pull cannula in the caudate nucleus and
another unilateral (same side) cannula in the lateral
ventricle (for eventual chronic infusion of morphine).
Resting euthermic animals were tested in a plexiglass
chamber (ambient temperature, Ta: 20-22°C) over a 2-3
hr period in which successive 30-min caudate perfusates
(perfusion rate: 20.6 µl/min) samples were collected.
Animals were allowed free movement by means of a swivel
coupling in the perfusion system. Hibernating animals
were tested in their cotton nests (Ta: 5°C) for a
similar period. Perfusion samples were analyzed for DA
(free and conjugate forms) and its metabolites (3,4-
dihydroxyphenylacetic acid [DOPAC], 3-methoxy-4-
hydroxyphenylacetic acid [homovanillic acid, HVA], and
3-methoxy-4-hydroxyphenethanol [MOPET] by high per-
formance liquid chromatography with electrochemical
detection (HPLC/EC). Conjugates of DA were cleaved by
acid hydrolysis prior to HPLC/EC analysis.
Our results (summarized in schematic form in Figure 3)
show clear differences between the euthermic and
hibernating brain in the performance of the caudate DA
system. Our data from the euthermic state are based on
a total of 26 samples collected from 4 animals. Free
DA was not detectable in 21 of the samples. It was
present in 5 of the samples at a mean level of 3.9
pmol/30 min. HVA was detected consistently at high
levels (12.1 pmole/30 min.) in all 26 samples. DOPAC
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EUTHERMIA
RELEASE
RE-UPTAKE,
DEGRADATION, SYNTHESIS
HIBERNATION
DIMINISHED RE-UPTAKE AND SYNTHESIS
DIMINISHED RELEASE
ALTERED DEGRADATION, CONJUGATION
FIGURE 3. Caudate nucleus DA turnover during euthermia
and hibernation in drug-naive ground squirrels. Upper
half summarizes events of release, reuptake, degrada-
tion, and synthesis during euthermia as suggested by
measurements of DA and its metabolites. Lower half
summarizes these events during hibernation; note the
shift in metabolism to the enzyme pathway utilizing
alcohol dehydrogenase and the increased formation of
conjugated DA (DA-SO4). HVA was not detected in half
of the samples collected during the early portion of
the bout and in none of the samples obtained during the
late portion of the bout.
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was not detectable in 12 of the samples, but was
present in 14 at a level of 0.9 pmol/30 min. Conju-
gated DA was not detected in 14 samples, but was
present in 12 of the perfusates at a level of 1.9
pmol/30 min.
In contrast, results from the hibernating state (N=13
samples, 4 animals) showed that free DA was present in
all samples at 35.0 pmol/30 min, but that HVA was not
present in 10 samples. In 3 samples, HVA was detected
at a level of 5.0 pmol/30 min. DOPAC was not detected
in any of the samples. We did, however, detect MOPET
in each sample, in quantities of 5.6 pmol/30 min.
Conjugated DA was present in 7 of 13 samples at a level
of 13.5 pmol/30 min.
Other interesting features of the hibernating DA system
became apparent when these data were grouped according
to the period of the hibernating bout in which they
were collected. Early in the bout, levels of DA (in 7
out of 7 samples) averaged 22.2 pmol/30 min, whereas
late-bout levels increased to 45.9 pmol/30 min (in 6 of
6 samples). The early-bout level of HVA in 3 samples
was 5.0 pmol/30 min and was not detectable in 3
samples; late in the bout, HVA was not detectable in
any of the 7 samples collected. MOPET was present
during the early portion of the bout at a level of 4.7
pmol/30 min (6/6 samples) and during the late portion
of the bout, it increased by 37% to 6.5 pmol/30 min
(7/7 samples). Conjugated DA was not detectable in any
of the 6 early-bout samples, but was consistently found
in all 7 of the late-bout samples (13.5 pmol/30 min).
Thus, the data show that caudate perfusates from
euthermic animals displayed consistent, high levels of
HVA and very little (usually no) DA. This probably
indicates a relatively constant and high turnover rate.
It appears that the released DA was rapidly and
efficiently converted to HVA through the normal route
of DA metabolism, as the perfusates contained small
amounts of DA and always contained HVA.
Caudate perfusates from the hibernating animals
appeared quite different. The level of DA was approxi-
mately 10-fold higher than in euthermic animals and
occurred in each perfusate sample (as opposed to eu-
thermia wherein DA appeared in few samples). Further-
more, there was very little HVA present. DA metabolism
continued to occur, however, albeit by a completely
different route. Rather than being metabolized through
the normal route to HVA, DA was converted preferential-
ly to MOPET (where levels in each sample were about
one-half the molar quantity of the euthermic levels of
HVA), indicating a shift from aldehyde dehydrogenase to
alcohol dehydrogenase. Thus, these data probably indi-
cate that DA was still being released by caudate
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neurons (although we cannot say how the rate of release
compared to that during euthermia), but was not con-
verted as efficiently to a metabolite. Because DA
appeared to be accumulating in the extracellular space,
it is likely that overall turnover was less. However,
DA turnover appeared to accelerate late in the bout,
but remained qualitatively similar to that in the early
portion of the hibernation bout.
Our data also suggest that DA conjugates may play an
important role in the conservation of DA during
hibernation. That is, conjugated DA appears to serve
as a reservoir for the large amount of unmetabolized DA
that accumulates during hibernation.
The results of these experiments suggest that the
hibernating ground squirrel, in order to efficiently
utilize the DA that is released from slowly firing
caudate neurons, alters the metabolism of DA such that
the synaptic concentration of DA is high enough to
maintain a requisite level of tone in the DA pathway.
This alteration appears to involve, at least in Part, a
shift in metabolism from HVA to MOPET and the use of
conjugated DA (which is resistant to oxidative and
methylating enzymes) as a storehouse for free DA. The
resulting increase in the potential availability of
free DA would serve as a buffer against the effects of
opioid-induced decreases in DA release, thereby
increasing the resistance of the dopaminergic system to
opioid-induced dopamine supersensitivity. Assuming
that DA supersensitivity is a component in the matrix
of CNS changes that constitute opioid physical
dependence, this adaptive change in DA metabolism
could, in part, explain the failure of physical
dependence to develop in the hibernating CNS. In order
to test this hypothesis, we are beginning experiments
to determine the effect of morphine administration
during hibernation and euthermia on these parameters Of
DA metabolism.
There is another aspect to the concept that the
development of morphine physical dependence involves
alterations in the activity of CNS neurotransmitter
systems. We have already noted that the experimental
manipulation of central monoamine dynamics can
influence physical dependence. Evidence has been
presented in recent years that extends the concept of
opioid-neurotransmitter interactions in physical
dependence to another class of neuroactive compounds,
the neuropeptides. Although there is some evidence to
the contrary (Olson et al. 1982), the results of
several studies on melanotropin-release inhibiting
factor (MIF) and TRH favor an inhibitory influence of
these compounds on opioid tolerance and physical
dependence. For example, MIF has been reported to
inhibit tolerance to the analgesic and cataleptic
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effect of beta-endorphin (Bhargava 1981a) and to block
beta-endorphin-induced increases in DA responsiveness
(Bhargava 1981d). Other studies found that MIF can
block morphine-induced increases in DA-responsiveness
(Bhargava 1980a) and reduce tolerance to morphine-
induced analgesia (Bhargava 1980a; Bhargava 1982),
locomotor depression (Bhargava 1982), hypothermia
(Bhargava 1981c), and catalepsy (Bhargava 1981c).
Similarly, an analogue of MIF(cyclo[Leu-Gly]) has been
reported to inhibit tolerance to morphine-induced
analgesia (Ritzmann et al. 1982; Bhargava 1980a, 1981a,
1982) as well as some signs of morphine physical
dependence, morphine-induced DA supersensitivity, and
increases in the ligand affinity of striatal DA
receptors (Ritzmann et al. 1982). TRH has been shown
to block tolerance to the analgesic effects of morphine
(Bhargava 1981b) and to exert an inhibitory effect on
the development of morphine physical dependence
(Bhargava 1980b). TRH and other peptide compounds have
also been shown to antagonize opioid-induced responses.
For example, TRH inhibited morphine-induced locomotor
depression and decreases in body temperature (Bhargava
et al. 1982), somatostatin inhibited beta-endorphin-
induced adrenal medullary release of epinephrine (Van
Loon et al. 1981), and cholesystokinin inhibited beta-
endorphin-induced catalepsy in rats (Olson et al.
1982).
These findings are potentially relevant to the hiber-
nating model system’s reduced morphine dependence lia-
bility because changes in the brain levels of these and
other neuroactive peptide compounds occur with hiber-
nation. Thus, the level of TRH is lower in the brain
of hibernating ground squirrels than in euthermic ani-
mals in all areas studied (cortex, septum, hippocampus,
preoptic area, hypothalamus, thalamus, midbrain, and
medulla) (Stanton et al. 1982). Curiously, TRH levels
in the pineal gland increased dramatically during the
late portion of the bout (Stanton et al. 1982). The
levels of somatostatin, cholecystokinin, bombesin, and
neurotensin were measured in five brain regions of
hibernating and summer euthermic ground squirrels,
with some interesting differences being displayed
(Muchlinski et al. 1983). Somatostatin levels generally
increased in hibernation in the thalamus and decreased
in cortex, cerebellum, medulla, and hypothalamus,
compared with average values measured during the summer
season. Hibernation levels of cholecystokinin in-
creased, relative to average summer values, in the
cortex and cerebellum, tended to decrease in medulla
and hypothalamus and showed no change in the thalamus.
Hibernating levels of bombesin were lower than average
Summer euthermic levels in the hypothalamus, thalamus,
and medulla but showed no changes in the cortex or
cerebellum. Neurotensin levels were unchanged in the
cortex during hibernation, but decreased in hypothal-
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amus, thalamus, and medulla compared to summer animals,
In another study, the content of met-enkephalin, leu-
enkephalin, and ACTH was measured in whole-brain ex-
tracts obtained from hibernating and winter euthermic
ground squirrels. The level of both met- and leu-
enkephalin was increased, and that of ACTH decreased,
in hibernating brain (Kramarova et al. 1983).
Whereas it is hazardous to infer particular changes in
the overall turnover (thus, in substance release and
alteration of neuronal activity) from data on changes
in brain neurotransmitter or neuromodulator levels, it
appears safe to assume that these results reflect
changes, albeit unspecified, in the functional activity
of these neuroactive compounds. This assumption
appears to be particularly valid in the case of the
increased levels of enkephalin. Recent work in our
laboratory (Llados-Eckman and Beckman 1983) suggests
that these increased levels reflect an increase in the
functional activity of the endogenous opioid system
during hibernation. We demonstrated that opioid
blockade produced by continuous icv infusion of
naloxone during hibernation produced a dose-dependent
decrease in bout duration. These and other results
(Margules et al. 1979; Kromer 1980) suggest that
disruption of the baseline activity of endogenous
opioid peptide systems during hibernation destabilizes
the state, perhaps by interfering with a fundamental
component of its controlling mechanism (Oeltgen et al.
1982).
As noted above, the proposed changes in functional
activity of neuropeptides such as TRH, somatostatin,
and cholesystokinin during hibernation could contribute
to the blockade of the development of morphine physical
dependence during this state. Another contributing
factor, alluded to earlier, may involve an increase in
the level of GABA in the hibernating brain (Robinson
and Bradley 1963); inhibition of the degradation of
GABA has been reported to attenuate physical dependence
(Contreras et al. 1979).
When we proposed (Beckman et al. 1981) that changes in
opioid binding might be a potential factor in
explaining the resistance of the hibernating state to
the development of physical dependence, our rationale
was quite straightforward: if morphine binding
decreased, either through increased competition with
naturally available endogenous ligands or through a
frank decrease in opioid binding sites, the potency of
morphine (and, hence, physical dependence) would
diminish. There is very recent evidence (Kramarova et
al. 1983), as reviewed above, that enkephalin levels do
increase during hibernation. Whether endorphin levels
(or, more to the point, endorphin release) also in-
crease during this state is still unknown.
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Changes in the Characteristics of Opioid Binding
In considering the role that changes in opioid receptor
parameters may play in the blockade of the development
of physical dependence during hibernation, we have
begun to study with Dr. James K. Wamsley regional brain
opioid binding in hibernating and euthermic ground
squirrels, using in vitro receptor autoradiography in
conjunction with computer-assisted densitometry. In
our initial studies, we have sought to avoid
preferential labeling of specific opioid receptor
subtypes and therefore have used a high concentration
(4 nM) of tritiated dihydromorphine as the agonist
ligand. The preliminary results show that, indeed,
overall opioid binding does decrease in the hibernating
brain, particularly in the dorsal aspects of the
cerebral cortex, in the septum, hippocampus, thalamus,
and in the amygdala. The decrease in intracerebral
binding during hibernation is not, however, uniform.
For example, binding in the rostra1 hypothalamus and
the habenula remain comparable to that during the
euthermic state. In addition, the overall decrease in
binding cannot simply be ascribed to the low body
temperatures associated with the hibernating state
because the trend toward decreased binding is evident
in euthermic winter animals, as compared to that ob-
served in the brains of animals during the fall.
It is tempting to speculate that the decline in opioid
binding in the winter euthermic and hibernating ground
squirrel brain is due to a down-regulation of opioid
receptors produced by the elevation of regional brain
concentrations of endogenous opioids. Although it
seems clear that the opposite phenomenon, up-
regulation, occurs following chronic treatment with
opioid antagonists such as naloxone or naltrexone
(Lahti and Collins 1978; Bardo et al. 1982; Zukin
et al. 1982), it remains uncertain whether chronic
administration of opioid agonists reliably induces
receptor down-regulation (Davis et al. 1975; Davis
et al. 1979; Tsang and Ng 1980; Sivam et al. 1981).
Contribution of Low Body Temperature to Reduced
Morphine Dependence Liablility During Hibernation
Although the evidence we have presented thus far
suggests that hibernation-related adaptive changes in
neurotransmitter or neuromodulator parameters (e.g.,
changes in DA metabolism or in opioid receptor binding)
may provide the main source of stabilization against
the development of morphine physical dependence, the
potential role of low body temperature yet needs to be
defined in the ground squirrel. Certainly, evidence
obtained in nonhibernating species has identified a
temperature-dependent component in the development of
dependence and tolerance. Thus, lowered temperature
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exerted a short-term (less than 4 hours) inhibition of
dependence on normorphine in the isolated guinea pig
ileum (Collier et al. 1981), and also blocked the
development of tolerance to morphine depression of
sensory evoked responses in mouse spinal cord-dorsal
root ganglion explants (Crain et al. 1979).
In initial experiments, we have begun to compare the
naloxone-precipitated abstinence syndrome in euthermic
animals that have received continuous icv infusion of
morphine (55 µg/µl/hr) with that displayed by post-
arousal euthermic animals that had just completed
receiving the same dosage of morphine, while
hibernating at 20°C. Our initial results indicate that
animals hibernating at this elevated temperature (usual
hibernation temperature, 5°C) display a feeble
abstinence syndrome that includes a few body shakes and
vocalizations, and the occasional presence of milky
dacryorrhea, chewing, dyspnea, eyetwitch, and forward,
fanned tail during the 30-minute period following
naloxone administration. One animal also displayed
stereotypy, as observed previously in animals that
received morphine during deep hibernation (Beckman et
al. 1981). These data are too preliminary to adequately
describe the effect of low temperature on the
hibernation-induced block of physical dependence. They
do however, indicate that low body temperature may
contribute to this phenomenon. Continuing work will
determine its extent.
CONCLUSION
These studies on the ground squirrel have progressed to
the point where it is clear that the hibernating model
can make an important contribution to our understanding
of the neural correlates of opioid physical dependence.
Its unique advantage is that it permits a direct
comparison of the performance of designated CNS systems
following chronic opioid administration in states of
high or low dependence liability. We can, therefore,
identify changes in performance that do, or do not,
correlate with the development of physical dependence
and thereby describe the important determinants of
morphine dependence. It is not inconceivable that the
critical elements of the natural stabilizing mechanisms
utilized by the hibernating CNS could be adapted for
the therapeutic prevention of opioid physical
dependence.
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Neurophysiological Investigations
of Opiate Tolerance and Depend-
ence in the Central Nervous
System
Steven Jon Henriksen
Most pharmacological studies investigating opiate- and opioid-
induced tolerance, dependence or addiction liability have utilized
In vitro bioassay systems or whole animal preparations. These
studies, although critical for the elucidation of rank order
potency series and the characterization of the variety of opiate
receptor subtypes, have not led to the understanding of the
cellular processes underlying opiate tolerance and dependence.
More recently, studies using hybrid cell lines (see previous papers
in this volume) and the investigation of opiate receptor up-or-down
regulation (Zukin et al., this volume) have suggested important
receptor Iigand and second messenger processes that are candidates
for participation in cellular events leading to the phenotype of
the opiate-tolerant organism. Neurophysiological approaches have
also been employed in the study of opiate and oploid neuropharma-
cology. These studies, using a variety of electrophysiological
approaches at the cellular level, have begun to address those
bioelectric events associated with acute and chronic drug exposure.
Electrophysiological Techniques: An Inherent Advantage For The
Investigation Of Tolerance And Dependence:
(1) They allow the opportunity for real-time analysis of the cel-
lular processes occurring during acute, chronic, and drug
withdrawal conditions; (2) they provide a unique wide dynamic range
of measured events exemplified by encephalographic and field
potential analysis as well as analysis of intracellular events
associated with synaptic and nonsynaptic processes; and (3)
electrophysiological measurements can be made in several different
in vitro and in vivo animal preparations of which each provides
particular technical advantages for answering specific questions
regarding mechanisms of opiate tolerance and dependence.
In this essay, I will review the evidence of the neurophysiological
correlates of acute and chronic opiate (and oploid) exposure, and
will discuss how these data generate hypotheses regarding the
cellular mechanisms underlying these phenomena. This review is in
no way meant to be exhaustive; rather, it has been focused solely
239
on the central nervous system, and then only on particular examples
from investigators using specific neurophysiological tools to study
the mechanisms of tolerance.
Four considerations are important when discussing central neuronal
responses to acute or chronic opiate treatment: (1) What is the
nature of event being measured, i.e., is it evoked or spontaneous?
(2) What is the time course of the alteration in the event
recorded, and what is the stability of this effect?; (3) Can
dependence be ascertained by precipitation with naloxone? and (4)
Are the changes at the cellular level following chronic opiate
exposure due to the same mechanisms that produce the acute effects
of these drugs?
Encephalographic Analysis
The electroencephalograph to record spontaneously generated
cortical bioelectric events has long been used as a tool to assess
both acute and chronic effects of opiates (Khazan 1975). Systemic
or intraventricular administration of acute doses of morphine, In
numerous experimental animal species, results in a widespread
cortical desynchrony and 4-10 Hz burst activity associated with
behavioral stupor (Khazan et al. 1967; Khazan and Colasanti 1971;
Nakamura and Winters 1973; Tortella et al. 1978). In addition,
changes in cortical and subcortical electrical activity in response
to repeated morphine administration has been investigated and
electroencephalographic tolerance to opiates has been observed
(Khazan et al. 1967; Teitelbaum 1976).
Multiple intracerebral injections of morphine into specific subcor-
tical brain loci can result In electrographic tolerance at those
injected sites (Teitelbaum et al. 1976). In addition, specific
brain lesions have been shown to reverse electrographically
assessed morphine tolerance (Teltelbaum et al. 1979).
In addition to those studies evaluating the action of opiates on
the spontaneous electroencephaIogram, other investigations have
focused on the effects of opiates on evoked potentials in naive,
tolerant and withdrawn animals (Straw and MitchelI 1964; Domino
1968; Gildenberg et al. 1976). These studies have demonstrated
that particular components of stimulation-evoked potentials, and
not others, are dramatically altered by acute opiate administra-
tion. These effects diminish on continued administration and
therefore exhibit tolerance.
Studies such as these have demonstrated that the electroencephalo-
graphic technique is a valuable tool to monitor those cellular
electrical events that parallel the development of behavioral
tolerance to opiates. This approach has also been used to demon-
strate more localized cerebral electrical changes associated with
the opiate dependence cycle.
The same encephalographic techniques used to assess the acute and
chronic effects of opiates on brain electrical activity have been
applied to the study of the endogenous opioid peptides.
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ß-endorphin, methionine and leucine enkephalin, as well as several
enkephalin derivatives, have been shown to have nonconvulsive
epileptogenic properties when administered intraventricularly to
rats (Henriksen et al. 1978; Urca et al. 1977; Neal and Keane 1978;
Tortella et al. 1978). This epileptiform activity seems to have
its origin in limbic structures (an area rich in opiate receptors)
as determined by localized recording and 2-deoxyglucose techniques
(figure 1). Another major opioid peptide, Dynorphin A (1-17), is
not epileptogenlc in rats, suggesting specific opiate receptor
specificity for the generation of this activity (Henriksen et al.
1983).
LATERAL
SEPTUM
VENTRAL
CA3
FIGURE 1. 2-DG. EEG traces and 14C-2 deoxyglucose (2DG) auto-
radiographic illustrations of the response to intraventricularly
administered ß-endorphin (B-E, 3 nM) in a representative rat.
A) Electrographic tracing of ictal seizure episode elicited by B-E.
B) 14C-2DG autoradiographs of representative sections of control
rat brain and a brain of a rat exhibiting a seizure following B-E.
(Henriksen et al. 1983. © Alan R. Liss, Inc. 1983).
241
Visual inspection of the autoradiographs reveals a marked uptake of
DG, bilaterally, in the dorsal and ventral hippocampus, posterior
and ventral subiculum, dentate gyrus, lateral septum, and the
posterior part of the medial nucleus of the amygdala (amygdala-
hippocampal area). There was also a marked decrease of uptake
bilaterally in the medial geniculate body.
The electrographic changes seen in the EEG following repeated
ventricular or in situ administration of opioid peptides result in
the development of tolerance to the effect of the peptide simiIar
to opiates (Elazar et al. 1979). Figure 2 illustrates the develop-
ment of tolerance to the epileptogenic action of a daily injection
of ß-endorphin (3 nM i.c.v.) in a rat.
These encephalographic studies provide important information
regardlng localized electrographic patterns associated wlth acute
and chronic opioid/opiate administration. Therefore they suggest
specific brain areas, and even nuclei, that are highly sensitive to
the effects of these drugs. On the other hand, this experimental
approach is unable to distinguish between a direct pharmacological
effect and an indirect, secondary, effect of these drugs. Because
of this technical limitation other neuropharmacological approaches
have been employed to investigate more directly the action of
narcotics and opioid-peptides on single neurons.
Extracellular Analysis
1. Acute effects of opiates and opioid peptides
Prior to the knowledge of the endogenous opioid peptides or
specific opiate receptors, most central pharmacological effects of
systemically administered opiate alkaloids were attributed to their
action on known transmitter systems (Clouet 1971; Way 1972; Way and
Shen 1971; Clouet and lwatsubo 1975). However, in their extensive
review, Clouet and lwatsubo (1975) could not attribute a causative
role to any single transmitter system for the development of
tolerance to opiates.
In an attempt to characterize more precisely the possible inter-
action of opiates with other neurotransmitters, the neuropharma-
cological technique of microiontophoresis combined with single cell
recording has been employed. This approach has the important
advantage of allowing the direct assessment of drug (or putative
transmitter) efficacy on a single recorded neuron thereby allevi-
ating the complication of indirect effects of systemically adminis-
tered drugs. In addition, the effects of iontophoretically applied
opiates (or, as we are now aware, opioid peptides) on cellular
responses to other neurotransmitters can be evaluated. Early
studies using this approach demonstrated compIex neuronal act ions
of iontophoretically applied opiates. In the brainstem of the rat,
iontophoretically applied morphine produced both excitatory (43%)
as well as inhibitory (22%) actions on the spontaneous discharge of
individual neurons (Bradley and Dray 1974). In addition, ionto-
phoretically applied morphine was able to block, in many cases, the
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CHANGES IN BETA-ENDORPHlN INDUCED ICTAL EPISODES FOLLOWING
REPEATED INJECTIONS
FIGURE 2. Endorphin Tolerance. Amygdala EEG traces taken from a
rat injected once daily wIth ß-endorphin (3 nM) intraventricularly.
IPSILAT: refers to same side of the brain as the injection;
CONTRA: refers to the opposite side from the injection. Note the
slow but marked tolerance that develops to the ictal epileptiform
events as recorded from the amygdala. WDS: wet-dog-shakes; NM=no
movement.
normal excitatory response of these neurons to iontophoretically
applied acetylcholine, noradrenaline and 5-hydroxytryptamine. On
the other hand, the excitatory effect of glutamate on these neurons
could not be blocked by morphine (Bradley and Dray 1974). In an
attempt to assess the specificity of these morphine effects, it was
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found that only the depressions in brain stem unit activity were
capable of being antagonized by naloxone, suggesting that the
direct excitatory effects of morphine observed in a majority of the
neurons tested was a nonspecific effect (Bramwell and Bradley
1974). In another important observation, these investigators
rarely observed the phenomenon of tachyphylaxis (i.e., desensitiza-
tion) to repeated iontophoretic applications of opiate and never
observed such an effect to the inhibitory (i.e., specific) action
of morphine.
Numerous other investigators have studied the action of opiates in
other brain areas using the microiontophoretic technique. In
general, these studies show that the specific (i.e., naloxone-
reversible) effect of electrophoretically applied opiates is to
depress the spontaneous activity of recorded neurons (Bradley and
Dray 1974; Henry and Neuman 1975; Zieglgansberger and BayerI 1975;
Zieglgansberger et al. 1975; Satoh et al. 1976; Fry et al. 1980;
but see Davies 1976). Figure 3 illustrates a representative
example of the effect of normorphine, iontophoretically applied
onto rat amygdala neurons.
Soon after the isolation, characterization, and synthesis of the
first endogenous opioid peptide, neuropharmacologists began to
evaluate this new, growlng list of peptides for central opiate-Iike
activity. Of paramount importance in these investigations has been
the localization of oploid receptors through autoradiographic
analysis (Goodman et al. 1980; Duka et al. 1981; Goodman and Snyder
1982) as well as the distribution of the endogenous opioid peptides
thorough the use of immunohistochemical techniques (Bloom et al.
1977, 1978; Watson et al. 1977 and others).
In this way, the cellular physiologists have been able to direct
their studies to those areas in the mammalian brain appropriate for
each opiate receptor subtype being investigated as well as for the
specific oploid peptide locally dlstributed. Early surveys of the
response of neurons to iontophoretically applied opioid peptides
suggested great similarities to what had previously been observed
with opiate alkaloids (Nicoll et al. 1977; Siggins et al. 1978;
Zleglgansberger et al. 1975; French and Siggins 1980). In most
brain areas studied, the great majority of single neurons demon-
strate naloxone-reversible inhibition of spontaneous discharge
following electrophoresis of the enkephalins (either leucine or
methionine) or ß-endorphin (figure 4). A notable exception to this
general inhibitory effect is observed in the hippocmapal formation
where mostly excitatory effects are observed (NicolI et al. 1980;
and Zieglgansberger et al. 1979). These results supported earIier
encephalographic data suggesting excitatory, epileptogenic, actions
of intraventricularly administered opioid peptides on the hippo-
campal formation (Henriksen et al. 1978). Because of the unique
excitatory actions of most opioid peptides on hippocampal neurons,
a great number of investigators have focused their attention on
this structure in an attempt to explain this paradox. Simply
stated, it now appears that these opioid-induced excitatory effects
244
FIGURE 3. Amygdala. Inhibitory effects of morphine (MS; panel A)
on a single neuron in anterior central amygdala, and of methionine-
enkephal in (ME) and ß-endorphin (ß; panel B) on a neuron in
anterior basolateral amygdala. Apparent differences here in sensi-
tivity of these neurons to the opiates or peptides were not consis-
tently observed in other neurons. Note: the magnitude of response
to MS in panel A is correlated with the iontophoretic current
(French and Slggins 1980, ©
Biomedical Press).
are most likely the result of
the peptides on adjacent
Zieglgansberger et al. 1979).
1980 by Elsevier North Holland -
an indirect disinhibitory action of
inhibitory interneurons (see
These physiological data are supported by anatomical evidence sug-
gesting the presence of opioid-containing neurons in close
proximity to putative inhibitory interneurons (Gall et al. 1981).
2. Extracellular effects of opiates and oploids in tolerant
preparatlon
Microlontophoretic and micropneumatic techniques have been used to
assess the cellular response to applied opioid peptides and opiates
in animals previously made tolerant to opiate alkaloids. In most
brain areas studied in tolerant rats, extracellular application of
opiates and opioids results in a diminished responsiveness to their
action compared to their effect in naive animals (Satoh et al.
1974, 1975 1976; Zieglgansberger et al. 1976; Zieglgansberger and
Fry 1976; Fry et al. 1979; Aghajanian 1978). In addition, cellular
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FIGURE 4. Excitatory action of methionine-enkephalin (ME) and
acetylcholine (ACh) in the hippocampus, and the blockade of the ME
act ion by iontophoretic naIoxone. Thin bar indicates ME applica-
tion and thicker bar, ACh application. Same neuron throughout
record. Note that firing rate and ACh response is not much
affected at 2-3 minutes of naloxone application, when ME responses
are totally blocked, but less selective naloxone effects emerge
later, when the ACh response is reduced by about 30% (French and
Siggins 1980, © 1980 by Elsevier North Holland - Biomedical Press).
dependence to morphine has been demonstrated by studies indicating
a higher incidence of excitatory responses to microiontophoreti-
cally administered naloxone has been observed for neurons recorded
in the medial thalamus (Frederickson et al. 1975), frontal cortex
(Satoh et al. 1976), locus coeruleus (Aghajanian 1978) and striatum
(Fry et al. 1980) of morphine-tolerant rats.
These studies offer strong evidence that both tolerance, as well as
dependence, to opiates and opioid peptides can be observed at the
single neuron level in the vertebrate CNS.
Recent studies have attempted to assess opioid tolerance and depen-
dence using a CNS in vitro preparation, the hippocampal, or locus
coeruleus slice. This preparation offers several technical advan-
tages over the in vivo preparation for the study of opiate toler-
ance and dependence. Of foremost importance is the abiIity to
accurately control drug concentration, which allows true pharmaco-
logical studies to be done with agonist and antagonist drugs.
As was previously discussed, opiates and opioids produce excitatory
effects in the hippocampal formation. In rat hippocampal slices,
opiates and opioid peptides potentiate the synaptic activation of
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pyramidal neurons as revealed by a shift to the left in the input-
output curves of monosynaptically evoked CA1 field potentials
(Robinson and Deadwyler 180; Corrigall et al. 1981; French and
Zieglgansberger 1982; Valentino and Dingledine 1982; Robinson et
al. 1982). Figure 5 illustrates the effect of normorphine and
methionine-enkephalin on hippocampal slice CA1 field potentials in
a slice obtained from a naive rat.
FIGURE 5. Effect of normorphine (NM, 1 µM) on the population spike
evoked in hippocampal pyramidal cells (CA1) by stimulation of
Schaffer collaterals. A. Spikes at several time points (3,4,6
minutes) after onset of opioid perfusion. Washout taken at 20
minutes after termination of drug application. Note the emergence
of a secondary wave (6 minutes). Stimulus intenslty was 40 V,
duration 0.1 ms. Calibration: 1 mV, 5 ms, B. Effect of
methionine-enkephalin (ME, 1 µM) at various time points (5, 25
minutes) and with different stimulus intensities (23,30,40 V).
Note the large secondary and tertiary wave forms at the 25-minute
time point. The responses to ME + NX were taken 5 minutes after
the onset of perfusion of ME (1 µM) + naloxone (NX, 1 µM).
Calibration: 1 mV, 5 ms (same recording and stimulation sites as
In A) (French and Zieglgansberger 1982, © 1982 by Springer-Verlag).
Hippocampal slices obtained from rats made tolerant to morphine
exhibit tolerance to morphine but not to opioids when challenged in
vitro (French and Zieglgansberger 1982). These results suggest
that, while both opiate agonists increase neuronal excitability of
hippocampal pyramidal celIs, this effect is likely to be mediated
via different opiate receptor populations (figure 6).
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FIGURE 6. Effect of methionine-enkephalin (ME) and lack of effect
of a high concentration of normorphine (NM) when applied to slices
obtained from chronically morphinized rats:
control; ME, 5 µM; NM, 5 µM;~ washout
of Me response (French and Zieglgansberger 1982, © 1982 by
Springer-Verlag).
In a recent study utilizing the locus coeruleus slice preparation
(Andrade et al. 1983), tolerance was observed to the normal
decrease in spontaneous firing of locus coeruleus neurons produced
with acute administration of morphine. However, in contrast to
what has been reported in in vivo studies (Aghajanian 1978),
naloxone administered to the tolerant slice did not precipitate
supranormal firing rates of locus coeruleus neurons. These results
strongIy suggest that, at least for noradrenergic locus coeruleus
neurons in vitro, tolerance and dependence can be dissociated. It
also suggests that dependence (withdrawal activation) in locus
coeruleus neurons is mediated by factors present in vivo but not in
vitro (i.e., extrinsic excitatory inputs to this area).
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FIGURE 7. Acute desensitization to phoretically applied
methionine-enkephalin. A: methionine-enkephal in (ME, 20 nA)
reduces spontaneous and glutamate-induced (G, 10 nA/20 s) discharge
activity. Despite ongoing application of ME, the firing rate
increased again and showed a clear rebound after termination of
drug application. The inhibitory action of GABA (5 nA) before (not
shown), during and after ME application was not altered signifi-
cantly. Applications are indicated by bars. Doses are indexed.
B: ordinates in B and C give activity during pulses (10 s) of
glutamate (10 nA). The applications were spaced 60 s apart.
Microiontophoretic administration of D-Ala2-D-Leu5-enkephalin (D,
50 nA) causes inhibition which is not changed despite the desensi-
tization to morphine (M, 100 nA). C: the inhibitory effect of
morphine (M, 40 nA) was lost after the neuron was rendered insensi-
tive to ME (65 nA). After termination of drug administration the
neuron showed a marked rebound in its firing rate and reached
control levels and sensitivity to morphine after about 15 minutes
(Williams and Zieglgansberger 1981, © 1981 by Elsevier North
Holland - Biomedical Press).
3. Acute desensitization to opiates/opioids
Cellular studies of opiate/opioid tolerance and dependence have the
unique capability of accurately monitoring the developmental time
course of subsensitivity to opiate agonists. Some investigations
have suggested very short-term tolerance, or tachyphylaxis, to
opiates can occur (Fry et al. 1980; Gahwiler 1981; Williams and
Zieglgansberger 1981. Figure 7 illustrates an example of
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FIGURE 8. Dynorphin A(1-17), 30 nA, induces excitatory response in
a CA3 hippocampal neuron recorded from anesthesized rat. Because
space does not allow, this rate-meter represents only the last four
of 50 dynorphin A 30-second pulses. No acute desensitization was
observed.
desensitization of a frontal cortical neuron to a continuous
iontophoretic puIse of methionine-enkephalin. In addition, in this
same study, an apparent one-way cross-desensitization was observed
for morphine and D-Ala-D-Leu-enkephalin (figure 70).
Other studies in other brain areas faiIed to demonstrate acute
tolerance to either opiates or opioids peptides. Figure 8 illus-
trates the effect of iontophoretically applied dynorphin on a rat
hippocampal neuron and the lack of tachyphylaxis.
In addition, studies of opiate/opioid effect on hippocampal neurons
in the slice preparation have failed to show any short-term toler-
ance to either agent (Valentino and Dingledine 1982; Robinson and
Deadwyler 1980). In fact, even after 4-hours of superfusion with
morphine (20 M), no diminution in the augmentation of the evoked
population spike was observed.
It is possible that some of the earlier investigations demon-
strating tachyphylaxis to opiates may have been confounded by
technical problems associated with long-term ejection artifacts
observed when using iontophoretic pipettes. The issue of acute
tolerance to opiates and opioid peptides, therefore, remains
unresolved.
Intracellular Analysis
Following the lead of in vivo pharmacological studies of the action
of opiates and opioid peptides on single neurons in brain, several
investigators recently have begun to investigate the intracellular
processes associated with acute and chronic drug exposure.
Recordings have been made from neurons penetrated in the hippo-
campal and locus coeruleus slice preparation (See Siggins and
Zieglgansberger 1981; Masukawa and Prince 1982; Robinson and
Deadwyler 1981; Nicoll et al. 1980; Dingledine 1980; Haas and RyalI
1980; Pepper and Henderson 1980; WiIIiams et al. 1982). In the
locus coeruleus slice preparation, methionine5-enkephalin, D-Ala2-
D-Leu5-enkephalin (DADLE) and morphine produce a naloxone-sensitive
increase in potassium conductance resulting in hyperpolarization of
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FIGURE 9. Enkephal inhibits cell firing. The figure shows an
intracellular recording from a spontaneously firing locus coeruleus
neuron. DADLE was applied by a brief (50 ms) pulse of pressure (70
kN M-2, 10 p.s.i.) to a pipette positioned just above the brain
slice at the time indicated by the arrows. The cell hyperpolarized
and the action potential discharge was inhibited. The pen recorder
did not reproduce the full action potential amplitude, which was
70-100 mV among different neurons. These recordings were made from
a completely submerged slice of pons (thickness 300 M) continuously
superfused with a solution of the following composition (nM): NaCL
11, which was equilibrated a 37°C with 95 O2, 5% CO2 (Williams et
126, KCl 2.5, CaCI2 2.4, NaH2PO4 1.2, MgCI2 1.3, NaHCO3 25, glucose
al. 1982, © 1982 by MacMillan Journals Ltd.).
the cell and cessation of spontaneous firing (Williams et al. 1982;
North and Williams 1983; see figure 9). Note the lack of acute
desensitization to this response.
in contrast, pyramidal cells penetrated in the hippocampal slice
preparation show little or no direct transmembrane effects of
either morphine or several opioid peptides. On the other hand
these agents do alter synaptic responses to afferent stimulation,
which is consistent with a modulatory action, of opioids in this
structure (Masukawa and Prince 1982; Siggins and Zieglgansberger
1981). As yet, there exists no consensus as to the exact
mechanisms by which opioids alter these hippocampal synaptic poten-
tials but most studies suggest a reduction of recurrent and feed
forward inhibitory post-synaptic potentials (IPSPs) implying a
disinhibitory mechanism. This interpretation is also suggested by
extracellular studies previously discussed.
One recent study has investigated the changes in transmembrane
properties and sensitivity to opiates following prolonged exposure
to morphine (Williams and North 1983). In this interesting study,
intracellular recordings were made from locus coeruleus neurons in
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the slice preparation after three treatment paradigms: (1)
recordings made from slices cut from naive rats and superfused with
morphine for 8-12 hours, (2) recordings made from slices taken from
rats previously implanted with morphine pellets and superfused with
morphine; and (3) recordings made from slices taken from pelleted
rats but superfused in a morphine-free solution. In "naive" locus
coeruleus slices, normorphine (1-3 M) produced the usual hyper-
polarization of these neurons; however, the hyperpolarization
lasted for as long as the superfusion continued (up to 12 hours).
That is, no tolerance was observed to the hyperpolarizing effect of
normorphine in this time period. Neurons recorded from pelleted
rats showed only mild tolerance to the hyperpolarizing action of
superfused normorphine (3-10-fold less potent). In studies taken
from pelleted rats, naloxone caused a depolarization of recorded
neurons and the return to baseline of the spontaneous firing rate.
These studies indicate that no acute tolerance to normorphine is
seen during 8-12 hours of perfusion in the locus coeruleus slice.
In addition, only minimal tolerance is observed in the slices taken
from peIIeted rats. This is to be compared to strong behavioraI
and cellular tolerance seen in vivo with the same treatment
schedule. Therefore, at least for neurons in this preparation,
much of those observed signs of tolerance and dependence seen in
vivo must derive from a larger neural net influencing secondarily
the excitability of locus coeruleus neurons, Studies such as these
intracellular investigations will be very important to follow for
neurons from other brain areas where acute tolerance has been
observed.
SUMMARY
In this essay I have presented several examples of cellular neuro-
physiological approaches used to investigate opiate tolerance and
dependence. In many ways, these central nervous system studies
parallel earlier investigations carried out in in vitro prepara-
tions and celI culture systems reviewed by others in this volume.
The examples presented here have demonstrated that opiate/opioid
tolerance and dependence are observed at alI levels of electro-
physiological analysis. Moreover, recent studies utiIizing the
locus coeruleus slice preparation have shown the feaslbiIity of
separating the processes underlying opiate tolerance and those of
dependence (Andrade et al. 1983). Several important issues remain
unresolved: (1) Can acute tolerance to opiates/opioids be demon-
strated in alI preparations (and in alI brain areas studied) or is
this phenomenon, in part, due to technical shortcomings of ionto-
phoresis? (2) What are the characteristics of the subpopulations
of opioid receptor agonists and their differential ability to
alter, in naive or tolerant preparations, synaptic and nonsynaptic
processes in neurons? and (3) What are the intracellular events
associated with dependence on other brain areas known to contain
neurons that are post-synaptic to endogenous opioid peptides? In
addition, what is the relationship, at the synaptic level, of
opioid-induced synaptic activity and the cascade of intracellular
events coupIed to "second messenger" processes? Are these Intra-
cellular processes ubiquitous for all opioid agonist subtypes or
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are regional as well as intracellular coupling mechanisms
heterogeneous?
Many of these questions currently remain unanswered. However,
taking our lead from investigators using molecular approaches to
study receptor function (see Sigworth 1982; Walker et al. 1982;
Taylor et al. 1983; Dunn et al. 1983 and others vis-a-vis
muscarinic ACh receptor), "opiold" physiologists are likely to play
a major role in elucidating and characterizing endogenous
ligand/receptor interactions in the coming years.
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Spinal Cord Tissue Culture Models
for Analyses of Opioid Analgesia,
Tolerance and Plasticity
Stanley M. Crain
I. MODELS OF OPIOID FUNCTIONS USING FRESHLY ISOLATED TISSUES
OR CELL CULTURES
In vitro preparations of freshly isolated guinea pig ileum and
mouse vas deferens have provided simple model systems for bio-
assays of opioid agonists and antagonists (Kosterlitz and
Waterfield 1975; Kosterlitz and Hughes 1977). The validity of
these models rests on demonstrations of close correlation between
the agonist potencies of opioid agents as measured by their
ability to depress electrically induced contractions and: 1) their
analgesic potencies in man (Kosterlitz et al. 1973); 2) their
relative opiate receptor binding potencies in rat brain homogen-
ates as well as in guinea pig ileum (Creese and Snyder 1975; Simon
1976). Although peripheral nerve muscle preparations may be limit-
ed in their usefulness for analyses of the specific opioid systems
within the CNS (e.g. Van Neuten et al. 1976; Ward and Takemori
1976a,b), they have indeed provided valuable insights into some of
the cellular mechanisms involved in opioid tolerance and depend-
ence. Studies of isolated guinea pig ileum during chronic ex-
posure to opioids for periods up to 24 hours (e.g. Hammond et al.
1976; Collier et al. 1980, 1981a,b; North and Karras 1978a,b;
North and Zieglgansberger 1978; North and Vitek 1979; Johnson and
North 1980; see reviews by Duggan 1980; North 1979; Collier 1980)1
have demonstrated that some of the basic phenomena characteristic
of opioid tolerance and dependence-withdrawal in the CNS can be
elicited in isolated neurons. (See, however, discussion in Sect.
III-A on differences in the opioid tolerance properties observed
in freshly isolated preparation of myenteric neurons innervating
peripheral muscle vs. dorsal root ganglion neurons co-cultured
with spinal cord.) The data obtained by North and co-workers
from myenteric ganglia suggest that significant components of
opioid tolerance and dependence may be mediated by plastic changes
in the bioelectric excitability and propagative properties of in-
dividual neurons (see, however, results with brainstem slices,
below)--whereas Collier has emphasized the possible role of “an
hypertrophy of the cyclic AMP system in these neurons in response
to inhibition by opiate of a neuronal adenylate cyclase” (see
below).
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Freshly isolated slices or strips of neonatal spinal cord with
attached dorsal root ganglia (DRGs) (Otsuka and Konishi 1974)
have provided useful preparations for electrophysiologic analyses
of the acute effects of opioids on primary afferent networks of
the CNS (Suzue and Jessell 1980; Hentall and Fields 1983). Further-
more, intracellular recordings of neurons in slices from adult rat
spinal cord have recently demonstrated that morphine and D-ala-
D-leu enkephalin (DADLE) can directly hyperpolarize dorsal-horn
inter-neurons by opening membrane K+ channels (Yoshimura and North,
1983), in addition to previous evidence from cell cultures that
opioids may depress the release of transmitter from nociceptive
DRG fibers (see below and Sect. II, III). However, studies of
the long- term effects during chronic exposure to opioids require
maintenance of these isolated neural tissues under more stable
conditions such as those provided by tissue culture techniques
(see Sect. III). For example, no signs of tolerance to the hyper-
polarizing action of opiates on locus ceruleus neurons were detec-
ted when freshly isolated slices of normal rat brainstem were ex-
posed to normorphine for 8-12 hours (Williams and North 1983),
whereas slices prepared from morphine-tolerant rats were 3- to
10-fold less sensitive to opiates as determined by similar electro-
physiologic tests. Since the degree of tolerance to the hyper-
polarizing action of opiates on locus ceruleus neurons was, never-
theless, small compared to the tolerance assessed in these rats by
behavioral tests, the authors suggested that “tolerance (and de-
pendence) observed in experiments which examine the behavior of
complex networks of neurons results from or is amplified by an
adaptive process which occurs in transmission between cells”
(Williams and North 1983). 2
Cultures of dissociated fetal rodent spinal cord neurons and DRG
cells (Ransom et al. 1977) have also been fruitfully used to
analyze physiologic mechanisms of action of opioids. With intra-
cellular recording techniques, MacDonald and Nelson (1978)
demonstrated that etorphine depressed excitatory postsynaptic
potentials (EPSPs) elicited in spinal cord cells by activation of
co-cultured DRG cells. Statistical analysis of the quantal para-
meters for the DRG-evoked EPSPs in cord neurons revealed that
etorphine reduced EPSP quantal content at this synapse without
altering quantal size, thereby indicating a presynaptic de-
pressant action. The data suggested that etorphine may have a
direct depressant effect on transmitter release at the DRG-cord
synapse, but partial blockade of spike propagation into the
presynaptic terminals could not be ruled out. Analyses by Mudge
et al. (1979) in cultures of dissociated DRG neurons provided
more direct evidence that opioids depress transmitter release,
possibly by decreasing the influx of Ca++ across the membrane of
th DRG presynaptic terminal (see Sect. III-C).
Although no studies of the effects of chronic opioid exposure of
dissociated DRG or cord neurons have been reported, cultures of
dissociated mouse neuroblastoma x glioma hybrid cells, which show
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high stereospecific opiate binding levels (Klee and Nirenberg
(1974), develop significant alterations in cyclic nucleotide and
adenylate cyclase levels during chronic exposure to opiates.
Whereas acute exposure of these cells to opioids results in in-
hibition of adenylate cyclase and a decreased cyclic AMP level
after chronic exposure to morphine, basal levels of adenylate cyclase
increase so that higher concentrations of opiates are required to
produce decrements in cyclic AMP (Sharma et al. 1975a). These
workers suggested a provocative model for tolerance and dependence,
based on their demonstrations of sequential early inhibition and
compensatory increase in adenylate cyclase activity and cyclic AMP
levels during chronic opiate exposure (Klee et al. 1975; Sharma
et al. 1975b; Lampert et al. 1976; see also Traber et al. 1975,
and reviews by Hamprecht 1977 and Collier 1980).3 No correlative
electrophysiological data have been reported on alterations in
dissociated neuroblastoma x glioma cells during chronic exposure
to opioids. However, electrophysiological analyses of myenteric
neurons in the guinea pig ileum (Karras and North 1979), dorsal-
horn neurons in cat spinal cord (Duggan and Griersmith 1979), and
dorsalhorn networks in mouse cord-ganglion explants in culture
(see Sect. II; Crain, unpublished observations) have not detected
any signs of altered sensitivity to opiates during acute exposure
to cyclic nucleotides or phosphodiesterase inhibitors (see reviews
by Duggan 1980 and Collier 1980). These physiological data do
not, however, preclude possible alterations in cyclic AMP functions
in neurons during development of tolerance and dependence following
chronic exposure to opiates (see Sect. III-B).
Although these cultures of tumor-derived cells do not develop
sufficient organization to permit analyses of mechanisms involved
in the specific physiologic effects of opioids on synaptic net-
works of the CNS, recent biochemical studies of these cells by
Sharma and Khanna (1982) have, nevertheless, provided interesting
clues to a possible role of vitamin C in the development of opioid
tolerance. They reported that introduction of ascorbate (1-5mM)
attenuated the delayed etorphine-induced compensatory increase
in cyclic AMP levels (tested at 4 hrs of incubation) without
effecting the short-term (15 min) inhibitory response of these
neuroblastana cells to the drug. Prompted by the data obtained
from this in vitro model system, co-administration of high levels
of vitamin C (-1mg/kg) with morphine in mice was shown to “suppress
the development of tolerance and physical dependence on the drug
without significantly affecting its analgesic properties” (Khanna
and Sharma 1983).
In addition to the enhancement of adenylate cyclase activity and
cyclic AMP levels in these neuroblastoma cells during chronic ex-
posure to opioids, Dawson et al. (1979) have shown that a stereo-
specific dose-dependent, naloxone-reversible inhibition of the
biosynthesis of membrane glycosphingolipid and glycoprotein also
occurred within 24 hours. It is not yet clear whether these
opiate-induced cell-surface changes are a consequence of cyclic
nucleotide changes or vice versa.
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II. SPINAL CORD TISSUE CULTURE MODELS OF OPIOID ANALGESIA
Cultures of organized explants of fetal mouse spinal cord cross-
sections with attached sensory dorsal-root ganglia (DRGs) (Crain
and Peterson 1974; Crain 1976) have been particularly useful for
analyses of cellular mechanisms underlying opioid analgesia and
tolerance (Crain et al. 1977, 1978, 1979, 1982b). Single focal
DRG stimuli evoke prominent negative slow-wave responses restrict-
ed to dorsal regions of spinal cord explants (Fig. 1A,D), arising
abruptly after latencies of 2-3 msec, with amplitudes up to 2 mv,
and often lasting more than 500 msec (Crain and Peterson 1974).
These potentials resemble primary afferent depolarization (PAD)
and secondary sensory-evoked synaptic network responses in dorsal
cord in situ (e.g. Eccles, 1964). Simultaneous recordings in
ventral cord regions generally show small positive or polyphasic
slow-wave potentials and spike barrages, after latencies of 5-10
msec (Fig. 1).
DRG-evoked ‘PAD’ responses in dorsal cord are generally maintain-
ed or augmented in the presence of 1 mM -aminobutyric acid
(GABA), whereas most other synaptic network discharges in the cord
explants are rapidly depressed (Crain and Peterson, 1974). In
contrast to the enhancing effects of GABA on sensory-evoked
dorsal-horn network responses in cord-DRG explants, these respons-
es are selectively depressed by acute exposure to low concentrat-
ions of morphine and other opiates (Crain et al. 1977). Intro-
duction of 0.1-1 µM morphine into the culture leads to marked and
sustained depression of major components of the DRG-evoked, PAD-
like, slow-wave responses in dorsal cord within a few min, where-
as ventral cord discharges are either unaltered or enhanced (Fig.
1B). A series of opioid peptides with a wide range of analgesic
potencies produced similar selective depressant effects on the
sensory-evoked dorsal-horn network discharges of cord-DRG explants
(Table 1) (Crain et al. 1978), at concentrations remarkably pro-
portionate to their potency in the intact animal. After return
to control medium, restoration of opioid-depressed dorsal cord
responses gradually occurs during periods of 30-60 min (Fig. 1C).
Exposure to opiate antagonists, e.g. naloxone (10-100 nM) or
diprenorphine (1-10 nM), prevents development of the character-
istic depression of sensory-evoked dorsal cord responses by these
opiates and opioid peptides (Fig. 1D) (Crain et al. 1977, 1978).
whereas they are ineffective against the acute effects of non-
opioid-receptor-mediated depressant agents, e.g. high-Mg++,
xylocaine, serotonin (see Sect. III-B).
The depressant effects of opiates and opioid peptides on dorsal
cord explant responses were often markedly reduced or prevented
when the Ca++ level was raised to 5mM, especially in the
presence of 0.lmM 4-aminopyridine (4-AP) (Fig. 2) (Crain et al.
1982a). Receptor assays showed that 0.1mM 4-AP ± 5mM Ca++ had no
effect on stereospecific opiate binding, indicating that the
antagonist actions of these agents in our cultures do not occur at
the level of the opiate receptor. 4-AP has been shown to
markedly potentiate synaptic transmitter release by depressing
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FIGURE 1
Selective opiate depression of sensory-evoked dorsal-horn network
responses in cord-DRG explant (4 weeks in vitro). A: Short-latency
negative slow-wave potential in dorsal cord (d) and small longer-
latency, positive slow-wave response in ventral cord (v) are evoked
by a single large DRG stimulus. B: 5 min after introduction of
morphine (1µM), major components of the dorsal cord responses
have disappeared. In contrast, the ventral cord response is en-
hanced. C: 10 min after return to BSS, the dorsal cord response
to DRG stimuli remains small, and the ventral cord discharge is
still large. Dl: 3 min after introduction of naloxone (3µM) the
dorsal cord slow-wave response is restored and enhanced; short-
latency components are seen at faster sweep (D2). E: 20 min after
return to BSS, 1µM morphine partly depresses DRG-evoked dorsal
cord response (more complete depression occurred after increase to
10µM morphine). Note: Upward deflection indicates negativity at
recording electrode; onset of stimulus is indicated by first
sharp pulse or break in baseline of each sweep. All records in
Figs. l-4 show maximal response evoked by large stimuli with stand-
ard placements of recording microelectrodes within the cord and
stimulating electrodes within the DRG tissue. BSS is balanced salt
solution consisting of (in mmol/l distilled water) of NaCl, 137;
KCl, 5.5; KH2PO4, 0.4; CaCl2, 1.3; MgCl2, 0.5; MgSO4, 0.4; Na2HP04,
0.3; NaHCO3, 4.2; and glucose, 5.5 (From Crain et al. 1977.
©1977, Elsevier Biomedical Press.)
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TABLE 1
Comparison of depressant potency in vitro and analgesic
potency in situ for a series of opioid peptides
Compound
Effective depressant
concentration (µM)
Molar potency ratios
in vitroa Sensory network Analgesic potency
in rodentsdepressant potency
in vitro in situb
Tyr-gly-gly-phe-met 10 1
Tyr-gly-gly-phe-leu 10
0.1-1.0
1
Tyr-D-ala-gly-phe-met 10-100 100;700
Tyr-D-ala-gly-phe-D-leu 0.02 500 1000
D-ala-tyr-gly-gly-phe-met 10 1
[D-Met2,Pro5]-enkephalinamide
1
[D-ala2-MePhe4,Met-(0)5-ol] -
0.005-0.01 1000-2000 2000
enkephalin (Sandoz FK 33-824) 0.002-0.005 2000-5000 30,000
ß-Endorphin 0.1 100 200-1000
Endorphin 1.0 10 < 1
Morphine 0.3 30 30
aMolar concentration required to produce marked and sustained depression (>50%) of sensory-evoked
dorsal-horn network responses in explants of mouse spinal cord with attached dorsal root ganglia.
411 of these opiate depressant effects were prevented by naloxone (0.01-0.1µM) or diprenorphine
(0.001-0.01 µM).
bDetermined by tail-flick test after intracerebral. intraventricular. or spinal subarachnoid injections
(see references to in situ studies in Crain et al. 1978).
(From Crain et al. 1978. © 1978. Elsevier Biomedical Press.)
FIGURE 2
Antagonism by 4-aminopyridine (4-AP) of the depressant effects
of morphine on sensory-evoked dorsal-horn network responses in
cord-DRG explants. (Al): Characteristic short-latency negative
slow-waves are evoked in two sites in dorsal cord by DRG stimulus.
(A2): Dorsal cord responses are blocked after 10 min in 1µM
morphine. (A3): Cord responses gradually recover after addition
of 0.1 mM 4-AP along with 1µM morphine and can still be elicted
one hour later (A4). (B): Dorsal horn responses in another
explant (B1) are remarkably enhanced in 0.1 mM 4-AP + 5 mM Ca
++
(B2). (B3): Cord responses are not significantly attenuated
after 10 min exposure to 10µM morphine + 0.1 mM 4-AP + 4 mM Ca++,
nor after 10 min in 100µM morphine + same 4-AP/Ca++ levels (B4).
(From Crain et  al .  1982a.  © 1982,  Pergamon Press Inc. )
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membrane K+ conductance during depolarization of nerve
terminals, thereby prolonging the presynaptic spike and enhanc-
ing Ca++ influx (e.g. Illes and Thesleff 1978). Furthermore,
4-AP antagonized the depression of synaptic transmission in
spinal cord produced by high Mg++ or EGTA (Galindo and Rudomin
1978) and the depressant effects of adenosine on cerebral neurons
(Perkins and Stone 1980; Stone 1981a). The effects of 4-AP and
high Ca++ on cord-DRG cultures are in good agreement with studies
in the mouse vas deferens where similar concentrations of these
agents were shown to reverse the inhibitory action of morphine
on neuromuscular transmission (Illes et al. 1980; Stone 1981a).
Although these effects of 4-AP and high Ca++ on cord-DRG cultures
do not clearly distinguish between presynaptic or postsynaptic
mechanisms of opiate depressant action on afferent cord networks,
a primary action of opioids at presynaptic DRG terminals in the
dorsal horn appears to be more probable (see below) but does not
preclude direct inhibitory effects on cord interneurons (Yoshimura
and North 1983; Murase et al. 1982). Either mode of opioid action
could probably be overcome by 4-AR/high Ca++-enhanced transmitter
release, as in studies of botulinum- or curare-blocked motor
endplates (Kim et al. 1980). Nevertheless, our in vitro results
demonstrate that the depressant effects of opiates on afferent
spinal cord networks involve relatively restricted physiological
actions that can be readily antagonized by Ca++, even in the
presence of extremely high opioid concentrations (Crain et al.
1982a). The effects of increased Ca++ concentration on the
opioid-sensitivity of the sensory-evoked responses in cord-DRG
explants are in agreement with the suppression of opiate analgesic
effects in situ by intracerebroventricular injections of calcium
(Kakunaga et al. 1966; Harris et al. 1975) and the reversal of
morphine analgesia in rats by injections of 4-AP (Tung and Brandom
1981). They are also consonant with evidence that the depressant
effects of opioids may be due to interference with Ca++ conductance
in presynaptic terminals, thereby impeding transmitter release
(see Sect. III C; also Dunlap and Fischbach 1978; Macdonald and
Nelson 1978).
The development of opiate-sensitive DRG-evoked responses restrict-
ed to dorsal-horn regions of our cord explants is in good agree-
ment with microelectrophoretic injection of morphine into the sub-
stantia gelatinosa in cat spinal cord, resulting in selective
depression of cell responses to noxious, but not tactile, stimuli
(Duggan et al. 1977). Furthermore, physiologic analyses of these
opioid networks in vitro and in situ correlate well with binding
assays showing that high levels of stereospecific opiate receptors
develop in the dorsal-horn regions of the adult monkey spinal
cord (Lamotte et al. 1976) and in our fetal mouse cord-DRG
explants (Hiller et al. 1978b). In addition, we have demonstrated
that even higher levels of receptors develop in the neuritic
outgrowth of isolated DRG cultures (Hiller et al. 1978a). The
latter assays provided the first direct evidence that opiate
receptors are located on DRG nerve fibers which are destined to
establish presynaptic afferent connections with the spinal cord
(sec also Lamotte et al. 1976; Fields et al. 1980).
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III. CORD TISSUE CULTURE MODELS OF OPIOID TOLERANCE AND
PLASTICITY
A. Development of Tolerance in Cord-DRG Explants During
Chronic Exposure to Opiates and Opioid Peptides
Most in vitro analyses of tolerance to opiates have utilized
peripheral neurons or neuroblastoma cells (as noted in Sect. I).
Our electrophysiologic experiments during chronic exposure of
cord-DRG explants to opiates and opioid peptides (Crain et al.
1979) have provided the first demonstration that isolated mammalian
CNS tissues can, indeed, develop marked tolerance after several
days of chronic exposure in vitro. Earlier studies of tolerance
in chronic spinal dogs by analyses of spontaneous and reflex act-
ivities during chronic morphine exposure and hyperactivity of
these reflexes after withdrawal of morphine (Wikler and Frank 1948;
Wikler 1953; Wikler and Carter 1953) suggest that this cord-DRG
explant model is reasonable and likely to provide significant
insights into some of the complex problems of opiate addiction.
Following exposure of cord-DRG explants to low levels of morphine
(1 µM) for 2 or more days (at 35°C), the initial opiate-depressant
effects on sensory-evoked dorsal-horn network responses disappeared
and characteristic dorsal cord responses could again be evoked by
DRG stimuli in the presence of morphine-- even after large in-
creases in concentration (up to 100-fold: Fig. 3B2,3) (Crain et
al. 1979). These manifestations of tolerance to opiates could
still be observed for 2 days after transfer to drug-free culture
medium, and characteristic sensitivity to opiates returned during
the subsequent few days. The stereospecificity of these opiate-
tolerance effects was demonstrated by the fact that chronic ex-
posure of cord-DRG explants to 1 µM levorphanol produced similar
tolerance to opiates as occurred after 1 uM morphine, whereas
chronic exposure to 1 µM dextrorphan was ineffective.
Tolerance also developed after chronic exposure of cord-DRG
explants to low concentrations (10 nM) of the synthetic enkephalin
analog, {D-ala2, MePhe4, Met - (0) 5-o1}-enkephalin (Sandoz FK 33-824),
consonant with the tolerance that occurs in rodents following daily
injections of this potent, long-lasting analgesic (Roemer et al.
1977). Acute application of this opioid peptide to our explants
depressed DRG-evoked dorsal cord responses at levels as low as
1 nM (Table 1) (Crain et al. 1978). Furthermore, tolerance de-
veloped after chronic exposure of cord-DRC explants to opioid
peptides (0.1-1 µM) that bind predominantly to delta-type
receptors, e.g. D-ala-D-leu enkephalin (DADLE) (Wuster et al.
1979; Kosterlitz et al. 1980) as well as to mu-type receptors,
e.g., tyr-D-ala-gly-N-Me-Phe-Gly-ol (DAGOL) (Handa et al. 1981).
Morphine-tolerant cultures showed cross-tolerance to FK 33-824
met-enkephalin, DADLE, and ß-endorphin when tested at concentra-
tions up to 10-fold higher than required to produce acute de-
pressant effects on naive cord-DRG explants. On the other hand,
cultures rendered tolerant to FK33-824 (at 0.01 µM) showed un-
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FIGURE 3
Development of tolerance to acute opiate-depressant effects
on sensory-evoked dorsal-horn network response in cord-DRG ex-
plants (3 weeks in vitro). A1: Short- latency negative slow-wave is
evoked in dorsal cord (d) by DRG stimulus. A2: Within 10 min in
0.1 µM morphine, dorsal cord response is attenuated, whereas
ventral cord discharge (v) shows little change. A3: In 0.3 µM
morphine, dorsal cord slow-wave response is almost abolished.
(No recovery occurred during exposure to 0.3-1 µM morphine for
several hrs.) B1: Large dorsal-cord network response is evoked in
another cord-DRG explant after chronic exposure to 1 µM morphine
for 2 days at 35°C (of. A2,3). B2: Dorsal cord response remains
large even after increasing morphine concentration to 10 µM.
(Ventral cord discharges were often enhanced at high opiate
levels.) B3: Even after increase to 100 µM morphine dorsal cord
response shows no further attenuation (10 min test; partial de-
pression developed after longer exposure at 100 µM level). C1:
Only small dorsal-horn responses can be evoked in another explant
(2 sites) after exposure to 1 µM morphine for 4 days at 20°C,
resembling attenuation after acute exposure to morphine (cf. A2).
C2: 1 µM naloxone restores characteristic dorsal cord response
within a few min; some recording sites as in C1. Sharp rising
phases of these DRG-evoked dorsal cord responds are shown at
faster sweep (C3). (From Crain et al, 1979. © 1979, Pergamon
Press Inc.)
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usually strong cross-tolerance to morphine; dorsal cord responses
could still be evoked even after acute exposure to high levels of
morphine (about 100 µM), or 1,000-fold higher than the depressant
level required to depress cord responses in a naive explant (i.e. ,
cross-tolerance ratio = 1,000).
In contrast to the high degree of selective tolerance to specific
types of opiate receptors (delta vs. mu) that has been observed
in mouse vas deferens (Schulz et al. 1980)5, preliminary tests on
cord-DRG explants chronically exposed to either DADLE or DAGOL (at
0.01-1 µM) have often shown evidence of at least sane degree of
cross tolerance to agonists binding to other receptor subtypes
including the kappa agonists, dynorphin and ethylketocyclazocine
(Chang et al. 1981; Chavkin et al. 1982; Kosterlitz et al. 1981)
However, cross-tolerance ratios were often much lower than in tests
made with agonists binding to similar opiate receptor subtypes.
The variability observed in these cross-tolerance tests may be due
in part to marked heterogeneities in the distribution of opiate
receptor subtypes that develop in the DRG neurons (Werz and Mac-
donald, 1982a,b, 1983), as well as the cord neurons, explanted from
various levels of the neuraxis into these cultures. In guinea
pig ileum tissue, where cross-tolerance was observed between
delta and mu agonists, Schulz et al. (1981) interpreted these data
as support for “the notion that these drugs act via a common
receptor, possibly a mu-receptor type” (see alternative views in
sect.  III-R).
The tolerant state did not develop if morphine was prevented from
binding to the opiate receptors by concomitant chronic exposure
to low levels of naloxone (01µM). Within an hour after removal
of naloxone from the culture medium, morphine produced character-
istic depressant effects on dorsal cord responses. Furthermore,
when the incubation temperature was lowered to < 25°C, no evidence
of tolerance was detected after sustained exposure to 1 µM
morphine (as long as 7 days). Dorsal cord synaptic network res-
ponses remained depressed in these cord-DRG cultures during chronic
incubation in 1 µM morphine at 20°C (Fig. 3C1); the opiate
sensitivity tests were carried out after returning the cultures to
35°C. However, characteristic sensory-evoked cord responses were
rapidly restored after introduction of 0.1-1 µM naloxone (Fig. 3
C2,3), demonstrating that the depression of dorsal cord responses
in these cultures was opiate-mediated and not merely due to
metabolic deficits resulting from incubation at suboptimal temper-
ature. Control 2-week-old cultures incubated in regular media at
20°C for 1 week showed no significant electrophysiologic deficits.
The data indicate that a temperature-dependent metabolic change
occurs in the neurons of these mouse cord-DRG explants after 2
days of chronic exposure to morphine at 35% leading to a sustain-
ed decrease in sensitivity to opiate-depressant effects (Crain
et al. 1979).4 These results are compatible with evidence that
tolerance to opiates in rats is blocked by inhibitors of protein
and RNA synthesis (Cox and Osman 1970); more critical tests are
required to characterize the specific molecular alterations that
may underlie the development of tolerance in neurons.
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The temperature-dependence of the opiate-tolerance mechanism in
our mouse spinal cord-DRG explants is in contrast to the opiate
tolerance which develops in myenteric neurons of freshly isolated
guinea pig ileum within 1 day after incubation in 1 µM morphine
at 4°C (Hammond et al. 1976) and at 21-24°C (North and Karras 1978
a,b) . These differences in temperature requirements may be due
to differences in processes involved in the development of toler-
ance in central vs. peripheral neurons and they may provide clues
to some of the molecular mechanisms underlying the development
of tolerance in CNS neurons. It should also be noted that the
tolerance observed following the 1-day morphine exposure of fresh-
ly isolated guinea pig ileum preparations disappeared within a
few hours after transfer to drug-free medium (Hammond et al. 1976),
whereas our cord-DRG explants continued to show tolerance effects
for several days after return to regular culture medium. The
marked tolerance to opiates that develops in cord-DRG explants
may also be enhanced due to the relatively immature stage of these
fetal mouse tissues during the period of chronic exposure in vitro
as observed in neonatal mice at 1-2 weeks of age (Nicak and Kohut
1978).
As noted above, in the presence of 4-AP and high Ca++ acute intro-
duction of morphine to cord-DRG cultures at concentrations as high
as 100-1,000 times the level required to depress afferent cord
responses in regular medium is ineffective (Fig. 2B), resembling
the tolerance observed in these explants several days after chronic
exposure to opiates (Fig, 3B). These results are consonant with
evidence suggesting that neurons may become tolerant during chronic
exposure to opioids by developing higher levels of intra-cellular
calcium in their presynaptic terminals (e.g. Harris et al. 1977;
Yamamoto et al. 1978; Huidobro-Toro et al. 1981)--as occurs during
acute 4-AP/high Ca++ exposure of naive explants--thereby overcoming
opioid inhibitory effects produced at presynaptic, and perhaps also
at postsynaptic, sites (Crain et al. 1982a).
It is generally considered to be unlikely that tolerance to
morphine is caused by down-regulation of opiate receptors since
most analyses in vivo have not detected alterations in the number
nor the affinity of these receptors after chronic treatment with
morphine (e.g. Pert and Snyder 1976; Chang et al. 1981; Bardo
et al. 1982). Nevertheless, Davis et al. (1975, 1979) reported
a significant decrease in opiate binding after development of
analgesic tolerance in rats when the assays were made on thin
slices of brainstem tissue rather than on brain homogenates, and
Kirby(1983) observed decreased opiate binding in the spinal cord
of young rats that had been chronically exposed to morphine during
the last half of gestation. Furthermore, chronic incubation of
aggregating brain cells cultured with etorphine appeared to induce
a down-regulation of mu and kappa opiate receptors (Lenoir et al.
1983), in extension of previous evidence demonstrating down-
regulation of delta receptors following 4-hour DADLE exposures of
cultured neuroblastoma-glioma hybrid cells (Chang et al. 1982;
Simantov et al. 1982) and freshly isolated rat hippocampal slices
(Chang et al. 1983). In view of the ambiguities in the data on
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possible receptor down-regulation following chronic exposure
of CNS tissues to opiate agonists, cord-DRG explants may provide
a useful system to determine if opiate receptors do, in fact,
undergo significant alterations during the development of toler-
ance, just as we have demonstrated up-regulation during chronic
exposure of these explants to opiate antagonists (see Sect. III-D).
Marked increases in the spike-firing rate of opiate-tolerant
myenteric neurons occurred in the guinea pig ileum preparation
after agonist removal, or after introduction of an antagonist
(North and Karras 1978 a,b). This was interpreted as evidence
of opiate-dependence in the ileum preparation (see also Hammond
et al. 1976). Although we have not detected such increased
spike-firing in our CNS explants, we have observed that the sensory-
evoked dorsal-horn network responses in opiate-tolerant cultures
were generally much larger in amplitude (e.g. Fig. 3B), and could
often be recorded over larger areas of the dorsal cord, than the
responses evoked in control cultures. The generation of unusually
large amplitude dorsal cord responses during chronic exposure to
opiates may, indeed, be an expression of dependence following
development of tolerance to the opioid level available to the
neurons in these cultures. Furthermore, in tolerant cord-DRG
explants that did not show unusually large amplitude sensory-
evoked dorsal cord responses, acute exposure to naloxone often
produced marked increases (up to 50%) in the amplitude of these
responses. {Naloxone also enhanced dorsal cord responses in some
of our naive cord-DRG explants (Crain et al. 1977), but the
effects in these untreated cultures were generally smaller and
more variable}.
B. Cross-Tolerance to 5-Hydroxytryptamine in Morphine-Tolerant
Cord-DRG Explants
Explants that had become tolerant to morphine after chronic ex-
posure for >2 days often developed a significant degree of cross-
tolerance to the depressant effect of serotonin (5-HT) on dorsal-
horn network responses (Crain et al. 1982b), as well as to other
opioid peptides (Crain et al. 1979). In some morphine-tolerant
explants (Fig. 4Bl) 3- to 10-fold increases in the usual 5-HT con-
centration were required in order to produce depression of the dor-
sal cord responses comparable to that in naive explants (Fig.4B2,3
versus 4A2,3 and Fig. 5). In contrast, morphine-tolerant ex-
plants did not show cross-tolerance to other types of agents that
depressed cord responses, e.g. high Mg++, xylocaine, alcohol.
Moreover, acute exposure of morphine-tolerant explants to
naloxone (1 µM) further attenuated the effects of 5-HT so that the
minimum depressant levels of 5-HT were often increased up to 30-
fold (Fig. 4B5,6 and Fig. 5).
Increasing the extracellular Ca++ concentration from the usual
1 mM to 5 mM level or introduction of 4-AP markedly antagonized
the depressant effects of 5-HT on DRG-evoked cord responses, so
that 5-HT concentrations comparable to those used on morphine-
tolerant explants were required to depress naive explants. Further-
more, exposure of cord-DRG explants to 4-AP in the presence of
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FIGURE 4
Depressant effects of 5-HT on sensory-evoked dorsal-horn network
responses in fetal mouse spinal cord-DRG explants (A) and
development of cross-tolerance to 5-HT after chronic exposure to
morphine (B). (Al): Short-latency negative slow-waves are evoked in
two regions of dorsal cord by DRG stimulus. (A2): Cord responses
are marked depressed after 10 min in 25 nM 5-HT (in other
cultures levels as low as 3 nM were effective). (A3): After
several min in 250 nM 5-HT, responses are almost completely block-
ed. (A4): Cord responses recover in BSS (+ 1 µM naloxone).
(A5.6): Similar 5-HT-induced depression of cord responses occurs
in presence of 1 µM naloxone (cf. A5,6 and A2,3. (5-HT antagonists
methysergide and cyproheptadiene were ineffective as naloxone
up to 10 µM.) (B1): After 3-day exposure to 1 µM morphine,
tolerance develops and dorsal-horn responses can be evoked in the
presence of morphine. (B2): Relatively little attenuation of the
cord responses occurs in this opiate-tolerant explant after 10 min
in 25 nM 5-HT (+ morphine) (cf. A 2). (B3): A significant cord re-
sponse can still be evoked even after 5 min in 250 nM 5-HT (cf. A3).
(B4): Cord response recovers within 5 min after adding 1 µM naloxone
to bathinq fluid. (B 5): No depression of cord response occurs
after 10 min in 25 nM 5-HT in the presence of naloxone (cf. A2,B2)
and a response can still be elicited even after 10 min in 250 nM
5-HT (cf. A3,B3). (From Crain et al. 1982b. © 1982, Pergamon
Press Inc.)
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FIGURE 5
Shift in 5-HT dose-response curve after chronic exposure of cord-
DRG explants to morphine. Naive explant in BSS; morphine-
tolerant explant in BSS (after 3 days in 1 µM morphine);
shortly after exposure of morphine-tolerant explant to naloxone
(1 µM). (*Based on response data in Fig. 4 and similar tests
in >20 cultures) (From Crain et al. 1982b. © 1982, Pergamon
Press Inc.)
5 mM Ca++ was even more effective in preventing the usual
depressant effects of 5-HT -- as well as morphine (Fig. 2)-- on
cord responses. In the presence of 4-AP/high Ca++, large dorsal
cord responses could still be evoked after introduction of con-
centrations of 5-HT about 10- to 100-fold higher than required to
produce comparable depression in control medium (Crain et al.
(1982b) .
Our in vitro results are consonant with evidence that 5-HT admin-
istration near the cell bodies of dorsal horn neurons and in the
substantia gelatinosa of the cat reduced the excitation of these
neurons by noxious stimuli (Headley et al. 1978; Belcher et al.
1978) and depressed spinal segmental nociceptive reflexes (Bell
and Matsumiya 1981). Furthermore, depression of opiate-sensitive
dorsal-horn network responses by bath perfusion with 5-HT provides
an in vitro model that correlates well with analgesia produced in
the rat by intrathecal administration of 5-HT (Yaksh and Wilson
1979). The absence of naloxone-antagonism of 5-HT depressant
effects on DRG-evoked cord responses in naive explants indicates
that the 5-HT effects are not mediated by opioid receptors in
these cultures, in agreement with studies of 5-HT-induced anti-
nociception and analgesia in situ (Headley et al. 1978; Bell and
Matsumiya 1981; Yaksh and Wilson 1979). Similarly, the absence
of methysergide- and cyproheptadine-antagonism of the depressant
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effects of 5-HT on DRG-evoked cord responses suggests that these
effects may not be mediated by 5-HT receptors. Alternatively,
another type of 5-HT receptor may be involved (e.g. Peroutka
et al. 1981). Further studies are required to clarify the
mode of action of 5-HT in producing these potent depressant
effects on dorsal-horn responses and the remarkable similar-
ities in the effects of 5-HT and opiates on the responses of
both naive and opiate-tolerant explants. In cultures of
dissociated chick DRG neurons where 5-HT and opiates attenuate
the duration of Ca++-mediated soma action potentials, the effects
of 5-HT also failed to be antagonized by methysergide (Dunlap and
Fischbach 1978). These data suggest that 5-HT may block neuronal
components of dorsal-horn networks at similar regions to those
that are depressed by opiates, e.g. presynaptic DRG nerve terminals
where abundant opiate receptors are located (see above; and re-
lated studies of 5-HT effects in situ by Belcher et al. 1978;
Carstens et al. 1981). Furthermore the marked attenuation of the
depressant effects of both 5-HT and opioids on cord-DRG explants
by high Ca++ and 4-AP (Crain et al. 1982a,b) raises the possibility
that cross-tolerance to 5-HT and to other types of opioid peptides
in morphine-tolerant explants (see Sect. III-A) may result from
a more generalized physiological alteration in presynaptic com-
ponents of dorsal-horn networks {e.g., enhanced Ca levels (Harris
et al. 1977; Yamamoto et al. 1978; Huidobro-Toro et al. 1981)} that
renders them tolerant to a broad spectrum of agents whose depress-
ant actions are mediated by interference with Ca++-dependent
synaptic transmitter release (Crain 1984).
Finally, the marked increase in degree of cross-tolerance to 5-HT
after acute introduction of naloxone in morphine-tolerant cord-DRG
cultures may be an expression of opiate dependence, possibly med-
iated by the same mechanism underlying naloxone-enhancement of
the amplitude of sensory-evoked dorsal-horn responses observed in
opiate-tolerant explants (Crain et al. 1979). Both of these
naloxone-elicited alterations may reflect the onset of hyperexcit-
ability properties in dorsal-horn networks associated with sudden
withdrawal from chronic exposure to opiates (see reviews by Duggan
1980; Wikler 1980; Johnson and North 1980).6
These interpretations have been strengthened by recent studies of
the effects of Mn++ on opioid-tolerant explants. In previous tests
with elevated Mg++concentrations, no clearcut evidence of cross-
tolerance to this Ca++-antagonist had been detected (as noted
above). Mn++ is much more potent than Mg++ in selectively compet-
ing with Ca++ for a common site on presynaptic membrane in
neuromuscular junctions (Meiri and Rahamimoff 1972; Balnave and
Gage 1973) and other synapses (e.g. Nichols and Nakajima 1975).
At concentrations of about 1mM, Mn++ produces negligible depressant
effects on postsynaptic membrane conductances or action potentials,
and it appears to act primarily in blocking excitation-secretion
coupling mechanisms in presynaptic terminals (Nichols and Nakajima
1975). In preliminary tests on cord-DRG cultures, introducticm
of 1mM Mn++ often produced much weaker depressant effects on
opioid-tolerant vs. naive explants, especially after acute addition
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of naloxone, resembling the effects of 5-HT on these cultures
(see above) .
C. Alterations in Presynaptic DRG Functions in Cord-DRG
Explants Monitored by Intracellular Recordings from DRG Neurons
Analyses by Mudge et al. (1979) in cultures of dissociated chick
embryo DRG neurons demonstrated that D-ala 2 enkephalinamide
inhibited the K+-evoked (Ca++-dependent) release of substance
P from these DRG cells. Furthermore, enkephalin also decreased
the duration and magnitude of the Ca++ component of the spike
recorded in the DRG perikarya without affecting the resting
membrane potential or resting membrane conductance. Since Ca++
spikes in perikarya appear to be generated by specialized membranes
with high densities of Ca++ channels comparable to those present
in the less accessible presynaptic terminal membrane (Stinnakre
and Tauc 1973), the data suggest that opioids may depress synaptic
transmitter release by decreasing the voltage-dependent influx of
Ca++ across the active membrane of the DRG terminal as well as
the perikaryon.
Our extracellular bioelectric recordings of DRG-evoked dorsal-horn
responses in cord-DRG explants during chronic opioid exposure have
demonstrated that tolerance to the depressant effects of opioids
develops after 2-3 days in vitro. A mechanism that may possibly
underlie thus sustained decrease in responsiveness to opioids is
that some functional alteration occurs in the presynaptic DRG
terminals in the dorsal cord which attenuates the effectiveness
of the postulated opioid-induced depression of voltage-dependent
Ca++ influx in these terminals (see Section III-B). For example,
an increased density of Ca++ channels uncoupled to opiate re-
ceptors might develop in DRG terminals during chronic exposure
to opioids, or voltage-dependent Ca++ influx might become much
larger due to altered ionic concentration gradients or conduct-
ances across the membrane of DRG terminals (as may occur during
acute introduction of 4-AP and high Ca++ in naive cord-DRG
cultures; Fig. 2). We are attempting to test this hypothesis by
carrying out intracellular electrophysiologic recordings from DRG
neuron perikarya in cord-DRG explants during chronic exposure to
opiates to determine whether significant alterations in Ca++-
mediated components of DRG action potentials, or other evidence
of enhanced Ca++-mediated functions, can be detected in tolerant
explants. In order to establish baselines for evaluating
possible alterations in DRG functions that may develop in tolerant
explants, we have carried out intracellular recordings fran DRG
neuron perikarya in organotypic cord-DRG explants (grown for 3-5
weeks in regular culture media) during acute application of
opioids (Chalazonitis and Crain 1983). Intracellular recordings
were made with beveled micropipettes (40-80 M on DRG neuron
somas (20-50 µm diam) (Fig. 6A). Opiate agonists were tested on
DRG spikes evoked in a BSS containing 5 mM Ca++ and 5 mM Ba++ in
order to enhance inward current through Ca++ channels and block
delayed voltage-dependent K+ channels. A “hump" developed in the
repolarizing phase of the spike under these conditions (Fig. 6B)
which was blocked by 5-10 mM Co++, confirming Ca++ mediation of
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FIGURE 6
Exposure to DADLE results in sustained attenuation of the duration
of the action potential of a DRG neuron in an explant of mouse
spinal cord with attacked DRGs (2 months in vitro). (A): Typical.
somatic action potential is evoked by intracellular depolarizing
current during initial perfusion of culture with BSS containing
5.4 mM Ca++. (B): After addition of 5mM Ba++ to the high-Ca++ BSS,
the duration of the action potential increased more than 3-fold;
note prominent 'hump' on repolarizing phase. (C1): By 2 min after
bath perfusion with 10µM DADLE (in high-Ca++, high-Ba++ BSS) the
duration of the action potential was sharply reduced and remained
short as long as the agonist was present (4-10 min tests). (C2):
After 5 min in DADLE, action potential duration was still attenuat-
ed (8 superimposed sweeps at 0.lHz). (D): After return to high-
Ca++, Ba++ BSS, action potential became markedly prolonged again.
(E): Introduction of l0µM DADLE in the presence of 3µM naloxone
was ineffective in altering the action potential. Calibration
bars: 20mV and 5 msec. (Unpublished data from Chalazonitis and
Crain 1983 and in preparation).
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this hump. Opiate agonists were bath-perfused (0.5 ml/min) for
test periods up to 10 min. In about 80% of the neurons in isolated
DRG explants, the duration of the Ca++ component of the action
potential was reduced by about 50% in the presence of DADLE at
10 µM (Fig. 6C; Table 2). These effects were reversed after
return to Ca++-Ba++ BSS and prevented by perfusion of naloxone
(3 µM) together with DADLE. This widespread distribution of
opioid-sensitive neuron perikarya in relatively mature, organotypic
DRG explants is similar to the large fraction of opioid-sensitive
cells (ca. 75%) observed in dissociated chick and mouse embryo
DRG cultures (Mudge et al. 1979; Werz and Macdonald 1982a). On
the other hand, no significant alterations in the action potentials
generated by adult mouse DRG neurons were detected during acute
application opioid to freshly isolated ganglia (Williams and
Zieglgansberger 1981; see also North 1979). The marked difference
in opioid sensitivity of DRGsin these in vitro vs. in situ studies
may reflect normal developmental changes that occur in at least
some types of DRG perikarya during establishment of synaptic
connections with cord neurons or, alternatively the in vitro
results may be due to abnormal opioid hypersensitivity resulting
from isolation of these embryonic cells and their maintenance in
a relatively immature state. In order to clarify this ambiguity,
we compared the opioid sensitivity of sensory neurons in
organotypic explants of DRGs attached to spinal cord (Fig. 1) vs.
isolated DRG explants. These tests showed that a significantly
smaller fraction of DRG neuron somas were sensitive to DADLE when
grown attached to spinal cord vs. isolated DRGs: 51% vs. 78%
(Table 2; Chalazonitis and Crain 1983). Furthermore, recordings
made 8-16 days after dorsal-root transection in 2-to 3-week-old
cord-DRG explants revealed that 84% of these decentralized DRG
neurons were opioid-sensitive (Table 2). Although the duration
of the Ca++ hump of the somatic DRG action potential was
significantly shorter in attached vs. isolated cultures, some of
the opiate-insensitive neurons still generated prominent Ca++
humps. This suggests that a decrease in functional opiate re-
ceptors rather than in Ca++ channels may underly the observed
decrease in opioid-sensitive DRG somas in DRG-cord explants. The
data obtained thus far are consistent with the hypothesis that
as the central terminals of fetal DRG neurites participate in the
formation of opioid synaptic networks within the dorsal-horn
region of DRG-cord explants the opioid sensitivity of the
perikaryal region of these DRG neurons may decrease (Chalazonitis
and Crain 1983).
During maturation opiate receptors on DRG neuron sanas may de-
crease in number or they may become non-functional, e.g. by un-
coupling from Ca++ channels in the soma membrane, whereas at
embryonic stages, opiate receptors may be distributed all over the
surface of DRG neurons just as acetylcholine receptors are dis-
tributed all along embryonic un-innervated muscle fibers (Diamond
and Miledi 1962). Perhaps opiate receptors are translocated
during maturation to the terminal regions of DRG neurites as these
neurites establish synaptic connections in the spinal cord,
analogous to the clustering of ACh receptors during formation of
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TABLE 2
Opioid-Sensitivity of DRG Neurons Grown
Either Attached to Cord or Alone
DRG neurons with opioid-sensitive Ca++-mediated
action potentialsa
Type of explant
Explants DRG neuron
tested somas tested
Opioid-sensitive
neuronsb
Isolated DRG
DRG attached to cord
DRG-cord, 8-16 days
after dorsal-root
transection in vitro
n n n Fraction
36 49 38 78%
58 67 34 51%*
17 19 16 84%
aTests made by bath-perfusion of 10µM D-ala-D-leu enkephalin (DADLE) during
intracellular recordings in BSS containing 5mM Ca++ and 5mM Ba++ (at 3-5 weeks
in vitro;  sac text).
bNeurons showing marked reduction (about 50%) in duration of Ca++ component of
action potential during exposure to DADLE (see text).
*This fraction is significantly lower than that of the isolated DRG population
(x² test: p < 0.005) and from the DRG population that had been decentralized
(p < 0.01).
(Unpublished data from Chalazonitis and Crain 1983 and in preparation.)
neuromuscular junctions. Alternatively, opiate receptors might
still be present on many DRG somas- -as evidented by autoradiographic
localization of 3H-etorphine on some types of adult DRG neurons
(Ninkovic et al. 1982)--but the distribution of Ca++ channels on
these somas may decrease during maturation (Matsuda et al. 1978;
Yoshida and Matsuda 1979; Spitzer 1979) or these channels may no
longer be regulated by linkage with opiate receptors. These
ambiguities may be clarified by more systematic intracellular re-
cordings from DRG neurons at different stages of maturation in
cultures of DRG-cord explants and is isolated DRG explants, and by
correlative autoradiography of opiate receptor distributions on
these DRG neurons. Studies of these types of plasticity in opioid
networks during development of DRG-cord synapses or after decentra-
lization of DRG neurons may also provide insights into mechanisms
underlying plastic alterations in opiate receptor distributions
that occur following chronic pharmacologic interventions (see
Sect. III-D).
We have demonstrated that about 50% of the DRG neuron perikarya in
mature cord-DRG explants still show marked sensitivity to opiates
(Table 2) under culture conditions where reliable tolerance develops
in dorsal cord afferent networks after chronic opioid exposure.
Intracellular recording from these DRG perikarya during chronic
exposure of cord-DRG explants to opiates may, therefore, lead to
significant clues to alterations in DRG functions that may play a
role in the development of opioid tolerance and dependence in the
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dorsal horn of the spinal cord6. Although such data are not yet
available, we have observed an interesting type of short-term
“desensitization” during intracellular recordings from about 30%
of the opioid-sensitive DRG neurons in both cord-DRG and isolated
DRG explants. In these neurons, after an initial reduction (-50%)
in the duration of the DRG action potential within 2-3 minutes after
introduction of DADLE, the characteristic Ca++-hump progressively
reappeared and the action potential regained its original width
during the following 5-6 minutes, even though the agonist was
still present (Chalazonitis and Crain 1983, and unpublished
observations). In the rest of the DRG neurons, the opioid-induced
decrease in the duration of the Ca++-hump was stably maintained
(during 4-10 min tests). It will be of interest to determine if
this desensitization is temperature-dependent and fails to occur
at 20°C, as in the “acute tolerance” studies of hippocampal explants
exposed to FK 33-824 (Gahwiler 1981) and in our long-term tolerance
test on cord-DRG explants (Crain et al. 1979). We have not
observed signs of desensitization in our previous extracellular
recordings of DRG-evoked dorsal-horn field potentials in cord-DRG
explants exposed to DADLE (or morphine) for periods up to several
hours, and the transitory depressant effects of DADLE on DRG neuron
perikarya may, therefore, be a type of tachyphyllaxis2 unrelated
to cellular processes mediating long-term opioid tolerance.
D. Opiate Receptor Upregulation During Chronic Exposure of Cord-
DRG Explants To Opiate-Antagonists
Chronic administration of naloxone in rats resulted in enhanced
morphine-induced analgesia (Tang and Collins 1978) and an in-
creased number of opiate binding sites in brain tissue (Lahti and
Collins 1978). Chronic naloxone treatment of guinea pigs also led
to increased opiate binding in the ileum and brainstem and en-
hanced sensitivity to opiate-depressant effects on the isolated
ileum preparation (Schulz et al. 1979). These preliminary reports
of enhanced opiate binding after chronic naloxone have been con-
firmed and extended by Zukin et al. (1982), using improved assay
techniques and controls, demonstrating that chronic naltrexone in
rats resulted in a nearly two-fold increase in brain opiate re-
ceptor number (the actual increase ranged widely in specific re-
gions of the (CNS) (see Zukin et al., this volume).
Since high levels of stereospecific opiate receptors develop in
fetal mouse cord-DRG explants (Hiller et al. 1978 a,b; see
Sect. II), we used this system to examine the mechanism underlying
the regulation of opiate receptors in response to chronic
antagonists (Tempel et al. 1983). Cord-DRG explants were grown
for two weeks, and then exposed to naloxone (10µM) for an additional
week. Assays of cultures exposed to naloxone for 1 week revealed
a 50% increase in 3H-dihydromorphine binding (Tempel et al. 1983)
relative to that in either control cultures (Table 3) containing
regular nutrient media or 10µM (+)naloxone {the (+)enantiomer of
naloxone which does not bind to opiate receptors (Ijima et al. 1978)}.
In order to answer the question as to whether antagonist-induced
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TABLE 3
Opiate Receptor Upregulation During Chronic Exposure
of Cord-DRG Cultures to Naloxone
Drug Exposure* No. of Opiate Receptor % Change
Agents(s) Period Assays** Binding § in Binding
(days) (fmoles bound Relative to
per mg protein) Control
Control medium 8 100
Naloxone (10µM) 0-1 3 100 0
" 2 2 125 +25%
" 5 2 150 +50%
" 7 4 151 +51%
(+)Naloxone (10µM) 7 1 88 -12%
Naloxone (10µM) +
cyclohexamide (1µM) 5 1 93 +50% § §
Cyclohexamide (1uM) 5 1 62
*Cultures were grown in regular medium for 2 weeks prior to drug
exposure
**For each assay, 7-9 cultures were pooled, homogenized and
washed free of residual naloxone
§ Aliquots of homogenates were incubated in 3H-dihydromorphine(5nM)±
levorphanol(10µM)
§§ %change in binding relative to cyclohexamide control; 1µM
cyclohexamide blocked >90% of protein synthesis in cord-DRG
cultures (measured by incorporation of 14C-leucine into total
protein)
(Unpublished data from Tempel, Crain, Simon and Zukin 1983, and
in preparation.)
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receptor upregulation requires the synthesis of new receptors,
cultures were exposed to naloxone (10µM) together with
cycloheximide (1µM), a relatively selective inhibitor of protein
synthesis, for 5 days at 35°. These conditions blocked protein
synthesis by greater than 90% in cord-DRG explants, as measured
by incorporation of 14C-leucine into total protein, yet
upregulation of opiate receptors still occurred (Table 3). This
result suggests that upregulation may be due to an unmasking of
previously-existing receptors. No significant change in receptor
density was observed following 1 day of naloxone treatment; a
modest increase was observed after 2 days; and maximal upregulation,
after 5 days of chronic exposure (Table 3). The maximal increase
of 50% was quite comparable to the 52% increase observed in assays
of spinal cord after chronic naltrexone in situ (Tempel and
Zukin, in preparation; see also Zukin et al. 1982 and this volume).
These data demonstrate the feasibility of utilizing cord-DRG
explants as an in vitro model system for analyses of cellular
mechanisms underlying the plasticity of opioid networks during
chronic exposure to opioid antagonists, as well as agonists (see
Sect. III-A). Attempts are also being made to detect electro-
physiologic evidence of opioid supersensitivity in correlation
with experimental upregulation of these receptors as observed
in situ by Tang and Collins (1978), Schulz et al. (1979), Zukin
et al. (this volume); see, however, Bardo et al. (1982) .
IV. CONCLUDING REMARKS
Electrophysiologic analyses of dissociated DRG and cord neurons
have provided valuable insights into some of the primary effects
of opioids on transmitter release and conductance changes at DRG
terminals and cord-DRG synapses (Sect. I and III-C). However, many
important aspects of sensory-evoked dorsal-horn network functions
mediating opioid analgesia, tolerance and dependence may be
difficult to study in randomly dispersed, monolayer arrays of DRG
and cord neurons in dissociated cultures. Cord-DRG explants, on
the other hand, provide a specific opioid-sensitive network of
CNS and DRG neurons which can maintain not only an organized set
of physiological properties, but also an organotypic multi-layered
geometrical arrangement of neuron perikarya and fiber tracts
clearly related to the original body axes of the explanted tissue
(Crain 1976; Crain et al. 1978; Crain 1980, 1984). Studies
with organotypic CNS explants can, therefore, bridge the gap be-
tween experiments in the whole animal -- which are often difficult
to analyze because of the large number of complex interacting
networks -- and experiments in cell cultures of relatively dis-
organized, but more accessible, arrays of dissociated neurons.
Our experiments with cord-DRG explants show the potentialities of
this model system for analyses of cellular mechanisms associated
with opioid tolerance (Sect. III) and they provide a foundation
for more systematic experiments with these tissue culture models
to gain further insights into physico-chemical factors that re-
gulate development of tolerance and dependence during chronic
exposure to opioids.
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Furthermore, developmental studies of the effects of opioids in
cultures of immature fetal CNS tissues may be useful in relation
to problems arising in the human fetus during maternal narcotic
addiction. Finally, analyses of factors leading to increased
opiate receptor levels and possible opioid supersensitivity in
cord-DRG explants after chronic exposure to naloxone at various
stages of maturation provide an opportunity to correlate studies
of opioid tolerance with the more general problem of plasticity
in opioid systems of the CNS.
FOOTNOTES
1See reviews by Herz, Tucker, Klee, Loh and Wuster (this volume).
2See review by Henriksen (this volume).
3See reviews by Tucker, Klee, Loh and Wuster (this volume).
4See review by Beckman (this volume).
5See review bv Herz (this volume).
6Hyperexcitability in opioid-tolerant cord-DRG explants observed
after sudden withdrawal of opiates may, indeed, be mediated by
compensatory alterations in the cord, as well as DRG , neurons of
these complex dorsal-horn networks (see reviews by Herz and Wuster,
this volume). Similarly, emphasis in this review on presynaptic
DRG factors that may be involved in opioid analgesia and tolerance
does not, of course, preclude a significant role for postsynaptic
cord neurons (e.g. Williams and North 1983).
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NOTE ADDED IN PROOF
Following the discussions at the NIDA Symposium (Boston,
Nov. 1983) on Dr. Collier’s hypothesis regarding the possible
roles of adenylate cyclase (AC)/cyclic AMP in opioid tolerance
and dependence, attempts were initiated to utilize forskolin,
a selective activator of AC (Seamon and Daly), to facilitate
evaluation of the effects of increased AC/CAMP levels on the
sensitivity of cord-DRG explants to opiates (see above: Sect. I).
When naive explants were treated with forskolin (10-50µM) for
10-30 min prior to and during exposure to 0.3µM morphine, the
usual depressant effects on dorsal-horn responses often failed
to occur (10-30 min tests) (Crain et al, 1984). Dibutyryl
cAMP (10µM) or the more potent analog, dioctanoyl cAMP(0.1mM),
produced a similar degree of “tolerance” to opiates as 10µM
forskolin. With high levels of forskolin (50µM), even con-
centrations of morphine up to 10µM were far less effective in
depressing cord responses. These anti-opiate effects of exo-
genous cAMP and forskolin are probably both mediated by
increases in intracellular cAMP. The onset of opioid-“toler-
ance” in cAMP-or forskolin-treated cord-DRG explants provides
the first electrophysiologic support for the hypothesis that
neurons may develop tolerance/dependence during chronic opioid
exposure by a compensatory enhancement of their AC/CAMP system
following initial opioid-depression of AC activity (see review
by Collier, 1980). Previous evidence relied primarily on
behavioral tests (Ho et al. 1973; Collier et al. 1975) and
biochemical analyses in cell cultures (Sharma et al. 1975).
It will be of interest to determine if dorsal-horn tissues
of cord-DRG explants do, in fact, develop increased AC/cAMP
levels as they become tolerant during chronic exposure to
opiates.
ADDITIONAL REFERENCES
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Experimental Approaches Toward
Determining the Neuronal Circuits
Most Affected by Chronic Opiate
Administration
Robert Elde
INTRODUCTION
A wide variety of studies have explored the expression of
tolerance to opiates at behavioral, cellular and molecular levels.
However, very little is known concerning the anatomical identity
of neuronal systems that are most affected by chronic opiate
administration. Since the discovery of opiate receptors and the
characterization of opioid peptides, a great deal of information
has been gathered concerning the regional distribution of opiate
binding sites as well as the distribution of neuronal cell bodies,
fibers and terminals that contain enkephalins, endorphins and
dynorphins. It has been hypothesized that the activity of neurons
that bear opiate receptors is likely to be perturbed by chronic
opiate adminstration, perhaps by alterations in receptor number or
affinity (Klee et al., Law et al., Zukin et al, this volume). In
addition, it has been suggested that the activity of opioid neurons
themselves may be altered in the tolerant state, perhaps through
receptor-mediated autofeedback mechanisms. It is also quite
possible that the major effects of chronic opiate administration are
expressed by neurons that are regulated by the above classes of
neurons, but separated from them by one or more synaptic connections
(Wuster and Costa, this volume). Moreover, it has not been
established if chronic opiate administration leads to chronic
excitation or inhibition of the affected neuronal circuits.
PREVIOUS STUDIES
Little is known of the neuroanatomical substrates of opiate
tolerance because of limitations inherent to techniques used to
measure neuronal activity. Microelectrode physiological methods
provide precise records of neuronal activity of single cells or
small groups of cells over times that range from milliseconds to
minutes. Chronic or periodic recording from chronically implanted
electrodes may extend the period for recording of activity to
several days. However, the number of neurons that can be sampled by
these methods is very small. Considering the large number of brain
regions and the large number of neurons within each region, it is
clear that unit recording of neuronal activity is not an adequate
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method for sampling the entire nervous system for the effects of
chronic opiate administration on neuronal activity.
Electroencephalographic methods overcome some of the limitations of
microelectrode recording in that large regions of brain can be
measured for net neuronal activity. However, the neuroanatomical
resolution of these methods is poor.
Introduction of the autoradiographic method for detecting regional
accumulation of radiolabeled 2-deoxyglucose provided the technical
means to survey the entire brain for changes in glucose utilization.
Regional deoxyglucose accumulation has been found to closely
parallel neuronal activity during the time of exposure to
deoxyglucose, the duration of exposure usually being an hour or less
(Sokoloff et al. 1977).
Several studies have been reported on the effects of opiate
administration on 2-deoxyglucose accumulation. Lightman and
colleagues (1982) found that acute morphine produced a naloxone-
reversible increase in glucose utilization in the posterior lobe of
the pituitary. Chronic administration of morphine also produced an
increase in glucose utilization in the posterior pituitary, although
a subsequent acute challenge with morphine produced a decrease in
glucose utilization. Wooten and colleagues (1982) surveyed
regional glucose utilization in the di- and telencephalon of
morphine-dependent rats and in rats in which withdrawal was
precipitated with naloxone. Optical densitometry of autoradiograms
from morphine-dependent animals revealed significant increases in
some regions, significant decreases in other regions and no change
in glucose utilization in other regions (table 1).
These data are of considerable interest, however it is important to
note that the relative activity of neurons as measured in these
studies may not genuinely reflect the sites most prominent in
expressing the tolerant state. In the first place, it is debatable
whether or not a genuine state of tolerance was achieved during the
periods of measurement, since the morphine injections were halted or
morphine pellets were removed some hours prior to infusion of
radiolabeled deoxyglucose. Thus, it is possible that some of the
changes in deoxyglucose accumulation could be due to early phases of
withdrawal from the tolerant state. Secondly, at least some of the
changes in glucose utilization may reflect the morphine-treated
animals' behavioral response to the handling that was necessary for
cannulae insertion and deoxyglucose administration.
It is important to stress that limitations inherent to the
deoxyglucose method produce difficulties for the design of
experiments that will differentiate changes in glucose utilization
that are directly attributable to a drug's action from those which
occur as secondary effects. General hypoxia secondary to opiate-
induced respiratory depression represents another example of
possible counfounding effects that may be detected by the
deoxyglucose method. Wuster and colleagues (1981) attempted to
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TABLE 1
Regions with Changes in Brain Glucose Utilization
after Chronic Morphine Treatment*
Increased
Medial preoptic area, lateral preoptic area, bed nucleus stria
terminalis, preoptic magnocellularis, parasubiculum, subiculum,
medial entorhinal cortex, lateral entorhinal cortex; CA-1 pyramidal
layer, CA-1 striatum radiatum, perforant path, dentate gyrus, CA-3
pyramidal layer, CA-Z.
Decreased
Frontal motor cortex, medial frontal cortex; striatum; thalamic
anterior ventral nucleus; medial habenula nucleus.
*Data from Wooten et al. (1982)
avoid the effects of opiate-induced respiratory depression by
studying glucose utilization in an in vitro whole brain perfusion
system. Whereas such an approach may provide information on the
sites of acute effects of opiates, it is unlikely to provide
information on the sites where the chronic effects of opiate
administration may be manifest.
Recent work on levels of enzymes involved in brain energy metabolism
suggests an alternate approach for studying the sites involved in
the expression of tolerance to opiates. Wong-Riley (1979) and
colleagues (Wong-Riley et al. 1978; Wong-Riley and Welt 1980) have
explored the intensity of histochemically-revealed cytochrone
oxidase activity as a function of neuronal activity. When auditory,
visual and somatosensory systems were denervated, cytochrome oxidase
staining intensity was shown to decrease within neurons as far as
several synapses distal to the site of sensory deprivation. Using
more quantitative assays, several other enzymes related to energy
metabolism were shown by Dietrich and colleagues (1981) to be
significantly depressed within specific targets of whisker afferent
pathways after cauterization of whiskers. Thus, there is striking
evidence that long-term inactivation of neuronal pathways leads to
decreases in energy-related enzyme levels.
Kageyama and Wong-Riley (1982) have further reported that the level
of cytochrome oxidase staining within hippocampal neurons correlates
positively with the known spontaneous activity of those neurons.
That is, spontaneously active neurons have higher levels of
cytochrome oxidase activity than those which are tonically silent.
Most importantly, Dietrich and colleagues (1982) have demonstrated
increases in levels of three energy metabolism-related enzymes in
cortical barrel fields that are the targets of intact whisker
afferents in animals in which other whisker afferents had been
removed. The authors suggest this is the first demonstration of an
increase of energy-related enzymes in brain in response to chronic,
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experimental stimulation of a pathway. As they point out, however,
these changes are not without biological precedent, since similar
long-tern changes in levels of enzymes of energy metabolism are
observed in skeletal muscle as a function of exercise and disuse
(see Karpati and Engel 1968, Holloszy and Booth 1976).
Metabolic enzyme histochemistry provides a possible means to detect
changes in neuronal activity that are manifest and maintained over a
period of weeks. The technique is attractive for identification of
sites affected by chronic opiate administration, since transient
phenomena that may accompany handling and treatment of animals are
unlikely to be detected. In contrast to the deoxyglucose method,
enzyme histochemistry does not require intensive manipulation of
animals (such as restraint, intravenous cannulation and injection)
immediately prior to and during the time of the measurement.
Thus, it can be expected that neurons identified by enzyme
histochemistry as most altered by chronic exposure to opiates will
represent those neurons that are responsible for the physiological
and behavioral expression of tolerance.
PILOT STUDIES
An experiment was conducted to compare the intensity of cytochrome
oxidase staining in brains of animals chronically exposed to
morphine and in brains from control animals. Morphine was made
available to Swiss-Webster mice ad libitum in drinking water that
contained 10% sucrose (Khavari and Risner 1973). During the first
16 days, mice consumed an average of 69 mg morphine sulfate/kg/day.
During the last 9 days the concentration of morphine was doubled
resulting in mean consumption of 146 mg/kg/day. Control mice
received sucrose drinking water for 25 days. At several intervals
during the study, tolerance was assessed in cohorts by naloxone-
precipitated withdrawal. Brains of mice were fixed by vascular
perfusion with 4% formaldehyde. Frozen sections sampling the entire
neuraxis were processed for cytochrome oxidase activity according to
Wong-Riley and Welt (1980). Specificity controls for staining were
obtained by inclusion of sodium azide in the incubation media.
Staining patterns and density were examined and, in limited areas to
date, quantified by optical densitometry.
Cytochrone oxidase staining was heterogeneous within the brain.
Staining for this enzyme complex appeared to be specific since
inclusion of the electron transport inhibitor, sodium azide,
prevented staining. The intensity of staining in many regions did
not appear to differ between morphine-treated and control mouse
brains (figures 1 and 2). However, in certain discrete regions such
as the mammillary nuclei, a striking decrease in the staining
intensity was observed in morphine treated animals (74% of control,
p<0.05; figures 1 and 2). Decreases in staining in
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FIGURES 1 and 2. Photomicrographs of coronal sections of rat
midbrain after processing for cytochrome oxidase histochemistry.
Many regions in vehicle control (figure 1) and chronic morphine-
treated animals (figure 2) exhibit similar staining intensity.
However, the mammillary nuclear complex (arrows) of the morphine-
treated animals was strikingly decreased in staining intensity.
morphine-treated mice were apparent in some other regions. No
increases in cytochrome oxidase staining were noted in morphine-
treated mice.
This pilot study demonstrates the feasibility of using enzyme
histochemistry to determine sites where neuronal activity is most
altered as a consequence of chronic morphine administration.
Previous reports (Dietrich et al. 1981, 1982) have suggested that
levels of enzymes involved in energy metabolism change only over a
time course of several weeks. This phenomenon is exploited by
enzyme histochemistry and thereby avoids detection of transiently
occurring events. Thus histochemical detection of metabolic enzymes
has an advantage over the 2-deoxyglucose method in that it is less
susceptible to revealing changes in neuronal activity that are
actually a consequence of periodic handling of the animal or
responses to manipulation of the animal in the period immediately
prior to sacrifice.
However, cytochrome oxidase histochemistry is unlikely to
demonstrate all of the sites involved in tolerance to morphine. As
noted above, neither this pilot study nor previous studies in other
systems have noted increases in levels of cytochrome oxidase. The
findings of Dietrich and colleagues (1982) suggest that increases as
well as decreases of malate dehydrogenase or citrate synthase may be
histochemically demonstrable, Thus histochemical study of these
enzymes may be more appropriate to determine the variety of changes
in neuronal activity which occur as a consequence of long-term
perturbation by opiates.
SUMMARY AND FUTURE QUESTIONS
The investigation of neuroanatomical substrates, through which
opiate tolerance and dependence phenomena are manifest, now appears
to be feasible. Histochemical processing of brains to reveal certain
enzymes of energy metabolism is likely to identify neurons most
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involved in the tolerant state. The following specific questions
can be addressed.
1. IS the net activity of neurons bearing opiate receptors altered
by chronic opiate adninistation? Are neurons bearing different
classes of opiate receptors differentially affected? Are neurons
that produce opioid peptides affected? Do opioid neurons in
discrete regions, or those producing particular opioid peptides,
differ in their activity during chronic exposure to morphine? Is
the net effect inhibition or excitation?
2. What neurotransmitters are produced by neurons most affected by
chronic exposure to morphine? Such inquiry may suggest the use of
new therapeutic means of countering the untoward effects of
tolerance to opiates.
3. Which neurons in the brain are principally involved in the
manifestation of withdrawal from chronic opiates? Which
neurotransmitters do they contain and which receptors do they bear?
Such data may suggest new therapeutic means of countering the
untoward effects of withdrawal from opiates.
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Effects of Opiates and
Neuropeptides on Immune
Functions
Robert E. Faith, N. P. Plotnikoff, and A. J. Murgo
INTRODUCTION
In recent years there has been an increase in interest in the
effects of drugs and pharmaceuticals on immune function. Indeed a
number of chemicals have been identified and developed because they
possess immunomodulatory properties. This includes both immuno-
stimulants and immunosuppressants. In addition to drugs developed
specifically for their immunomodulatory properties, it has become
clear that a number of chemicals, including environmental pollu-
tants, various anesthetics and analgesics, drugs of abuse, and
hormones, including neuropeptides, can influence immune functions.
In this chapter we will discuss the effects of the opiates and
neuropeptides on immune function.
OPIATE EFFECTS
While the opiates have been abused, or used as recreational drugs
for centuries, very little is known about the possible effects of
these chemicals on immune function, direct or indirect. Most of
what is known was recently reviewed by Sheagren and Tuazon (1977).
It is difficult to investigate the effects of opiates on immune
function in the addict. However, some knowledge has been gained
from studying these individuals. It is recognized clinically that
infectious disease is often a complication of drug abuse. It must
be kept in mind that a number of factors other than direct immuno-
suppression could lead to increased incidence of infections in
opiate addicts. These include nutritional factors, living condi-
tions and contamination of injection paraphernalia. However,
Sheagren and Tuazon (1977) state, "Most authors do agree that the
incidence of infections is increased in most common forms of drug
abuse and that immune alterations probably do exist."
The immune system is composed of nonspecific as well as specific
components. Cellular elements, macrophages and neutrophils, and
serum factors, complement and interferon, participate nonspecifi-
cally in immunity. Several studies have shown these elements of
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immunity to be affected by opiates. One study has shown that
neutrophil chemotaxis is suppressed by morphine (Stanley et al.
1976) while another has shown that phagocytic and bactericidal
functions of neutrophils from patients taking methadone and mor-
phine are normal (Nickerson et al. 1970). Studies in mice have
shown that injections of morphine, dilaudid or methadone signifi-
cantly reduce the ability of these animals to produce interferon in
response to induction by either poly I:C or bacterial endotoxin
(Hung et al. 1973). Finally, Wetli et al. (1974) have shown that
some heroin addicts have elevated complement levels, others have
depressed complement levels and the rest are not affected.
Recent studies have presented evidence that lymphocytes possess
receptors which bind opiates such as morphine (Wybran et al. 1979)
and naloxone (McDonough et al. 1980, Mehrishi and Mills 1983). The
presence of these receptors would indicate that the opiates may be
able to affect the immune system directly. Indeed there is some
evidence to suggest that this is the case. It has been reported
that opiate users often have hyperglobulinemia (Sheagren and Tuazon
1977). The IgM levels are most frequently increased, but increases
in IgG are also seen. These increases in immunoglobulin levels are
most likely a result of either repeated injections of antigenic
materials along with the abused drug or the presence of chronic
infections which affect many addicts. Opiates have been reported
to inhibit specific antibody production in experimental animals.
Mice given large doses of morphine or methadone had reduced anti-
body production when compared to nontreated controls (Lefkowitz and
Yang 1974; Gungor et al. 1980).
There is also some evidence that opiates may directly affect
T-lymphocytes. Brown et al. (1974) investigated the ability of
peripheral blood lymphocytes from heroin addicts to proliferate in
response to mitogenic stimulation. They found the responses of
cells from heroin addicts to stimulation with phytohemagglutinin
(PHA), Concanavalin A (Con A) or pokeweed mitogen (PWM) to be
significantly less than the responses of cells from normal volun-
teers. The proliferative responses of PBL's to mitogenic stimula-
tion tended to return to normal when the study subjects were not
taking heroin. McDonough et al. (1980) have shown that opiate
addicts have a significant reduction in the number of total T-
lymphocytes in circulation as measured by the ability of the
lymphocytes to form rosettes with sheep red blood cells (a marker
for T-lymphocytes). They also showed an increase in the number of
"null" lymphocytes, but there was no significant change in the B
lymphocytes or total white blood cell count in opiate addicts. The
T cell decrease and "null" cell increase were reversible by nalox-
one. Similarly, Wybran et al. (1979) have shown that in vitro
treatment of peripheral blood lymphocytes from normal human volun-
teers with morphine significantly reduces their ability to form
active rosettes with sheep red blood cells. This effect is com-
pletely reversed by naloxone.
One final set of studies must be mentioned when discussing the
effects of opiates on host defense mechanisms. These are studies
involving the effects of opiates on tumor growth and survival times
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of mice implanted with a transplantable neuroblastoma cell line.
Zagon and McLaughlin (1981a, b, 1983) have shown the heroin,
naloxone or naltrexone inhibit tumor growth and prolong survival
times at relatively low doses, while high doses may enhance tumor
growth. These studies are somewhat difficult to interpret because
the neuroblastoma possesses receptors for the opiates, and the
drugs may be exerting their action on the tumor cells rather than
on host defense mechanisms. The opiates may exert their effects on
both the tumor cells and host defense mechanisms, or their action
on the tumor cells may not be a factor in host resistance to this
tumor. Studies with other tumor systems are required to more fully
elucidate the effects of the opiates on the ability of a host to
resist a tumor challenge.
NEUROPEPTIDE EFFECTS (ENKEPHALINS - ENDORPHINS)
Recently several studies have been performed to investigate the
effects of the opioid neuropeptides, endorphins and enkephalins on
immune function. Initially Wybran et al. (1979) produced data
indicating that human lymphocytes possess receptors for methionine-
enkephalin. At the same time Hazum et al. (1979) reported that
cultured human lymphocytes possess specific receptors for beta-
endorphin. Subsequently it has been shown that alpha-, beta- and
gamma-endorphin are capable of suppressing the in vitro antibody-
producing cell response of mouse splenic lymphocytes immunized in
vitro (Johnson et al. 1982). Suppression with beta- and gamma-
endorphin occurred at high concentrations. There have been two
studies reported in which the effects of beta-endorphin on the
proliferative response of lymphocytes to mitogen stimulation were
investigated. McCain et al. (1982) reported that beta-endorphin is
a potent suppressor of PHA-induced T-lymphocyte blastogenesis when
human peripheral blood lymphocytes are exposed early in the course
of mitogenic activation. This suppression was not blocked by
pretreatment with naloxone. In contrast, Gilman et al. (1982) have
reported that beta-endorphin significantly enhances the prolifera-
tive response of rat splenic lymphocytes to the T cell mitogens PHA
and Con A. Treatment with naloxone did not reverse the enhancing
effect of the beta-endorphin. The differences observed in these
two studies may be due to one or more of the following:
1) Different concentrations of beta-endorphin were utilized in the
two studies; 2) Rat lymphocytes may respond differently to beta-
endorphin than do human lymphocytes; or 3) Lymphocytes in spleen
contain somewhat different subpopulations than those found in
peripheral blood, which may result in a different effect observed
following treatment with beta-endorphin. Based on results obtained
with the enkephalins in our laboratory, the first possibility
listed may be the most likely. We have observed that varying
concentrations of enkephalins exert a biphasic effect on lymphocyte
function with some concentrations exerting stimulatory effects
while other concentrations are suppressive. The final reported
study on the effects of beta-endorphin on immune functions is that
of Mathews et al. (1983). This study reports that beta-endorphin
significantly enhances natural cytotoxicity exhibited by natural
killer (NK) cells in peripheral blood lymphocytes of normal human
volunteers. In these studies lymphocytes were isolated from the
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peripheral blood of normal volunteers and incubated with beta-
endorphin. This treatment resulted in enhanced NK cell activity as
measured in a cytotoxicity assay. This enhancement appears to
result from an increase in the numbers of NK cells and increased
cytotoxic efficiency of the NK cells. This enhancement of NK
activity was reversible with naloxone treatment.
TABLE 1. Effect of enkephalins on thymus
and spleen weights in micea
Enkephalin dosage Thymus wt. Spleen wt.
(mg/kg) (mg±SE) (mg±SE)
Methionine-enkephalin
0 68.6±3.6 101.8±3.1
10 78.1±2.9 68.3±2.2
(p=O.O5)b (p<O.OO1)b
30 79.1±4.5
(p<0.1)b
69.8±l.7
(p<O.OO1)b
Leucine-enkephalin
0 56.1±O.9 115.2±6.1
10 49.3±2.8
(p<0.05)b
98.0±4.0
(p<0.05)b
30 63.O±1.7
(p<0.005)b
71.3±1.9
(p<O.OO1)b
a. Mice were injected daily for 1 week with varying dilu-
tions of methionine-enkephalin or leucine-enkephalin.
b. Statistical difference from control; N.S. = no signifi-
cant difference (p>0.1).
The effects of the enkephalins on immune functions have been
studied more extensively than beta-endorphin. It is becoming quite
clear that the enkephalins have the ability to modulate a number of
immune functions. Studies in our laboratory have shown that daily
injection of mice for 1 week with either methionine- or leucine-
enkephalin results in significant changes in lymphoid organs
(table 1). This treatment resulted in significant increases in
thymus size and significant decreases in spleen size. Further
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studies are required to completely explain the mechanism(s) of
these lymphoid organ weight changes.
The finding that lymphocytes possess receptors for enkephalins
(Wybran et al. 1979) prompted us to investigate the potential
effects of the enkephalins on various immune functions. Wybran
et al. (1979) reported that lymphocytes not only possess receptors
for enkephalins but also were influenced by enkephalins. Their
studies showed that peripheral blood lymphocytes from normal human
volunteers were enhanced in their ability to form rosettes with
sheep red blood cells (SRBC) following treatment with methionine-
enkephalin. This enhancement could be inhibited by naloxone.
Studies in our laboratory confirmed these findings and were expand-
ed to include a population of immunosuppressed individuals (Miller
et al. 1983). Peripheral blood lymphocytes from a group of lympho-
ma patients were used to investigate the effects of methionine- and
leucine-enkephalin on the ability of lymphocytes from immunosup-
pressed individuals to form rosettes with SRBCs. It was found that
both enkephalins significantly enhance the ability of these cells
to form active T cell rosettes (table 2). Methionine-enkephalin
was active over a wide range of concentrations (1O-2 to 10-14 mg/ml)
while leucine-enkephalin was only active at one low concentration
(10-14 mg/ml).
TABLE 2. Effect of methionine- and leucine-enkephalin
on the percentages of active T-cell rosettes formed
by peripheral blood lymphocytes from lymphoma patients
Enkephalin
concentration
(mg/ml)
Methionine- Leucine-
enkephalin enkephalin
10-2 27.6±5.3 32.0±4.1
10-6 46.6±4.2* 41.1±5.6
10-10 46.8±3.0* 40.3±5.7
10-14 48.5±5.6* 52.7±2.8*
*
= significant difference from untreated samples, p<0.05.
Clin. Immun. Immunopath. 26, 446-51, Copyright (1983).
Academic Press
In order to gain some insight into the possible effect of enkepha-
lin treatment on host defense mechanisms the following study was
undertaken (Plotnikoff and Miller 1983). BDF1 mice were inoculated
intraperitoneally with either 102 or 104 L1210 tumor cells. Follow-
ing tumor challenge the animals were injected daily with saline
vehicle, methionine-enkephalin or leucine-enkephalin. The animals
were observed daily following tumor challenge and deaths recorded
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on the day of occurrence. Table 3 illustrates results obtained in
mice challenged with 104 tumor cells and treated with 30 mg/kg
daily of either enkephalin. Methionine-enkephalin provided signifi-
cant protection from tumor challenge. Similar results were ob-
tained in mice challenged with 102 tumor cells and treated with
10 mg/kg daily leucine-enkephalin.
Day of
study
13
14b
15
16
17
18
19
20
21
TABLE 3. Effect of enkephalins on
survival of mice challenged
with L1210 tumor cells
Treatment groupa
Non-treated Methionine- Leucine-
enkephalin enkephalin
7/25c 5/30 3/30
10/25 7/30 5/30
16/25 8/30 12/30
20/25 12/30 17/30
21/25 15/30 22/30
21/25 18/30 22/30
21/25 l8/30 26/30
22/25 19/30 26/30
22/25 19/30* 26/30
a. BDF1 mice were inoculated with 10
4 L1210 tumor cells ip.
Following tumor challenge the animals were injected daily
with saline vehicle, 30 mg/kg methionine-enkephalin or
30 mg/kg leucine-enkephalin. Deaths were recorded on the
day of occurrence.
b. The approximate median time to death is underlined for
each group.
c. The data is reported as the number of dead over the total
* number of animals in the group.
Indicates a significant difference (p<0.05) between
treated and nontreated animals.
Int. J. Immunopharm., 5, 5, 437-441, 1983. Copyright (1983).
Pergamon Press Ltd.
The effect of enkephalins on in vitro lymphocyte proliferative
responses has been studied in our laboratory and in the laboratory
of Gilman et al. In our laboratory, using mouse splenic lympho-
cytes and varying dilutions of either methionine-enkephalin or
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leucine-enkephalin, the response to varying dilutions of PHA was
investigated. Both enkephalins were found to significantly enhance
the blastogenic response of lymphocytes to PHA (Plotnikoff and
Miller 1983). Results obtained with PHA at a dilution of 1:1OO are
illustrated in table 4. Similar results were obtained with other
dilutions of PHA. Methionine-enkephalin tended to enhance the
response over a broader range of dilutions than did leucine-enkepha-
lin, while the leucine-enkephalin was active at lower concentra-
tions than the methionine-enkephalin. These results are in
contrast to those obtained by Gilman et al. (1982) who reported no
stimulation of the blastogenic response of rat splenic lymphocytes
to stimulation with Con A following treatment of the lymphocytes
with enkephalin.
TABLE 4. Effect of enkephalins
on lymphocyte blastogenesisa
Enkephalin Methionine- Leucine-
concentration enkephalin enkephalin
(mg/ml)
0 1458±90b 1458±90
1 4393±664* 1114±310
10-1 5258±990* 1516±207
10-2 3144±500* 165O±180
10-4 2123±228* 1918±293
10-6 2357±155* 2425±323*
10-8 1884±188* 2759±387*
10-10 1538±170 2065±360*
a. Murine splenic lymphocytes were treated in vitro
with various concentrations of either methionine- or
leucine-enkephalin and then assayed for lymphocyte
transformation in response to PHA stimulation.
b. Stimulation was measured by incorporation of 3H-
thymidine into acid insoluble material. The data is
* presented as mean cpm± SE.
Indicates significant enhancement of transformation
in enkephalin treated cells as compared to non-
treated cells (p<0.05).
Int. J. Immunopharm. 5, 5, 437-441, 1983. Copyright
(1983). Pergamon Press Ltd.
Johnson et al. (1982) have studied the effect of the enkephalins on
the in vitro antibody response. Murine splenic lymphocytes were
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cultured in the presence of sheep red blood cells and varying
dilutions of either methionine- or leucine-enkephalin. After 5
days of culture the number of specific antibody-forming cells was
enumerated in each culture. Both enkephalins were found to cause
suppression of the antibody response.
Recently studies have been undertaken in our laboratory to investi-
gate the effects of the enkephalins on natural killer cell activi-
ty- Initially isolated peripheral blood lymphocytes from normal
human volunteers were utilized in these studies. These cells were
incubated for 1 hour with varying concentrations of either methionine-
or leucine-enkephalin. Following incubation the cells were washed
and then used in NK cell assays. Table 5 illustrates data obtained
in these studies. Both enkephalins have the ability to signifi-
cantly enhance natural killer activity over a range of concentra-
tions. Leucine-enkephalin appears to be more active in this
enhancement than is methionine-enkephalin. We are presently
performing similar studies with peripheral blood lymphocytes from a
variety of cancer patients. Our results to date indicated the
enkephalins are capable of enhancing NK activity in cancer patients
as well as normal volunteers.
TABLE 5. Effect of enkephalins on natural
killer cell activitya
Mean difference of enkephalin-
treated cells vs. nontreated cells
Enkephalin
concentrationb
(mg/ml)
Methionine- Leucine-
enkephalin enkephalin
10-4 1.41±3.19(NS)C 10.00±4.75(p<0.05)
10-6 6.41±3.41(p<O.O5) 11.29±6.06(p<0.05)
10-8 5.35±3.74(p<0.05) 12.44±5.99(p<O.O5)
10-10 6.56±4.53(p<0.05) 11.20±6.16(p<0.05)
10-14 2.55±3.19(NS) 8.72±6.26(p<O.O5)
a. NK assays were performed at an effector to target
cell ratio of 11:1.
b. Effector cells were incubated in the presence of the
indicated concentration of enkephalin for 1 hour,
washed 3 times and used in NK assays.
c. Significance of difference from control value. NS
indicates not significant.
CONCLUSIONS
While there are still many questions to be answered, it is now
clear that opiates and the natural opioid neuropeptides can influ-
ence immune function. We feel that part of the normal function of
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the enkephalins and endorphins is to participate in immune regula-
tory pathways. Many more studies are required to fully define the
role that these neuropeptides play in immune regulations.
Studies with lymphocytes from normal human volunteers as well as
cancer patients suggest that methionine-enkephalin is more active
than leucine-enkephalin in enhancing active T-cell rosettes (Miller
et al. 1983). In addition, the two enkephalins exhibit potency
differences in mouse splenic lymphocyte blastogenesis induced by
PHA. Leucine-enkephalin was active at low concentrations and
inactive at higher levels (Plotnikoff and Miller 1983).
These apparent differences in activity or potency of the enkepha-
lins may indeed represent major differences in affinities for
cellular receptors. Thus, Vaught and Takemori (1979) reported that
leucine-enkephalin, but not methionine-enkephalin, potentiated
effects of morphine. Different subpopulations of receptors for
morphine, enkephalins and endorphins have now been established
(Bloom 1983). These various receptors are only partially antago-
nized by naloxone. The difference in receptors for morphine, which
has been reported to be immunosuppressive, and the enkephalins
supports the concept that natural enkephalins may have separate
and/or complementary functions in the immune system.
We are proposing that the enkephalins play a role in a central
nervous system-endocrine-immune interrelationship in which dysfunc-
tions in the immune system may be related to chronic stress and be
accompanied by perturbations in enkephalin levels in the adrenals,
the primary source of enkephalins in peripheral circulation (Viveros
et al. 1980; Hanbauer et al. 1982; Dumont et al. 1983). Large
amounts of enkephalins, catecholamines and steroids are secreted
simultaneously from the adrenals during stress (Amin et al. 1980).
It is well known that the central nervous system and behavior can
influence immune function (Stein et al. 1976; Ader 1981; Brooks
et al. 1982; Renoux et al. 1983). Recently behavioral states have
been shown to influence cerebral spinal fluid levels of endorphins
(Pickar et al. 1981), and exercise has been shown to increase
plasma levels of endorphins (Carr et al. 1981; Farrell et al.
1982). Exercise has also been shown to enhance human NK activity
(Targan et al. 1981). Due to these facts and the effects of
enkephalins referred to above, we feel that the enkephalins,
influenced by a number of factors, may play a central role in
natural immunomodulation.
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Changes in CNS Sensitivity to
Cannabinoids with Repeated
Treatment: Tolerance and
Auxoesthesia
R. Karler, L.D. Calder, and S.A. Turkanis
INTRODUCTION
Repeated or chronic treatment with drugs can result in pharmacody-
namic changes, which classically manifest themselves in decreases
in drug sensitivity or tolerance. There are, however, reports
that, in some instances, repeated treatment results not in toler-
ance but in the quantitatively opposite effect, that is, an in-
crease in drug sensitivity or auxoesthesia*. Although this seem-
ingly paradoxical response to repeated treatment was first de-
scribed over fifty years ago for cocaine (Tatum and Seevers 1929),
the phenomenon was not investigated until it was recently redis-
covered (Post and Kopanda 1975). Now it is of particular signifi-
cance to drug-abuse research because, in addition to cocaine
other drugs in repeated doses have been found to cause auxoesthe-
sia; these include amphetamine (Segal and Mandell 1974), PCP
(Smith et al. 1981), alcohol (Pinel and Van Oot 1976) and morphine
(Shuster et al. 1975). This kind of change in pharmacodynamics
presents an entirely new dimension to our understanding of the
chronic effects of these drugs. With respect to the cannabinoids,
the reported effects of repeated treatment range from tolerance to
auxoesthesia (Pried 1977). Although what determines the direction
of the change in drug responsiveness has not been elucidated, it
*Any descriptive consideration of a change in an effect which is
quantitatively the opposite of tolerance suffers at the outset
from the lack of a word to refer to the phenomenon. "Reverse tol-
erance" has been used, but it is at once inadequate and mislead-
ing. Other words that are sometimes used include sensitization,
hypersensitivity and supersensitivity. None of these is appropri-
ate because each already has a restricted meaning in pharmacolo-
gy: Sensitization and hypersensitivity classically refer to al-
lergic phenomena; while supersensitivity is the enhanced respon-
siveness of an effector system following denervation. In the ab-
sence of an appropriate existing word, we offer "auxoesthesia,"
which is both pristine and novel, as well as etymlogically appo-
site. We are indebted to Dr. B.Z. Karler for coining the term.
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is clear that any interpretation of the available data is compli-
cated by species differences, dosage and treatment differences,
and, possibly most important, differences in drug effects, which
include functional as well as behavioral effects. The data de-
scribed below were derived from experiments designed to minimize
sane of these variables, specifically by using only one species
treated daily with a constant dose of drug. Under these condi-
tions, several different effects on CNS excitability were measured
simultaneously in order to compare the quantitative character of
changes in drug responsiveness with repeated treatment.
REPEATED CANNABINOID TREATMENT AND CHANGES IN PHARMACODYNAMICS IN
CONVULSIVE THRESHOLD TESTS
In figures 1, 2 and 3 are data obtained from mice that were
treated daily for 22 days with an anticonvulsant dose 50
determined in a maximal electroshock test (Karler et al. 1974).
FIGURE 1. Repeated THC treatment: ESTs and brain- and plasma-drug
concentrations. In each test 60 mice given 100 mg/kg THC (i.p.),
another 60, vehicle; median effective currents or voltage deter-
mined at peak drug effect time. l = differences in EST between
drug and vehicle groups. --- = period of daily treatments.
--- = period of withdrawal. Brain and plasma values come from
6-8 mice (Karler et al. 1982). © 1982, Springer-Verlag.
The activities of the drugs were assessed in three different elec-
troconvulsive threshold tests at weekly intervals. In this study,
the effects of delta-9-tetrahydrocannabinol (THC) were compared
with those of cannabidiol (CBD), another major constituent of
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marijuana. Both drugs have previously been extensively investi-
gated for their acute anticonvulsant properties (Karler et al.
1974; Turkanis et al. 1974). Phenytoin (PHT) was included as a
standard anticonvulsant drug in these tests. The results from the
THC study are shown in figure 1. As can be seen, THC acutely (day
1) raises both the 6-Hz (6-Hz-EST) and maximal electroshock
thresholds (MEST); but the identical dose decreases the threshold
for convulsions in the 60-Hz-electroshock threshold (60-Hz-EST)
test. With repeated treatment, however, tolerance developed to
all three effects. Similar results were obtained for another pro-
convulsant effect not shown in figure 1; that is, THC acutely can
lower the minimal seizure threshold to pentylenetetrazol (PTZ)
and, here again, tolerance develops to that effect. In summary,
in two seizure tests in which THC is anticonvulsant and in two
tests in which it is proconvulsant, tolerance develops. That the
tolerance is cellular in nature rather than metabolic is evidenced
by the brain concentrations of THC which remained unchanged at the
test times throughout the experiment.
FIGURE 2. Repeated CBD treatment (120 mg/kg): ESTs and brain- and
plasma-drug concentrations. On day 1 only 6-HZ-EST and MST vehi-
cle-control values were significantly different from CBD-treated
groups. See figure 1 for details. © 1982, Springer-Verlag.
The data shown in figure 2 are the results of an experimental
design identical to that used to generate the data in figure 1,
except that CBD rather than THC was administered daily. There are
some striking differences in the results. First, acutely (on day
1), CBD has no apparent activity on the 60-Hz-EST, although, like
THC, it raises the thresholds on both the 6-Hz-EST and the MEST.
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In the 6-HZ-EST, however, daily treatment resulted in a progres-
sive increase rather than the decrease in activity found in the
THC study. In contrast, tolerance developed on the MEST as it did
for THC. Although there was no CBD effect initially on the 60-Hz-
EST, after one week, activity was evident, and thereafter appeared
to increase progressively. Again, as in the case of THC, the
changes in the activity of CBD were independent of any changes in
brain-drug concentration, which remained relatively constant at
the various test times.
The data from the CBD experiment clearly illustrate that the can-
nabinoids have the potential of producing auxoesthesia, as well as
tolerance, with repeated treatment. The development of tolerance
in one of the tests of CNS excitability demonstrates that under
identical conditions quantitatively opposite changes in drug sen-
sitivity can occur simultaneously. These data emphasize the
necessity of identifying the specific effect when repeated treat-
ment results in a pharmacodynamic change. A priori, there is no
reason to assume, for example, that, if tolerance develops to one
effect, tolerance will generalize to other effects (except in the
case of a metabolic type of tolerance); therefore, to state simply
that tolerance develops to a drug may be an inappropriate descrip-
tion of the consequences of repeated treatment on some effects.
The CBD results also raise a point in relation to the general
characteristics of effects to which increased vs. decreased re-
sponsiveness develops with repeated treatment. Tolerance has
generally been associated with depressant effects, such as the
depressant effects of the opiates, the barbiturates and alcohol.
A simplistic explanation of tolerance to a CNS depressant effect
is that the nervous system compensates for the effect, thereby
diminishing drug potency. The withdrawal hyperexcitation as-
sociated with CNS depressant drugs can be construed to support the
concept that these agents elicit compensatory excitatory re-
sponses. On the other hand, auxoesthesia has generally been ob-
served with excitatory effects; for example, the production of
seizures by subconvulsant doses of convulsant drugs such as PTZ
(Mason and Cooper 1972), and the increase in motor stimulant
activity of morphine, cocaine and amphetamine (Shuster et al.
1975; Shuster et al. 1977; Segal and Mandell 1974). Because many
drugs, like the cannabinoids, produce both depressant and excita-
tory effects, the influence of repeated treatment on a specific
effect may depend upon whether the effect is excitatory or depres-
sant. With respect to the cannabinoids, Fried (1977) surveyed the
literature and concluded that tolerance developed to THC's depres-
sant effects and an increase in sensitivity developed to its exci-
tatory effects. The threshold data described above for THC, how-
ever, do not fit this pattern, because tolerance developed to both
anticonvulsant and proconvulsant effects. Furthermore, the
hypothesis is not supported by the CBD data which illustrate that
increases in drug sensitivity can develop to anticonvulsant or
depressant effects. The notion that chronic treatment results in
apposite quantitative responses to depressant and excitatory ef-
fects does not appear to be valid, at least not for the
cannabinoids.
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FIGURE 3. Repeated PHT treatment (7 mg/kg): ESTs and brain- and
plasma-drug concentrations. On day 1 only 6-HZ-EST and MEST vehi-
cle-control values were significantly different from PHT-treated
groups. See figure 1 for details. © 1982, Springer-Verlag.
The data shown in figure 3 represent the results obtained for PHT
under conditions identical to those in the experiments of figures
1 and 2. The PHT results differ from those of THC and CBD in that
there is no change in the drug's activity in 6-HZ-EST. Like CBD,
there is an increase in activity in the 60-Hz-EST and, like THC
and CBD, tolerance developed in the MEST test. As in the THC and
CBD experiments, the PHT results were independent of any change in
brain-drug concentration.
The PHT data illustrate that all three possibilities resulting
from repeated treatment can occur simultaneously: that is, toler-
ance, no change in activity and auxoesthesia. Here again, the re-
sults emphasize the hazard of generalizing from one chronic effect
of a drug to other chronic effects. In addition, the enhanced
anticonvulsant efficacy of PHT in one test reinforces the CBD ob-
servation that an increase in drug activity can occur in response
to a depressant effect, or that such reactions are not necessarily
the domain of excitatory phenomena.
The PHT data also raise the question: How common is the develop-
ment of auxoesthesia with chronic drug treatment? Although PHT
has been investigated extensively for about fifty years, the
failure of others to observe this phenomenon earlier is
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noteworthy. This failure probably relates to the almost complete
absence of chronic studies with PHT, even though clinically the
drug is used chronically. Studies of the influence of chronic
treatment on the pharmacodynamics of many drugs are lacking, and
the PHT data suggest that enhanced drug responsiveness with re-
peated treatment maybe a more widespread phenomenon than hitherto
recognized.
INTERACTION OF THC ON KINDLING REACTIONS
We have approached the study of auxoesthesia with the use of kin-
dling as a potential model for this type of reaction. The term
kindling was first introduced by Goddard et al. (1969), who ob-
served that repeated electrical stimulation of the brain with a
subconvulsant stimulus could ultimately elicit convulsions. In
other words, the sensitivity of the nervous system to the stimulus
increased with repeated application of the stimulus. Subsequently,
chemical kindling to convulsions was demonstrated with the daily
administration of subconvulsant doses of such drugs as PTZ (Mason
and Cooper 1972). Conceivably, the development of increased re-
sponsivity to a drug or stimulus could be affected by drug inter-
actions. Starting with this hypothesis, we tested the influence of
THC treatment on electrical and chemical kindling to convulsions.
0 2 4 6 8 10 12 14 16
DAYS
FIGURE 4. THC effects on electrical kindling to minimal convul-
sions. 3 Groups of 25 mice were given THC or vehicle (i.p.) every
other day for 13 days; at peak brain concentration (2 hr), cor-
neal electroshock-kindling stimulus (2 sec, 3.5 mA, 60 Hz) was
given. After day 13, drug withdrawn; on day 16, electroshock only.
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The results in figure 4 represent the interaction of THC with
electrical kindling. Here we see that high doses enhance the
development of convulsions, whereas low doses retard the phenome-
non. The persistence of the drug-caused enhancement of kindling
after cannabinoid withdrawal suggests that the interaction is a
true effect on the kindling process as opposed to a readily re-
versible effect on the convulsive activity of the electrical stim-
ulus. The complexity of the THC interaction with electrical stim-
ulation is illustrated by the opposite low- and high-dose effects
of the drug on the development of seizures.
FIGURE 5. THC effects on PTZ kindling to minimal convulsions.
3 Groups of 25 mice were given THC or vehicle (i.p.) every 3rd
day for 16 days; at peak brain concentration (2 hr), PTZ kind-
ling stimulus (40 mg/kg, s.c.) was given. After day 16, drug
withdrawn; on day 23, kindling stimulus only.
The ability of THC to enhance kindling to chemical stimuli is
shown in figures 5 and 6. Figure 5 shows that THC augments the
development of convulsions to PTZ and, like the results fran the
electrical experiment, the enhancement persisted after cannabinoid
withdrawal. Figure 6 depicts the influence of THC on kindling by
picrotoxin. In this instance, the interaction appears to be
fundamentally different from that observed in the electrical and
PTZ studies because, after cannabinoid withdrawal, there was no
persistence of the convulsions associated with the THC treatment.
The rapidly reversible nature of the interaction argues against a
true effect on kindling, which is known to be be a long-lived phe-
nanenon (Racine 1978; Sangdee et al. 1982).
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The diversity of results from the study of THC's interactions with
the various kindling stimuli illustrates that the drug-caused
increase in sensitivity to convulsions appears to be a relatively
selective, rather than a generalized, effect. This conclusion is
based on the failure of THC to promote kindling to picrotoxin.
FIGURE 6. THC effects on picrotoxin kindling to minimal convul-
sions. 3 Groups of 25 mice were given THC or vehicle (i.p.) once
daily, 5 days/week for 2 weeks; at peak brain concentration
(2 hr), picrotoxin-kindling stimulus (1 mg/kg, s.c.) was given.
After day 14, drug withdrawn; on day 16, kindling stimulus only.
Supporting evidence for the selectivity in the drug interaction
was observed in other experiments in which we demonstrated that
subconvulsant doses of PTZ do not affect the development of con-
vulsions to an electrical stimulus (unpublished data). This
failure of PTZ was surprising because it is a convulsant drug,
which suggests that the mechanism of PTZ kindling is different
fran that of electrical kindling. This conclusion is further
strengthened by our observation that animals electrically kindled
to minimal convulsions do not show cross-sensitivity to PTZ-
induced minimal convulsions (unpublished data).
If kindling represents a valid model for the study of auxoesthetic
reactions in general, then the present data suggest that THC may
augment the development of the phenomenon to some drugs but not to
others. The ability of THC to enhance these reactions represents
a toxic potential of the drug that has not yet been investigated.
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CONCLUSIONS
Classically, repeated exposure to drugs has been viewed pharmaco-
dynamically in terms of only two alternatives, either tolerance or
no change in sensitivity. The data presented above, however,
serve to reinforce the evidence that suggests that the con-
sequences of repeated drug exposure may also include auxoesthesia
or an increase in sensitivity. The frequency of the occurrence of
auxoesthesia in pharmacology is not known. To date many such re-
ported phenomena have involved drugs of abuse, such as amphetamine
(Segal and Mandell 1974), cocaine (Shuster et al. 1977), morphine
(Shuster et al. 1975), PCP (Smith et al. 1981) and alcohol (Pinel
and Van Oot 1976). In general, the observed effect is an increase
in locomotor activity with repeated drug exposure; the extent to
which other effects are involved is also unknown. In addition,
the significance of auxoesthesia to the pharmacology of drugs of
abuse is not clear, but some ideas have been proposed (Post et al.
1976). Our ignorance, in part, reflects the paucity of informa-
tion available on the phenomenon; nevertheless, because auxoesthe-
sia has been described for a number of drugs of abuse, it should
be considered in our attempts to understand the pharmacology of
these substances.
There are many questions about auxoesthesia that should be ad-
dressed. To wit: What is the relationship of this response to
dose and to the frequency and duration of exposure? How
persistent and how generalized are these adaptations of the CNS?
Can concomitant drug exposure influence the development of auxoes-
thesia? Is there a relationship between the development of toler-
ance and auxoesthesia? These are but a few of the questions that
need to be answered in order to appreciate the significance of
this phenomenon.
The data here presented on the cannabinoids represent only a
beginninq of the description of the characteristics of auxoesthe-
sia as related to these drugs. Specifically, within the context
of the limited number of drugs and effects observed, both toler-
ance and auxoesthesia can develop and these can exist simultane-
ously. The data indicate that to describe properly the influence
of chronic treatment on the pharmacodynamics of the cannabinoids,
both the specific drug and the effect must be identified. The
changes, for example, do not generalize either to all cannabinoids
or to all effects. Finally, THC's enhancement of kindling reac-
tions raises the possibility that the use of marijuana may
adversely interact with some environmental or pathological or
pharmacological factors to result in the very long-lasting changes
in CNS excitability characteristic of kindling (Racine 1978;
Sangdee et al. 1982). To illustrate, the development of some
types of human epilepsy, especially the posttraumatic type, appear
to be kindling-like, which raises the possibility that marijuana
use in such individuals may increase their liability for epilepsy.
The THC potential to interact with other drugs is supported by the
observation that the cannabinoid enhances PTZ kindling; in addi-
tion, others have reported that THC can also augment the motor-
stimulant activity of amphetamine (Garriott et al. 1967) and of
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morphine (Ayhan et al. 1979). Such drug interactions deserve
further investigation, especially among the drugs of abuse because
many of them have been reported to produce auxoesthesia and many
of them are used concomitantly.
REFERENCES
Ayhan, I.H., Kaymakcalan, S., and Tulunay, F.C. Interaction
between delta-9-tetrahydrocannabinol and morphine and the motor
activity of mice. Psychopharmacol, 63:169-172, 1979.
Fried, P.A. Behavioral and electroencephalographic correlates of
the chronic use of marijuana--A review. Behav Biol, 21:163-
196, 1977.
Garriott, J.C., King, L.J., Fomey, R.B., and Hughes, F.W. Ef-
fects of some tetrahydrocannabinols on hexobarbital sleeping
time and amphetamine induced hyperactivity in mice. Life Sci;
6:2119-2128, 1967.
Goddard, G.V., McIntyre, D.C., and Leech, C.K. A permanent change
in brain function resulting from daily electrical stimulation.
Exp Neurol, 25:295-330, 1969.
Karler, R., Cely, W., and Turkanis, S.A. Anticonvulsant proper-
ties of delta-9-tetrahydrocannabinol and other cannabinoids.
Life Sci, 15:931-947, 1974.
Karler, R., Borys, H.K., and Turkanis, S.A. Influence of 22-day
treatment on the anticonvulsant properties of cannabinoids.
Naunyn-Schmiedebergs Arch Pharmacol, 320:105-109, 1982.
Mason, C.R., and Cooper, R.M. A permanent change in convulsive
threshold in normal and brain-damaged rats with repeated small
doses of pentylenetetrazol. Epilepsia, 13:663-674, 1972.
Pinel, J.P.J., and Van Oot, P.H. Generality of the kindling phe-
nomenon: Some clinical implications. In: Wada, J.A., ed.
Kindling. New York: Raven-Press, 1976. pp. 151-171
Post, R.M.. and Kopanda. R.T. Cocaine, kindling, and reverse tol-
erance. Lancet, 1:409-410, 1975.
Post, R.M., Kopanda, R.T., and Black, K.E. Progressive effects of
cocaine on behavior and central amine metabolism in rhesus
monkeys: Relationship to kindling and psychosis. Biol
Psychiatry, 11:403-419, 1976.
Racine, R. Kindling: The first decade. Neurosurgery, 3:234-252,
1978.
Sangdee, P., Turkanis, S.A., and Karler, R. Kindling-like effect
induced by repeated corneal electroshock in mice. Epilepsia,
23:471-479, 1982.
Segal, D.S., and Mandell, A.J. Long-term administration of d-am-
phetamine: Progressive augmentation of motor activity and
stereotype. Pharmacol Biochem Behav, 2:249-255, 1974.
Shuster, L., Webster, G.W., and Yu, G. Increased running response
to morphine in morphine-pretreated mice. J Pharmacol Exp Ther,
192:64-72, 1975.
Shuster, L., Yu, G., and Bates, A. Sensitization to cocaine
stimulation in mice. Psychopharmacology, 52:185-190, 1977.
321
Smith, R.C., Leelavathi, D.E., Hsu, L., Ho, B.T., Tansey, W.,
Taylor, D., and Biggs, C. Acute versus chronic administration
of phencyclidine: Effects on behavior and brain biochemistry.
In: Domino, E.F., ed. PCP (Phencyclidine) Historical and Cur-
rent Perspective. Ann Arbor: NPP Books, 1981. pp. 243-291.
Tatum, A.L., and Seevers, M.H. Experimental cocaine addiction. J
Pharmacol Exp Ther, 36:401-410, 1929.
Turkanis, S.A., Cely, W., Olsen, D.M., and Karler, R. Anticonvul-
sant properties of cannabidiol. Res Commun Chem Pathol
Pharmacol, 8:231-246, 1974.
ACKNOWLEDGEMENT
This research was supported by research grant DA-00346 from the
National Institute on Drug Abuse. Dr. Monique C. Braude, NIDA
Division of Preclinical Research, served as Project Officer.
AUTHORS
Ralph Karler, Ph.D.
Larry D. Calder, B.S.
Stuart A. Turkanis, Ph.D.
Department of Pharmacology
University of Utah School of Medicine
Salt Lake City, UT 84132
322
Catecholamine-Independent
Behavioral and Neurochemical
Effects of Cocaine in Rats
Karen Gale
Classically, the mechanism of action of cocaine has been attrib-
uted to the augmentation of catecholamine neurotransmission.
Many of the acute and chronic effects of cocaine administration
on the CNS, and consequently on behavior, have been ascribed to
such an enhancement of norepinephrine- and/or dopamine-mediated
function. However, data has recently begun to accumulate indi-
cating that cocaine may influence certain behaviors, both acute-
ly and chronically, by mechanisms that do not involve stimula-
tion of either dopaminergic or adrenergic receptors. The
present report will describe some actions of cocaine on behavior
and neurochemistry in rats that cannot be blocked or attenuated
by catecholaminergic receptor antagonists: (1) behavioral
sensitization produced by repeated administration of cocaine,
(2) changes in GABA-related neurochemical parameters in the
striatum of rats treated chronically with cocaine, and (3)
cocaine-induced conditioned taste aversions.
Behavioral Sensitization Following Chronic Cocaine Treatment
Repeated administration of cocaine in rats consistently has been
found to result in “sensitization” to the motor stimulant
act ions of this drug (Downs and Eddy 1932; Tatum and Seevers
1929; Post and Rose 1976; Stripling and Ellinwood 1976; Post et
al. 1981). Activation of dopaminergic transmission is an
essential feature of the stereotyped hyperactivity induced by
cocaine, since drugs that block dopamine receptors can prevent
the appearance of these behaviors in both naive as well as in
“sensitized” animals The experiments to be described here were.
designed to determine firstly, whether the blockade of dopamine
receptors could prevent the sensitization to cocaine, and
secondly, whether animals sensitized to cocaine would also show
sensitization to a directly-acting dopamine receptor agonist.
In our studies, cocaine was administered subcutaneously to 250
gram rats; each rat received 0.1 ml of a 400 mg/ml solution.
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This route of administration results in a slow rate of absorp-
tion due to the vasoconstrictive action of cocaine. By 30 min
after injection, the cocaine-treated rats showed hyperactivity
and sympathomimetic activation; this increased in intensity to a
peak (stereotyped head movements and some gnawing) by 90 min.
The stereotypies were maintained for 8-10 hr after a single
injection. Injections were given daily for 10 days. After the
last injection, rats were tested for behavioral responses to
cocaine or apomorphine.
The chronic treatment groups were as follows:
(1) cocaine
(3) droperidol
(2) cocaine + droperidol (given simultaneously)
(4) saline
Droperidol was selected as the dopamine antagonist for this
study because its short half-life made it possible to match the
duration of action with the duration of the cocaine stimulation.
The treatment regimen involved giving droperidol (1 mg/kg i.p.)
twice a day, 3 hr apart. This resulted in noticeable cata-
lepsy--even in those animals receiving cocaine concurrently; the
catalepsy lasted for approximately 3 hr after each droperidol
injection. In rats receiving cocaine and droperidol simultane-
ously, no stereotypy or hyperactivity of any kind was observed.
Three days following the last drug treatment, the rats were
tested for their behavioral responses to cocaine (20 mg/kg i.p.)
or apomorphine (.25 mg/kg s.c.). The scale used to rate the
stereotyped behavior is shown in the legend to table 1.
Table 1 shows the behavioral scores of the animals after the
challenge dose of cocaine, as a function of time following
inject ion. A marked difference between “controls” (rats that
received chronic injections of saline) and the “chronic cocaine”
group is evident: all rats in the “chronic cocaine” group
showed restricted stereotypies with gnawing during the first 30
min. Controls engaged in locomotor activity with some rearing
and sniffing. This difference reflects the phenomenon of
“sensitization” to the motor stimulant effects of the drug.
Although not shown in table 1, we found that animals showing
sensitization to cocaine also exhibited enhanced hyperactivity
in response to d-amphetamine.
The rats which had been receiving chronic droperidol + cocaine
simultaneously were similar to those receiving cocaine alone.
The behavior of these rats was clearly distinguishable from both
“control” and “chronic droperidol” groups.
Thus, despite the fact that concurrent treatment with droperidol
prevented the behavioral manifestations of cocaine administra-
tion, this treatment did not prevent the development of “sensi-
tization” to a subsequent cocaine challenge. This indicates
that the acute psychomotor stimulant actions of cocaine and the
changes in drug sensitivity caused by its chronic administration
are separable phenomena.
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TABLE 1
Stereotyped behavior induced by cocaine (20 mg/kg i.p.)
in rats treated chronically with cocaine and/or droperi-
dol
Chronic Treatment Time After Cocaine (min)
10 20 3 0
control 2.0 2.0† 2.0
droperidol 2.0 3.0† 2.5
cocaine 4.6 5.5† 3.2
cocaine + droperidol 3.6 4.0 5.0†
Values represent behavioral ratings based on the
following scoring scale: 0 = little or no activity--
occasional grooming; 1 = intermittent rearing and
exploratory activity; 2 q continuous activity involving
locomotion, rearing and sniffing; 3 = repetitive
sniffing of cage walls or floors; 4 = repetitive head
movements and restricted sniffing of small areas of the
cage; 5 = continuous sniffing with discontinuous gnawing
or licking; 6 = gnawing with occasional sniffing;
7 = continuous gnawing; 8 q self-directed gnawing.
Each value represents the mean of 4 rats. The range of
scores for any given determination was not greater than
1 unit on either side of the mean; at peak effect, the
largest difference between any 2 rats was 1 scoring
unit. † Denotes peak effect.
The behavioral scores of the chronic treatment groups in
response to apomorphine are shown in table 2. The control rats
showed marked stereotypies in response to apomorphine. In con-
trast, the rats which had been chronically exposed to cocaine
showed only mild stereotyped responses which were of short dura-
tion. Rats in the chronic droperidol’ group were similar to
controls in their response to the apomorphine challenge, except
that many of them exhibited restricted gnawing behavior during
the peak effect. The groups of rats that had been chronically
treated with the combination of cocaine and droperidol were
similar to controls in their response to apomorphine.
Thus, it appears that exposure to chronic cocaine causes a
reduction in the subsequent responsiveness to the behavioral
stimulant actions of apomorphine. We have since replicated this
study using additional test doses of apomorphine (.17-.4 mg/kg)
and found that the dose-response relationship was shifted to the
right in animals which had received chronic cocaine. This
apparent tolerance to apomorphine was prevented by concurrent
droperidol treatment, suggesting that it may be mediated by
stimulation of dopamine receptors.
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TABLE 2
Stereotyped behavior (scored as described in table 1)
induced by apomorphine (0.25 mg/kg s.c.) in rats treated
chronically with cocaine and/or droperidol.
Chronic Treatment Time After Apomorphine (min)
10 20 30
control 2.0 4.4† 1.2
droperidol 2.5 5.5† 1.8
cocaine 2.5† 2.0 0.0
cocaine + droperidol 3.8 4.0† 0.5
The range of scores within each group at each time point
was within 1 scoring unit. † Denotes peak effect.
The two aspects of this study, taken together, raise some inter-
esting points. First, the same treatment--namely, chronic
cocaine--which caused “sensitization” to cocaine, caused “desen-
sitization” or tolerance to apomorphine. Second, chronic treat-
ment with a dopamine receptor antagonist which is also, inci-
dentally, an alpha-adrenergic receptor antagonist, blocked the
development of tolerance to apomorphine but not the development
of sensitization to cocaine. This suggests that at least two
different phenomena are taking place in response to repeated,
prolonged exposure to cocaine: (1) chronic stimulation of dopa-
mine transmission, leading to an eventual decrease in the sensi-
tivity of the dopamine receptors (or changes in other neural
links in series with dopamine-receptive cells), and (2) altera-
tions in parameters independent of dopamine and alpha-adrenergic
receptors, which augment the sensitivity of the system to
cocaine. In addition, it is noteworthy that the presence of the
chronic behavioral stimulation is not required for the develop-
ment of sensitization to cocaine.
Changes in CABA Synthesis and GABA Receptors in Striatum Follow-
ing Chronic Cocaine Treatment
Measurements of GABA-related neurochemical parameters were made
in the striatum of rats treated chronically with cocaine and/or
droperidol. The striatum was examined because of its known
involvement in the generation of dopamine-related stereotyped
behavior; GABAergic parameters were examined because of the
importance of GABAergic interneurons in striatum and the fact
that GABA synthesis in this region has been previously shown to
change in response to chronic interference with dopamine trans-
mission (Gale and Casu 1981).
Table 3 shows the activity of glutamic acid decarboxylase (GAD),
the enzyme responsible for GABA synthesis, in rats that had been
chronically treated in the exact manner as described for the
behavioral studies. A significant increase in GAD activity in
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striatum was seen in rats in the 'chronic cocaine' group; this
effect was still present in rats that had received concurrent
treatment with droperidol. The increase in GAD activity was
still observed 10 days after cessation of chronic treatment.
Studies are now in progress to determine the time course of
recovery. It should be noted that the behavioral ‘sensitiza-
tion’ to cocaine that we have described is still present at 10
days after stopping chronic treatment.
TABLE 3
Glutamic acid decarboxylase activity (GAD) in rat
striatum after chronic cocaine administration
GAD Activity
Chronic Treatment (n) umol/mg prot/hr % Control
control (12) .35 ± .02
cocaine (10) .50 ± .03* 143%
cocaine + droperidol (8) .48 ± .03* 137%
droperidol (6) .31 ± .03
10 days after
chronic cocaine (8) .43 ± .04* 123%
*Significantly different from control p < .05
GAD activity was measured in tissue homogenates, in the
presence of saturating concentrations of substrate
(glutamate) and cofactor (pyridoxal phosphate), based on
the method of Sims and Pitts (1970). See text for
details of experimental design.
Table 4 shows the effect of the chronic cocaine treatment on the
rate of striatal GABA accumulation in vivo following irreversi-
ble inhibition of GABA degradation. This gives us an indication
of GABA turnover. The GABA-transaminase inhibitor, gamma-vinyl-
GABA (GVG) was injected directly into the striatum and the
accumulation of GABA was measured at 3 hr. The net GABA accumu-
lation in striata of rats that had been chronically exposed to
cocaine was significantly greater than that of controls. No
change in steady-state levels of GABA was found. This suggests
that chronic exposure to cocaine results in an enhanced turnover
rate of GABA in striatum, an observation consistent with our
finding of increased GAD activity in striatal homogenates.
The effect of chronic cocaine exposure on GABA binding in stria-
tum is shown in table 5. It can be seen that a significant
decrease in GABA binding in striatum was associated with chronic
cocaine treatment. This effect was not prevented by concurrent
treatment with droperidol. As in the case of GAD, the change in
GABA binding was still present at 10 days following cessation of
cocaine treatment.
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TABLE 4
Effect of chronic cocaine administration on accumulation
of GABA in viva in striatum.
Chronic
Treatment
GABA (nmol/mg prot)
3 hr Net
Basal After GVG Increase % Control
control 24.0 ± 0.4 77.2 ± 2.0 53
cocaine 24.5 ± 0.5 97.4 ± 3.8* 73
*Significantly different from control p < .05
138%
GABA accumulation was measured 3 hr after the microin-
jection of gamma-vinyl-GABA (GVG, 20 ug) into striatum.
Basal values are those obtained from tissue not treated
with GVG. Each value is the mean ± S.E. of 5 rats.
TABLE 5
Specific [3H]-GABA binding in rat striatum after chronic
cocaine administration
[3H]-GABA Binding
Chronic Treatment (n) fmol/mg prot % Control
control (12) 424 ± 30
cocaine (10) 301 ± 25* 71%
cocaine + droperidol (8)
(6)
288 ± 29* 68%
droperidol 373 ± 35
10 days after
chronic cocaine (8) 350 ± 32* 83%
*Significantly different from control p < .05
Binding was done in the presence of 80-120 ug membrane
protein, 30 nM [3H]GABA, at 0°C in a Na+-free medium;
binding in the presence of 10 mM nonradioactive GABA was
subtracted from total binding to calculate specific
binding. Membranes were prepared by freeze-thawing,
Triton-X 100 incubation (.01% at 37°C for 60 min) and
extensive washing.
To determine whether the changes in GABA binding and GAD activ-
ity represented a general response of GABAergic synapses to
prolonged cocaine treatment, cerebellum and cerebral cortex of
the same rats were examined for these parameters. No signifi-
cant changes in GAD or GABA binding were found in neocortex or
cerebellum. This suggests that the changes in GABAergic param-
eters observed in the striatum of rats exposed chronically to
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cocaine represent adjustments which may be specifically related
to the neural circuitry of this nucleus. In view of these
results, it is unlikely that cocaine exerts a direct effect on
GABAergic transmission.
Cocaine-Induced Conditioned Taste Aversion
We have also obtained evidence for acute actions of cocaine that
are insensitive to dopaminergic and/or adrenergic blockade using
a conditioned taste aversion paradigm. Since the reinforcing
properties of cocaine have been demonstrated to depend upon
central dopaminergic and possibly noradrenergic transmission
(Gill et al. 1978; Wilson and Schuster 1972), we were inter-
ested in determining whether aversive properties of cocaine
would be mediated by the same neurotransmitter systems. In
these experiments, rats were trained to drink water for one 20
min session each day. On the first day of drug exposure, the
rats received saccharin instead of water, and 20 min following
the drinking session drugs were administered.
Cocaine was administered subcutaneously as it had been for the
chronic studies previously described. In addition to cocaine,
separate groups of rats received one of the following dopamine
and/or adrenergic antagonists: haloperidol (1 mg/kg), chlor-
promazine (20 mg/kg), pimozide (1 mg/kg), or propranolol
(5 mg/kg). An additional group that received both chlorproma-
zine and propranolol in addition to cocaine was also examined.
In this way, we were able to completely block all hyperactivity,
stereotypy and/or sympathomimetic stimulation due to cocaine for
the entire duration (approximately 8 hr) of the cocaine effect.
The antagonist drugs, under our experimental conditions, did not
by themselves cause conditioned taste aversion. Cocaine admin-
istration caused a marked taste aversion, which was evident on
the first post-drug saccharin exposure (saccharin test 1)
initiated 4 or 5 days after the first saccharin exposure. The
rats that had received cocaine following the pre-drug saccharin
exposure showed a 50-60% decrease in saccharin intake on the
first saccharin test (table 6). No change in saccharin con-
sumption was seen in controls and in rats receiving the dopamine
and noradrenergic antagonists without cocaine. None of the
antagonists, or antagonist combinations, when administered
concurrently with cocaine, were able to prevent or attenuate the
taste aversion produced by exposure to cocaine. It should be
noted that the dose of cocaine used to produce the taste
aversions was equivalent to only twice the minimum dose neces-
sary for causing a significant (but submaximal) decrease in
saccharin consumption. Thus, it should have been sensitive to
alteration by antagonists if the antagonists acted on a system
involved in mediating the aversion produced by cocaine.
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TABLE 6
Cocaine-induced conditioned taste aversions: Effect of
dopaminergic and adrenergic antagonists
Saccharin Consumption: % Control
1† 2†
control
cocaine
chlorpromazine
propranolol
propranolol + cocaine
chlorpromazine + propranolol
chlorpromazine + propranolol +
cocaine
haloperidol
pimozide
pimozide + cocaine
100%
50%
105%
90%
53%
92%
45%
110%
90%
59%
100%
20%
98%
93%
21%
85%
10%
105%
95%
25%
† 1 = first (2 = second) saccharin test session.
Each group contained 4 or 5 rats, matched for initial
(pre-drug) saccharin consumption. Standard errors of
the mean saccharin consumption for each exposure were
less than 20% of the mean value. Control saccharin
consumption = 25 ml on test session 1 and 23 ml on test
session 2. All tests involved access to a single bottle
of saccharin only.
To determine whether the cocaine-induced taste aversions were
related to the local anesthetic action of cocaine, we tested a
group of animals with equivalent doses of lidocaine in combina-
tion with epinephrine (the epinephrine was included to simulate
the local vasoconstrictive action of the cocaine injections).
This treatment resulted in no measurable change in subsequent
saccharin consumption, indicating that local anesthetic actions
per se are not responsible for the taste aversions produced by
cocaine.
Thus, it appears that the conditioned taste aversion that
develops with cocaine is mediated by a system other than one
containing catecholamines. While blockade of catecholaminergic
transmission eliminated all behavioral signs of motor and auto-
nomic stimulation induced by cocaine, the aversive character-
istics of the exposure to cocaine were not altered. Since the
reinforcing properties of cocaine can be eliminated by blockade
of central dopaminergic transmission, it appears that the
reinforcing and aversive properties are mediated by distinctly
different neurotransmitter systems. We have yet to identify the
system responsible for the aversive characteristics of cocaine.
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Discussion
We have seen several instances in which cocaine-induced effects,
either chronic or acute, are obtained despite blockade of
noradrenergic and dopaminergic transmission. Evidently, there
are one or more noncatecholaminergic neurotransmitter systems
with which cocaine can interact directly in order to induce
these effects. At present, we do not know whether the relevant
system or systems even involve known neurotransmitters; it is
possible that the neuromodulator mediating some of these actions
has yet to be described. In this context, the findings of
Sershen, Reith and Lajtha (1980) are of interest. These authors
have described a binding site for [3H]cocaine in brain tissue
which appears to be related to central stimulatory actions of
cocaine (as opposed to local anesthetic actions). The binding
of cocaine to this site was relatively insensitive to displace-
ment by classical neurotransmitters such as dopamine, norepi-
nephrine, acetylcholine, serotonin and GABA or receptor antago-
nists for these neurotransmitters (Reith et al. 1980a). These
same authors have found that a low molecular weight peptide
extracted from brain homogenates is capable of inhibiting the
saturable binding of cocaine to crude mouse brain membranes
(Reith et al. 1980b). Thus, it is possible that cocaine may
interact with receptors for a yet-to-be-identified neuroactive
peptide. It is interesting that while no loss of these cocaine
binding sites occurred following lesions of dopamine neurons, at
least a portion of these binding sites appeared to be associated
with terminals of serotonergic neurons (Reith et al. 1983).
Thus, even if cocaine may exert some of its actions via unchar-
acterized receptors, it is likely that one or more classical
transmitter substances may indirectly mediate these effects. It
will therefore be worthwhile examining the ability of agonists
and antagonists of serotonin and other noncatecholaminergic
neurotransmitters to prevent the development of cocaine-induced
sensitization, conditioned taste aversions, and/or changes in
striatal GABA utilization. In addition, by examining different
cocaine analogs for their ability to elicit catecholamine-
independent actions, we may be able to determine: (1) whether
the different catecholamine-independent actions are correlated
with each other (in terms of relative potencies of cocaine
analogs), and (2) whether any of the cocaine-induced effects
that are catecholamine-independent are related to the cocaine
binding site described by Reith et al. (1980).
By pursuing this line of investigation, we may find that the
classical actions of cocaine as an uptake inhibitor for cate-
cholamines represent only a small part of the mechanism by which
this drug can have an impact on central nervous system function,
in the context of both short-term and long-term exposure to the
drug.
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Barbiturate Tolerance and
Physical Dependence: Contribu-
tion of Pharmacological Factors
Michiko Okamoto
INTRODUCTION
Sedative-hypnotics and anti-anxiety drugs comprise a large group of
chemically different compounds that are classified pharmacologically
as CNS depressants. These compounds manifest a spectrum of effects
ranging from calming and sedative activity through profound CNS
depression, manifested as anesthesia, coma and respiratory paral-
ysis, and finally death. For the most part, the acute effects
exhibited by individual compounds are nonspecific, and any selec-
tivity, in terms of the clinical indications for which an individ-
ual compound is used, is conferred by (1) the dose and schedule of
administration, (2) the slope of the dose-response curve along the
continuum of CNS depression, and (3) the pharmacokinetic profile of
the compound. Therefore, a clear understanding of these pharmaco-
logic properties is essential to the appropriate selection of a
sedative-hypnotic or anti-anxiety drug for therapeutic use.
Since the introduction of sodium barbital into clinical medicine in
1903, considerable effort has been devoted to identifying and
understanding the risks associated with both acute and chronic
administration of sedative-hypnotics. Although all of these drugs
have similar acute effects, there is no question that abuse among
this class of drugs differs, and so do the risks. For example, the
large number of deaths each year from overdose of self-administered
barbiturates attests to the narrow margin of safety of these
drugs. On the other hand, the more widely available benzodiaz-
epines rarely cause death from overdose unless they are used in
combination with other sedative-hypnotics.
Despite these differences, all sedative-hypnotics, including non-
barbiturates, can produce tolerance, psychological and physical
dependence, and a barbiturate-like withdrawal syndrome with the
risk of convulsions when they are taken in sufficient amounts.
Thus we chose barbiturates as the prototype sedative-hypnotic to
study the underlying pharmacodynamic and pharmacokinetic factors
which govern the production of tolerance and physical dependence.
333
Clinical studies indicate that the pattern of sedative-hypnotic use
that culminates in withdrawal hyperexcitation is a prolonged period
of continuous drug intoxication. This suggests that the functional
depression of the CNS is an important factor in the development of
physical dependence. Accordingly, in designing an animal model of
sedative-hypnotic dependence, techniques for measurements of drug
response (CNS depression), in addition to measurement of dose and
frequency of drug administration throughout chronic treatment,
enable the evaluation of this factor.
Quantitative measurement of response is also essential to the
characterization of the tolerance to sedative-hypnotics which
invariably develops during their chronic administration. According
to Kalant et al. (1971), this tolerance can be dispositional (i.e.,
primarily due to an increased rate of elimination) or functional
(i.e., decreased sensitivity of the CNS to depression) or both.
The dissection of "total" tolerance into these components and the
separate characterization of their development and mechanisms can
be achieved by concurrent measurements of daily drug effect (CNS
depression) and drug load (dose and blood or brain concentration)
during chronic administration.
RESULTS
Using these techniques and pentobarbital and barbital as prototype
barbiturates, we characterized the development of functional and
dispositional tolerance during chronic barbiturate treatment in our
animal model (Okamoto and Boisse 1981). Cats were treated with Na
pentobarbital twice daily or Na barbital once every 3 days for 5
weeks. Each dose was adjusted to produce a preset peak level of
CNS depression; in this case, a light surgical anesthesia (Boisse
and Okamoto 1978a). The kinetics of barbiturate elimination were
determined once a week to monitor the dispositional component of
tolerance (Boisse and Okamoto 1978b).
The average dose required to produce the peak effect of surgical
anesthesia increased during chronic treatment for both pento-
barbital and barbital, showing the development of "total" tolerance
to both drugs (figure 1). At the beginning of treatment, the dose
of Na pentobarbital increased more rapidly than the dose of Na
barbital. Elimination kinetics showed that the half-life of
pentobarbital decreased rapidly during this initial rapid increase
in the dose of Na pentobarbital, a demonstration of the quick onset
of the development of dispositional tolerance to Na pentobarbital.
The decrease in the pentobarbital half-life was presumably due to
induction of the hepatic microsomal drug-metabolizing enzymes which
biotransform pentobarbital (Remer 1969). In contrast, the half-
life of barbital did not change during the Na barbital treatment;
thus, there was no dispositional component of tolerance to
barbital, a drug which is known to be eliminated unchanged
primarily through the kidney.
The development of the functional component of tolerance was shown
by the steady increase in the blood concentration of pentobarbital
334
FIGURE 1. Chronic pentobarbital and barbital treatments and
characteristics of tolerance in each. Ordinates: (a) average CNS
depression ratings: peak after each morning dose residual
depression just prior to subsequent dose (b) average total
CNS depression based on areas under time-action curves summed at
3-day intervals; (c) average administered dose; (d) elimination
half-life; a decrease indicates dispositional tolerance; (e)
average blood concentration at the time of peak drug response; an
increase indicates functional tolerance. Abscissa: time during
chronic treatment (Okamoto and Boisse 1981. Copyright 1981,
Elsevier Publications).
or barbital which was required to achieve the preset level of CNS
depression. Cellular tolerance increased slowly and steadily as
the treatment duration increased (figure 1, Boisse and Okamoto,
1978b). Most interestingly, when animals were treated with these
"chronically equivalent" doses (Boisse and Okamoto 1978a) of
pentobarbital and barbital (that is, doses which produce the same
peak and residual CNS depression shown in figure 1, functional
tolerance developed in a parallel fashion to pentobarbital and
barbital.
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FIGURE 2. Recovery from cellular (functional) tolerance and
dispositional tolerance after chronic Na pentobarbital treatment.
Ordinates: (A) pentobarbital concentration (ug/ml blood) that pro-
duced CNS depression ratings of 11 (surgical anesthesia), 5 (ataxia),
and 1 (loss of fine motor coordination). (B) pentobarbital elimin-
ation half-life from blood. Vertical bars indicate ± S.E. (N=6).
Abscissae: "C" stands for control, prior to chronic Na pentobar-
bital treatment, "WD" stands for day 1 of withdrawal or just after
the last dose of chronic Na pentobarbital, and numbers indicate days
after the last chronic Na pentobarbital dose (Okamoto et al.
unpublished observations).
The "reverse" of the development of functional and dispositional
tolerance, i.e., the return to normal after abrupt termination of
chronic drug administration, was also studied. To investigate
this, Na pentobarbital chronic administration was abruptly
terminated, and the pentobarbital elimination kinetics and CNS
sensitivity to a challenging dose of Na pentobarbital were evaluated
every 3 days until recovery was complete. The 3-day interval was
chosen because preliminary experiments had shown that animals
treated chronically with Na pentobarbital once every 2 days
did not develop functional or dispositional tolerance (Okamoto et
al. unpublished observations); thus, the testing procedure was not
expected to affect the processes being studied.
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FIGURE 3. Peak withdrawal intensity rating after various durations
of chronic "high" or "low" dose barbiturate treatment.
Ordinate: peak withdrawal intensity rating, mean ± S.E.
Abscissa: duration of chronic treatment in weeks. Number of
observations per point: 10 to 67 for high dose barbiturate, 8 to
19 for low dose barbiturate (Okamoto et al. 1981. Copyright 1981,
American Society for Pharmacology and Experimental Therapeutics).
Recovery from the two types of tolerance occurs after the abrupt
termination of Na pentobarbital (figure 2). These results show that
the kinetics of recovery were almost the mirror image of the induc-
tion of tolerance. Dispositional tolerance was reversed within 2
weeks. In contrast, recovery from functional tolerance was slow
and not complete at the end of the 2-week observation period.
The relationship between chronic dosing levels and the degree of
functional tolerance and physical dependence that develops is also
an important issue to be investigated. Accordingly, we compared
the development of tolerance and dependence in groups of animals
treated chronically either with a "high" or "low" dose of
barbiturate (Okamoto et al. 1978). The "high" dose group received
Na pentobarbital twice daily sufficient to produce light surgical
anesthesia (this corresponds to a CNS Depression Rating of 10-11 on
our scale). The "low" dose group received Na barbital sufficient
to produce gross ataxia (this corresponds to a CNS Depression
Rating of 5-6). Both groups were treated for 1 to 5 weeks and
groups of animals were abruptly withdrawn after treatment for
various durations to evaluate the time-course of development of
dependence. The severity of physical dependence was measured by an
overall withdrawal intensity rating system developed in our
laboratory (Okamoto et al. 1981), and the development of functional
tolerance was measured as described above.
The "low" dose produced less physical dependence than the "high"
dose after equal durations of treatment (figure 3). However,
physical dependence increased in a parallel fashion in both
treatment groups and was still increasing in the "low" dose group
after 5 weeks. Indeed, when the "low" dose treatment was further
increased to 100 days, it produced approximately the same severity
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FIGURE 4. Incidence of convulsions and total number of convulsions
per animal after various durations of chronic "low" dose barbital or
pentobarbital treatment. Abscissa: duration of chronic treatment in
weeks. Ordinates: (A) percent incidence of cats with grand mal type
convulsions during withdrawal. (B) average total number of grand
mal-type convulsions per animal during withdrawal. Vertical bars rep-
resent ± S.E. Number of observations per point: 10 to 15 animals
(Okamoto and Hinman 1984, Copyright 1984, Pergamon Press, Ltd.).
of physical dependence as had the 5 weeks of "high" dose treatment
(figure 4). These results indicate that physical dependence develops
more slowly with "low" dose barbiturate treatment, but that the same
level of dependence eventually develops if the treatment is continued
at doses sufficient to achieve a preset level of CNS depression
(Okamoto and Hinman 1984).
Another important factor to consider during chronic sedative
hypnotic treatment is the frequency of administration. This was
clearly demonstrated by Goldstein (1972) for the production of
ethanol physical dependence. The relationship between dosing
frequency and elimination determines the drug concentration at any
time. The maintenance of certain drug concentrations may be a major
factor in the development of functional tolerance and physical
dependence. Small individual differences in the half-life of drug
elimination affected the development of physical dependence to Na
pentobarbital when the drug was given on a fixed schedule (figure
5). A group of animals was treated with "high" dose Na pentobar-
bital twice a day for 5 weeks. The elimination half-life of
pentobarbital was determined for each animal on the last day of
treatment. The number of grand mal-type convulsions was tabulated
for each animal upon abrupt termimation of the drug as a measure of
withdrawal severity. The range of the half-life of pentobarbital
in these animals was 3-13 hours, and the longer the half-life, the
more severe was the physical dependence (Okamoto and Hinman 1983).
338
FIGURE 5. Relationship between pentobarbital half-life and total
number of convulsions displayed during pentobarbital withdrawal.
Abscissa: pentobarbital half-life in hours. Ordinate: total
number of convulsions displayed by each animal during the
withdrawal (Okamoto and Hinman, 1983. Copyright 1983, American
Society for Pharmacology and Experimental Therapeutics).
FIGURE 6. Relationship between the peak withdrawal intensity and
total number of "high" Na pentobarbital doses. Abscissa: total
number of Na pentobarbital doses. Ordinate: average peak with-
drawal intensity. dosed every 12 hours; dosed every 24
hours, dosed every 48 hours (Okamoto et al. unpublished
preliminary observations).
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Reducing the frequency of chronic barbiturate administration
reduces the risk of development of physical dependence. That is,
the longer the interval between doses, the less severe was the
withdrawal (figure 6). It is apparent that dosing once every 2
days produced a negligible level of physical dependence. In other
experiments, as the dosing interval exceeded 36 hours, the drug
concentration just prior to succeeding doses was below the limits
of detection ( <500 ng/ml blood; Okamoto et al., unpublished
communications). These findings underscore the importance of
adjusting dosing frequency so as not to maintain sufficient drug
levels within biological systems that would risk producing physical
dependence.
Other studies have demonstrated how critical the kinetics of
elimination of sedative-hypnotics are in understanding the
underlying state of physical dependence. Since physical dependence
can only be measured by the intensity of the withdrawal syndrome,
it is difficult to dissect the phenomena of physical dependence
from withdrawal so as to study either independently. To start
with, it has been accepted that long-acting barbiturates such as
barbital or phenobarbital are less liable to produce physical
dependence than the short-acting barbiturate drugs such as
pentobarbital or secobarbital (cf. Jaffe 1980). Also, in clinical
subjects and in animals, the onset of withdrawal was slower and its
intensity less severe in barbital dependency than in pentobarbital
dependency (Boisse and Okamoto 1978c). For example, the average
elimination half-lives of barbital and pentobarbital in these
animals were 30 and 5 hours, respectively. To determine whether
the slow rate of barbital elimination was responsible for the
slower onset of withdrawal, we experimentally "slowed" the
elimination of pentobarbital by readministering proportionally
smaller doses of pentobarbital intravenously at hourly intervals
according to a computer calculation based on first-order
elimination kinetics (Boisse and Okamoto 1978d).
The added drug effectively altered the apparent rate of
pentobarbital elimination from a half-life of 5 hours to 27 hours
(table 1). This procedure also slowed the onset of withdrawal and
dramatically reduced its severity, as indicated by the withdrawal
intensity rating and the incidence of grand mal convulsions (Boisse
and Okamoto 1978d). Additional evidence that the elimination of
the drug is critical for the expression of withdrawal signs was
obtained by experimentally increasing the rate of barbital elim-
ination to mimic that of pentobarbital. The rate of barbital
elimination was increased by peritoneal dialysis after the last
dose of chronic barbital. This procedure decreased the apparent
half-life of barbital elimination from 30 hours to 7 hours (table 1).
As a result, the barbital withdrawal signs appeared much sooner and
were markedly intensified (Boisse and Okamoto 19784).
These results support Hollister's hypothesis (1980) that the
severity of the withdrawal reaction is related to the rate of
disappearance of sedative drugs from plasma. He predicted that the
sedative-hypnotics with half-lives in the range of 12-24 hours
(e.g., pentobarbital, secobarbital, and glutethimide) will produce
the most severe withdrawal syndrome in patients.
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TABLE 1. Reconstructed from Table 3 in Boisse and Okamoto 1978d.
Copyright 1978, American Society for Pharmacology and Experimental
Therapeutics).
In contrast, drugs which have short half-lives have little
potential for producing tolerance and physical dependence because
their residual CNS concentrations at the time of successive doses
are small. There is insufficient drug to produce and maintain
functional tolerance and physical dependence. In the other
direction, drugs which have long half-lives are less likely to
result in severe withdrawal signs and symptoms despite the fact
that they produce severe physical dependence. That is, the CNS can
gradually readapt, when the drug in no longer administered, due to
the slow elimination of the drug from the CNS.
Although the behavioral aspects of sedative-hypnotic withdrawal
have been well documented, the pathophysiology of physical
dependence in terms of underlying neuronal mechanisms has not yet
been well elucidated. Barbiturate withdrawal in humans consists of
a variety of overt signs (Isbell et al. 1950); Fraser et al. 1958;
Wulff 1959) accompanied by characteristic EEG abnormalities
recorded through surface electrodes (Isbell et al., 1950; Wikler et
al. 1955; Wulff 1959). These abnormalities consist of high
amplitude slow waves, paroxysmal discharges, and spike-and-dome
activity. Interestingly, paroxysmal discharges were more prominent
during withdrawal from moderate doses of barbiturate than in
withdrawal from high doses (Wikler et al. 1955). Seizure activity
usually originated in subcortical rather than in cortical areas
(Essig 1962, 1967); Sharpless and Jaffee 1967; c.f. Kalant et al.,
1971). Although barbiturates and other sedative-hypnotics depress
all CNS activity as a function of dose, it is possible that chronic
use of these drugs affects various CNS loci differently in relation
to the chronic dose administered. Therefore further information
regarding the most sensitive site(s) and characteristics of
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FIGURE 7. EEG recordings during moderate-intensity barbiturate
withdrawal, 40 hours after last dose. Recordings are from
hippocampus (HPC) with spike-and-wave activity, amygdala (AMY) with
paroxysmal discharge, motor cortex (MC), auditory cortex (AC),
visual cortex (VC), caudate (CAU), hypothalamus (HYP), mid-brain
reticular formation (MRF), and lateral geniculate (LGB) (Hinman and
Okamoto 1984. Copyright 1984, Academic-Press).
abnormal brain activity during withdrawal, especially in
subcortical loci, is essential to understanding the mechanisms of
barbiturate tolerance and physical dependence.
To pursue this information, we have recorded electroencephalo-
grams from cortical and subcortical brain regions during
moderate-intensity barbiturate withdrawal (Hinman and Okamoto
1984). The EEG pattern showed 4-6 Hz rhythmic bursts in the hippo-
campus and visual cortex during withdrawal (figure 7). The bursts
in the hippocampus were a spike-and-wave type. In animals which
had spontaneous seizures, 4-6 Hz bursts occurred also in the motor
cortex; this motor cortex abnormality did not occur in animals
which did not have spontaneous generalized seizures. Prolonged
high frequency, high voltage discharges and spikes were also
recorded frequently from the amygdala and the LGB during withdrawal
(figure 8). Animals displayed bizarre behaviors suggestive of
hallucinations during these periods of prolonged discharges,
especially during prolonged bursts from the hippocampus and the
visual cortex (Hinman and Okamoto 1984).
In order to explore more fundamental neuronal mechanisms of the
development of tolerance and physical dependence and the neuronal
mechanisms responsible for the expression of CNS hyperexcitation
during withdrawal, electrophysiological studies of well-charac-
terized spinal cord reflexes were performed in our physically
barbiturate-dependent animals. After 5 weeks of treatment with our
standard chronic "high" dose pentobarbital regimen (Rosenberg and
Okamoto 1974; Okamoto et al. 1975), animals were prepared for
spinal cord reflex function studies 48 hours after the last dose.
Several alterations in spinal cord reflex function during
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FIGURE 8. EEG recording during a spontaneous partial seizure
during moderate-intensity barbiturate withdrawal. The animal
remained standing during the seizure. Recordings are from various
loci: motor cortex (MC), visual cortex (VC), hippocampus, right
side (RHPC), hippocampus, left side (LHPC), amygdala (AMY), nucleus
centralis centralis (CC), and lateral geniculate (LGB). (Hinman
and Okamoto 1984. Copyright 1984, Academic Press).
FIGURE 9. Recurrent inhibition of the reflex discharge (2N
response). Measured in 12 control and 14 withdrawing animals
48 hours after the last dose of chronic pentobarbital treat-
ment. Vertical bars indicate ± S.E.; asterisks indicate P .05 by
t-test. Inset: A schematic drawing of electrode locations: GS
(gastrocnemius-soleus muscle nerve), St (stimulating electrode,
test impulse), VRL7 (ventral root L-7), Sc (stimulating
electrode on one-sixth to one-third of L-7 ventral root to deliver
conditioning impulse), R (recording electrode). (Rosenberg and
Okamoto 1978. Copyright 1978, American Society for Pharmacology
and Experimental Therapeutics).
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FIGURE 10. Presynaptic inhibition of the 2N response. Measured in
14 control and 14 withdrawing animals 48 hours after the
last dose of chronic pentobarbital. Vertical bars indicate ± S.E.;
asterisks indicate P < .05 by t-test. Inset: Schematic drawing of
experimental electrode locations: GS (gastrocnemius-soleus muscle
nerve), St (stimulating electrode, test impulse), PSBT (posterior
biceps and semitendinosus muscle nerve), SC (stimulating
electrode to deliver conditioning impulse), (VRSl (ventral root
S-l), R (recording electrode) (Rosenberg and Okamoto 1978.
Copyright 1978, American Society for Pharmacology and Experimental
Therapeutics).
barbiturate withdrawal were demonstrated (Rosenberg and Okamoto
1976). These included (1) increased polysynaptic but not
monosynaptic (2N) reflex discharges; (2) decreased synaptic
refractoriness, allowing more efficient transmission of repetitive
impulses; (3) increased sensitivity to lower frequency tetanic
stimulation in the production of post-tetanic potentiation (PTP);
and (4) augmented spontaneous discharge. All of these results
indicate generalized augmentation of neuronal activity during
withdrawal.
Since the overall excitability of the CNS depends to a large extent
on a delicate balance between excitatory and inhibitory functions,
the hyper-excitability displayed in withdrawing animals may be a
consequence not only of increased activity in excitatory pathways
but also of decreased activity in inhibitory pathways. Further
electrophysiological studies of inhibitory function at the spinal
reflex level (Rosenberg and Okamoto 1978) indicate that recurrent
inhibition disappeared almost totally during barbiturate withdrawal
(figure 9). Presynaptic inhibition also decreased dramatically
(figure 10). Loss of inhibition during withdrawal may be causally
related to the enhancement of inhibition by the presence of the
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barbiturate, as has been demonstrated in the hippocampus (Nicoll et
al. 1975), the olfactory bulb (Nicoll 1972), and possibly in the
(Hurlbrink and Boyd 1969). The neurochemical basis of this drug
enhancement of inhibition and reduced inhibition during withdrawal
is of great interest. Barbiturates appear to selectively
facilitate GABA-mediated responses (Ransom and Barker 1976; cf. Ho
1981) and to increase presynaptic inhibition in the spinal cord,
which is thought to be GABA mediated (Eccles et al. 1963; Schmidt
1963; Bell and Anderson 1972; Davidoff 1972). Accordingly it was
possible that our findings of decreased presynaptic inhibition
during withdrawal might be related to altered GABA levels or
kinetics, although this would not explain our findings of the loss
of recurrent inhibition, since GABA is not thought to be involved
in the recurrent inhibitory pathway. Glycine is the proposed
transmitter for both the Renshaw cell and also for neurons which
mediate Ia inhibition (Werman et al. 1968; Curtis 1969). However,
our findings do not specifically implicate glycinergic mechanisms
either. Although recurrent inhibition, involving the Renshaw cell,
was nearly abolished during withdrawal, direct inhibition involving
the Ia inhibitory interneuron was not changed.
The results of these studies support the hypothesis of a
nonspecific adaptation of the nervous system during chronic
barbiturate treatment, i.e., adaptation not specific to a
particular neurochemical system. A major part of this adaptation
is a decreased activity in certain inhibitory pathways. This view,
if correct, means that the adaptation is a response to chronic
depression of the nervous system rather than a specific response to
the particular drug. Further studies should be forthcoming to
elucidate the underlying mechanisms which contribute to a
development of cellular tolerance and physical dependence.
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Behavioral and Biochemical
Studies in Rats After Chronic
Exposure to Nicotine
Leo G. Abood, Susan Grassi, Maria Costanzo, and
Jeffrey Junig
INTRODUCTION
Since nicotine is the major constituent in cigarette smoke responsible
for the reinforcing effect of smoking, studies on the behavioral and
pharmacologic tolerance of nicotine are of considerable interest to
the health consequences of smoking. As discussed by Russell (1979)
in a NIDA monograph, there are diverse pharmacologic, as well as
psychologic, factors involved in the assessment of smoking as a
dependence process; but attempts to develop appropriate animal
models towards this end have not been very successful. Although
to lerance  i s  a  requirement  for  a  dependence  produc ing  drug ,
tolerance occurs with a wide variety of psychotropic drugs not
producing dependence and can involve behavioral mechanisms as well
a s  a l t e r a t i o n s  i n  d r u g  d i s p o s i t i o n  a n d  p h a r m a c o d y n a m i c
responsiveness (Jaffe 1980).
A review of the literature on the effect of chronic administration of
agonists or antagonists on various neurotransmitter receptors reveals
findings which are often conflicting and difficult to interpret.
Chronic administration of amphetamine (a dopamine agonist) has
been reported to decrease both agonist and antagonist binding (Muller
and Seeman 1979; Howlett and Nahorski 1979), while others failed to
o b s e r v e  a n y  e f f e c t  o n  s t r i a t a l  b i n d i n g  o f  3 H - h a l o p e r i d o l  ( a
dopaminergic receptor antagonist).
I t  was  recent ly  reported  that  chronic  t reatment  o f  rats  with
di isopropyl f luorophosphate  (DFP)  (a  chol inesterase  inhib i tor )
decreased  3H-acety lchol ine  b inding  to  cerebral  cortex  by  23%;
whereas chronic exposure to nicotine increased the amount of binding
by 25% (Schwartz and Kellar 1983). No change was observed on the
affinity of 3H-acetylcholine with either agent.
In another study involving continuous infusion of various doses of
nicotine to DBA female mice for 10 days, significant increases in 3H-
nicotine binding, as well as 125I-bungarotoxin binding, occurred in
the midbrain and hippocampus with no change in the Kd values (Marks
et al. 1983). Although nicotine infusion had no effect on baseline
rotarod performance to acute injections of nicotine, the nicotine-
induced bradycardia was diminished. They also observed a significant
tolerance to the acute effects of nicotine on rotarod performance
and body temperature.
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Tolerance after Chronic Administration of Nicotine
In order to determine whether behavioral tolerance develops after
chronic administration of nicotine to rats, nicotine was chronically
administered either intraperitoneally of by infusion into the lateral
ventricles (table 1).
TABLE 1
Effect of Various Dosage Regimens and Routes of Administration on
Prostration Following Nicotine Administration into Fourth Ventricles
of Rats.
Dosage Schedule
Syndrome
Incidence of Prostration
5 nmoles nicotine twice daily
into fourth ventricles for 4 days
All rats responded day 1; 60%
responded day 2; 30% responded
day 4; 90% responded fully
after 3 days without nicotine.
Alzet minipump (50 nmoles/hr)
into lateral ventricle for 10 days
Normal response to 5 nmoles of
nicotine into fourth ventricle
on last day of infusion.
Acute injection of 12 µmole/kg of Most rats responded to 5nmoles
ip twice daily for 14 days. of nicotine into fourth
ventricles 12 hr after last
injection. Response was
slightly less than in controls.
When 5 nmoles of (-)-nicotine (neutralized with HCl and in a volume
of 1 µl) was administered twice daily for 4 consecutive days into the
fourth ventricle, all rats exhibited prostration on day 1, 60% on day
2, and only 30% on day 4. At least 90% of the rats responded to
5 nmoles of nicotine when administered into the fourth ventricle on
day 7 (3 days after the 4 daily doses of nicotine). After nicotine was
infused continuously into the lateral ventricle for 10 days at a rate of
50 nmoles/hr, the rats exhibited full prostration when 5 nmoles
nicotine was administered into the fourth ventricle on the last day of
in fus ion .  In  a  th ird  protoco l ,  a f ter  rats  were  in jected  intra-
peritoneally with 12 µmoles/kg of nicotine twice daily for 14 days,
they exhibited prostration when given 5 nmoles of nicotine into the
fourth ventricle 12 hr after the last injection of nicotine.
A number of conclusions can be inferred from these studies. The
administration of nicotine into the fourth ventricle for 4 days appears
to produce some tolerance in the prostration syndrome; however, the
tolerance vanishes 3 days after the last dose. When nicotine is
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infused continuously into the brain for 14 days, no tolerance develops
to the administration of nicotine directly into the fourth ventricle.
Finally, the chronic administration of nicotine systemically for 14
days resulted in only slight tolerance to nicotine given into the fourth
ventricle. It would appear that behavioral tolerance to nicotine, as
assessed by the prostration syndrome, is transient and diminishes with
chronic administration. The findings are in agreement with those of
Stollerman et al. (1974) that following chronic exposure to nicotine,
the development of tolerance initially increased and then decreased
as the dose of nicotine was increased.
Effect of Chronic Nicotine Treatment on 3H-Nicotine Binding in Rat
Brain
After administering 12 µmole/Kg of nicotine ip twice daily to a total
o f  10  rats ,  the  K d  and B m a x  f or  ( - ) -
3H-nicot ine  b inding  were
determined 15 hr after the last injection on membrane preparations
of whole brain employing Scatchard analyses. A control group of rats
maintained under similar environmental conditions received saline. A
third group of 5 rats, which received a continuous infusion of nicotine
into the lateral ventricle from an Alzet minipump at the rate of
50 nmole/hr for a period of 10 days, was analyzed similarly 15 hr
after infusion ceased. The binding studies revealed no significant
differences between the control and nicotine-exposed groups in either
the high or low Kd or Bmax values (table 2).
TABLE 2
Effect of Chronic Nicotine Treatment on Bm a x  and Kd  of  
3H-(-)-
Nicotine Binding to Rat Brain Membranes
Conditions
B m a x K d
moles /mg ×10 1 4 x 1 0
1 0
High Low High Low
Normal 0.5 ± 0.1 2.9 ± 0.4 1.0 ± 0.3 3.5 ± 0.2
Chronic (twice 0.4 ± 0.1 2.7 ± 0.2 0.8 ± 0.2 3.3 ± 0.3
daily)
Chronic (infusion) 0.4 ± 0.1 2.8 ± 0.3 1.1 ± 0.2 3.5 ± 0.3
Values are expressed as mean ± sd with n=3-4 rat brains. Data were
derived from Scatchard plots.
These findings, which fail to demonstrate any alteration in the
nicotine receptor in rat brain following chronic exposure to nicotine,
are consistent with the behavioral studies demonstrating only a slight
decrease in the sensitivity of the nicotine-induced prostration.
Although they would appear to be at variance with the study of Marks
et al. (1983) reporting up-regulation of nicotine binding, their studies
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were performed on DBA mice which developed a significant behavior-
al and pharmacologic tolerance after nicotine infusion. It is also
conceivable that regional brain areas may reveal differences not
observable in whole rat brain.
Binding of Nicotine Analogues and Other Agents to Rat Hepatocytes
Using Either (-)- or (+)-3H-Nicotine
In the course of investigating the metabolism of nicotine by isolated
rat hepatocytes, it was observed that the hepatocytes exhibited a
specific affinity for nicotine and its analogues and that the affinity
appeared to be greater for the (+)- than the (-)-enantiomer (table 3).
TABLE 3
Binding of Nicotine Analogues and Other Agents to Rat Hepatocytes
Using Either (-)- or (+)-3H-Nicotine.
Agent
I C 5 0 M
(-)-3H-nicotine (+)-3H-nicotine
(-)-nicotine
(+)-nicotine
nornicotine
N'-nicotonium
(-)-cotinine
N'-ethyl nornicotine
N-methyl nicotine
N'-ethyl nornicotine
N'-propyl nornicotine
N'-butyl nornicotine
mecamylamine
haloperidol
chlorpromazine
imipramine
carbamylcholine
hexamethonium
1 x 10-6
3 x 10-7
3 x 10-5
1 x 10-3
5 x 10-4
3 x 10-6
1 x 10-3
5 x 10-6
8 x 10-6
2 x 10-5
2 x 10-5
2 x 10-4
3 x 10-4
1 x 10-4
1 x 10-3
1 x 10-3
5 x 10-7
3 x 10-8
1 x 10-5
1 x 10-3
3 x 10-4
1 x 10-6
1 x 10-3
2 x 10-6
2 x 10-6
8 x 10-6
1 x 10-5
1 x 10-4
1 x 10-4
8 x 10-5
1 x 10-3
1 x 10-3
At a final concentration of 1 x 10-9M (-)- or (+)-3H-nicotine, the IC50
values were found to be 1 x 10-6 and 3 x 10-7M in the presence of a
100-fold excess of the unlabeled (-)- and (+)-nicotine respectively;
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whereas, with (+)-3H-nicotine the values were 5 x 10-7 and 3 x 10-8M
in the presence of a 100-fold excess of the unlabeled enantiomers,
With increasing chain length of alkyl substituents on the pyrrolidine N
of nicotine, there was a corresponding decrease in the affinity, using
either (-)- or (+)-3H-nicotine. As discussed elsewhere (Abood et al.,
1983), there was an excellent correlation between the binding affinity
of this homologous series of nicotine analogues and their ability to
produce prostration when administered ivc. Quaternisation of either
the pyrrolidine or pyridine N of nicotine greatly reduced the affinity
f o r  h e p a t o c y t e s ;  w h i l e  n i c o t i n i c  c h o l i n e r g i c  a g e n t s  s u c h  a s
carbamylcholine and hexamethonium exhibited no affinity.
It can be concluded from these studies that specific nicotine binding
exists  in  iso lated  hepatocytes .  The  b inding  is  revers ib le  and
nonstereoselective; and since it is not saturable at concentrations of
(-)- or (+)-nicotine lower than 10-4M, the binding may be related to a
transport system involved in the metabolism-disposition of nicotine.
When the hepatocytes are even slightly damaged, they lose their
abi l i ty  to  b ind or  take  up nicot ine .  I t  i s  noteworthy  that  the
relationship of binding affinity of the various nicotine analogues in
hepatocytes agrees with the relative psychotropic potency of the
analogues.
Effect of Chronic Nicotine Treatment on the Metabolism of (-)- and
(+)-3H-Nicotine by Isolated Hepatocytes
In an effort to determine whether chronic nicotine administration
(systemic administration for 14 days) altered its metabolism by liver,
hepatocytes were isolated from rat liver after collagenase perfusion
and modification of the method of Baur and Heldt (1971).
The hepatocytes were incubated for various times at 37°C in Hank’s
buf fer  containing 10 - 9M (- ) -3H-nicot ine  +  10 - 5M unlabeled  ( - ) -
nicotine + l0-3M nicotinamide at pH 7.5. The rate of disappearance
of the nicotine present was 2.5 x 10-6 mmoles/min/mg protein for the
control preparation compared to a value of 3.0 x l0-6 for the rats
chronica l ly  exposed  to  n icot ine .  S ince  the  d i f ference  was  not
stat ist i ca l ly  d i f ferent ,  i t  would  appear  that  chronic  n icot ine
treatment does not alter its metabolism by liver. The results are in
agreement with those of Marks et al. (1983) who failed to observe any
e f f e c t  o f  c h r o n i c  n i c o t i n e  i n f u s i o n  o n  t h e  r a t e  o f  n i c o t i n e
disappearance from the blood of DBA mice in vivo.
Effect of Chronic Nicotine Administration on Lever Press Avoidance
of Aversive Shock
A number of groups have reported on the antinociceptive actions of
nicotine in rodents (Tripathi et al. 1982; Sahley and Bemtson 1979).
Dewey et al.  (1970) have reported that the analgetic action of
nicotine on a molar basis was comparable to that of morphine. A
number of mechanisms have been proposed for the antinociceptive
action of nicotine including a nicotinic cholinergic one (Sahley and
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Berntson 1979; Tripathi et al. 1982), an opioid one in mice but not
rats (Tripathi et al. 1982), and one involving a-adrenergic receptors
(Tripathi et al. 1982). It is apparent from such studies that the action
of nicotine on antinociception is a complex one. There also remains
the issue as to whether nicotine is analgetic or is simply elevating the
animal’s threshold to an aversive stimulus (Abood et al. 1981). In an
effort to further investigate this action of nicotine, another paradigm
was employed for measuring the response to an aversive stimulus.
In a previous study (Abood et al. 1981), it was reported that nicotine
administered intraventricularly to rats significantly elevated the
threshold  to  an  avers ive  shock ,  employing  a  shock-avoidance
paradigm in which the animals were delivered 16 random shocks over
a 5-min period beginning with an initial near-subthreshold shock
(0.4 mA) and extending to a maximal shock of 1.4 mA. (Abood et al.
1981; D’Amato and Fazzaro 1966; for experimental details.) A
c o m p a r i s o n  o f  t h e  e f f e c t s  o f  a c u t e  a n d  c h r o n i c  n i c o t i n e
administration on the frequency of lever pressing for shock avoidance
is presented in table 4. After rats had established a frequency
TABLE 4
E f f e c t  o f  A c u t e  a n d  C h r o n i c  N i c o t i n e  A d m i n i s t r a t i o n  o n
Discriminative Lever-Pressing for Shock Avoidance
Mean Frequency % Decrease
Acute Study
Before nicotine 40.4 ± 2.6
After nicotine 19.9 ± 2.3 50
Naloxone + nicotine 22.0 ± 3.0 45
After Before nicotine 35.5 ± 3.0
chronic
nicotine After nicotine 25.5 ± 2.5 28
Results are presented as mean frequency of lever pressing before and
after saline or 15 nmoles (-)-nicotine ivc. Analysis of variance
employing a univariate and multivariate regression problems program
yields p <0.0001. Values are expressed as mean frequency of
responses with variance. Chronic rats received nicotine ip twice
daily for 14 days as described in text. A dose of naloxone of 4 mg/kg
ip was administered 20 min prior to nicotine ivc.
baseline of lever pressing, they were administered 15 nmoles of (-)-
nicotine (5 µl) ivc and again tested. In the group not receiving
nicotine chronically, a 50% decrease in the frequency of lever
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pressing occurred after nicotine ivc; and, in the chronically treated
groups  the  decrease  was  28%.  After  chronic  administrat ion  o f
nicotine, the mean frequency of response prior to ivc nicotine was
lowered while the frequency after nicotine ivc was elevated. When
naloxone was administered 20 min prior to nicotine ivc, there was no
effect on the frequency of response. It would appear from these
studies  that  fo l lowing chronic  n icot ine  administrat ion,  some
tolerance had developed to the ability of nicotine to elevate the
t h r e s h o l d  t o  s h o c k .  F u r t h e r m o r e ,  t h e  e f f e c t  o f  n i c o t i n e  o n
aversiveness does not appear to be mediated by an opioid system.
CONCLUSION
A number of conclusions concerning the problem of tolerance to
nicotine may be derived from the present study. Although tolerance
develops in rats during the earlier stages of chronic administration,
behavioral tolerance to intraventricularly administered nicotine tends
to diminish with further exposure to nicotine. Some tolerance
appears to develop in the ability of nicotine to attenuate aversiveness
to electric shock; while the initial tolerance to nicotine-induced
prostration appears to disappear. There does not appear to be any
alteration in either the affinity or density of 3H-nicotine binding
sites in rat brain with chronic administration of nicotine, nor any
increase in its rate of metabolism by liver.
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Psychobiological Foundations of
Behaviors Induced by
Amphetamines
Philip M. Groves and David S. Segal
The abuse of psychomotor stimulants such as amphetamine and
cocaine is a problem of major proportions in contemporary life.
It has been well documented that drug abuse results in serious
untoward medical and social consequences. Research on the effects
of amphetamine has attempted to establish models of the behavioral
consequences of stimulant administration in animal subjects and to
determine the biomedical sequelae of acute and long-term abuse of
amphetamine, especially as the stimulant drug affects the struc-
ture and function of the brain. It is now well known that long-
term amphetamine administration can result in the development of
psychosis in humans. Further, when amphetamine is administered to
animal subjects it produces a characteristic pattern of behavioral
response which includes locomotor activation and the occurrence of
repetitive species-specific stereotyped behaviors. Extensive
research efforts have now established numerous sites of action of
stimulant drugs in the brain and have begun to relate the biochem-
ical and neurophysiological effects of the drug to the charac-
teristic behavioral profiles that have been described.
BEHAVIORAL CONSEQUENCES OF ACUTE AND CHRONIC AMPHETAMINE ADMINIS-
TRATION
When administered acutely to animal subjects, amphetamine produces
a characteristic dose- and time-related pattern of behavioral
responding. The laboratory rat has now been studied extensively
as a model for understanding the biomedical and behavioral effects
of the drug. Some of the features of the amphetamine response
following acute administration of the drug and following multiple
daily injections are illustrated in figure 1 where it  can be seen
that the acute effects of the drug as well as the changes that
occur in the behavioral response with chronic administration are
both dose- and time-dependent. Repeated administration of rela-
tively low doses (0.5 - 1.5 mg/kg), which initially produce
enhanced locomotion as the predominant response, results in a gra-
dual increase in locomotor activity with respect to both peak
effect and duration. With moderate doses of the drug (1.5 - 2.5
mg/kg), amphetamine-induced locomotion during the early period of
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FIGURE 1. Alterations in response pattern with repeated daily
injections of a constant dose of d-amphetamine sulfate. Top: For
low doses, 5 to 10 days of administration results in a progressive
increase in locomotion as reflected in the magnitude and duration
of the response. Middle: For intermediate doses, the duration of
stereotypy episodes is increased, and by 3 to 5 days, a continuous
stereotypy phase (stippled shading) emerges. Poststereotypy
hyperactivity is also enhanced. Bottom: For the high dose range,
stereotypy (stippled shading) appears more rapidly and is intensi-
fied by the second injection, although the duration of the stereo-
typy phase is not correspondingly prolonged. Locomotion after the
stereotypy phase is progressively increased. Reprinted from David
S. Segal, Marc A. Schuckit, 1983, with permission. @Raven Press,
1983.
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the response pattern is gradually replaced by progressively longer
episodes of focused stereotypies. Repeated injections of higher
doses (2.5 - 7.5 mg/kg), which acutely produce triphasic response
patterns consisting of an initial increase in locomotion followed
by a period of intense stereotyped behavior and a subsequent phase
of enhanced locomotion, result in a more rapid onset of the
storeotypy and a progressive augmentation in the later phase of
hyperactivity. Observation of the animal subjects confirms the
more rapid onset of stereotypy with a corresponding decrease in
locomotion.
Although repeated amphetamine administration augments various com-
ponents of the acute response without apparent qualitative change,
the behavior that emerges does not simply reflect a shift to the
left in the amphetamine dose-response curve. Although the stereo-
typy appears more rapidly and is intensified at some doses, the
duration of the stereotypy phase is not correspondingly increased,
as it is with increasing doses administered acutely. Evidence
such as this has nor accumulated and shows a complex, dose- and
time-dependent alteration which can be characterized as a sequen-
tial pattern of behavioral change resulting from multiple amphe-
tamine injections in an extensive array of animal species. Such
evidence is clearly important in the evaluation of potential
underlying mechanisms. Further, alterations in the behavioral
response to amphetamine have nor been detected in animal subjects
at least one month following a single acute injection of the drug,
suggesting an extremely powerful and potentially long-lasting
influence of amphetamine and rolatod psychomotor stimulant drugs
on the brain.
NEURONAL MECHANISMS OF ACTION OF AMPHETAMINE
Substantial evidence accumulated ovor the past 2 decades suggests
that a significant site of action of amphetamine in the brain can
be identified with the catecholamine cell groups of the brainstem.
By releasing catecholamines, amphetamine is believed to act
indirectly on various targets in the brain including both post-
synaptic targets of catecholamine neuron projections as roll as
the presynaptic neurons themselves (Groves et al. 1975; Groves and
Rebec 1976; Groves and Tepper 1983; Segal and Schuckit 1983).
This has been demonstrated convincingly by recording the activity
of catecholamine neurons during the administration of amphetamine
to experimental animals. Among the early and best documented evi-
dence illustrating the effect of amphetamine on catecholamine neu-
rons was the demonstration that amphetamine administration led to
a marked inhibition of neuronal activity in two intensively stu-
died cell groups of the brain, the dopaminergic pars compacta of
substantia nigra (Bunney et al. 1973) and the noradrenergic locus
coeruleus (Graham and Aghajanian 1971). This effect is illus-
trated for two representative neurons in figure 2. Intravenous
administration of amphetamine produces a decline in neuronal fir-
ing of dopaminergic neurons of tho substantia nigra while a simi-
lar and even more pronounced effect also occurs for neurons in the
noradrenergic locus coeruleus.
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This profound influence of amphetamine on the activity of catecho-
lamine neurons was originally believed to be due to changes in
long-axoned feedback loops from sites of catecholaminergic inner-
vation but is now thought to include the release of catecholamines
locally within those cell groups. For example, amphetamine has
now been shown to release dopamine from dopaminergic neurons of
substantia nigra both in vitro (Paden et al. 1976) and in vivo
(Cheramy et al. 1978). Anatomical evidence suggests that both
catecholaminergic presynaptic axons and dendrites are found within
the catecholaminergic cell groups (Groves et al. 1979; Groves and
Wilson 1980; Grovos and Linder 19833) and would be available to
release these neurotransmitters in response to amphetamine.
FIGURE 2. Illustration of the difference in sensitivity to
intravenously administered amphetamine between noradrenergic neu-
rons of the nucleus locus coeruleus and dopaminergic neurons of
the substantia nigra pars compacta. The solid line indicates the
spontaneous firing rate of a representative dopamine neuron; the
dashed line is the firing rate of a noradrenergic neuron. Sequen-
tial intravenous injections of 0.25 mg/kg d-amphetamine sulfate
were given (arrows) for a cumulative dose in each case of 0.75
mg/kg. Whereas the locus coeruleus cell shows greater than 80%
inhibition to 0.75 mg/kg, the substantia nigra neuron only exhi-
bits a 25% reduction in firing rate to this doss. Reprinted from
Philip M. Groves, James M. Tepper, 1983, with permission. ©Raven
Press,  1983.
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NEUROPHYSIOLOGICAL CONSEQUENCES OF PRESYNAPTIC RECEPTOR ACTIVATION
Since activation of catecholamine receptors on dopaminergic and
noradrenergic neurons causes an inhibition of neuronal firing by
these cells,  it  was of particular interest to determine if activa-
tion of presynaptic receptors presumed to exist on the terminals
of these neurons would affect excitability in the same way. Groves
and associates have now developed a method for measuring the exci-
tability of catecholaminergic synaptic endings in the brain. This
method is illustrated in figure 3. Electrical stimulation of the
dopaminergic terminal field is affected while recording simultane-
ously from the region of the dopaminergic cell body. Antidromic
action potentials reaching the initial segment and/or cell body of
the dopaminergic neuron are recorded to determine whether the
stimulus has produced an action potential. By plotting the proba-
bility of antidromic activation of the neuron against a range of
stimulation currents, a excitability curve may be constructed that
may be used to define the excitability of the synaptic terminal
field. Now by administering various pharmacological or other
treatments, variations in terminal excitability can be seen and
appear to correlate with the release of catecholamines by the
catecholaminergic synaptic endings. Using this paradigm for
determining terminal excitability of individual dopaminergic and
other monoaminergic neurons in the brain, Groves and associates
have now been able to show that activation of these receptors,
like those in the region of the cell body and dendrites, also
seems to be accompanied by a decrease in terminal excitability, as
illustrated in figure 4. As shown there, the currents necessary
to activate dopaminergic cells antidromically by stimulation of
their terminal fields in the neostriatum are uniformly increased
by systematically administered amphetamine, and a similar effect
occurs when amphetamine is infused in low concentrations and
volumes directly into the vicinity of the terminals activated by
the electrical stimulus. As illustrated in figure 5, antidopam-
inergic drugs such as the receptor-blocking agent haloperidol pro-
duce increased terminal excitability and can reverse the agonist-
induced decrease in terminal excitability, the effects being
represented by a uniform shift to the left in the excitability
curve.
Evidence such as this suggests that the extracellular accumulation
of dopamine that is produced by amphetamine causes activation of
presynaptic receptors and that these, in turn, result in a change
in polarization and/or conductance of the dopaminergic synaptic
ending. Such an effect could, for example, represent a hyperpo-
larization of the synaptic ending produced by presynaptic receptor
activation (Groves et al.  1981).
When similar experiments are carried out while monitoring the
excitability of noradrenergic terminals in frontal cortex, a simi-
lar influence is also seen. Catecholaminergic agonists for the
alpha-2-noradrenergic receptor lead to reduced terminal excitabil-
ity when infused locally into the region of the terminal field,
including low concentrations and volumes of d-amphetamine
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FIGURE 3. Schematic illustration of the experimental paradigm used
for measuring nigrostriatal dopaminergic terminal excitability. A
bipolar electrode is positioned within the neostriatum for
antidromic stimulation of the dopaminergic striatal afferents ori-
ginating in the ipsilateral substantia nigra pars compacta. An
extracellular recording electrode is positioned within the ipsila-
teral pars compacta, and the frequency of antidromic response to
neostriatal stimulating currents of varying strengths is measured.
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FIGURE 4. Top: Decrease in neostriatal dopamine terminal excita-
bility following intravenous administration of d-amphetamine sul-
fate. Following an initial injection of 0.5 mg/kg d-amphetamine,
the plot of neostriatal stimulating currents versus the proportion
ofantidromic responses detected by an extracellular recording in
the ipsilateral substantia nigra pars compacta is shifted uni-
formly to the right, indicating a decrease in terminal excitability
at all current values. A second injection of 0.5 mg/kg d-
amphetamine produces a further shift to the right in the excita-
bility curve and an additional decrease in terminal excitability.
Bottom: Decrease in excitability of dopaminergic terminal in neo-
striatal induced by the local microinfusion of d-amphetamine di-
rectly into the stimulating site. Following an infusion of 0.31
µl of 1 µM d-amphetamine, the excitability curve is shifted to the
right, indicating a decrease in terminal excitability. A second
infusion of d-amphetamine (0.31 µl, 1 µM) 5 min later produces a
further decrease in terminal excitability. Reprinted from Philip
M. Groves, James H. Tepper, 1983, with permission. ©Raven Press,
1983.
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(Nakamura et al. 1981). However, systemically administered amphe-
tamine produces a more complex influence on terminal excitability.
Low doses of the drug that do not lead to a profound inhibition of
firing produce a decrease in terminal excitability, but this
effect is reversed when the drug is administered in quantity suf-
ficient to produce a cessation of impulse flow in the neuron
(Nakamura et al. 1981). This has been interpreted to indicate
that the release of catecholamine by the noradrenergic neuron in
response to amphetmine is partly dependent upon impulse traffic.
Evidence such as this has now demonstrated persuasively that
amphetamine, by releasing catecholamines, affects the activity and
excitability of the catecholamine neuron and, by inference, the
various postsynaptic targets of these systems throughout the
brain. While there has been a continuing effort to ascertain the
mechanisms underlying the inhibition of neuronal activity in there
cell groups following amphetamine administration, there has only
recently been a concerted attempt to determine mechanisms of
action at these manifold sites where amphetamine produces altera-
tions in the brain. A recent review of such evidence indicates
that amphetamine administration leads to marked alterations in
neuronal firing throughout the reticular formation of the brain-
stem, the caudate nucleus, putamen and globus pallidus and related
striatal cell groups, the hypothalamus, cerebellum, and the cere-
bral cortex (see recent review by Groves and Tepper 1983). From
evidence such as this, it becomes apparent that the influence of
the drug is extremely widespread, is both dose- and time-
dependent, and cannot be easily explained by a monotonic increase
in the release of catecholamines.
A recent theoretical framework for intrastriatal neuronal circui-
try has emphasized the interconnections of the common spiny neu-
rons of neostriatum and has proposed that these form a large,
lateral inhibitory network which has been termed the Spiny I cell
matrix (Groves 1983). When this network is affected by amphetam-
ine, we can imagine that at low doses of the drug, the processing
of information through this lateral inhibitory matrix is improved
but as the dose is increased or as repeated doses are admin-
istered, the ability of the neostriatum to respond to the patterns
of activation that arrive from substantia nigra, midline thalamus,
and cerebral cortex in time and space becomes compromised, and
stereotyped behaviors and other emergent patterns of behavioral
responding become apparent. The analysis of the environment and
the interaction with it that normally require information process-
ing by the neostriatum become impaired and only those most primi-
tive and securely represented patterns of behavioral responding
emerge, signalling a progressive constriction of the behavioral
repertoire. The various components of the emergent behaviors may
reflect an augmentation or diminution of component behaviors that
appeared upon acute administration of the drug, and lateral inhi-
bitory processes intrinsic to the neostriatum may be expected to
lead to the evolution of these different degrees of apparent
behavioral sensitization and tolerance. New approaches toward
understanding the manifold mechanisms of action of amphetamine and
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FIGURE 5. Top: Increase in neostriatal dopaminergic terminal exci-
tability induced by intravenous injection of haloperidol lactate
(Haldol).  Following an initial injection of 0.025 mg/kg haloperi-
dol the excitability curve is shifted nearly uniformly to the
left,  indicating an increase in terminal excitability inferred
from the reduced neostriatal stimulating currents necessary to
elicit varying proportions of antidromic responses in the ipsilat-
eral substantia nigra pars compacta. A second injection of 0.025
mg/kg haloperidol produces a further increase in terminal excita-
bility. Bottom: Reversal of the increase in dopaminergic terminal
excitability caused by a local infusion of amphetamine by a subse-
quent local infusion of haloperidol. In this representative exam-
ple, after a control level of excitability was determined, an
infusion of d-amphetamine (0.31 µl, 1 µM) was made into the neo-
striatal stimulating rite which resulted in a shift to the right
in the excitability curve (O--O), indicating a decrease in excita-
bility. Approximately 5 min later, an infusion of haloperidol
(0.31 µl, 0.10 µM) was made into the same site via a second can-
nula. This infusion reversed the effects of the first infusion
and within 5 min the excitability curve was shifted dramatically
to the left (X--X), past the baseline, representing an overall
increase in terminal excitability. Reprinted from Philip M.
Groves, James R. Tepper, 1983. ©Raven Press, 1983.
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the way in which its actions are altered by long-term administra-
tion of the drug have now begun (e.g., Gale, this volume). Con-
tinued effort along these various lines of research holds consid-
erable promise for further understanding the ways in which this
and related drugs affect the brain and behavior.
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